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 Aromatic compounds represent one of the most abundant classes of organic molecules, and 
are suitable precursors for synthesizing functionalized alicyclic hydrocarbon frameworks. 
Accordingly, many unique and enabling dearomative transformations have been developed and 
applied to the total synthesis of complex bioactive compounds. However, a significant challenge 
remains to be addressed in this field. That is, simple and non-activated arenes, such as benzene 
and naphthalene, have seldom been employed in the dearomative functionalization reactions due 
to their extreme inertness. Considering a wide availability of such simple arenes, the development 
of novel dearomative methods for non-activated arenes which would allow site-selective 
introduction of functionality with concomitant loss of aromaticity would provide ideal platforms 
for accessing alicyclic structures with functional and stereochemical diversity.  
 To this end, this thesis is based on the development of a dearomative strategy that employs 
an arenophile, such as N-methyl-1,2,4-triazoline-3,5-dione (MTAD), which undergo a visible-
light-mediated formal [4+2] para-cycloaddition with simple arenes. The resulting dearomatized 
arene-arenophile cycloadduct possesses multiple functional handles, which can be further 
elaborated in situ to a variety of functional groups. Based on this concept, Chapter 2 discusses the 
application of olefin chemistry to achieve a site-selective reduction of the parent arenes. On the 
other hand, Chapters 3–6 describe an alternative mode of activating the arene-arenophile 
cycloadduct through transition metal-catalysis. An arenophile-mediated dearomative syn-1,4-
aminofunctionalization protocol was established using palladium complexes as catalysts and with 
carbon-, nitrogen-, and oxygen-based nucleophiles. The key features of these processes compared 
to existing dearomatization reactions are: 1) amenable aromatic substrates encompassing a wide 
range of non-activated arenes as well as heteroarenes, 2) selective installation of functional groups 
to the dearomatized arene occurs in a single pot, 3) broad functional group compatibility, and 4) 
functionalization of least aromatic, non-activated aromatic ring within the polynuclear arenes.  
 In each chapter, derivatizations of the resulting dearomatized products were explored 
through a variety of functional group elaboration. Based on the arenophile 
cycloreversion/fragmentation and olefin functionalization, highly functionalized alicyclic motifs 
with defined stereogenic centers were synthesized, most of which are not synthetically accessible 
using other existing dearomatization reactions. Furthermore, the versatility of the arenophile-
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mediated dearomatization strategy was also demonstrated by enabling novel disconnections 
towards the synthesis of natural products and bioactive compounds. This is highlighted by the 
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Chapter 1: Introduction 
1.1 Dearomatization of arenes 
Aromatic compound 
 Ever since Friedrich Wöhler synthesized urea from inorganic materials (potassium cyanate 
and ammonium sulfate; Wöhler synthesis) in 1828,[1] the role of organic chemistry has 
significantly expanded from simply studying compounds in living organisms to synthesizing 
organic compounds and materials. The synthetic targets nowadays include natural products, 
pharmaceuticals, agrochemicals, polymers, and other functional materials that are vital to modern 
human lives. Another groundbreaking discovery that greatly enhanced the advancement of organic 
synthesis is arguably the proper understanding of the physical properties of benzene (1.1a), 
reported by Friedrich A. Kekulé in 1865, which hypothesized the structure of benzene to consist 
of a six-membered ring of carbon atoms with alternating single and double bonds.[2] This idea was 
later advanced to the concept of resonance structures by Linus Pauling in 1928 that the π-electrons 
in the ring are completely delocalized. This explains the unusual stability, namely the resonance 
stability, of benzene compared to the theoretically unconjugated analogue, cyclohexatriene.[3] 
 Benzene (1.1a) belongs to a class of organic molecules called aromatic compounds, along 
with other compounds such as naphthalene (1.2a), phenol, and pyridine, many of which are 
commercially available and are abundant motifs in nature. One of the key features of these 
aromatic compounds is their chemical inertness imposed by the aromaticity, which is related to 
their resonance stabilization energy (Figure 1-1).[4] Nonetheless, the dearomatizations of arenes 
fascinated organic chemists, having been recognized as fundamentally important transformations. 
Aromatic compounds are suitable precursors for the synthesis of complex alicyclic frameworks, 
as the dearomative transformations provide ideal platforms for further introductions of both 
functional and stereochemical diversity. Accordingly, many unique and enabling dearomatization 
processes have been developed,[4-11] and have been applied to the total synthesis of complex 
bioactive compounds.[12] 






















Dearomatization reactions and their applications to total synthesis 
 Among the many dearomative strategies that have been explored and utilized in the past 
few decades, dissolving metal reduction (Birch reduction) is one of the most classical examples, 
which generates 1,4-cyclohexadienes (1.4) in the case of mononuclear arenes, and a variety of 
alicyclic structures with polynuclear arenes.[11,13] As for substituted benzenes, the electronic nature 
of the substituents is responsible for dictating the substitution pattern, whereas for the polynuclear 
arenes, the least aromatic ring that preferentially be reduced (Scheme 1-1, top). The Birch 
reduction has found extensive applications in the total synthesis of bioactive compounds.[12] For 
example, the synthesis of (–)-cepharamine, reported by Schultz in 1998, exploited an single-
electron reduction and subsequent stereoselective alkylation using benzoic acid derivative 1.7 
bearing a chiral auxiliary (Scheme 1-1, bottom).[14] The chiral enolate intermediate formed in situ 
as a result of Birch reduction was alkylated with alkyl iodide 1.8 to provide 1,4-cyclohexadiene 
1.9 in high yield (95%) as a single diastereomer, which was further elaborated to complete the first 
asymmetric synthesis of the hasubanan alkaloids. 
 Transition metal-catalyzed dearomative hydrogenation, both homogeneous and 
heterogeneous, is another important reductive dearomatization method known to reduce aromatic 
cores to their saturated counterparts, and has been widely used in both academia and 
industry.[7c,11,15] Not only are these transformations amenable to benzene-derived substrates, but 
are also competent for heteroarenes. Furthermore, in the presence of multiple reducible functional 
groups, the dearomative hydrogenation could be operated chemoselectively. The reaction outcome 
is highly dependent on multiple factors such as the metal catalyst, solvent, and hydrogen pressure 
(Scheme 1-2, top). An elegant application of this reaction was accomplished by Roche in the 







































synthesis of oseltamivir, where the penta-substituted mononuclear arene 1.16 was reduced to 
cyclohexane 1.17 using Ru/Al2O3 as the catalyst (Scheme 1-2, bottom).[16] Remarkably, five 
contiguous stereogenic centers were stereoselectively introduced in this single step.  
 Transition metal-mediated dearomative functionalization is a distinctive from Birch 
reduction and transition metal-catalyzed hydrogenation by enabling dearomative addition of 
nucleophiles/electrophiles to the parent arene via temporary formation of activated metal-arene 
complex.[5] Tungsten, chromium, manganese, and osmium complexes are often used, and are 
known to form either h6-complexes or h2-complexes with mononuclear arenes. Upon activation 
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of arene, either nucleophilic addition (for h6-complex, 1.18a) or electrophilic addition (for h2-
complex, 1.21) to the arene can proceed regioselectively, and the resulting carbanion or 
carbocation species can be trapped by an electrophile or nucleophile. Not only is the process 
amenable to simple benzene derivatives, but also to heteroarenes such as pyridine and furan to 
prepare highly functionalized heterocycles (Scheme 1-3, top). Although currently limited, there 
have been a few applications to the syntheses of natural products. For example, erythro juvabione 
was synthesized from arene-chromium complex 1.18b through net dearomative hydroalkylation 
as a key step (Scheme 1-3, bottom).[17] 
 The cycloaddition reaction is an atom-economical process that generates molecular 
complexity within a single step. When combined with dearomatization, facile access to bicyclic 
motifs with multiple stereogenic centers become feasible. While dearomative cycloaddition of 
activated arenes such as furans, pyrroles, indoles, and other heteroarenes under thermal conditions 
are relatively mild, the use of non-activated arenes under same conditions are practically 
impossible. However, despite the tremendously high activation barriers to dearomatize, 
photocycloadditions of non-activated arenes have been established.[8] These reactions are typically 
conducted using a low-pressure mercury lamp (254 nm) to photo-excite the arenes to their p-p* 





















































































singlet state. With benzene (1.1a) for example, three distinct modes of photocycloaddition can 
occur with alkenes to give the following periselectivities: [2+2] or ortho-, [3+2] or meta-, and 
[4+2] or para-addition (Scheme 1-4, A, 1.25–1.27). Although literature precedents for ortho- and 
para-cycloadditions are scarce, meta-cycloaddition has been well-documented,[8b,8c] and has also 
been employed in synthesis to rapidly form complex carbon skeletons. (–)-Penifulvin A was 
synthesized enantioselectively utilizing intramolecular meta-cycloaddition of the chiral 
mononuclear arene 1.28 (Scheme 1-4, B).[18] Representative examples involving polynuclear 
arenes are shown in Scheme 1-4, C. Naphthalene derivatives (1.2a, 1.2c, 1.2d) can be used in a 
variety of different photocycloaddition reactions, with activated (substituted) rings preferentially 
undergoing dearomatization (1.30–1.32). Anthracene (1.5a) is another common substrate used in 
such a transformation, which selectively reacts at the least aromatic internal ring (1.33). Although 
these reactions represent highly enabling ways to rapidly construct elaborated structures, these 
processes have not received much attention from the synthetic community due to extremely limited 
scope. 
 Dearomative transformation that utilize pre-existing functional handles on arenes, such as 
the hydroxyl group of phenols (1.34), have also been exploited extensively. Most commonly, these 
activated arenes are dearomatized through an oxidation mediated by hypervalent iodine reagents, 
with concomitant addition of a nucleophile to afford cyclohexa-2,4- or -2,5-dienone frameworks 
(1.35 or 1.35', Scheme 1-5, top).[9a] In some cases, asymmetric oxidative dearomatization is 
performed using chiral hypervalent iodine reagents.[7c] Owing to its high chemoselectivity, 
oxidative dearomatization of phenols have found various applications in complex settings.[12] In 
2009, Sorensen reported a synthesis of cortistatin A through a cascade sequence triggered by a 
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diastereoselective intramolecular oxidative dearomatization of phenol 1.34a, and subsequent [3+2] 
dipolar cycloaddition between the resulting dienone and nitrile oxide present in the intermediate 
1.36 (Scheme 1-5, bottom).[19] 
 The addition of strong nucleophiles to activated electron-poor arenes, so called 
nucleophilic dearomatization (DNAr), represents another type of dearomatization that utilizes the 
inherent functional groups present on the arene.[6] As shown in Scheme 1-6 top, a variety of 
activated mononuclear and polynuclear arenes are shown to undergo nucleophilic addition with 
ranges of nucleophiles. The reaction mechanism for the addition is similar to conjugate addition, 
with the resulting carbanion being quenched with appropriate electrophiles (1.38–1.41). For 
example, carbon-based nucleophiles used in these processes, such as Grignard reagents or 
organolithium reagents (1.42, 1.43), are usually highly basic. Asymmetric addition of the 
nucleophile has also been reported using chiral organolithium species (1.45, Scheme 1-6, bottom). 
The reactivity mode of the arene exhibited in this process as an electrophile is complementary to 
a Friedel-Crafts reaction, where electron-rich arenes serve as nucleophiles.  
 Although the majority of commonly used dearomative transformations require 
stoichiometric amounts of promoter, catalytic as well as asymmetric versions of such methods 
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have begun to receive significant attention in recent years. The term “Catalytic Asymmetric 
Dearomatization (CADA)” was coined by You in 2012, which describe reactions that convert 
readily accessible aromatic starting materials to alicyclic compounds bearing stereogenic centers 
through asymmetric catalysis.[7] In general, activated arenes such as indoles, phenols, naphthols, 
pyrroles, and aniline derivatives, serve as nucleophiles in this process to afford dearomatized 
compounds. Pioneered by Trost, and later further expanded by You, transition metal-catalyzed 
asymmetric allylic substitution is one of the most explored platforms for the CADA reaction 
(Scheme 1-7, A, 1.47, 1.49).[7b,20,21] Transition metal-catalyzed asymmetric cross-coupling 
reactions have also played a large role in expanding the utility of CADA reactions. Originally 
reported by Buchwald (Scheme 1-7, B, 1.51)[22] and Bedford[23], the scope of electrophile and 
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nucleophile, amenable metal 
catalyst, and modes of catalysis 
have continued to grow. 
Furthermore, formation of 
carbon–heteroatom bonds using 
chiral phosphoric acid-catalyzed 
CADA reactions have been 
reported (Scheme 1-7, C, 1.44).[24] 
As CADA reactions continue to 
exhibit their potentials, the major 
limitation that needs to be overcome is the narrow scope of amenable arenes, which is currently 
limited to activated arenes. Rendering non-activated arenes such as benzene and toluene to be 
applicable substrates would greatly enhance the significance of these transformations, and allow 
for the applications in synthesis. 
 Besides chemical transformations, enzymatic dearomatization has been used in the 
synthesis of complex natural products, most of which utilize the asymmetric arene cis-
dihydroxylation catalyzed by arene dioxygenase enzymes (Scheme 1-8, top, 1.54, 1.55). [7b,25,26] 
Arene-derived cis-diols are highly versatile building blocks in total synthesis, evident by numerous 
applications of arene cis-diols as a starting material. For example, bromobenzene-derived cis-diol 
1.56 offers multiple functional handles for the concise synthesis of Amaryllidaceae alkaloid (+)-
lycoricidine (Scheme 1-8, bottom).[27] 
 Despite the developments and advances made in dearomatization methods described above, 
certain limitations prevent these processes from being versatile. For instance, many of the 
dearomative transformations require harsh reaction conditions to break the aromaticity, as 
evidenced by the use of dissolving metals, high pressure hydrogen atmospheres, stoichiometric 
amounts of highly reactive but extremely toxic metal complexes, and high energy UV light. In 
order to tolerate a variety of sensitive functional groups within the substrates, establishment of 
reactions with much milder conditions are necessary. The dearomatization of activated arenes with 
lower resonance stability such as phenols and indoles can be promoted in milder conditions; 
however, these types of transformations are far from broadly applicable to other non-activated 
arenes. Moreover, although the excellent site-selectivity achieved in dearomatizing an activated 


























aromatic ring within a substrate bearing multiple arenes (both activated and non-activated) are 
useful, processes that realize the opposite selectivity, that is, to selectively dearomatize non-
activated rings would significantly broaden the synthetic toolbox. Furthermore, a majority of 
dearomative transformations do not introduce new functionalities to the resulting alicyclic system 
other than hydrogen or carbon-based groups. Thus, considering the numerous natural products and 
drug compounds possessing heteroatom-functionalities with defined stereogenic center on the six-
membered alicyclic scaffolds, the development of dearomative functionalization processes that 
address the aforementioned shortcomings is of high interest. The use of simple non-activated 
arenes also provides promising and sustainable methods, as many of such chemicals are abundant 
and inexpensive industrial feedstocks.  
 As described in the examples from transition metal-mediated dearomative 
functionalization using non-activated arenes (Scheme 1-3), the key to achieving such a process in 
a chemo-, regio-, and stereoselective fashion is to render the parent arene appropriately activated. 
Such activation must be enough to overcome the chemical inertness of the arene and facilitate the 
desired functionalization, but at the same time not enough to promote undesired side reactions or 
decomposition. Thus, in order to develop a novel and more versatile dearomative functionalization 
methods, establishing transient activation to the arene with a readily accessible and 
environmentally benign compound is advantageous (Scheme 1-9). The arene activated in situ is 
preferentially amenable to different types of transformations, as the resulting alicyclic structures 
with functional and stereochemical diversity are of high value. Overall, the direct conversion of 
simple and abundant planar aromatic feedstocks to complex three-dimensional synthetic building 
blocks with broad functional group compatibility would greatly expand the accessible chemical 
space within the context of dearomative functionalization. 
  





1st step 2nd step
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1.2 Arenophile-mediated dearomatization strategy 
Triazolinediones as dearomatizing agents 
 Although examples for para-cycloaddition between simple arenes and dienophiles are 
scarce, unusual para-photocycloadditions involving arenes and triazolinediones[28] have been 
reported. In 1984, photo-induced para-cycloaddition of N-methyl-1,2,4-triazoline-3,5-dione 
(MTAD, 1.57a) to naphthalene (1.2a) was achieved for the first time by Sheridan via visible-light 
irradiation (1000 W incandescent bulb) to a solution of MTAD and naphthalene in either 
dichloromethane or carbon tetrachloride as a solvent at room temperature for 6 h (Scheme 1-10, 
A).[29,30] This reaction was in fact intended to prepare the [2+2] photo-cycloadduct 1.58 between 
MTAD and naphthalene, which is the expected selectivity of naphthalene towards cycloadditions 
in general. However, the resulting product was para-cycloadduct 1.59 exclusively, and was 
thermally and acid labile (cycloreversion half-life: t1/2 ~ 12 hours at room temperature; t1/2 ~ 45 
min at 40 ºC), but reasonably stable to perform flash chromatography on silica gel to provide ca. 
40% of the pure naphthalene para-cycloadduct 1.59. The scope of the arene was probed, and 
although none of the mononuclear arenes tested provided the cycloadduct (vide infra), 
cycloadducts derived from substituted naphthalene such as 1-methyl-, 2-methyl-, 1-
chloronaphthalene, and ethyl-1-naphthoate were isolated by chromatography (>90% purity by 1H 
NMR analysis of crude mixtures) to give 5,8-photoadducts as single product (for 2- 
























































methylnaphthalene, 1:1 mixture of 5,8- and 1,4-addition was observed).  
 Through mechanistic investigations, Sheridan postulated that the formation of the 
naphthalene cycloadduct 1.59 could proceed via either (or both) singlet or triplet MTAD (1.60, 
1.61), as well as by direct charge-transfer (CT) excitation to 1.62 (Scheme 1-10, B).[29,30] The 
application of the Rehm-Weller equation has shown that the electron transfer from naphthalene to 
1MTAD* is an exergonic process. In addition, the quantum yield of the process showed a strong 
dependence on solvent polarity, which is consistent with photochemical reactions that proceed 
through polarized intermediates.[31] It is worth noting that this visible-light-promoted para-
cycloaddition is mechanistically distinct from the general photocycloaddition of arenes using lights 
in UV ranges (Scheme 1-4). While UV light selectively activates arenes to form a p-p* singlet 
state, visible light having much lower energy is incapable of interacting with arenes, and instead 
photo-excites MTAD to a n-p* state to promotes the dearomative para-cycloaddition. 
 The isolation of a phenanthrene-MTAD para-cycloadduct 1.64 was later reported in 1988 
by Sheridan, where the cycloaddition occurred on the terminal ring, rather than on the activated 
internal ring with ortho-selectivity (Scheme 1-11).[32] The cycloadduct 1.64 was formed along with 
small amounts of products containing two MTAD molecules and one phenanthrene (1.65, both 
diastereomers) when the reaction was conducted in dichloromethane at room temperature for 2 h, 
whereas the cycloadduct 1.64 was generated as a single product when the irradiation was done at 
–65 ºC. Cycloadduct 1.64 was more thermally labile than that of naphthalene, as the cycloreversion 
half-life (t1/2) was about 1 h at room temperature.  









































 The mechanism of this transformation 
was suggested to be a concerted [4+2] 
cycloaddition of excited MTAD to 
phenanthrene, supported by the fact that 
compound 1.67, expected to arise from the 
intermediate 1.66 via a stepwise pathway, was 
not isolated, and that intermediate 1.66 was not 
intercepted with any external nucleophiles 
(Scheme 1-11). Although photochemical [4+2] 
cycloadditions are generally symmetry 
forbidden according to the Woodward–Hoffman rules,[31] it has been proposed that such 
constraints may be relaxed in the case of very polar cycloadditions with substantial charge-transfer 
character.[33,34] Furthermore, unlike typical [4+2] cycloadditions, where the dienes react with their 
LUMO, this reaction proceeds through interaction between the ground-state phenanthrene–HOMO 
and the 1MTAD*–SOMO with proper symmetry overlap at the 1,4-position of the terminal ring, 
ultimately giving rise to unusual periselectivity to afford para-cycloadduct 1.64 (Figure 1-2). 
 Another striking result was reported by Sheridan in 1989, when he succeeded in observing 
benzene-MTAD cycloadduct 1.68 using low-temperature NMR spectroscopy at –40 ºC after 
visible-light irradiation to a solution of benzene (1.1a) and MTAD (1.57a) in deuterated 
chloroform at –60 ºC for several hours (Scheme 1-12).[35] The difficulty associated with analyzing 
benzene-cycloadduct 1.68 is attributed to its thermal instability compared to the polynuclear arene-
cycloadducts; cycloreversion readily proceeds above –10 ºC, and the cycloreversion half-life (t1/2) 
at 0 ºC was about 1 h. Nonetheless, 1H NMR analysis indicated that >80% of MTAD was converted 
to the cycloadduct 1.68. As for the reaction mechanism, the cycloaddition was proposed to be 
concerted; however, application of the Rehm-Weller equation revealed that the electron transfer 
from benzene to 1MTAD* is an endergonic 
process, suggesting that a different 
mechanism may be operative for benzene 
compared to naphthalene and phenanthrene. 
 Compared to the photochemical 
cycloaddition of triazolinediones with 
Figure 1-2: Energy diagram and corresponding 
orbital coefficients of phenanthrene 





Scheme 1-12: para-Photocycloaddition of MTAD 



















arenes, the corresponding thermal 
reactions are scarcely reported.[28] 
In 2000, Breton studied the thermal 
cycloaddition between substituted 
naphthalene (1.2) and MTAD 
(1.57a), and found that the ratio of 
the resulting constitutional isomers 
(1.69 vs. 1.70) changes as the 
reaction proceeds (Table 1-1).[36] 
For example, whereas the reaction 
with 1-methylnaphthalene initially proceeds exclusively at the substituted ring (1.69), the ratio of 
isomers after a long enough reaction time showed that the cycloadduct 1.70 was formed as the 
major isomer with a slightly decreased amount of 1.69 (entry 1). On the other hand, 2-
methylnaphthalene exhibited the complete opposite selectivity, favoring the cycloaddition at the 
non-substituted ring (1.69, entry 3). These results were explained by the reversible nature of the 
cycloaddition process under thermal conditions, which eventually shifts the equilibrium 
predominated by thermodynamic stability of the cycloadducts. The solvent effect was also tested, 
and showed much lower conversion when polar solvents were used (Table 1-1, entries 1–4). This 
was attributed to the superior solvation effect by the polar solvents on MTAD which retarded the 
reaction. The mechanism of the thermal cycloaddition was proposed to be a concerted [4+2] 
cycloaddition. The formation of a charge-transfer complex was also confirmed using UV-vis 
spectroscopy, and although the role of the complex is not entirely clear, the following two 
possibilities were suggested: 1) the charge-transfer complex serves as a fast equilibrium step prior 
to cycloaddition, and 2) the charge-transfer complex only exist as a nonproductive equilibrium 
process independent of the cycloaddition. 
 The lack of examples for thermal [4+2] cycloaddition between triazolinediones and arenes 
may be due to the high reactivity of the triazolinediones with other functionalities under thermal 
conditions. This will be discussed further in the next subsection. 
 As exemplified with above examples, para-cycloaddition between triazolinediones and a 
wide variety of aromatic compounds proceed with high selectivity and efficiency. Notably, the 
unique site-selectivity as well as the periselectivity observed in these processes, where the para-
Table 1-1: Thermal [4+2] cycloaddition of MTAD (1.57a) 
































initial (time) equilibrium (time)
15 / 0 (10 min)
–
9 / 6 (<30 min)
–
10 / 29 (24 h)
<5 / 5 (24 h)
58 / 6 (48 h)








cycloaddition occurs at the least activated terminal ring, is complementary to any other known 
dearomatization reaction that predominantly dearomatize the activated/substituted ring. 
Nonetheless, since most of these prior efforts were focused on isolating the cycloadduct for 
studying the properties of novel azo compounds, accessed via further functional group 
manipulations, the resulting cycloadducts have never received attention as dearomatized arenes 
possessing readily reactive functional groups, such as isolated olefins, capable of undergoing 
further transformations. Considering the high reactivity of such uniquely dearomatized motifs, the 
arene-MTAD cycloadducts (1.59, 1.64, 1.68) may serve as highly potent intermediates towards 
developing novel dearomative functionalization methods where MTAD (1.57a) could be regarded 
as arene activator (Scheme 1-13, see also Scheme 1-9). As these cycloadducts are formed under 
exceptionally mild conditions (room temperature ~ cryogenic temperature, visible light, and no 
additives), this strategy is anticipated to be accommodating of various functional groups. 
Furthermore, by converting the thermally labile cycloadduct formed in situ without isolation, 
highly productive processes can be envisioned, circumventing the unnecessary loss of the 
cycloadduct via decomposition. Lastly, MTAD could also serve as a source of heteroatoms 
incorporated during dearomatization; thus, through subsequent functional group derivatizations, 
the synthesis of highly decorated alicyclic structures could be realized. 
Anticipated limitations from known reactivity of triazolinediones 
 Triazolinediones are highly active compounds that exhibit a wide range of reactivity modes, 
as they are not only photochemically active, but are also well known to be thermally active.[28] For 
example, electrophilic aromatic substitution (SEAr) with relatively electron-rich mononuclear 
arenes to form arylurazoles has been well-documented (Scheme 1-14).[37] Interestingly, although 
the substitution is generally conducted in the absence or the presence of an acid additive, the 
















reaction can be enhanced by irradiation of visible light.[37d] Moreover, for light-promoted reactions,  
substitution can also occur at the benzylic position, presumably through the formation of a radical 
cation intermediate.[37d] On the other hand, pericyclic reactions with triazolinediones 1.57 as  
electrophiles, such as the Ene-reaction, Diels-alder reaction, [2+2] cycloaddition, and homo Diels-
Alder reaction, are often used as convenient means to construct C–N bonds (Scheme 1-15).[28] 
Importantly, the homo Diels-Alder reaction between MTAD (1.57a) and benzene-MTAD 
cycloadduct 1.68 has been observed.[35]  
 Photo-excited triazolinediones 1.57 are also known to react readily with ether to undergo 
C–H abstraction, presumably via initial hydrogen atom abstraction at the position α to the oxygen 
in the ether substrate.[38] Moreover, MTAD (1.57a) itself is also susceptible to unimolecular 
decomposition[39] and polymerization[40] upon irradiation with light.  
 Thus, the reactions described above may work unfavorably for the proposed 
dearomatization strategy in terms of 
amenable substrates and conditions. 
However, regardless of these 
anticipated side reactions, a 
triazolinedione-based dearomative 
strategy has high potential for 
developing novel dearomative 
functionalization reactions that can 
address many of the problems posed 
by currently available methods. 































































































TFA (1 eq.), 62 ºC: 
visible light, rt:
99%, >99:1 (7 h)








 With a view to developing a novel dearomative strategy based on triazolinedione 1.57, 
such para-selective photo-active arene activators were termed arenophiles, in analogy to thermal 
cycloaddition processes.[26,41] Based on Sheridan’s analysis, arenophiles are likely to react with 
arenes through photo-excitation of the arenophile, followed by the formation and collapse of two 
different types of exciplexes: a photo-induced electron-transfer (I) or charge-transfer (II) exciplex 
(Figure 1-3, A). In order for the exciplex formation to occur, the fundamental electronic 
requirement for both HOMO and LUMO energy levels of the arenophiles is to be close enough to 
arene HOMO for the electron transfer to occur effectively (see also Figure 1-2). In addition, the 
HOMO-LUMO gap of the arenophile should be small enough to be photo-excited with visible 
light. To this end, computational analysis (B3LYP/6-311+G(d,p)) was conducted to evaluate 
potential arenophiles for the desired para-photocycloaddition using benzene (1.1a) and 
naphthalene (1.2a) as the standards.[26] Among a variety of triazolinediones examined, MTAD 
(1.57a) was identified to be the optimal arenophile to study, both in terms of having appropriate 
HOMO-LUMO levels, and for the reason of synthetic practicality (Figure 1-3, B).[42]  
  





















































Electronic criteria for discovery of potential arenophiles: 
∑ narrow HOMO–LUMO gap of the arenophile




























Olefin-like functionalization of arene-arenophile cycloadducts 
 The concept of a novel arenophile-based 
dearomative functionalization strategy lies on the 
view that the dearomatized arene intermediates, or 
the cycloadduct, formed in situ, reveal readily 
reactive functional groups capable of undergoing 
further transformations. As an initial investigation, 
the formation of the cycloadduct was recognized as a formal isolation of p-bonds within an 
aromatic starting material, which could potentially be transformed by applying olefin chemistry 
(Scheme 1-16). Accordingly, this hypothesis was first proven by developing arenophile-mediated 
dearomative dihydroxylation, where the resulting disubstituted olefin moieties of a variety of 
cycloadducts were dihydroxylated using a modified Upjohn procedure and Narasaka conditions 
(Scheme 1-17, 1.77, 1.81).[26] The versatility of this method was further demonstrated by the 
elaboration of the arenophile moiety to afford highly functionalized alicyclic structures, such as 
dihydrodiols 1.79, and diaminodiols 1.80 and 1.82.  
 Among other existing olefin-type functionalization, Chapter 2 in this thesis will describe 
the application of a reductive transformation, specifically the hydrogenation.[43] This approach is 
complementary to the oxidative dihydroxylation processes, and is envisioned to enable the 
synthesis of alicyclic structures such as 1,3-cyclohexadienes and diaminocyclohexanes, which are 
highly valuable building blocks from simple arenes.  
Scheme 1-16: Olefin-like functionalization 







































1. N2H4 or KOH;
































then: Raney Ni, H2
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Transition metal-catalyzed dearomative aminofunctionalization 
 As mentioned earlier, the cycloadduct formed in situ is preferentially amenable to different 
types of transformations for the strategy to be highly versatile in delivering functional and 
stereochemical diversity. On the other hand, transition metal catalysis is a robust and reliable 
method for the construction of C–X and C–C bonds in an enantioselective manner with high 
functional group tolerance. Thus, expanding the scope of the arenophile-based dearomative 
strategy to the field of transition metal catalysis would further enable the method to be versatile.  
 Having an acidic urazole functional group allylic to the isolated olefin moiety in the 
cycloadduct structure opens an opportunity for further functionalization through transition metal 
catalysis. That is, the cycloadduct could be regarded as an allylic electrophile, having the same 
scaffold as the typically employed electrophiles shown in Figure 1-4, A. Transition metal-
catalyzed allylic substitution will be the reaction of interest in this thesis, which is well-established 
for a wide array of nucleophiles.[44] In this thesis, such a process will be called arenophile-mediated 
dearomative aminofunctionalization, since this process installs both amine-based functionality 
derived from urazole, and another functional group derived from the nucleophile (Figure 1-4, B). 
Furthermore, since the development of highly efficient and selective methods for the construction 
of new stereogenic centers is one of the paramount importance for continued advancement in 
organic synthesis, the development of dearomative aminofunctionalization in asymmetric fashion 
will be investigated.[45]  
 Relevant examples for transition metal-catalyzed ring-opening reactions using 
heterobicyclic alkene electrophiles exist, and are mostly explored by Lautens. A variety of 
symmetric bicyclic motifs, derived from cycloaddition between heteroarenes (furan or pyrrole) 
and dienophiles (benzyne derivatives, alkynes, and alkenes) were shown to undergo 






































enantioselective desymmetrization with transition metal catalysts to create new C–C as well as C–
heteroatom bonds.[46] As the catalytic cycle is initiated by syn-nucleometallation of metal–Nu 
species to the olefin moiety, followed by the ring-opening event, these processes provide cis-1,2-
relation of the leaving group to the incoming nucleophile, regardless of its nature. These methods 
are highly capable of providing facile accesses to net-cis-1,2-difunctionalized arene. However, if 
these transformations could be achieved directly by dearomatizing simple arenes and 
simultaneously installing functional groups, then the efficiency of the process could be 
significantly improved. 
 Several mechanistic considerations must be taken when applying arene-arenophile 
cycloadduct to metal-catalyzed allylic substitution. In this proposed transformation, the metal 
catalyst is anticipated to react with cycloadduct via oxidative addition to form p–allyl species 1.83, 
and subsequently couple with nucleophiles (Figure 1-4, B). Since the electrophile is a cyclic 
system with one of the C–N bond from urazole leaving group remains attached to the product, 
formation of two constitutional isomers 1.84 and 1.85, as well as two stereoisomers for each of the 
constitutional isomer, could be expected as the resulting aminofunctionalized products. For the 
stereochemical outcome, literature precedents on transition metal-catalyzed allylic substitution 
provide guideline for anticipated stereoselectivity per nucleophile. Palladium-catalyzed allylic 
substitution with cyclic electrophile for example, two distinct mechanisms are depicted in Figure 
1-5, based on the nature of the 
nucleophile.[44,45] While both 
mechanisms begin with p–
coordination of palladium(0) species 
to the electrophile 1.86 anti to its 
leaving group and subsequent 
oxidative addition to afford p–allyl 
palladium complex 1.87, in the case 
of soft nucleophiles (typically pKa < 
25), direct nucleophilic substitution 
through outer-sphere mechanism 
proceeds anti to the metal to give 
palladium(0)-coordinated species 
Figure 1-5: General mechanism for palladium-catalyzed 
allylic substitution. 
[Pd(0)]
R     [Pd]X

























1.88, and finally resulting in the formation of product 1.89 with net-retention (or double-inversion) 
of the configuration in the substitution process. Hard nucleophiles (typically pKa > 25), on the 
contrary, under goes transmetalation to the p–allyl palladium complex 1.87 to form intermediate 
1.90, which then undergoes reductive elimination to afford 1.91 with overall inversion of the 
stereochemistry. As for the formation of constitutional isomers, metal catalysts are expected to 
dictate the fate of substitution site. For example, palladium catalysts are well-known to promote 
allylic substitution at the linear or least hindered end of the p–allyl species, whereas the iridium 
complexes are highly capable of substituting at branched sites.[44,47] Furthermore, owing to its bis-
allylic nature of the intermediate resulting from the oxidative addition, both h3- or h5-complex 
(1.93 or 1.94) may be formed, and this could also affect the regiochemical outcome of the 
substitution.[48] Overall, four constitutional- and stereoisomers could be formed. All potential 
reaction pathways considered, the reaction parameters must be well-controlled for the arenophile-
mediated dearomative aminofunctionalization process to be highly selectivity (Scheme 1-18). 
 When arenophile-mediated dearomative aminofunctionalization was conducted with 
nickel complex as the catalyst in the presence of Grignard reagents as nucleophiles, exclusive 
trans-1,2-selectivity was observed for the product 1.96 with high enantioselectivity (Scheme 1-
19).[49a,49b] This reaction outcome was explained by the formation of h5-nickel cyclohexadienyl 
intermediate (1.95), which then undergo reductive elimination with the carbon nucleophile, via 
inner-sphere mechanism, to deliver trans-1,2-carboaminated compound 1.96. This method was 
Scheme 1-18: Possible products in arenophile-mediated dearomative aminofunctionalization 
















































also successfully applied to the enantioselective total synthesis of isocarbostyrils: pancratistatin, 
7-deoxypancratistatin, narciclasine, lycoricidine, and their analogues (Scheme 1-19).[49a,49c]  
 From Chapter 3 to Chapter 6 in this thesis are dedicated for the exploration of arenophile-
mediated dearomative aminofunctionalization using palladium catalysts, where complementary 
regio- as well as stereoselectivity were observed compared to the nickel catalysis.[41,50,51] Further 
elaboration of the aminofunctionalized products to complex alicyclic compounds with a diverse 
set of functional groups are also discussed in each chapter, which exemplify the novel and facile 
access to such scaffolds that are otherwise tedious or not possible to synthesize using other 
dearomatization reactions. Furthermore, Chapter 7 will briefly cover the mechanistic aspect of the 
palladium-catalyzed dearomative aminofunctionalization, in comparison to typical palladium-
catalyzed allylic substitution processes. 
 
 
Scheme 1-19: Nickel-catalyzed dearomative trans-1,2-carboamination and 
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Chapter 2: Arenophile-Mediated Dearomative Reduction† 
2.1 Background and significance 
 The reductive dearomatization reaction represents one of the fundamental transformations 
in organic synthesis for converting simple aromatic compounds to their alicyclic counterparts 
(Figure 2-1). As mentioned in the introduction, the dissolving metal reduction (Birch reduction) is 
a widely utilized dearomative process to provide 1,4-cyclohexadienes,[11,13] whereas 
hydrogenations with heterogeneous transition metal catalysts are known to fully reduce aromatic 
cores to give saturated cyclohexane derivatives.[7c, 11,15] Although these reactions have been studied 
and used both in academia and industry for decades, harsh conditions generally required for these 
transformations limit their functional group compatibilities. On the other hand, although limited 
in number, examples for partial reduction of arenes exist; osmium-arene or chromium-arene h2-
complexes have been shown to undergo chemoselective partial hydrogenation of the arene 
ligand.[5] Furthermore, enzymatic dearomative processes involving mononuclear arenes have also 
been investigated, and Birch-like reductive enzymatic process which employs Ferredoxin and ATP 
as electron donors have been reported.[52] While these transformations are extremely powerful in 
conducting chemoselective dearomatization, wide applications in organic synthesis have not been 
realized due to toxicity and the cost of precious metals used (osmium and chromium), and the lack 
of easy access to these enzymes in chemical laboratories. Accordingly, despite the significant body 
of research conducted in this area, there are no general and mild methods available to dearomatize 
simple arenes in a reductive manner with high chemoselectivity.  
 The topic described in this chapter is the development of a novel approach for performing 
dearomative reductions on simple non-activated arenes using an arenophile-based dearomative 
strategy (Figure 2-1). Specifically, it is proposed that the isolated olefin functionality revealed in 
the arene–arenophile cycloadduct (1.57a) should be amenable to in situ hydrogenation and 
subsequent cycloreversion, providing 1,3-cyclohexadienes that are highly versatile building blocks 
in synthesis.[53] It is worth mentioning that such site-selective dearomative reduction of a parent 
arene for the synthesis of 1,3-cyclohexadienes has never been achieved in a general sense, as the 
†Portions of this chapter are reproduced from the following publication with permission from the 
authors. M. Okumura, S. M. Nakamata Huynh, J. Pospech, D. Sarlah, Angew. Chem. Int. Ed. 




resulting dienes have much higher reactivity towards reduction under identical conditions. 
Furthermore, by taking advantage of the two nitrogen-functionalities installed onto the 
dearomatized carbocycle during the arenophile-mediated approach, a variety of highly 
functionalized alicyclic compounds could be synthesized efficiently through conversion of the 
arenophile moiety. Thus, this method could provide access to dearomatized compounds that are 
complementary to those obtained by known dearomative reductions.  
2.2 Reaction optimization with benzene 
 To validate the feasibility of performing dearomative reduction of simple arenes through 
an arenophile-mediated dearomatization strategy, benzene (1.1a) was chosen as a model substrate, 
and in situ reduction of the benzene-MTAD cycloadduct (1.68) was attempted. Initially, transition 
metal-catalyzed hydrogenation using both homogeneous and heterogeneous catalysts, such as 
Pd/C and Wilkinson’s catalyst, were examined at cryogenic temperatures; however, no reduced 
products (2.1a or 2.2a) were observed. Next, the use of diimide[54] was considered, since this 
reagent is reported to be capable of engaging olefins at low temperature and has a broad functional 
group compatibility. Thus, it was found that the diimide generated in situ from potassium 
azodicarboxylate and acetic acid under ambient atmosphere effectively promoted the mono-
reduction of the cycloadduct. Accordingly, by performing the cycloaddition of benzene (1.1a) and 
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NH3 (liq.)
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MTAD (1.57a) in ethyl acetate at –78 ºC followed by diimide reduction at –50 ºC for 5 hours, the 
desired product (2.1a) was obtained in 65% isolated yield (Table 2-1, entry 1). It is important to 
note that formation of 2.2a was not observed under these conditions, most likely due to a steric 
effect introduced by the first reduction. The data in Table 2-1 illustrate the impact of reaction 
parameters, which are noteworthy in the transformation. Diimide reduction at lower temperatures 
resulted in a significant decrease in reaction efficiency (entry 2). Although the reactions in 
dichloromethane and propionitrile gave comparable yields, much lower reactivity was observed in 
acetone (entries 3–5). Hydrazine-based generation of diimide[55] was not effective under these 
conditions, presumably due to inefficient formation of diimide at cryogenic temperature (entry 6). 
The use of a stronger acid such as formic acid as proton source gave similar yields, whereas 
trifluoroacetic acid (TFA) was not suitable for this transformation (entry 7–8).  
 
Table 2-1: Optimization of reaction conditions. 
entry deviations from standard conditions yield (%)a 
1 none 65b 
2 diimide reduction at –78 ºC 36 
3 CH2Cl2 was used instead of EtOAc 61b 
4 acetone was used instead of EtOAc 31b 
5 EtCN was used instead of EtOAc 55b 
6 
o-NO2-C6H4-SO2Cl and N2H4•H2O was used instead 
of KO2CN=NCO2K and HOAc 
10 
7 HCO2H was used instead of HOAc 61 
8 TFA was used instead of HOAc 16 
9 10 eq. HOAc was used instead of 15 eq. 26 
10 7.5 eq. benzene (1.1a) was used instead of 10 eq. 49 
11 5.0 eq. benzene (1.1a) was used instead of 10 eq. 31 
12 2.0 eq. KO2CN=NCO2K was used instead of 3.0 eq. 48 
aDetermined by GC analysis relative to an internal standard. bIsolated yield. 
X
MTAD (1.57a, 1.0 eq.)
EtOAc (0.1 M)




–50 ºC, 5 h












Finally, lowering the stoichiometry of the acetic acid, benzene, or the potassium azodicarboxylate 
salt had detrimental effects on the reaction outcome (entry 9–12).  
2.3 Mononuclear arene scope of the arenophile-mediated dearomative reduction 
 With optimized conditions in hand (Table 2-1, entry 1), the scope of the transformation 
with various mononuclear arenes was probed (Table 2-2). A range of mono-substituted arenes 
bearing an alkyl group (2.1b–2.1d), ester (2.1e, 2.1g, 2.1h, 2.1m, 2.1n, 2.1q), protected amine 
(2.1i, 2.1j, 2.1m), epoxide (2.1k, 2.1l), halide (2.1f, 2.1o, 2.1p, 2.1r, 2.1v, 2.1w), acetal (2.1s), 
ketal (2.1t), and orthoester (2.1u) gave the corresponding reduced bicycles in high yields. 
Importantly, substrates with benzylic heteroatom-containing functional groups), which are not 
compatible with most of other dearomatization reactions, were well tolerated in this process (2.1n, 
2.1o, 2.1p, 2.1q, 2.1r, 2.1s, 2.1t, 2.1u. The chemoselectivity of the reduction was highly dependent 






MTAD (1.57a, 1.0 eq.)
EtOAc (0.1 M)




–50 ˚C, 5 h






















2.1o (R=Br): 64% (10:1)




































2.1v (R=Br): 43%c (>20:1)








         68% (10:1)b
2.1h: 67% (7.7:1) 2.1i (R=Boc): 62%c (>20:1)
2.1j (R2=Phth): 62%c,d (>20:1)
2.1m: 72% (>20:1, 1.1:1 dr)
X
R2B







Reaction was run on 1.0 mmol scale. aMeOH was added with AcOH. bReaction was run on gram-scale. cReaction was conducted in 
CH2Cl2 instead of EtOAc. d3.0 eq. of arene was used. eStereochemistry of 2.1x’ was determined by converting to 2.8x’ in Table 2-6 
and conducting structural analysis using 2D NMR. Stereochemistry of 2.1y’ was assigned in analogy to 2.8x’.
X2
2.1k: 46% (>20:1, 1:1 dr)
X






on the nature of the substituent; generally, less bulky substituents gave lower chemoselectivity 
(2.1b, 2.1h). Interestingly, when phenyltrimethylsilane (1.1x) was employed, nearly equal 
mixtures of constitutional isomers were obtained (2.1x, 2.1x’), whereas the reaction with pinacol 
phenylboronate (1.1y) resulted in the reduction of the vinylboronate moiety exclusively to provide 
the boronate ester 2.1y’ as the only product. The diminished chemoselectivity for 
phenyltrimethylsilane (1.1x) may be due to the prolonged C–Si bond length compared to the C–C 
bonds of other substrates that attenuated the steric effect; however, the origin of the high selectivity 
for pinacol phenylboronate (2.1y’) remains unaccounted for when only considering C–B bond 
length and the electronic effects. Nonetheless, this method enables the preparation of a 
stereodefined secondary alkyl boronate ester that is synthetically valuable for elaborating the 
dearomatized product. Finally, this process could be performed on mutigram-scale without a 
significant loss of reactivity, as demonstrated in the preparation of 2.1g (2.0 g, 17.7 mmol of 
MTAD used, 68% isolated yield, 10:1). 
 Substrates bearing multiple mononuclear arenes such as biphenyls (2.3a, 2.3b) and 
phenylpyridines (2.3c–2.3e) were examined to interrogate the site-selectivity of the cycloaddition 
(Scheme 2-1). When biphenyl 2.3a was used, the product with mono-cycloaddition/reduction was 
Scheme 2-1: Scope of the arenophile-mediated dearomative reduction on substrates bearing 













MTAD (1.57a, 1.0 eq.)
EtOAc (0.1 M)






















isolated in low yield (2.4a). On the other hand, the electronically differentiated biphenyl derivative 
2.3b underwent the dearomative reduction on both arenes to provide mixtures of constitutional 
isomers, with slight preference for the more electron-rich phenyl ring (2.4b, 2.5b). It is also worth 
mentioning that the biphenyl 2.3b is currently the only successful disubstituted mononuclear arene 
to successfully undergo such transformation. As for the phenylpiridines, the substitution pattern 
turned out to be important. While 2-phenylpyridine (2.3c) provided the product 2.4c in low yield 
with no formation of 2.5c, 3-phenylpyridine (2.3d) as well as 4-phenylpridine (2.3e) did not 
undergo cycloaddition even after prolonged reaction times. These examples showcase the selective 
nature of the cycloaddition process between the arene and the MTAD arenophile. 
  Although a variety of mononuclear arenes have been shown to be amenable to dearomative 
reduction protocol, several limitations exist owing to the inherent reactivity of MTAD (1.57a) and 
arenes. Compared to n-heptylbenzene and tert-butylbenzene, a much lower yield was observed for 
toluene-derived product 2.1b due to undesired C–H oxidation at the benzylic proton by MTAD 
(1.57a).[37d] For electron-rich arenes, formal electrophilic aromatic substitution products were 
observed instead of the desired dearomative cycloaddition, whereas some substrates with electron-
withdrawing groups did not promote the cycloaddition under optimized conditions (Figure 2-2).[37] 
Olefin-containing arenes are not applicable in this process due to their tendency to undergo an 
Ene-reaction with MTAD, and styrenyl substrates were also not compatible for their known 
reactivity with MTAD.[28]  
2.4 Synthesis of 1,3-cyclohexadienes and 1,4-diaminocyclohexenes through arenophile 
cycloreversion and fragmentation 
 Having achieved access to a wide range of reduced cycloadducts 2.1, conditions to promote 
arenophile cycloreversion were examined to synthesize 2-substituted-1,3-cyclohexadiene 2.6. 
Retro-cycloaddition of MTAD (1.57a) under thermal conditions (>200 ºC) was unsuccessful, and 
Figure 2-2: Examples of unsuccessful substrates under the optimized conditions. 
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only recovered starting material or decomposition were observed by crude 1H NMR analysis. On 
the other hand, hydrolysis of the urazole moiety under basic conditions proceeded smoothly to 
reveal cyclic hydrazine functionality. Subsequently, the resulting cyclic hydrazine was  oxidized 
to a diazine through CuCl2-mediated oxidation,[56] and concomitant loss of molecular nitrogen 
through retro [4+2] cycloaddition afforded the 2-substituted-1,3-cyclohexadiene 2.6. This one-pot 
protocol provided high yields of the corresponding cyclohexadienes 2.6, and a variety of 
representative set of reduced cycloadducts can be found in Table 2-3. While many sensitive 
functional groups were tolerated such as acetal (2.6s), ketal (2.6t), orthoester (2.6u), alkyl chloride 
(2.6f), and silyl groups (2.6x, 2.6x’), esters and amides were hydrolyzed to alcohols (2.6g, 2.6n, 
2.6q), amines (2.6j; isolated after Boc protection), or carboxylic acids (2.6e, 2.6h, 2.7b). Benzylic 
halides were similarly converted to the corresponding isopropoxy ethers (2.6o) through 
nucleophilic substitution. Nonetheless, this protocol is highly scalable without a significant 
decrease in yield; the conversion of reduced product 2.1g to the corresponding 1,3-diene 2.6g 
delivered a 77% yield.  
 In a similar fashion, the fragmentation of the arenophile moiety through one-pot urazole 
hydrolysis/hydrazine protection and subsequent N–N cleavage was examined to prepare 1,4-
diaminocyclohex-2-ene derivatives 2.8. The products formally represent dearomative bis-1,4-  










































Reaction was run on 0.4 mmol scale. Isolated yield shown after flash chromatography. aDetermined by 1H NMR. bReaction was 
run on 3.15 mmol scale. cN2H2 was used instead of KOH, followed by in situ protection with Boc2O.
R
X
R KOH (10 eq.), iPrOH (0.2 M), 100 ˚C;










Table 2-4: Condition screening for the fragmentation of urazole to diaminocyclohexene 2.8d. 
entry hydrolysis conditions protection conditions yield (%)a 
1 KOH, iPrOH BzCl, iPrOH 79 
2 KOH, iPrOH BzCl, iPrOH/H2O 85 
3 KOH, H2O BzCl, H2O <5 
4 KOH, iPrOH CF3CO2Et, Et3N, iPrOH <5 
5 KOH, iPrOH Boc2O, Et3N, DMAP (cat.), iPrOH <5 
aIsolated yield. 
 
hydroamination of the parent arene. Accordingly, 1,4-diaminocyclohex-2-ene 2.8d was 
synthesized in 79% overall yield by conducting the hydrolysis with potassium hydroxide in 2- 
propanol, and cleaving the N-N bond using SmI2 after bis-benzoylation of the resulting cyclic 
hydrazine moiety (Table 2-4, entry 1).[57] Higher yields of 2.8d were obtained by adding solvent 
quantities of water during the benzoylation step for improved solubility (entry 2). Replacing 2-
propanol with water for the hydrolysis step had detrimental effect on the reaction yield (entry 3). 
Introduction of protecting groups other than the benzoyl group were also tested. Although the 
acylations using ethyl trifluoroacetate and Boc-anhydride were successful, the cleavage of the 
resulting hydrazides did not proceed using SmI2 as the reductant (entries 4–5). 
Table 2-5: Condition screening for the diaminocyclohexene synthesis from 2.1p. 
entry hydrolysis conditions yield (%)a 
1 KOH, iPrOH 43 (2.8o: X = OiPr) 
2 KOH, H2O 
no desired product observed 
(X = Cl, OiPr, OtBu, OH) 
3 KOH, tBuOH/H2O 







1) base (10 eq.), solvent (0.3 M), 100 ºC, 12 h; 
    then: acylating reagent, solvent (0.3 M), rt, 8 h











1) base (10 eq.), solvent (0.3 M), 100 ºC, 12 h; 
    then: BzCl (5.0 eq.), solvent/H2O (1:1, 0.15 M)










 When the conditions in Table 2-4, entry 2 were applied to the reduced cycloadduct 2.1p, 
although 43% of the diaminocyclohexene 2.8d was obtained, the benzylic chloride was converted 
to the corresponding isopropoxy ether 2.6o in the hydrolysis step (Table 2-5, entry 1). Thus, to 
find milder hydrolysis conditions, the use of tert-butyl alcohol or potassium tert-butoxide were 
examined instead of potassium hydroxide in 2-propanol. However, in all cases no desired product 
was observed (entries 2–4). 
 To probe the scope of the synthesis of 1,4-diaminocyclohex-2-ene derivative 2.8, a 
representative set of reduced cycloadducts 2.1 were subjected to the arenophile fragmentation 
sequence (Table 2-6). The reaction with benzene-derived product 2.1a and other substrates bearing 
alkyl functional groups (2.1b–2.1d) proceeded smoothly to give the corresponding 1,4-
diaminocyclohex-2-enes (2.8a–2.8d) in high yields. Furthermore, a variety of functionalities were 
tolerated under these conditions, such as alkyl chloride (2.8f), vinyl chloride (2.8v), and silyl 
groups (2.8x, 2.8x’). The stereochemical outcome for 2.8x’ was determined by 2D NMR analysis. 
As was also the case for 1,3-cyclohexadiene derivatives 2.7, esters and amides were hydrolyzed to 
carboxylic acids (2.8e, 2.7h) alcohol (2.6), and amine (2.6j; isolated as benzoyl amide).  
























































1) KOH (10 eq.), iPrOH (0.3 M), 100 ˚C;
    then BzCl (5 eq.), rt
2) SmI2 (2.5 eq.), MeOH (0.1 M),  0 ˚C to rt
2.1
2.8




















2.5 Application of hydrogen-atom-transfer (HAT) reaction to reduced cycloadducts 2.1 
 In order to further functionalize the tri-substituted olefin moiety present in the reduced 
cycloadduct 2.1, transformations based on transition metal-catalyzed hydrogen-atom-transfer 
(HAT) reactions were investigated.[58] It was proposed that the tertiary carbon radical formed via 
hydrometallation of the in situ-formed metal hydride could either be captured with a radical 
acceptor (R’) to achieve hydrofunctionalization (2.9), or undergo b-elimination of the urazole 
moiety to give 1-aminocyclohex-3-ene 2.10 (Scheme 2-2). When Mn(dpm)3 was employed as a 
catalyst in a ethyl acetate/2-propanol solvent mixture, Ph(iPrO)SiH2[59] gave the highest 
conversion among all other silane-based reductants examined (Table 2-7, entries 1–3). The major 
product obtained in these reactions was 1-amino-cyclohex-3-ene 2.10d, along with the over-
reduced product 2.11d. Importantly, hydrogenated product 2.9d was not detected, which implies 
that the b-elimination of the resulting tertiary carbon radical species is faster than a second C–H 
bond formation. Improvements in yields as well as product selectivity between 2.10d and 2.11d 
were observed when the reaction was conducted in only 2-propanol (entry 4). The addition of 
TBHP as an additive to facilitate the regeneration of the catalyst proved unsatisfactory (entry 5). 
Fe(III)-based catalysts were also screened, and it was found that Fe(dmp)3 gave much higher 
product selectivity, albeit with compromised yield due to slow conversion (entries 6–9). The use 
of Fe(acac)3 had detrimental effect on the product selectivity, presumably because the rate of the 
second reduction with this catalyst is much faster than it is for Mn(dpm)3 (entries 10–11). Finally, 
Co(acac)2 did not provide any desired product (entry 12). It is important to note that in all cases, 
increase in the amount of silane had some positive effect in promoting the conversion, but at the 















[M] (M = Fe, Co, Mn)
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Scheme 2-2: Derivatization of reduced cycloadduct 2.1 through metal-catalyzed HAT reactions. 
32 
 
Table 2-7: Condition optimization for HAT reduction of 2.1d.  






1d Mn(dpm)3 PhSiH3 – EtOAc/iPrOH  >95 – – 
2d Mn(dpm)3 Et3SiH – EtOAc/iPrOH – 20 2.1:1 
3 Mn(dpm)3 Ph(iPrO)SiH2 – EtOAc/iPrOH 40 40 2.5:1 
4 Mn(dpm)3 Ph(iPrO)SiH2 – iPrOH 47 49 7.1:1 
5 Mn(dpm)3 Ph(iPrO)SiH2 TBHP  iPrOH 32 44 5.6:1 
6 Fe(dpm)3 
Ph(iPrO)SiH2 
– iPrOH 62 34 14:1 
7 Fe(dpm)3 – EtOAc/iPrOH 77 21 >20:1 
8 Fe(dpm)3 – CH2Cl2/iPrOH 78 22 >20:1 





50 50 1.4:1 
11 Fe(acac)3 TBHP 58 33 1.7:1 
12 Co(acac)2 Ph(iPrO)SiH2 TBHP iPrOH >95 – – 
aDetermined by crude 1H NMR analysis. bIsolated yield.  
 
 At this point, the scope of HAT hydrogenation with a representative set of reduced 
cycloadducts 2.1 was tested (Table 2-8). Although the yield was moderate, high selectivity for 













































2.10d: 49% (7.1:1) 2.10g: 39% (6.7:1)
AcO 2
NUR
Reaction was run on 0.2 mmol scale. Isolated yield shown after flash chromatography. Ratio of 2.10 




2.6 Elaboration of dearomatized products derived from nheptylbenzene 
 Compounds obtained by arenophile-mediated dearomative reduction and subsequent 
arenophile conversion could be subjected to synthetic manipulations to provide access to a diverse 
set of highly functionalized cyclohexanes. Specifically, various olefin functionalization methods 
were tested to convert the tri-substituted olefin moiety in 2.8c. Through catalytic hydrogenation 
using Mn(dpm)3 as a catalyst and Ph(iPrO)SiH2 as a reductant,[58] full conversion was observed with 
no diastereoselectivity (Table 2-9, entry 1). This is presumably due to the scarce difference in 
conformational energy between the two possible tertiary carbon radical intermediates. On the other 
hand, the use of Pd/C under a hydrogen atmosphere provided much higher selectivity for 2.12, and 
this could be explained by a directing effect from one or both amide moieties (entry 2). 
 Cyclohexene 2.8c was also amenable to oxidative transformations. Both osmium-catalyzed 
dihydroxylation and mCPBA epoxidation proceeded smoothly to give diol 2.13 and epoxide 2.14 
in high yields (Scheme 2-3). The stereoselectivity for dihydroxylation could be explained by the 
catalyst approaching from less hindered face, whereas the epoxidation reaction seems to be 
directed by the benzamide groups. Moreover, installation of a tertiary alcohol was achieved using 
Co(III)-catalyzed Mukaiyama hydration,[60] giving a single diastereomer as the product. Finally, 
reductive olefin coupling with methyl acrylate using Fe(acac)3 as a catalyst and Ph(iPrO)SiH2 as a 
reductant[61] was effective in installing an all-carbon quaternary center, although with poor 
diastereoselectivity. 
 
Table 2-9: Catalytic hydrogenation of 2.8c. 
entry conditions conv.a 2.12 :2.12’a 
1 
Mn(dpm)3 (10 mol%), Ph(iPrO)SiH2 
TBHP, iPrOH, rt, 20 h 
full 1.4:1 
2 
Pd/C (5.0 mol%), H2 (1 atm) 
MeOH, 50 ºC, 30 h 
full (98)b 5.5:1 

































































































































then: Raney Ni, H2 (1 atm)
EtOAc (0.2 M)
50 ºC, 8 h
Reaction was run on 1.0 mmol scale. Isolated yield shown after flash chromatography. aReaction was run on a gram-scale.
RR
MTAD (1.57a, 1.0 eq.)
EtOAc (0.1 M)











2.18a 2.18b 2.18c 2.18d
2.18e 2.18f 2.18h 2.18i2.18g
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2.7 Polynuclear arene scope of the arenophile-mediated dearomative reduction 
 Polynuclear arenes could also be employed in the arenophile-mediated dearomative 
reduction, and through subsequent conversion of the arenophile moiety, net dearomative bis-1,4-
hydroamination of the parent arene was achieved (Table 2-10). Thus, subjecting the reduced 
cycloadducts 2.17 to hydrazinolysis[62] followed by N–N bond cleavage using catalytic amounts 
of Raney Ni[63] effectively provided the diamine 2.18 from a variety of polynuclear arenes 
including naphthalene derivatives (2.18a, 2.18b, 2.18c) and phenanthrene (2.18d). Notably, 
heteroarenes such as quinoline (2.18e, 2.18f), quinoxaline (2.18g), acridine (2.18h), and 
benzo[h]quinoline (2.18i) gave high yields of the reduced cycloadducts 2.17 as well as diamines 
2.18. Furthermore, sensitive functional groups such as a benzylic ketal (2.18b) and aryl bromide 
(2.18f) were tolerated under the optimized conditions. Lastly, the dearomative reduction of 
naphthalene could also be performed in a preparative scale, as demonstrated with the high yield 
obtained using naphthalene (1.13 g, 10.0 mmol of MTAD) as the substrate (2.18a). Although the 
dearomative reduction with most of the polynuclear arenes proceeded smoothly at the non-
substituted terminal aromatic ring, some of the substrates suffered from poor chemoselectivity in 
the cycloaddition step. As exemplified with 1-bromonaphthalene (1.2j), MTAD cycloaddition 
occurred at both sides of the aromatic rings with higher preference for the non-substituted side. 
Subsequent diimide reduction gave mixtures of the products 2.17j and 2.17j’ (Scheme 2-4).[36] 
Nonetheless, most of the known dearomatization methods proceed site-selectively at more 
substituted phenyl ring or the heteroarene, this dearomative reduction method offers a 
complementary way to dearomatize and functionalize the same polynuclear arenes at the least 
activated terminal benzene ring.  
2.8 Elaboration of dearomatized products derived from naphthalene  
 Elaboration of the naphthalene-derived reduced cycloadduct 2.18a was attempted through 
arenophile hydrolysis using hydrazine and subsequent substitution of the resulting cyclic hydrazine 




MTAD (1.46a, 1.0 eq.)
EtOAc (0.1 M)












with other functionalities. Thus, upon treating the hydrazine 2.20 with molecular oxygen and DBU,  
g-hydroxytetralone 2.19 was isolated in 52% overall yield (Scheme 2-5). Mechanistically, the 
reaction is thought to first undergo aerobic oxidation of the cyclic hydrazine moiety in 2.20, which 
spontaneously liberates molecular nitrogen, and in situ generates either diradical 2.21 or ortho-
quinodimethane 2.22.[64] In turn, this transient intermediate reacts with molecular oxygen to form 
endoperoxide 2.23 and subsequent in situ Kornblum-DeLaMare rearrangement[65] with DBU as a 
base affords g-hydroxytetralone 2.19. Notably, these two one-pot reactions convert readily 
available naphthalene that to a valuable bioactive natural product 2.19.[66] Similarly, the hydrazine 
oxidation could be performed with nitrosobenzene that generates the same intermediate 2.21 or 
2.22, which could be trapped with the nitrosobenzene, followed by N–O bond cleavage, to give 
aminoalcohol 2.24 (Scheme 2-6). 
2.9 Conclusion  
 A novel strategy for the formal dearomative reduction of simple arenes utilizing arene-
arenophile cycloadducts, derived from both mononuclear and polynuclear aromatic compounds 




1. N2H4 (20 eq.), 100 ºC, 12 h;
    then: PhNO (3.0 eq.), THF (0.2 M), 60 ºC, 30 min.




Scheme 2-6: Conversion of naphthalene-derived cycloadduct 2.18a to aminoalcohol 2.24. 
 




N2H4 (20 eq.), 100 ºC, 8 h















2.20 2.21 2.22 2.23
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successfully reduced by diimide, formed in situ from potassium azodicarboxylate in the presence 
of proton source, and subsequent arenophile cycloreversion and fragmentation enabled rapid 
access to 2-substituted-1,3-cyclohexadienes 2.6, 1,4-diaminocyclohexene derivatives 2.8, 3-
aminocyclohexenes 2.10, and 1,4-diamino-tetrahydronaphthalene derivatives 2.18. Compared to 
known dearomatization reactions, superior functional group tolerance was observed in these 
processes owing to its mild conditions, and the method provide products that are orthogonal to or 
inaccessible by those established dearomative transformations.  
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Chapter 3: Palladium-Catalyzed Dearomative syn-1,4-Carboamination with 
Enolates† 
3.1 Background and significance 
 A dearomative transformation that introduce functional groups other than hydrogen to the 
dearomatized arene core in a one-pot operation could allow facile access to complex molecules. 
Although limited in examples, dearomative alkylation of non-activated arenes are known, both in 
stoichiometric and catalytic reactions. For instance, reductive alkylation mediated by single 
electron reduction, such as the Birch reduction conditions, allows dearomatization and subsequent 
alkylation of the resulting carbanion intermediate with an appropriate electrophile in a one-pot 
procedure (Scheme 3-1, A).[11,13] However, due to harsh reaction conditions, these protocols are 
only applicable to a limited number of simple aromatic compounds bearing strong electron-
withdrawing groups, such as carboxyl group, or polynuclear arenes with poor functional group 
compatibility. Nucleophilic dearomatization (DNAr) is another enabling dearomative alkylation 
method, although similar constrains in viable substrates exist as do in the Birch reduction (Scheme 
3-1, B, see also Scheme 1-6).[6] On the other hand, in 2008 Yamamoto showed the coupling of p-
†Portions of this chapter are reproduced from the following publication with permission from the 
authors. M. Okumura, A. S. Shved, D. Sarlah, J. Am. Chem. Soc. 2017, 139, 17787.[50] 
 
Scheme 3-1: (A) General reaction scheme for reductive alkylation through single 
electron reduction. (B) Nucleophilic dearomatization (DNAr). (C) Palladium-catalyzed 









(C) Pd-catalyzed dearomative allylic alkylation
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[M] = [Sn], [B]
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benzyl palladium complexes, formed by reacting benzyl chlorides with Pd(0) complexes, with allyl 
stannanes as the first example of palladium-catalyzed dearomative alkylation. This demonstrated 
the feasibility of using simple arenes bearing a benzylic leaving group as electrophiles in such a 
process (Scheme 3-1, c).[67] Later, the scope of this process was expanded to include benzylic 
leaving groups other than chloride as well as activated C-nucleophiles such as malonates;[68] 
however, the necessity for using arenes with a benzylic leaving group for the formation of the p-
benzyl palladium complex narrows the substrate scope of this method. Thus, dearomatization of a 
non-activated arene and concomitant alkylation is still an unsolved challenge facing organic 
chemists. 
 In order to expand the utility of simple and non-activated arenes in a dearomative alkylation, 
a more versatile and mild activation toward dearomatization is desirable. To this end, application 
of an arenophile-mediated dearomatization strategy was envisioned such that an appropriate metal 
catalyst could oxidatively add to the arene-arenophile cycloadduct to form a p-allyl metal complex, 
which can then undergo substitution with an alkyl-nucleophile (Scheme 3-2). As mentioned in 
introduction, two possible mechanisms for the nucleophilic substitution step exist depending on 
the soft/hard nature of the nucleophile; soft/stabilized nucleophiles (pKa<25, DMSO) are known 
to proceed through double inversion/net retention of the configuration, whereas hard/non-
stabilized nucleophiles (pKa>25, DMSO) directly attach to the metal center and undergo reductive 
elimination, leading to an overall inversion of the stereochemistry (Figure 1-5).[44,45] Together with 
two possibilities in regiochemical outcome of the substitution step in cyclic system, four isomeric 
products were expected to form in this transformation (Scheme 3-2). Nonetheless, developing such 
method in highly selective manner would significantly expand the toolbox of synthetic organic 
chemistry. 



























 Since its discovery by Tsuji in 1965 in stoichiometric fashion,[69] the reaction of p-allyl 
palladium complexes with alkyl-nucleophiles has played a significant role in constructing C–C 
bonds. Pioneered by Trost and others, the past few decades have witnessed tremendous 
advancements both in catalytic and enantioselective versions of such transformations with high 
regio- and stereoselectivity, as well as functional group tolerance.[44,45] Although the palladium-
catalyzed allylic alkylations in their early development focused on stabilized carbanions such as 
malonates and b-ketoesters, the use of non-stabilized enolates have gained much attention in a past 
two decades.[70,71] One major problem for employing non-stabilized enolates is the propensity of 
the mono-alkylated product to undergo over-alkylation due to an equilibrium established between 
the enolate of the product and the starting material. Nonetheless, many successes in employing 
such enolates have been reported for mono-alkylation with high regio- and stereoselectivity, first 
by using tin-[72] and boron-enolates,[73] and later with lithium-enolates[74] as well as silyl enol 
ethers.[75]  
 In this regard, the topic of this chapter will describe the endeavor towards integrating the 
palladium-catalyzed allylic alkylation with the arenophile-mediated dearomatization strategy to 
develop a palladium-catalyzed dearomative carboamination protocol for simple, non-activated 
arenes. It was hypothesized that the proper tuning of reaction conditions would enable selective 
formation of one of the four possible products. Moreover, the use of chiral ligand with meso-
cycloadducts should promote a desymmetrization reaction, resulting in an enantioselective 
dearomative functionalization. The products obtained from the palladium-catalyzed dearomative 
carboamination should also be amenable to further elaborations for the facile access to highly 
functionalized motifs. 
3.2 Reaction optimization with naphthalene 
 Naphthalene-MTAD cycloadduct 1.59 was chosen as a model substrate to test the 
feasibility of a palladium-catalyzed dearomative carboamination. Thus, the cycloadduct prepared 
in situ in dichloromethane was subjected to alkyl nucleophiles in the presence of 
tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4) as a catalyst, and stirred for 5 hours at –30 
ºC. When activated nucleophiles such as diethyl malonate and Meldrum’s acid were used together 
with triethylamine as a base, no desired dearomatized product was obtained, and only unreacted  
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Table 3-1: Initial screening of alkyl nucleophiles. 
entry nucleophile additivea result 
1 
 






24% isolated as the 
only product.b 
aAdditive was pre-mixed with nucleophile in THF before the addition to cycloadduct. bNo other constitutional- 
and stereoisomers were observed in crude 1H NMR analysis. 
 
cycloadduct was observed by crude 1H NMR analysis (Table 3-1, entry 1). On the other hand, a 
substitution with an acetophenone-derived Li-enolate, prepared by pre-mixing acetophenone and 
lithium diisopropylamide (LDA) in tetrahydrofuran, proceeded smoothly to provide 24% of the 
syn-1,4-carboaminated compound 3.1a as the sole product (entry 2, see Figure 3-1 for x-ray 
structure). It is worth mentioning that no other constitutional- and stereoisomer were detected by 
crude 1H NMR analysis upon acidic quench and aqueous workup, and the rest of the mass balance 
was either unreacted or decomposed cycloadduct. As ketone enolates are known to undergo 
substitution with both outer-sphere and inner-sphere substitution mechanisms depending on the 
reaction conditions, based on the above reaction outcome, the plausible mechanism of this process 
is the former with net retention of the stereochemistry. 
 With an initial result in hand, condition optimization was carried out using naphthalene 
and acetophenone as substrates. First, the palladium source was examined using 
triphenylphosphine as a ligand (Table 3-2). Of all the palladium precatalysts tested, only 
bis(dibenzylideneacetone)palladium (0) (Pd(dba)2) gave a comparable result to Pd(PPh3)4 (entries 




















then: alkyl nucleophile (2.0 eq.)
additive (2.0 eq.)
Pd(PPh3)4 (5 mol%)
CH2Cl2/THF, –30 ºC, 5 h
MTAD (1.57a, 1.0 eq.)








Table 3-2: Screening of palladium source.  
entry [Pd] ligand yield (%)a 
1 Pd(PPh3)4 – (24) 
2 [Pd(allyl)Cl]2 PPh3 <5 
3 Pd(OAc)2 PPh3 <5 
4 Pd(dba)2 PPh3 29 
aDetermined by 1H NMR analysis. Isolated yield shown in parenthesis. 
 
Table 3-3: Screening of ligand. 
entry ligand yield (%)a 
1b PPh3 29 
2b P(p-MeOC6H4)3 48 
3b P(p-FC6H4)3 <5 
4 dppm <5 
5 dppe 25 
6 dppp 30 
7 dppb 72 
8 dpppe <5 
9 dpphex <5 
10 dppBen 71 
11 dppf 53 
12 rac-BINAP 65c 
13 Xantphos <5 







then: p-methoxyacetophenone (2.0 eq.)
LDA (1.9 eq.)
[Pd] (5.0 mol%), PPh3 (12 mol%)
CH2Cl2/THF, –30 ºC, 5 h
MTAD (1.57a, 1.0 eq.)











then: p-methoxyacetophenone (2.0 eq.)
LDA (1.9 eq.)
Pd(dba)2 (5.0 mol%), ligand (6.0 mol%)
CH2Cl2/THF, –30 ºC, 5 h
MTAD (1.57a, 1.0 eq.)








Table 3-4: Base screening.  
entry base yield (%)a 
1 LDA 72 
2 LiTMP 44 
3 LiHMDS 58 
4 NaHMDS 59 
5 KHMDS <5 
aDetermined by 1H NMR analysis. 
 
 When the electronic effect of monodentate phosphine ligands was probed, electron-rich 
P(p-MeOC6H4)3 gave a much higher yield of the desired product 3.1a compared to the electron-
poor P(p-FC6H4)3 (Table 3-3, entries 1–3). On the other hand, a variety of bidentate ligands such 
as diphenylphosphinobutane (dppb), diphenylphosphinobenzene (dppBen), diphenyl-
phosphinoferrocene (dppf), and rac-2,2-bis(diphenylphosphino)-1,1’-binaphthyl (BINAP) 
provided high yields of 3.1a, with dppb giving the highest yield among all the ligand tested (entries 
4–13). Since some unreacted cycloadduct remained after workup, further optimization of other 
parameters was continued to improve the conversion. 
 Next, the effect of base, as well as the countercation for the metal enolate, were examined 
(Table 3-4). For three lithium-amides tested, LDA gave the highest yield (entries 1–3). Comparing 
the countercation effect using metal bis(trimethylsilyl)amide (MHMDS) showed that although Li- 
and NaHMDS gave comparable outcomes, enolate formed with KHMDS did not promote the 
reaction (entries 3–5). Thus, LDA was chosen as the optimal base. 
 The temperature effect on the substitution step was also investigated, and it was found that 
increasing the temperature from –30 ºC to –10 ºC had detrimental effect on the reaction outcome 
(Table 3-5, entries 1–2). In this case, since no unreacted cycloadduct was observed after the 
reaction, cycloreversion likely competed with the desired pathway. As expected, conducting the 







then: p-methoxyacetophenone (2.0 eq.)
base (1.9 eq.)
Pd(dba)2 (5.0 mol%), dppb (6.0 mol%)
CH2Cl2/THF, –30 ºC, 5 h
MTAD (1.57a, 1.0 eq.)








Table 3-5: Temperature, solvent, and stoichiometry screening.  
entry [Pd] (mol%) solvent temp. (ºC) yield (%)a 
1 5.0 CH2Cl2 –30 72 
2 5.0 CH2Cl2 –10 47 
3 5.0 CH2Cl2 –50 43 
4 5.0 EtOAc –30 <5 
5 5.0 EtCN –30 85 
6 2.5 EtCN –30 64 
7 2.5 EtCN –50 to 0 91 (92) 
8 1.0 EtCN –50 to 0 66 
9 2.5 EtCN –50 to 0 82b 
10 2.5 EtCN –50 to 0 85c 
11 0 EtCN –50 to 0 <5 
aDetermined by 1H NMR analysis. Isolated yield shown in parenthesis. b1.4 eq. of 
enolate used. c1.5 eq. of naphthalene used. 
 
yield of unreacted cycloadduct: 55%, yield of 3.1a: 43%; measure by crude 1H NMR analysis). 
Solvent, however, had a profound effect in promoting the conversion. Although the use of ethyl 
acetate gave no desired product 3.1a, when it was replaced with propionitrile, 85% of 3.1a was 
obtained (entries 4–5). Lowering the catalyst loading to 2.5 mol% decreased the conversion; 
however, slowly warming up the reaction mixture for the substitution step from –50 ºC to 0 ºC, 
instead of keeping it at –30 ºC, improved the reaction outcome to give 92% isolated yield of 3.1a 
(entries 6–7). Finally, catalyst loading, amount of enolate, and naphthalene were examined, and 
concluded the conditions in entry 7 provided optimal (entries 8–11). 
 Several observations are worth noting. During the optimization, syn-1,4-carboaminated 
product 3.1a was observed as a single constitutional- and stereoisomer, regardless of the choice of 
ligand or solvent. Furthermore, the catalyst loading and the reaction temperature for the 
substitution step had no effect on the regio- and stereochemical outcome, and only impacted the 







then: p-methoxyacetophenone (2.0 eq.)
LDA (1.9 eq.)
Pd(dba)2 (x mol%), dppb (1.2x mol%)
solvent/THF, temp., 5 h
MTAD (1.57a, 1.0 eq.)








from previously reported palladium-catalyzed allylic substitution reactions; the nature of the 
ligands and solvents have no significant effect in changing the selectivity.[76] This could be due to 
the effects from the urazole leaving group, which remained attached to the dearomatized 
carbocycle; however, exact details of the effect are elusive at this point. Nonetheless, the ability of 
MTAD-mediated dearomative carboamination with palladium catalyst to deliver a product as a 
single constitutional- and stereoisomer is significant, and highly practical for the preparation of 
compounds that are otherwise not possible to synthesize through known dearomatization methods. 
3.3 Enolate scope of the dearomative syn-1,4-carboamination 
 Having found the optimal conditions, the scope of this process using different ketones was 
investigated (Table 3-6, top). A variety of aromatic ketones both with electron-donating and 
electron-withdrawing functional groups provided high yields of the carboaminated products (3.1a-
g). This transformation was also not sensitive to the steric effects of the arene, as exemplified by 







then: ketone or ester (2.0 eq.), LDA (1.9 eq.)
Pd(dba)2 (2.5 mol%), dppb (3.0 mol%)
EtCN/THF, –50 to 0 ºC, 5 h
MTAD (1.57a, 1.0 eq.)






(±)-3.1a (R = p-OMe):
(±)-3.1b (R = H):
(±)-3.1c (R = p-I):
(±)-3.1d (R = p-Br):
(±)-3.1e (R = p-Cl):
(±)-3.1f (R = p-CF3):
(±)-3.1g (R = o-Me):
(±)-3.1j: 86%a
O
(±)-3.1q (n=1): 78% (dr=1.2:1)
(±)-3.1r (n=2): 82% (dr=2.6:1)
(±)-3.1s (n=3): 64% (dr=10:1)e




























































Reaction was run on 1.0 mmol scale. Isolated yield shown after flash chromatography. Dr was determined by crude 1H NMR 
analysis. aSubstitution step was run at –30 ºC for 12 h. bReaction was run on a gram-scale. cReaction was conducted in CH2Cl2 
instead of EtCN, and with LiCl as an additive. dPd(dba)2/rac-BINAP (5.0/6.0 mol%) was used. eRelative stereochemistry was 




o-methylacetophenone (3.1g). Moreover, acetophenone derivatives bearing halogens at para 
positions were amenable to the process, providing functional handles (3.1c-e). An a-branched 
enolate prepared from propiophenone gave high yields of the product 3.1h with high 
diastereoselectivity at the a-stereogenic center (relative stereochemistry confirmed by x-ray 
analysis, see Figure 3-1), and the formation of an all-carbon quaternary stereogenic center was 
accomplished using isopropyl phenyl ketone (3.1i). Furthermore, reactions using enolates derived 
from ketones bearing polynuclear or heteronuclear arenes, such as naphthophenone (3.1j) and 2-
acetylfuran (3.1k), proceeded smoothly. 
 In addition to aromatic ketones, acyclic and cyclic aliphatic ketones could be incorporated. 
For example, enolates prepared from butanone, acyclic aliphatic ketones bearing an alkene or 
protected hydroxyl group, and other alkyl groups effectively underwent carboamination (3.1l-p). 
The gram-scale synthesis of 3.1o was achieved using the same protocol, without much loss of 
reactivity. Likewise, cyclic ketones with a wide range of ring sizes were amenable to this 
transformation, although the diastereoselectivity was highly dependent on the ring size (3.1q-t). 
For the product synthesized with cycloheptanone (3.1s) or cyclooctanone (3.1t), the major 
diastereoisomer was isolated by recrystallization, and the relative stereochemistry was 
unambiguously determined by x-ray analysis (Figure 3-1).  








 Using the conditions optimized for ketone enolates, the applicability of ester enolates was 
also tested (Table 3-6, bottom). For activated esters, such as a-phenyl ethyl acetate (3.1u) and 
benzophenone-protected glycine-ester (3.1v), the corresponding carboaminated products were 
obtained in high yield and high diastereoselectivity. The relative stereochemistry of the major 
isomer was unambiguously determined by x-ray analysis for each product, revealing opposite 
stereochemistry at a-carbon of the ester (Figure 3-1). This could be explained by chelation control 
in the glycine ester Li-enolate which changes the configuration of the enolate formed; kinetic 
enolates were formed for propiophenone and a-phenyl ethyl acetate using LDA at –78 ºC in THF, 
whereas the chelation control provided the thermodynamic enolate for benzophenone-protected 
glycine-ester under identical conditions (Figure 3-2).[70,77] While sterically hindered esters such as 
methyl isobutylate (3.1w) and methyl cyclohexylcarboxylate (3.1x) worked well, no 
carboaminated product was obtained using tert-butyl acetate (3.1y) under the optimized conditions. 
This is presumably due to similar pKa values of tert-butyl acetate (30.3 in DMSO) and propionitrile 
(32.5 in DMSO), which resulted in the undesired deprotonation of propionitrile by the ester enolate. 
Thus, the solvent was changed to dichloromethane, and after conducting additional screening, the 
use Pd(dba)2 with rac-BINAP as a catalyst and LiCl as an additive provided 55% of the desired 
product 3.1y.  
 While many of ketones and esters were amenable to dearomative carboamination reaction, 
limitations of the enolate nucleophile exist (Figure 3-3). For example, lactones, amides with a 
variety of functional groups on nitrogen atom, acetonitrile, and nitromethane were not applicable 
under the optimized conditions. The use of dichloromethane as a solvent, instead of propionitrile, 
was examined in all cases; however, no desired carboaminated compound was observed.  
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 Next, the scope of polynuclear arene was investigated using p-methoxyacetophenone as an 
enolate source (Table 3-7). Naphthalene derivatives with both symmetrical (3.2–3.4) and 
unsymmetrical substituents (3.5–3.10) proved viable substrates, albeit with the unsymmetrical 
arenes giving mixtures of constitutional isomers with varying ratios resulting from ring-opening 
at both sites of the arene-arenophile cycloadducts. In general, the major constitutional isomers 
exhibited urazole on the same side as the arene substituent, which may be due to the preference of 
the palladium complex on the p-allyl palladium species to be at the most remote site from the arene 
substituent. On the other hand, the carboamination with phenanthrene (3.11) and 
benzo[h]quinoline (3.12) proceeded in moderate yield and with diminished selectivity. It is worth 
mentioning that this process displayed broad functional group 
compatibility, as well as insensitivity to the electronic property of 
the substituents. Furthermore, a gram-scale reaction was conducted 
using 2,3-bis(pivaloyl)naphthalene, and 52% of the desired product 
3.4 was obtained.  
 Lastly, the use of benzene as a substrate was examined 
(Table 3-8). The conditions optimized for naphthalene were 
Figure 3-4: X-ray of 3.13a. 
Table 3-7: Scope of polynuclear arene. 
Reaction was run on 1.0 mmol scale. Isolated yield shown after flash chromatography. Ratio of constitutional isomers was 
determined by crude 1H NMR analysis, and major isomer shown in the table. Unless otherwise stated, two isomers were column 









PPh2then: p-methoxyacetophenone (2.0 eq.)
LDA (1.9 eq.)
Pd(dba)2 (5.0 mol%), dppb (6.0 mol%)
EtCN/THF, –50 to 0 ºC, 5 h
MTAD (1.57a, 1.0 eq.)


























(±)-3.6 (R = p-CF3C6H4):
(±)-3.7 (R = OPiv):
(±)-3.8 (R = CF3):



















applicable, except that cycloaddition was conducted at –78 ºC and the substitution step was carried 
out at –30 ºC for 12 hours. Representative ketone and ester enolates were successfully employed 
to give high yield of the carboaminated products (3.13a-d). The relative stereochemistry of 3.13a 
was confirmed by x-ray analysis to have syn-1,4-selectivity, which is identical to the selectivity 
observed for naphthalene-based products (Figure 3-4). In addition, mono-substituted benzene 
derivatives were tested. It was found that whereas n-heptylbenzene (3.14) gave a single 
constitutional isomer as the sole product, poor selectivity was observed for phenyltrimethylsilane 
(3.15). Other mono-substituted mononuclear arenes examined, such as tert-butylbenzene and 
benzyl acetate which had worked well for dearomative reduction, but did not provide the desired 
carboaminated product.  
3.4 Development of asymmetric variants for dearomative syn-1,4-carboamination 
 An asymmetric version of the palladium-catalyzed dearomative syn-1,4-carboamination 
on the meso-cycloadduct would enable a desymmetrization reaction. Thus, screening for an 
appropriate chiral ligand was conducted using naphthalene and p-methoxyacetophenone as model 
substrates. All conditions other than ligand were kept identical to the racemic version, and a wide 
range of chiral ligand classes were tested (Table 3-9). (S,S)-BDPP (L1), which is similar structure 
to dppb, afforded a high yield of the desired product 3.1a, albeit with low enantioselectivity (entry 
1). Likewise, the BINAP ligands (L2, L3) tested gave improved, but not satisfactory 
enantioselectivity (entries 2–3). Other analogous structures of BINAP, such as SEGPHOS (L4,  





Reaction was run on 1.0 mmol scale. Isolated yield shown after flash chromatography. aDr was determined by crude 1H NMR 
analysis. Relative stereochemistry was assigned by analogy. bRatio of constitutional isomers was determined by crude 1H NMR 
analysis. cMajor/minor structures of the constitutional isomers were not assigned due to difficulty in separating the two isomers.
then: ketone or ester (2.0 eq.)
LDA (1.9 eq.)
Pd(dba)2 (5.0 mol%), dppb (6.0 mol%)
EtCN/THF, –30 ºC, 12 h
MTAD (1.57a, 1.0 eq.)














































Table 3-9: Chiral ligand screening for the desymmetrization of naphthalene-cycloadduct with p-
methoxyacetophenone. 
entry ligand yield (%)a erb 
1 (S,S)-BDPP (L1) (84) 60:40 
2 (S)-BINAP (L2) (80) 77:23 
3 (S)-tol-BINAP (L3) (87) 79:21 
4 (S)-SEGPHOS (L4) <5 – 
5 (R)-DTBM-SEGPHOS (L5) <5 – 
6 (R)-MeBIPHEP (L6) <5 – 
7 (R,S)-PPF-PCy2 (L7) <5 – 
8 (S)-tBu-PHOX (L8) <5 – 
9 (S,Sp)-Ph-Phosferrox (L10) 63 77:23 
10 (S,Sp)-Bn-Phosferrox (L11) 82 74:26 
11 (R,Rp)-iPr-Phosferrox (L9) 70 87:13 
12 (S,Sp)-tBu-Phosferrox (L12) 63 96:4 
13 (S,Sp)-tBu-Phosferrox (L12) (75) 95:5 
aDetermined by 1H NMR analysis. Isolated yield shown in parenthesis. bDetermined by chiral 
HPLC. cPd(dba)2 5.0 mol% and (S,Sp)-tBu-Phosferrox (L12) 6.0 mol% were used. 
(S)-Ar-BINAP
L2: Ar = Ph
L3: Ar = tol
















L10: R = Ph
L11: R = Bn























then: p-methoxyacetophenone (2.0 eq.)
LDA (1.9 eq.)
Pd(dba)2 (2.5 mol%)
chiral ligand (3.0 mol%)
EtCN/THF, –50 to 0 ºC, 5 h
MTAD (1.57a, 1.0 eq.)













L5) and BIPHEP (L6), as well as other diphosphine ligands (L7), did not promote the reaction 
(entries 4–7). Finally, several P,N-bidentate ligands were examined, and although (S)-tBu-PHOX 
(L8) ligand showed no reactivity, phosferrox ligands (L9–L12)[78] gave a promising yield and 
enantioselectivity of the desired product 3.1a (entries 8–12). Of all the phosferrox ligands tested, 
(S,Sp)-tBu-Phosferrox (L12) provided the highest enantioselectivity of 96:4 (entry 12). Increase in 
the catalyst loading from 2.5 mol% to 5.0 mol% further improved the conversion, giving 75% 
isolated yield of 3.1a and 95:5 selectivity (entry 13). 
 With effective asymmetric conditions in hand, several representative ketone enolates were 
chosen to test the scope of this desymmetrization reaction (Table 3-10). With naphthalene as a 
substrate, a wide range of aromatic and aliphatic ketones proved viable (3.1a, 3.1h, 3.1o, 3.1p, 
3.1s), and x-ray analysis of 3.1p (after recrystallization, >99% ee) revealed the absolute 
stereochemistry as shown in Table 3-10. Notably, although slightly diminished in efficiency, both 
propiophenone (3.1h) and cycloheptanone (3.1s) gave high diastereo- and enantioselectivity. In 
addition, substituted naphthalene such as 2,3-bis(pivaloyl)naphthalene gave a high optical purity 
of the products (3.16, 3.17), although with moderate conversions of the cycloadduct.  









then: ketone (2.0 eq.), LDA (1.9 eq.)
Pd(dba)2 (5.0 mol%)
(S,Sp)-tBu-phosferrox L12 (6.0 mol%)
EtCN/THF, –50 to 0 ºC, 5 h
MTAD (1.57a, 1.0 eq.)


































Reaction was run on 0.5 mmol scale. Isolated yield shown after flash chromatography. Dr was determined by crude 1H NMR 
analysis. aEnantiomeric ratio of major diastereomer.
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Table 3-11: Chiral ligand screen for desymmetrization of naphthalene-cycloadduct with methyl 
isobutylate.  
entry [Pd] ligand yield (%)a erb 
1 Pd(dba)2 (S,Sp)-tBu-Phosferrox (L12) 55 66:34 
2 Pd(dba)2 (R,Rp)-iPr-Phosferrox (L9) 64 77:23 
3 Pd(dba)2 (S,Sp)-Bn-Phosferrox (L11) 79 75:25 
4 Pd(dba)2 (R,Rp)-Ph-Phosferrox (L10) 14 55:45 
5 Pd(dba)2 (S)-tBu-PHOX (L9) 55 72:28 
6 Pd(dba)2 (S)-BINAP (L2) 65 80:20 
7 Pd(dba)2 (S)-tol-BINAP (L3) 25 78:22 
8 Pd(dba)2 (S)-SEGPHOS (L4) 36 68:32 
9 Pd(dba)2 (R)-DTBM-SEGPHOS (L5) 17 92:8 
10 Pd(MeCN)2Cl2 (R)-DTBM-SEGPHOS (L5) 37 83:17 
11c [Pd(allyl)Cl]2 (R)-DTBM-SEGPHOS (L5) 34 92:8 
12d [Pd(allyl)Cl]2 (R)-DTBM-SEGPHOS (L5) (61) 95:5 
aDetermined by 1H NMR analysis using nitromethane as the internal standard. Isolated yield shown 
in parenthesis. bDetermined by chiral HPLC. c[Pd(allyl)Cl]2 1.25 mol% was used. d) [Pd(allyl)Cl]2 
2.5 mol% and (R)-DTBM-SEGPHOS (L5) 6.0 mol% were used. 
 
 When an ester enolate derived from methyl isobutylate was used under identical conditions 
(Table 3-9, entry 13), low conversion as well as low enantioselectivity of the desired product 3.1w 
was observed (Table 3-11). Thus, the chiral ligand was re-optimized. Unfortunately, none of the 
phosferrox ligands nor the PHOX ligand screened gave high enantioselectivity (entries 1–5). On 
the other hand, when BINAP and SEGPHOS ligands were tested, much improved optical purity 
was observed, especially with (R)-DTBM-SEGPHOS (L5, entries 6–9). Since low yield was 
observed in entry 9 despite the high enantioselectivity, several palladium sources were examined. 
As a result, it was found that [Pd(allyl)Cl]2 was better suited to this transformation, and increasing 
the catalyst loading from 2.5 mol% to 5.0 mol% improved the conversion to give 61% of 3.1w, 
with a slightly improved enantioselectivity of 95:5 (entries 9–12). Although limited in substrate, 
then: methyl isobutylate (2.0 eq.), LDA (1.9 eq.)
[Pd] (2.5 mol%)
chiral ligand (3.0 mol%)
EtCN/THF, –50 to 0 ºC, 5 h
MTAD (1.57a, 1.0 eq.)















the ester scope of desymmetrization of the 
naphthalene-cycloadduct was examined 
(Table 3-12), and shown to give high yield as 
well as enantioselectivity for the two esters 
examined.  
3.5 Product elaboration 
 The dearomatized products contain 
several functional groups amenable to 
derivatization. Thus, primary focus was put on 
alkene functionalization and the urazole 
conversion of 3.1o. Both transformations 
could be combined to demonstrate the facile accessibility to a variety of complex structures within 
just a few chemical steps from simple arenes. 
 
Olefin derivatization 
 First, conditions to hydrogenate the olefin functionality were investigated (Table 3-13). 
When Pd/C was used as a catalyst under a hydrogen atmosphere (1 atm) in methanol as a solvent  
 
Table 3-13: Catalyst screening for the hydrogenation of 3.1o. 
entry catalyst solvent conv. (%)a yield (%)b 3.18: 3.19a 
1 Pd/C MeOH full 60 1:>20 
2 Pd(OH)2 MeOH full – 1:5 
3 Pt/V/C MeOH <5 – – 
4 Rh/Al2O3 MeOH full 87 >20:1 
5 Rh/Al2O3 EtOAc full 93 >20:1 
























Table 3-12: Enantioselective dearomative 













Reaction was run on 0.5 mmol scale. Isolated yield shown after 
flash chromatography.
then: ester (2.0 eq.), LDA (1.9 eq.)
Pd(dba)2 (5.0 mol%)
(R)-DTBM-SEGPHOS L5 (6.0 mol%)
EtCN/THF, –50 to 0 ºC, 5 h
MTAD (1.57a, 1.0 eq.)









at room temperature, full conversion of 3.1o was observed along with the formation of 3.19 and 
3.20, but 3.18 was not obtained (entry 1). In order to find a catalyst suitable for the selective 
preparation of 3.18, other heterogeneous catalysts were tested. Accordingly, Rh/Al2O3 was 
successful in providing 3.18 exclusively with full conversion of the starting material 3.1o, albeit 
with a 87% yield due to the formation of 3.20 (entries 2–4). Product selectivity was further 
improved by changing the solvent from methanol to ethyl acetate, providing the desired 3.18 in 
93% isolated yield (entry 5). As a control experiment, 3.18 was re-subjected to hydrogenation 
conditions to probe the order of reduction. As shown in Scheme 3-3, no conversion was observed 
after 12 hours, suggesting that the benzylic C–N bond undergoes reduction only when it is both 
benzylic and allylic position. On the other hand, when the same conditions as Table 3-13, entry 5 
were applied to benzene-ketone-derived substrate 3.13a, a mixture of 3.21 and 3.22 were observed 
with 2:1 selectivity (Scheme 3-4).  
 Next, the feasibility of oxidative functionalization of the alkene moiety was investigated. 
When osmium-catalyzed dihydroxylation was conducted in acetone in the presence of N-
methylmorpholine N-oxide as an oxidant, 3.23 was obtained as the sole product (Table 3-14, entry 
1).[79] The stereochemical outcome could be explained by dihydroxylation proceeding from the 
less hindered side of the olefin. In order to inverse the stereochemistry, hydrogen-bonding-
mediated directed osmium dihydroxylation, reported by Donohoe,[80] was examined. Although the 







MeOH (0.1 M), rt, 12 h
(±)-3.18 (±)-3.19: <5% (no conv.)
(catalyst = Pd/C, Rh/Al2O3)
Scheme 3-3: Control experiment for the hydrogenation of 3.18. 







EtOAc (0.1 M), rt, 12 h
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Table 3-14: Dihydroxylation of 3.1o using OsO4. 
entry OsO4 additive (x eq.) solvent, temp., time 3.23 : 3.23’a yield (%)b 
1 5.0 mol% NMO (2.0) acetone/H2O, rt, 12 h >20:1 87 
2 1.05 eq. TMEDA (1.1) CH2Cl2, –78 ºC, 5 hc >20:1 (full conv.)a 
3 1.05 eq. TMEDA (1.1) CH2Cl2, –78 ºC, 5 hd >20:1 (full conv.)a 
aDetermined by crude 1H NMR analysis. bIsolated yield after flash chromatography. cQuenched with Na2SO3. 
dQuenched with HCl and MeOH. 
  
–78 ºC) proceeded in full conversion, only 3.23 was observed in crude 1H NMR analysis (entries 
2–3). Thus, urazole did not serve as a directing group for this transformation. 
 In contrast to dihydroxylation, the 
epoxidation attempted under several conditions, 
such as mCPBA and DMDO oxidation, was not 
successful (Scheme 3-5). In most cases, not only 
did the conversion suffer, but also crude 1H 
NMR analysis showed mixtures of many 
decomposed compounds.  
 Lastly, conditions to promote cyclopropanation[81] were investigated (Table 3-15). When 
typical conditions used for the Simmons-Smith reaction (CH2I2, Et2Zn, Furukawa’s reagent[82]) 
were employed at 40 ºC, although the full conversion was not achieved, the desired 
cyclopropanated product 3.24 was observed along with over alkylated product (±)-3.25 (entry1). 
Decreasing the reaction temperature and slowly warming up from 0 ºC to room temperature 
slightly improved the product selectivity, but large amounts of 3.1o remained unreacted (entry 2). 
The addition of trifluoroacetic acid (TFA), conditions reported by Shi,[83] provided full conversion 
to the undesired rearomatized 3.20 (entry 3). For an acid-sensitive compound, the addition of weak 
base is known to decrease the rate of decomposition caused by the formation of ZnI2 as a by-
product.[81a] Thus, diisopropylethylamine (DIPEA) was added, and although the decomposition 



































(oxidant = mCPBA, DMDO)
56 
 
Table 3-15: Condition screening for cyclopropanation of 3.1o. 
entry CH2IX (2x eq.) additive temp./time SM : 3.24 : 3.25a yield of 3.24 (%)b 
1 CH2I2 (8) – 40 ºC/12 h 1:2:1 – 
2 CH2I2 (8) – 0 to rt/12 h 1:3:1 – 
3 CH2I2 (4)c TFA 0 to rt/3 h full conv. to 3.20 – 
4 CH2I2 (8) DIPEA 0 to rt/15 h 
nd:1:1 
(3.20: 42% isolated) 
22 
5 CH2ICl (8) – 0 to rt/15 h nd:2:3 – 
6 CH2ICl (4) – 0 ºC/15 min low conv. – 
7 CH2ICl (4) – –10 ºC/24 h trace:1:trace 64 
aDetermined by crude 1H NMR analysis. bIsolated yield after flash chromatography. cEt2Zn 4.0 eq. 
 
other hand, when conditions reported by Denmark (CH2ICl, Et2Zn)[84] were examined, much 
higher reactivity was observed, and full conversion of 3.1o was obtained at room temperature 
(entry 5). However, this was also accompanied by a significant amount of over-alkylation to give 
a product ratio of 3.24 to 3.25 of 2:3. Although shorter reaction time at 0 ºC failed to give good 
conversion (entry 6), lowering the reaction temperature to –10 ºC and conducting the reaction over 
24 hours provided full conversion, and formed 3.24 with 64% isolated yield and high selectivity 
(3.25: trace, entry 7). 
 
Urazole conversion 
 The urazole moiety on 3.18 was first attempted to be converted to a free amine. In doing 
so, the ketone functionality was protected as a ketal group (3.26, Scheme 3-7). The urazole moiety 
was then first alkylated with a-bromoacetophenone, and subsequently treated with potassium 






iPrCH2IX (2x eq.), Et2Zn (x eq.)
additive (x eq.)






















 Next, oxidative transformation of the urazole moiety was investigated (Table 3-16). 
Although it has never been done with MTAD, there have been reports that N-phenyl-1,2,4-
triazoline-3,5-dione (PTAD) could be transformed to a carbonyl group using oxidants such as 
phenyliodine(III) diacetate (PIDA).[86] Thus, the PIDA oxidation of MTAD was tested by first 
conducting the oxidation under anhydrous conditions followed by the addition of water, and it 
was found that ketone 3.30 was formed as the only product in low yield (entry 1). When other 
hypervalent iodine-based oxidants such as phenyliodine(III) ditrifluoroacetate (PIFA) and 2-
iodoxybenzoic acid (IBX) were examined, no desired product was obtained (entries 2–3). On the 
other hand, when tert-butyl hypochlorite (tBuOCl) was used in anhydrous conditions,[87] followed 
by an aqueous quench, while ketone 3.29 did not form, a small amount of a-chloroketone 3.30 
was isolated as a single diastereomer (entry 4). Although the formation of a-chloroketone from 
MTAD or PTAD has never been reported, the plausible mechanism of this oxidative reaction 
based on the literature reports could be: 1) formation of a iminium-type intermediate IV via 
urazole oxidation of I, which upon hydrolysis with water gives ketone V, 2) tautomerization of 
intermediate IV under anhydrous conditions to VI and subsequent second oxidation to give another 
iminium-type intermediate VII, and 3) hydrolysis of VII to provide a-chloroketone VIII (Scheme 
3-8).[86,88] Alternative mechanism for the urazole oxidation may involve initial formation of 
urazole dimer via radical oxidation process, which has been reported to turn the reaction mixture  
Scheme 3-6: Conversion of urazole moiety to a free amine. 
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MeOH, 80 ºC,  24 h;

























Table 3-16: Oxidation of urazole moiety of 3.26.  
entry oxidant (x eq.) solvent 3.29 : 3.30a 3.29 (%)b 3.30 (%)b 
1 PIDA (1.2) MeCN; then quench with H2O >20:1 38 – 
2 PIFA (1.2) MeCN; then quench with H2O – <5 <5 
3 IBX (1.2) MeCN; then quench with H2O – <5 <5 
4 tBuOCl (1.0) MeCN; then quench with H2O 1:>20 – 10 (dr>20:1) a 
5 tBuOCl (2.5) MeCN; then quench with H2O 1:>20 – 77 (dr>20:1) a 
6 tBuOCl (2.5) MeCN:H2O=1:1 2.4:1 – – 
7 bleach MeCN 20:1 53 trace 
aDetermined by crude 1H NMR analysis. bIsolated yield after flash chromatography.  
 
to strong orange solution, and then one of the urazole moiety acting as a leaving group to form the 
azomethine yilide precursor III.[89] Since the reaction mixture for the oxidation of 3.26 turns bright 
orange, the latter radical mechanism may be operating, and regardless would provide same 
intermediate III. According to this proposed mechanism, two equivalents of oxidant is required to 
complete the formation of a-chloroketone 3.30. Thus, the amount of tBuOCl was increased to 2.5 







































































equivalents, and the conversion improved drastically to give 77% isolated yield of a-chloroketone 
3.30 as a single diastereomer (entry 5). It is of note that the second oxidation occurs from the less 
hindered opposite face of the ketal substituent. At this point, oxidations in aqueous conditions were 
also tested to promote the selective access to ketone 3.29. Using tBuOCl as an oxidant in an 
acetonitrile/water co-solvent system, a mixture of ketone 3.29 and a-chloroketone 3.30 was 
obtained (entry 6). Further optimization revealed that when commercial bleach (5% NaOCl in aq. 
NaOH) was used as an oxidant in acetonitrile instead, ketone 3.29 was obtained as the major 
product along with trace amount of a-chloroketone 3.30 (entry 7).  
 
Combining olefin functionalization with urazole oxidation 
 With methods for olefin functionalization and urazole oxidation in hand, both 
transformations were combined to convert carboaminated product 3.1o to a variety of highly 
functionalized tetrahydronaphthalene derivatives. The oxidation protocol of the urazole moiety 
was amenable to the reduced product 3.26, providing diketones 3.31 and 3.32 (Scheme 3-9, left). 
For compound 3.26, it was beneficial to add solvent quantities of acetic acid as an additive to 
ensure high selectivity for diketone 3.31 and prevent the formation of a-chlorodiketone 3.32, 
which was not an amenable condition for ketal 3.26 due to undesired decomposition. In addition, 
the dihydroxylated product 3.22 as well as cyclopropanated product 3.24 underwent oxidation to 
give corresponding ketones 3.33 and 3.34, albeit with only moderate conversion.  
Scheme 3-9: Derivatization of 3.1o through combination of olefin functionalization 




















































3.6 Attempt for the synthesis of alternamide A 
 As the syn-1,4-carboaminated products have multiple functional handles that are amenable 
to further derivatizations the application of this method to the synthesis of a bioactive compound 
was investigated. To this end, alternamide A, a compound with antiprotozoal activity isolated from 
aerial parts of Alternanthera littoralis P. Beauv. in 2017, was chosen as a target (Scheme 3-10).[90] 
Starting from 2,3-bis(pivaloyl)naphthalene, palladium-catalyzed dearomative syn-1,4-
carboamination (see Table 3-7 for details), followed by Rh/Al2O3-catalyzed hydrogenation gave 
3.35. Then, Baeyer-Villiger oxidation proceeded smoothly to give ester 3.36, and a-alkylation of 
the urazole provided 3.37. The stage was set for the global hydrolysis of the three esters and the 
urazole moiety;[85] however, no desired product was obtained under basic hydrolysis conditions 
used in Scheme 3-6, providing only a complex mixture of decomposed starting material. All 
attempts to improve the reactivity of this transformation, by prolonging reaction time, have yet to 
achieve successful isolation of amino acid 3.38.  








































MeOH, 80 ºC, 12 h; 






























3.7 Conclusion  
 An arenophile-mediated dearomative syn-1,4-carboamination has been achieved using an 
arenophile cycloaddition with MTAD (1.57a) and simple arenes, and subsequent palladium-
catalyzed substitution with non-stabilized lithium enolates derived from ketones and esters. The 
process exhibits high product selectivity among the four possible constitutional- and stereoisomers, 
and gives exclusive access to syn-1,4-carboaminated products for both mononuclear and 
polynuclear arenes. Such selectivity could be explained by a double-inversion mechanism for the 
substitution step, which results in net-retention of the configuration at the substituted site. As many 
of the known dearomative alkylation reactions of non-activated arenes generally required harsh 
reaction conditions, this catalytic method provides an advantage in tolerating a variety of sensitive 
functional groups. Furthermore, conditions for a highly enantioselective desymmetrization of 
meso-cycloadducts, derived from symmetrical polynuclear arenes, has also been established. 
Considering the wide range of other nucleophiles that have been reported to be viable for 
palladium-catalyzed allylic substitution, this arenophile-mediated dearomative method has a high 
potential to be further expanded to directly incorporate other functionalities onto the dearomatized 
core to prepare complex alicyclic structures. Such elaborations of the method will be described in 





Chapter 4: Palladium-Catalyzed Dearomative syn-1,4-Carboamination with 
Grignard Reagents 
4.1 Background and significance 
 As mentioned in the introduction in chapter 1 and Section 3.1, nucleophiles employed in 
transition metal-catalyzed allylic substitution could undergo two different mechanisms, depending 
on the soft/hard nature of the nucleophile. In Chapter 3, the exploration of the arenophile-mediated 
dearomative carboamination using enolates showed that these nucleophiles in this particular 
system behave as soft nucleophiles to provide syn-1,4-selectivity as a result of net-retention of the 
stereochemistry. In this chapter, other types of carbon-based nucleophile will be examined to gain 
further insight into stereo- and regioselectivity of the palladium-catalyzed dearomative 
carboamination process. 
 Although fewer examples are known, the use of hard nucleophiles in palladium-catalyzed 
allylic substitution have been reported. Most of these transformations are carried out with 
organometallic reagents involving aluminum, boron, magnesium (Grignard), silicon, tin, zinc, and 
zirconium.[44,45] In the case of a cyclic electrophile, a wide variety of these nucleophiles exhibit an 
overall inversion as the stereochemical outcome of the reaction.[76,91] For example, reactions using 
PhSnMe3[92] and PhZnBr[93] give complete inversion of the stereochemistry. As for NaBPh4[94] and 
PhMgBr,[95] these nucleophiles also give an overall inversion of configuration although small 
amount of erosion in stereoselectivity were observed (Scheme 4-1). 
 Specifically, this chapter focuses on the use of Grignard reagents as the nucleophiles. The 
employment of Grignard reagents in arenophile-mediated dearomative aminofunctionalization has 



































Scheme 4-1: Examples of stereoinversion in allylic substitution with hard nucleophiles. 
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carboaminated product with exclusive cis-1,2-selectivitiy.[49] The stereochemical outcome of this 
transformation is presumed to be explained by transmetalation of Grignard reagent to the nickel-
allyl complex, and subsequent reductive elimination (see reference 49 for details and discussion 
on the regioselectivity). Therefore, based on this result and literature precedents, a palladium-
catalyzed version was predicted to also exhibit net-inversion to give anti-1,4-selectivity, which is 
complementary to nickel-catalyzed reaction in regioselectivity (Scheme 4-2). Furthermore, the 
enantioselective reaction through desymmetrization of the meso-cycloadduct was investigated. It 
is worth mentioning that asymmetric allylic substitution with hard nucleophiles are still very rare, 
despite the long-standing history of such transformations using soft nucleophiles.[45] Thus, 
establishment of an asymmetric variants for arenophile-mediated dearomative carboamination 











































4.2 Reaction optimization with benzene and naphthalene 
 The investigation into the application of Grignard reagents in palladium-catalyzed 
dearomative carboamination began with simply substituting the nickel complex with a palladium 
complex for the conditions optimized for the nickel-catalyzed anti-1,2-carboamination[49] (Scheme 
4-3, left). Thus, when the benzene-cycloadduct formed in dichloromethane at cryogenic 
temperatures was subjected to PhMgBr (3.0 M in Et2O) as a nucleophile and Pd(PPh3)4 as a catalyst, 
and slowly warmed up from –50 to 0 ºC over 5 hours, 35% of the syn-1,4-product 4.2a was isolated 
(Scheme 4-3, right; see Table 4-4 for crystal structure). Based on the crude 1H NMR analysis, 
formation of the anti-1,4-counterpart, as well as any other isomers, was not observed. This result 
was highly unexpected, as the reactions with Grignard reagents to result in net-retention of the 
stereochemistry is unprecedented (vide infra). Nonetheless, further optimization was carried out 
using monodentate phosphine ligands both with aromatic and aliphatic substituents (Table 4-1, 
entries 1–9). While a variety of monodentate phosphine ligands were able to provide product 4.2a, 
the highest yield was obtained using tri(o-methylphenyl)phosphine (entry 5). In contrast to enolate 
nucleophiles, bidentate ligands such as dppe and dppf did not provide any desired product.  
 Next, in order to improve the conversion of the benzene-cycloadduct, palladium sources 
were screened. As shown in Table 4-2, Pd(dba)2 proved to be most effective (entries 1–3). The 
reaction temperature also turned out to be a key factor for this reaction. That is, although no 
significant effect was observed when the amount of PhMgBr was reduced from 2.5 eq. to 1.5 eq., 
as well as when the concentration in dichloromethane was increased from 0.1 M to 0.2 M, warming 
the reaction mixture up from –50 to 15 ºC, rather than stopping at 0 ºC, for the substitution step 
provided the product 4.2a with a 75% isolated yield (entries 4–6). Keeping the temperature 








MTAD (1.57a, 1.0 eq.)
visible light, CH2Cl2, –78 ºC;
then: PhMgBr (3.0 M in Et2O, 2.5 eq.)
Ni(acac)2 (1.5 mol%)
(S,SP)-iPr-Phosferrox (2.0 mol%)
CH2Cl2/THF, –50 to 0 ºC, 3 h
then: PhMgBr (3.0 M in Et2O, 2.5 eq.)
Pd(PPh3)4 (5.0 mol%)
CH2Cl2/THF, –50 to 0 ºC, 5 h
MTAD (1.57a, 1.0 eq.)









Table 4-1: Optimization with benzene and PhMgBr.  
entry [Pd] ligand yield (%)a 




3 P(p-FC6H4)3 34 
4 P(p-MeC6H4)3 <5 
5 P(o-MeC6H4)3 63 (57) 
6 PPh3 42 
7 PPh2Cy 11 
8 PPhCy2 11 




11 dppfb <5 
aDetermined by 1H NMR analysis. b6.0 mol% ligand used. 
 
Table 4-2: Further optimization with benzene and PhMgBr.  
entry [Pd] x [M] y (eq.) temp. (ºC) time (h) yield (%)a 
1 Pd(dba)2 
0.1 2.5 –50 to 0 5 
63 
2 Pd(MeCN)2Cl2 13 
3 Pd(OAc)2 48 
4 
Pd(dba)2 
0.1 1.5 –50 to 0 5 63 
5 0.2 1.5 –50 to 0 5 61 
6 0.2 1.5 –50 to 15 10 78 (75) 
7 0.2 1.5 –30 10 61 
aDetermined by 1H NMR analysis. Isolated yield shown in parenthesis.  
then: PhMgBr (3.0 M in Et2O, 2.5 eq.)
[Pd] (5.0 mol%)
ligand (12 mol%)
CH2Cl2/THF, –50 to 0 ºC, 5 h
MTAD (1.57a, 1.0 eq.)














MTAD (1.57a, 1.0 eq.)












at –30 ºC for 10 h gave 61% (entry 7). Thus, the conditions in entry 6 were chosen as the optimized 
conditions. 
 As for the cycloadduct derived from naphthalene, the ligand which worked well for the 
benzene–cycloadduct did not provide any desired product 4.3a (Table 4-3, entry 1). However, 
upon further optimization using both monodentate and bidentate phosphine ligands, dppf showed 
some reactivity to give 33% of 4.3a (entries 2–7). The same was observed as was for benzene as 
a substrate, exclusive syn-1,4-selectivity was observed (see Table 4-6 for crystal structure). 
Decreasing the amount of PhMgBr had a minimal effect in the reaction outcome (entry 8). On the 
other hand, an increase in yield was observed when the palladium loading was raised from 5.0 
mol% to 10 mol%, and further improved by changing the ratio of palladium to phosphine from 
1:1.2 to 1:2 (entries 9–10). For these two entries, the unreacted naphthalene–MTAD cycloadduct 
was not observed after workup. Thus, the conditions in entry 10 were concluded to be optimal.  
 
Table 4-3: Optimization of dearomative carboamination with naphthalene and PhMgBr.  
entry ligand (y) x (eq.) yield (%)a 
1 P(o-MeC6H4)3 (12) 2.5 <5 
2 dppp (6) 2.5 <5 
3 dppb (6) 2.5 <5 
4 dppf (6) 2.5 33 
5 dppBz (6) 2.5 <5 
6 rac-BINAP (L2) (6) 2.5 <5 
7 dppf (6) 1.5 37 
8 dppf (12)b 1.5 49 
9 dppf (20)b 1.5 55 (50) 
aDetermined by 1H NMR analysis. Isolated yield shown in parenthesis 
b6.0 mol% ligand used. bPd(dba)2 10 mol% used. 
 
 
then: PhMgBr (3.0 M in Et2O, x eq.)
Pd(dba)2 (5.0 mol%)
ligand (y mol%)
CH2Cl2/THF, –50 to 10 ºC, 10 h
MTAD (1.57a, 1.0 eq.)












 The lower yield of the product and poor mass balance with naphthalene and PhMgBr, 
compared to the results for enolate as nucleophile, is assumed to be due to the solvent effect of the 
cycloaddition step. Typically, the more polar the solvent is, the faster the cycloaddition proceeds 
under otherwise identical conditions. While the cycloaddition is taking place by the irradiation of 
visible light, unreacted MTAD is also decomposing to some extent, which was verified by a control 
experiment conducted in the absence of arene. Among all the solvents compatible with MTAD at 
cryogenic temperatures (dichloromethane, acetone, ethyl acetate, and propionitrile), 
dichloromethane is by far the slowest in completing the cycloaddition, thus presumably resulting 
in lower yield of the cycloadduct itself before proceeding to the substitution step. At this point, 
however, there is no quantitative analysis on the yield of naphthalene–cycloadduct formed in situ, 
and in-depth study of the cycloaddition step is necessary to support the hypothesis. 
 The exclusive syn-1,4-selectivity observed for both benzene and naphthalene with PhMgBr 
is worth noting some mechanistic insight. Although uncommon, non-stabilized hard nucleophiles 
to act as “soft” nucleophile (undergoes substitution through outer-mechanism to provide net-
inversion) in palladium catalysis has some precedent. For example, one of the first reports for such 
a transformation was done by Trost, in which 2-picoline-derived nucleophiles (pKa = 34) were 
used in the presence of BF3 as an activator (Scheme 4-4, A). [96,97] This allowed an increase in the 
acidity of the 2-picoline methyl group, promoting deprotonation using LiHMDS. Later, the same 
group expanded this strategy to incorporate more acidic heterocycles, such as pyrazine, pyrimidine, 















66 to 99% yield
88 to 99% ee
























and quinoxaline, and were successful in eliminating the activator from the reaction.[98] On the other  
hand, Walsh was able to employ toluene derivatives (RC6H4-CH2R’, pKa ~ 44) as “soft” 
nucleophiles by forming h6-complexes with stoichiometric amount of Cr(CO)3 (Scheme 4-4, 
B).[99] The use of toxic Cr(CO)3 could be avoided when diarylmethane derivatives (pKa 25 ~ 44) 
were used (Scheme 4-4, C).[100] 
 Compared to the above example, PhMgBr (Ph-H: pKa = 43) is a much harder nucleophile, 
and has not been reported to undergo an outer-sphere mechanism. However, since dearomative 
aminofunctionalizations with other nucleophiles, such as a ketone enolate (Chapter 2), amine 
(Chapter 5), or oxime (Chapter 6), under otherwise identical conditions (dichloromethane/THF as 
solvent, Pd(PPh3)4 as catalyst) all gave the same syn-1,4-products exclusively, it is reasonable to 
assume that these transformations proceed through double-inversion: oxidative addition occurring 
from opposite face of the leaving group, followed by outer-sphere attack of the nucleophile. The 
exception for Grignard reagents in this case might be due to the directing effect from the urazole 
leaving group, which could coordinate to the Grignard reagent and direct an outer-sphere attack, 
rather than a transmetalation. Yet, more detailed mechanistic studies are required to fully reveal 
the mechanism of the Grignard reagents as nucleophiles in the arenophile-mediated dearomative 
carboamination. 
 4.3 Scope of the dearomative syn-1,4-carboamination  
 The scope of the Grignard reagent in the dearomative syn-1,4-carboamination was probed. 
Using the benzene–cycloadduct, aryl Grignard nucleophiles bearing both electron-rich and 
electron-poor functional groups were well tolerated (Table 4-4, 4.3a–e). It is worth mentioning 
that ortho-substituted aryl Grignard were competent in this process, giving 4.3d and 4.3e in good 
yields. A 3,4-methylenedioxyphenyl group (4.3f), as well as a 1-naphthyl group (4.3g) were also 
installed effectively. In addition to the aryl Grignard, vinyl Grignard reagents were amenable; 2-
methyl-propene (4.3h) and 2-propene (4.3i) groups were successfully coupled to the dearomatized 
benzene. Furthermore, allyl Grignard underwent substitution to give access to a 1,5-diene 
derivative (4.3j). Remarkably, even the alkyl Grignard reagents were compatible in this 
transformation: MeMgBr, n-C6H12MgBr, and cyclopentyl Grignard gave high yield of the desired 




 Unlike for enolate nucleophiles, monosubstituted benzene derivatives proved to be  
highly viable substrates for Grignard reagents. Using PhMgBr as a representative example, 
benzenes with various substituents were subjected to the optimized conditions. However, only 
poor yields of the desired products were obtained. This problem was circumvented by simply 
replacing the ligand with DPEphos. As shown in Table 4-5, a variety of alkyl groups with different 
substitution patterns and functional groups were tolerated (4.4–4.8). Phenyltrimethylsilane was 
also compatible, giving high yields of the desired product 4.9. In all cases, only one constitutional 







then: PhMgBr (1.5 eq.)
Pd2(dba)3 (2.5 mol%)
DPEphos (6 mol%)
CH2Cl2/THF, –50 to 15 ºC, 10 h
MTAD (1.57a, 1.0 eq.)
visible light, CH2Cl2 (0.2 M), –78 ºC;
4







































Table 4-4: Scope of Grignard reagents with benzene. 







then: RMgBr (1.5 eq.)
Pd(dba)2 (5.0 mol%)
P(o-MeC6H4)3 (12 mol%)
CH2Cl2/THF, –50 to 15 ºC, 10 h
MTAD (1.57a, 1.0 eq.)
visible light, CH2Cl2 (0.2 M), –78 ºC;
4.2a (R = H):
4.2b (R = p-NMe2):
4.2c (R = p-OMe):
4.2d (R = o-Me):


























and stereoisomer was observed, which is distinctly different compared to the reactions with enolate, 
and this may be due to the increased bite angle of DPEphos (102 º), as compared to dppb (98 º).[101]  
 For the polynuclear arene scope, much lower yields of the desired products were observed 
for majority of the substrates tested (Table 4-6). For example, 1-substituted naphthalenes generally 
gave high selectivity between two constitutional isomers, albeit with low reactivity (4.10–4.14). 
Likewise, the reactions with symmetrical arenes did not proceed smoothly (4.15, 4.16). For 
phenanthrene, comparable reactivity to enolate nucleophile was observed, but with diminished 
selectivity (4.17). In addition, several heteronuclear arenes were examined. Although the yields 
were low, both 4-bromoquinoline (4.18) and acridine (4.19) were competent substrates.  
4.4 Development of asymmetric variants for dearomative syn-1,4-carboamination 
 An asymmetric version of the palladium-catalyzed dearomative syn-1,4-carboamination 
on the meso-cycloadduct with Grignard reagent was also attempted. To facilitate the screening 
process, isolated naphthalene–cycloadduct (1.48) was used as a model substrate in the presence of 
PhMgBr as the nucleophile ( Table 4-7). Initial screening of chiral ligands such as Phosferrox 
(L9–L12) and DACH-Ph Trost ligand did not promote the reaction, whereas BINAP (L2) gave  
[x-ray of 4.3a] 




Reaction was run on 0.5 mmol scale. Isolated yield shown after flash chromatography. Ratio of constitutional isomers was determined 
by crude 1H NMR analysis, and major isomer shown in the table. Unless otherwise stated, two isomers were column separable.
X
then: PhMgBr (1.5 eq.)
Pd(dba)2 (10 mol%)
dppf (20 mol%)
CH2Cl2/THF, –50 to 15 ºC, 10 h
MTAD (1.57a, 1.0 eq.)



































(±)-4.3a: 50% (±)-4.10 (R = CF3):
(±)-4.11 (R = TMS): 
(±)-4.12 (R = CH(OMe)2):
   (±)-4.13 (R = 4-CF3C6H4): 42% (3:1)










 Table 4-7: Screening for asymmetric variants of dearomative carboamination with PhMgBr. 




2 [Pd(allyl)Cl]2 40 80:20 
3 Pd(OAc)2 56 86:14 
4 Pd(TFA)2 25 83:17 
5 Pd(OAc)2 (S)-tol-BINAP (L3) 60 63:37 
6 Pd(OAc)2 (S)-H8-BINAP (L13) <5 – 
7 [Pd(allyl)Cl]2 (S)-SEGPHOS (L4) 67 84:16 
8 Pd(OAc)2 (S)-SEGPHOS (L4) 66 84:16 
9 Pd(OAc)2 (R)-DTBM-SEGPHOS (L5) <5 – 
10 Pd(OAc)2 (S)-SYNPHOS (L14) 15 85:15 
11 Pd(OAc)2 (R)-MeBIPHEP (L6) 50 81:19 
12 Pd(OAc)2 (R)-C3-TUNEPHOS (L15) 32 79:21 
13 Pd(OAc)2 (S)-Ph-GARPHOS (L16) 17 80:20 
14 Pd(OAc)2 CTH-(S)-P-PHOS (L17) 84 82:18 




















L2 (Ar = Ph)
































CH2Cl2/THF, –50 to 15 ºC, 10 h
PhMgBr (3.0 M in Et2O, 1.5 eq.)
[Pd] (5.0 mol%)
chiral ligand (10 mol%)
1.59
NUR4.3a














promising conversion and enantioselectivity. The choice of 
palladium source turned out to be crucial; while Pd(dba)2 was not 
effective, all of the Pd(II) complexes examined provided the 
desired product 4.3a with high enantioselectivity (entries 1–4). 
Thus, focus was put into the chiral ligands with biaryl motifs. 
When BINAP derivatives were examined, tol-BINAP (L3) gave a 
comparable yield with much lower enantiomeric ratio, whereas the 
H8-BINAP (L13) was ineffective (entries 5–6). As for SEGPHOS 
(L4), the reactions with [Pd(allyl)Cl]2 and Pd(OAc) 2 as the catalyst precursors gave similar yield 
as well asymmetric induction, which match the efficiency of BINAP (L2) (entries 7–8). DTBM-
SEGPHOS (L5) did not provide any desired product, while SYNPHOS (L14) exhibited high 
enantioselectivity, although with low yield. Further ligand screening using MeOBIPHEP (L6), C3-
TUNEPHOS (L15), GARPHOS (L16), and CTH-P-PHOS (L17) all provided the product 4.3a 
with high levels of enantioselectivity.  
 Beside the chiral biaryl ligands, a chiral version of the DPEPhos ligand[102] (L18, Figure 
4-1) was synthesized and applied to the conditions shown in Table 4-7. Although the reaction 
proceeded smoothly, only low enantiomeric ratio was observed. 
4.5 Application to the synthesis of Sertraline 
 Sertraline (4.22) is one of the best-selling antidepressant on the market today, classified as 
a selective serotonin reuptake inhibitor (SSRI).[103] Although many syntheses of Sertraline have 
been reported, the development of dearomative syn-1,4-carboamination provides a novel and 
alternative approach to such medicinally important molecules in expedient fashion, starting from 
inexpensive feedstock chemical, naphthalene (1.2a). Thus, the naphthalene–cycloadduct, formed 
in situ, was treated with 3,4-dichlorophenyl magnesium bromide to provide the carboaminated 
product 4.3b in 52% yield. The olefin functionality on 4.3b was then hydrogenated, followed by 
alkylation of the urazole moiety to give 4.20. At this point, the remaining transformation necessary 
to synthesize Sertraline was to convert the alkylated urazole to a requisite methylamino group. 
This was achieved by two-step protocol: treating 4.20 under basic conditions to provide urea 4.21 
through hydrolysis, followed by reduction with LiAl(OMe)3H[104] at reflux conditions (also see 




L18: 61% yield, 54:46 er
Figure 4-1: Carboamination 
with chiral DPEphos. 
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yield. Furthermore, as a preliminary result, the carboamination was attempted with asymmetric 
conditions, and high enantioselectivity was observed using Pd(OAc)2 and SEGPHOS (L4) (Figure 
4-2). 
 For the reduction of urea to a requisite methyl amine, the choice of reductant was crucial 
in promoting the reaction as well as preventing protodechlorination (Table 4-8). The use of lithium 
aluminum hydride was too reactive and gave a mixture of the desire product and the dechlorinated 
compounds (entries 1–2). Therefore, milder reductant was examined. While no conversion was 
observed with LiAl(OtBu)3H (entry 3), LiAl(OMe)3H[104] was effective in avoiding the undesired 
pathways in diluted conditions (0.01 M), providing Sertraline in 65% isolated yield (entries 4–6).  
Scheme 4-5: Synthesis of Sertraline using dearomative syn-1,4-carboamination. 
NUR




–50 to 15 ºC, 10 h
52%
MTAD (1.57a, 1.0 eq.)






1. Rh/Al2O3 (cat.), H2 (1 atm)
EtOAc (0.1 M), rt , 12 h
















































Figure 4-2: Preliminary result on asymmetric carboamination with 
3,4-dichlorophenyl magnesium bromide. 
NUR
CH2Cl2/THF
–50 to 15 ºC, 10 h
ArMgBr (2.0 eq.)
Pd(OAc)2 (5.0 mol%)
(R)-Ph-SEGPHOS L4 (10 mol%)







Table 4-8: Optimization for the reduction of urea 4.21.  
entry reductant x [M] time (h) yield (%)a 
1b LiAlH4 0.1 20 complex mixture 
2b LiAlH4 0.03 20 complex mixture 
3 LiAl(OtBu)3H 0.03 20 <5 
4 
LiAl(OMe)3H 
0.1 20 complex mixture 
5 0.01 20 65 
6 0.005 40 <5 
aIsolated yield. bReaction was conducted at rt. 
 
4.6 Conclusion  
 In this chapter, Grignard reagents were shown to be viable nucleophiles for the arenophile 
mediated palladium-catalyzed dearomative carboamination. As opposed to generally observed net-
inversion of stereochemistry of the resulting product, this method provides syn-1,4-carboaminated 
products exclusively for both mononuclear and polynuclear arenes. Nonetheless, arenes with a 
wide variety of functional groups were amenable to this transformation, and the asymmetric 
version has also been developed using meso-cycloadducts. Furthermore, the utility of this process 
was demonstrated by applying it to the concise synthesis of sertraline, which was achieved from 
naphthalene in just 5 steps with 20% overall yield.  
 Considering the limited examples of allylic substitution using hard nucleophiles, both in 
racemic and asymmetric reactions, the capability of this method to enable such process, 
concomitant with the dearomatization of simple non-activated arenes is significant. Although the 
exact reason for the unusual stereoselectivity is not clear at this stage, this discovery has opened a 


















Chapter 5: Palladium-Catalyzed Dearomative syn-1,4-Diamination† 
5.1 Background and significance 
 A dearomative transformation that directly installs heteroatom functionalities to the core 
carbocycle of simple arenes is an enabling process for rapidly synthesizing complex alicyclic 
structures. Thus, the aim of this chapter is to describe the extension of palladium-catalyzed 
dearomative carboamination methods beyond carbon nucleophiles. In particular, this chapter deals 
with the use of nitrogen nucleophiles, which provide facile access to diaminodienes that are 
effective precursors to diamine motifs prevalent in nature (Figure 5-1).[105,106] In chapter 2, 
arenophile-mediated dearomative reduction and subsequent arenophile fragmentation showcased 
the feasibility of preparing diamines within a few chemical transformations from simple arenes. 
Although highly effective, one of the unaddressed challenges in that method was to introduce two 
structurally different amines. Since the palladium-catalyzed dearomative aminofunctionalization 


























































Figure 5-1: Examples of diaminocyclohexane motifs in natural 
products and bioactive compounds. 
†Portions of this chapter are reproduced from the following publication with permission from the 
authors. W. C. Wertjes, M. Okumura, D. Sarlah, J. Am. Chem. Soc. 2019, 141, 163.[51] 
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 Historically, simple amines have been utilized in dearomative aminofunctionalization 
reactions, mainly in photoaddition of aliphatic amines to aromatic compounds.[107] First reported 
in 1967,[108] these transformations proceed via photoexcitation of the parent arene to its S1 state 
using a low-pressure mercury lamp, with or without an electron acceptor. The photoactivated arene 
then presumably forms a charge transfer complex with amine to generate an aromatic cation radical, 
and subsequent addition of the amine nucleophile proceeds.[109] For benzene, both 1,2- and 1,4-
addition occur, and the ratio of the products is highly dependent on the nature of the amine (Scheme 
5-1, top).[110] For polynuclear arenes, product selectivity between different constitutional isomers 
varies significantly and is highly dependent on the substituents (Scheme 5-1 bottom).[111] Although 
these transformations are very unique, significant limiting challenges include poor product 
selectivity and difficulty in purifying the isomeric mixtures, which makes them unpractical.  
 Other representative examples include palladium-catalyzed amination of 
chloromethylnaphthalene or chloromethylanthracene with amines, which is proposed to proceed 
through a p-benzyl palladium complex (Scheme 5-2, A).[112] In this transformation, stable products 
were obtained upon rearomatization. Another example involves a dearomative aziridination of 
naphthalene using 3-acetoxyaminoquinazolin-4(3H)-one, which undergoes oxidation in situ to 
form QNHOAc and acts as an aziridinating reagent (Scheme 5-2, B).[113]  














































    Compared to the literature known protocols for dearomative aminofunctionalization 
described above, arenophile-mediated dearomative diamination using a palladium catalyst and 
amine nucleophile is a conceptually different approach. Considering the ample precedent for 
catalytic allylic amination reactions, the dearomative diamination was anticipated to proceed using 
a range of amine nucleophiles. Furthermore, based on the arene substrate scope exhibited in 
chapter 3 and 4, this arenophile-mediated strategy was also expected to encompass a variety of 
simple arenes as viable substrates. As depicted in Scheme 5-3, the constitutional- and 
stereochemical outcome of these transformation is predicted to be syn-1,4-selective. Together with 
numerous possibilities for further diversifying the diaminated products, this novel process overall 
offers rapid and straightforward access to complex building blocks from simple arenes that are 
otherwise not readily accessible. 
5.2 Reaction optimization for naphthalene and benzene 
 It has been well documented that nitrogen-containing compounds ranging from anilines, 
amines, amides, to metal amides are viable nucleophiles in palladium-catalyzed allylic 
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(B) Dearomative aziridination of naphthalene





























aminations.[44,45] Thus, a suitable nitrogen nucleophile was first explored for the arenophile-
mediated dearomative diamination. As shown in Table 5-1, representative N-nucleophiles were 
tested using naphthalene as model substrates and Pd(PPh3)4 as a catalyst in 
dichloromethane/tetrahydrofuran mixture. Although most of the amines tested did not provide any  
 
Table 5-2: Catalyst optimization. 
entry [Pd] ligand yield (%)a 
1 Pd(PPh3)4 – 57 
2 [Pd(allyl)Cl]2 PPh3 51 
3 Pd(MeCN)2Cl2 PPh3 <5 
4 Pd(OAc)2 PPh3 <5 
5 Pd(dba)2 PPh3 55 
6 Pd2(dba)3 PPh3 52 
7 Pd2(dba)3 P(p-MeOC6H4)3 44 
8 Pd2(dba)3 P(p-FC6H4)3 10 
9 Pd2(dba)3 P(o-MeC6H4)3 <5 
10 Pd2(dba)3 PPh2Cy 48 
11 Pd2(dba)3 PPhCy2 22 
12 Pd2(dba)3 dppfb 36 
aDetermined by 1H NMR analysis. b6.0 mol% ligand used. 
Table 5-1: Initial screening of nitrogen nucleophile. 
then: N-nucleophile (2.0 eq.)
Pd(PPh3)4 (5.0 mol%)
CH2Cl2/THF, –50 to 0 ºC, 5 h
MTAD (1.57a, 1.0 eq.)





R = Me: <5%
R = Ac: <5%
NHR
R = Me: 57%










R = H: <5%
R = K: <5%
(±)-5.1a
Reaction was run on 0.5 mmol scale. Yield was determined by crude 1H NMR analysis.
then: BnNHMe (2.0 eq.)
[Pd] (5.0 mol%)
ligand (12 mol%)
CH2Cl2/THF, –50 to 0 ºC, 5 h
MTAD (1.57a, 1.0 eq.)














product, the reaction with N-benzylmethylamine proceeded smoothly to give a 57% isolated yield 
of the desired product 5.1a. The product was confirmed to have syn-1,4-selectivity based on x-ray 
crystal structure (see Table 5-5), and the 1H NMR analysis showed no other isomers present in the 
crude mixture. Thus, further optimization was conducted using N-benzylmethylamine. 
 Next, palladium sources as well as ligands were screened (Table 5-2). A variety of both 
Pd(II) and Pd(0) complexes were tested with PPh3 as a ligand, and found that Pd(PPh3)4 gave the 
highest yield (entries 1–6). Other monodentate phosphine ligands bearing aryl and alkyl groups 
did not improve the reaction (entries 7–11). Dppf was also tested as a representative bidentate 
ligand; however, it only resulted in a moderate yield (entry 12). Therefore, further optimization 
was carried out using Pd(PPh3)4 as the catalyst. 
 Since some unreacted cycloadduct was remained in the reaction mixture for Table 5-2, 
entry 1, in which the substitution step was conducted by slowly warming form –50 ºC to 0 ºC over 
5 hours, the mixture was instead kept at –20 ºC for 20 h (Table 5-3, entries 1–2). As a result, 
improved conversion was observed to give 70% yield of 5.1a. Other solvents such as propionitrile 
and ethyl acetate were equally effective, and 5.1a was obtained in 72% 1H NMR yield and 62% 
isolated yield using ethyl acetate (entries 2–4). The significant decrease in isolated yield is mainly 
due to the instability of the product 5.1a, which slowly decompose during the workup process. 
 
Table 5-3: Solvent and reaction temperature screening.  
entry solvent temp. (ºC) yield (%)a 
1 CH2Cl2 –50 to 0b 57 
2 CH2Cl2 –20 70 
3 EtCN –20 70 
4 EtOAc –20 72 (62) 
aDetermined by 1H NMR analysis. Isolated yield shown in parenthesis. 
bReaction for substitution step was 5 h. 
 
then: BnNHMe (2.0 eq.)
Pd(PPh3)4 (5.0 mol%)
solvent/THF, temp., 20 h
MTAD (1.57a, 1.0 eq.)














Table 5-4: Optimization for benzene.  
entry solvent x [M] yield (%)a 
1 EtOAc 0.1 <5 
2 EtCN 0.1 <5 
3 CH2Cl2 0.1 40 
4 CH2Cl2 0.2 63 (49) 
aDetermined by 1H NMR analysis. Isolated yield shown in parenthesis.  
 
 As for the benzene-cycloadduct, the diaminated product was not observed with the 
optimized conditions for naphthalene (Table 5-4, entry 1). However, solvent screening revealed 
that although propionitrile was also not suitable, high conversion to product 5.2a was obtained 
using dichloromethane. Further improvement was observed when the reaction concentration was 
increased from 0.1 M to 0.2 M, giving 63% 1H NMR yield and 49% isolated yield of 5.2a. The 
same syn-1,4-selectivity was confirmed for 5.2a compared to naphthalene counterpart, and the 
poor isolation yield was also due to the instability of the diaminated product. 
5.3 Scope of the dearomative syn-1,4-diamination  
 With optimized conditions for naphthalene in hand (Table 5-4, entry 4), the secondary 
amine scope was examined (Table 5-5). Beside N-benzylmethylamine, other acyclic amines such 
as dimethylamine (5.1b) and diethylamine (5.1c) gave products in high yields. Cyclic amines were 
also proved to be viable nucleophiles, as exemplified with pyrrolidine, piperidine, morpholine, and 
N-methylpiperazine (5.1d–h).  
 Next, a dearomative diamination process using primary amines as substrates was examined, 
and observed significant erosion in yield using Pd(PPh3)4. Thus, additional catalyst screening was 
performed, and it was found that the combination of Pd2(dba)3 and dppf greatly improved the 
reactivity for these substrates (Table 5-6). For example, reactions with linear propyl-, pentyl-, and 
benzylamine proceeded smoothly to provide the diaminated products (5.1i, 5.1j, 5.1n). Branched 
primary alkylamines such as isopropyl-, cyclohexyl-, and tert-butylamine were also viable 
then: BnNHMe (2.0 eq.)
Pd(PPh3)4 (5.0 mol%)
solvent/THF, –20 ºC, 20 h
MTAD (1.57a, 1.0 eq.)













 substrates (5.1k–m). Furthermore, this process was mild enough to tolerate amines with a variety 
of functionality, as demonstrated with an alkene, protected alcohol, and ester group (5.1o-q).  
Scalability of the process was also tested using n-propylamine, and 74% isolated yield of the 
desired product 5.1i was obtained on an 8.8 mmol scale. The decrease in the yield compared to the 
reaction on 0.5 mmol scale is mainly due to the prolonged workup/purification time necessary for 
a larger scale, which contributed to the decomposition.  
Table 5-6: Primary amine scope with naphthalene.  



















then: NHR1R2 (2.0 eq.)
Pd2(dba)3 (5.0 mol%)
dppf (6.0 mol%)
EtOAc/THF, –20 ºC, 20 h
MTAD (1.57a, 1.0 eq.)























[x-ray of 5.1a] 
Table 5-5: Secondary amine scope with naphthalene. 
then: NHR1R2 (2.0 eq.)
Pd(PPh3)4 (5.0 mol%)
EtOAc/THF, –20 ºC, 20 h
MTAD (1.57a, 1.0 eq.)



































Reaction was run on 0.5 mmol scale. Isolated yield shown after flash chromatography.
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 Dearomative diamination with polynuclear arenes was also investigated using n-
propylamine as the nucleophile (Table 5-7). Both symmetrical (5.3, 5.4) and non-symmetrical 
arenes (5.5–5.11) provided the diamine products, albeit with moderate yield due to the instability 
of the products during purification (in general up to 20% higher yield were observed in crude 1H 
NMR analysis of the crude material). As was observed with carbon-based nucleophiles, mixtures 
of constitutional isomers were formed for non-symmetrical substrates, resulting from the lack of 
regioselectivity in opening the arene–arenophile cycloadduct. Nonetheless, a wide range of 
functional groups such as ester (5.3, 5.4, 5.5, 5.10), acetal (5.6), halide (5.7), and protected amine 
(5.9) were tolerated under the optimized conditions. In some case, the reaction conditions were 
changed, such as reaction temperature or solvent used in order to enhance reactivity, as well as 
improve the solubility of the cycloadduct. In addition, not all the substrates that were amenable for 
dearomative carboaminations were viable for diamination. Representative failed substrates that 
form cycloadducts are shown in Table 5-7, bottom.  
Table 5-7: Polynuclear arene scope with propylamine. 
then: nPrNH2 (2.0 eq.)
Pd2(dba)3 (2.5 mol%), dppf (6.0 mol%)
EtOAc/THF, –20 ºC, 20 h
MTAD (1.57a, 1.0 eq.)


























Reaction was run on 1.0 mmol scale. Isolated yield shown after flash chromatography. Ratio of constitutional isomers was 
determined by crude 1H NMR analysis, and major isomer shown in the table. Unless otherwise stated, two isomers were 
column separable. aSubstitution step conducted at –20 ºC for 20 h. bCH2Cl2 was used instead of EtOAc. c10 mol% [Pd] 


































 On the other hand, dearomative diaminations were much more productive with polynuclear 
heteroarenes. As shown in Table 5-8, a range of heteroarenes encompassing quinoline (5.12–5.14, 
5.17–5.19), isoquinoline (5.20, 5.21), benzo[h]quinoline (5.22), quinoxaline (5.23, 5.24), acridine 
(5.15, 5.16), and benzoquinoxaline (5.25) derivatives bearing sensitive functional groups were 
viable substrates to give moderate to high yields of the desired diamines. However, the major 
problem encountered with many of these products was instability towards purification using 
column chromatography. Thus, only the diamines 5.12–5.16 were successfully isolated; others 
suffered from decomposition of either one or both constitutional isomers. Nonetheless, several 
observations could be made in terms of site-selectivity and stability for these heteroarenes. For 
instance, the major constitutional isomer obtained from quinoline derivatives (5.12–5.14, 5.17–
5.19) and acridine derivatives (5.15, 5.16) had the urazole moiety residing at the opposite side of 
































(±)-5.15 (R = H):









then: nPrNH2 (2.0 eq.)
Pd2(dba)3 (2.5 mol%), dppf (6.0 mol%)
EtOAc/THF, –20 ºC, 20 h
MTAD (1.57a, 1.0 eq.)




















Reaction was run on 1.0 mmol scale. Isolated yield shown after flash chromatography. Ratio of constitutional isomers was 
determined by crude 1H NMR analysis, and major isomer shown in the table. Unless otherwise stated, two isomers were 
























the pyridine nitrogen atom. In contrast, no such trend was recognized for the isoquinoline 
derivatives (5.20, 5.21), since the urazole moiety of the major isomer preferred to be adjacent to 
the substituent of the parent arene. As discussed in Chapter 3, this selectivity may be due to the 
preference of the palladium complex on the p-allyl palladium species to be at the most remote site 
from the arene substituent. Furthermore, despite the high yield, more electron-poor products , such 
as 5.17, 5.19, 5.23, and 5.24, usually decomposed more readily presumably owing to increased 
acidity of the benzylic positions. 
 The scope of the dearomative diamination for the benzene–cycloadduct was also explored 
using representative primary and secondary amines (Table 5-9). For secondary amines, both linear 
and cyclic amines were capable of forming diaminated products (5.2a–5.2d). Likewise, the 
reaction with primary amines proceeded smoothly (5.2e–5.2h). The stereoselectivity of the 
transformation for both primary and secondary amines with benzene were confirmed to be the syn-
1,4 selectivity exclusively, same as it was observed for naphthalene scope (x-rays see Table 5-9). 
 It is important to mention that all the syn-1,4-diaminated products, upon purification by 
column chromatography, were not bench-top stable for more than a couple of hours, unless the 
column-purified compound was triturated with either diethyl ether or ethyl acetate. Once these 
compounds were triturated and become a solid powder, then they are stable for at least a week in 
Table 5-9: Amine scope of benzene. 
[x-ray of 5.2d] 
[x-ray of 5.2f] 
5.2a: 48% 5.2b: 55% 5.2c: 57%
5.2e: 62% 5.2f: 72% 5.2g: 50%a
then: amine (2.0 eq.)
[Pd] (5.0 mol%), ligand (6.0 mol%)
CH2Cl2/THF, –20 ºC, 20 h
MTAD (1.57a, 1.0 eq.)
































the freezer. However, for those products that are liquid readily decomposed within a matter of few 
hours. 
5.4 Development of asymmetric variants for dearomative syn-1,4-diamination 
 An enantioselective variant of the dearomative syn-1,4-diamination was also developed. 
Thus, using (S,Sp)-tBu-Phosferrox (L12) as a chiral ligand, desymmetrization of the naphthalene–
cycloadduct with both secondary (5.1e, 5.1f) and primary (5.1i, 5.1k, 5.1l) amines proceeded 
smoothly to give high yields of the diaminated product, as well as high enantioselectivities (Table 
5-10).  
5.5 Product elaboration 
 The dearomative diamination serves as an entry point for rapid elaboration of simple arenes 
to a diverse set of functionalized compounds. For example, chemoselective reduction of the olefin 
moiety of 5.1i, followed by chemoselective benzylic C–N(urazole) bond cleavage through 
dissolving metal reduction afforded 5.27 (Scheme 5-4). The use of Rh/Al2O3 as a catalyst in the 
first step was crucial for the selectivity, as other catalysts such as Pd/C reduced the olefin and both 
benzylic C–N bonds unselectively to give a complex mixture of products. In contrast, acidic 
treatment of 5.26 triggered b-elimination of the urazole moiety, resulting in net-1,2-
hydroamination of the parent naphthalene (5.28). Furthermore, subjecting 5.1i directly to 
dissolving metal reduction conditions gave 1,4-hydroaminated naphthalene 5.29. Compared to the 
Table 5-10: Enantioselective dearomative syn-1,4-diamination of naphthalene. 
then: NHR1R2 (2.0 eq.)
Pd2(dba)3 (2.5 mol%)
L12 (6.0 mol%)
EtOAc/THF, –20 ºC, 20 h
MTAD (1.57a, 1.0 eq.)








































preparation of 5.28 and 5.29 using photoamination of naphthalene (Scheme 5-1), this dearomative 
diamination protocol provides a highly selective means to access these net-hydroaminated arenes. 
 On the other hand, oxidation of the urazole moiety in 5.29 afforded g-aminotetralone 5.30 
(Scheme 5-5). In this case, the product was isolated as HCl salt to avoid condensation. 
 Diaminated products provide facile 
access to differentially substituted syn-1,4-
diamines through a three-step protocol from 
5.26 (Scheme 5-6). Selective Boc-protection of 
the amine, followed by alkylation of the urazole 
moiety provided 5.32, which was then treated 
under basic conditions to give diamine 5.33.[85] As depicted in Figure 5-1, syn-1,4-diamines are 
prevalent motifs in many natural products and biologically active compounds; this dearomative 
diamination strategy provides straightforward and general route to such important structures. 
 








































Scheme 5-5: Oxidation of urazole moiety. 
K2CO3 (5.0 eq.)
DCM (0.1 M)



















80 ºC, 20 h;





















Scheme 5-6: Conversion of 5.26 to diamine 5.33. 
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 Compared to the 
naphthalene-derived diaminated 
products, the derivatization of 
benzene-derived products proved 
to be much more challenging due 
to their instability towards both 
basic and acidic conditions that promote rearomatization. Nonetheless, several transformations 
were established. For instance, dissolving metal reduction of 5.25f afforded a mixture of 5.34 
(major) and 5.35 (minor), albeit with only trace yields. Since the starting material 5.25f was 
completely consumed, most the material underwent decomposition.  
 To further explore the derivatization potentials of the diaminated 5.25f, a series of reactions 
were conducted to explore and improve the stability of 5.25f towards decomposition during 
derivatization. First, both the amino group and urazole moiety were protected by Boc group to 
afford 5.36. Then, selective Boc deprotection of the urazole was achieved using sodium methoxide 
to give 5.37, which was then alkylated (5.38). These two steps could be combined in one-pot; 
however, the overall yield was much lower than the stepwise protocol. 
 With the bis-Boc protected compound 5.36, conditions to oxidize the olefins through 
osmium-catalyzed dihydroxylation was investigated (Table 5-11). When typical Upjohn 
conditions with slight excess of N-methylmorpholine N-oxide (NMO) were employed, no 
conversion was observed (entry 1). Catalytic amounts of citric acid, known to accelerate Upjohn 














Scheme 5-7: Reductive cleavage of C–N(urazole) on 5.25f.  


































5.36: 60%5.25f 5.37: 78% 5.38
K2CO3 (5.0 eq.)
DCM (0.1 M)


















Table 5-11: Optimization for osmium-catalyzed dihydroxylation of 5.36. 
entry NMO (x eq.) additive (y eq.) solvent R SM:5.39:5.40a yield (%)a 
1 1.3 – acetoneb 
H 
1:0:0 – 
2 1.3 citric acid (0.3) acetoneb decomp. – 
3 2.0 – acetone:H2Oc 1:2.6:0 5.39a: trace 
4 2.0 – tBuOH:H2Oc 1:2.4:0 5.39a: trace 
5 2.0 nBuB(OH)2 (2.0) CH2Cl2 
 
0:0:1 5.40b: 10% 
6 4.0 nBuB(OH)2 (4.0) CH2Cl2 0:0:1 5.40b: 87% 
aDetermined by 1H NMR analysis. Isolated yield shown in parenthesis. bH2O 20 eq. added. c1:1 ratio. 
 
(entry 2). When the amount of water was increased to solvent quantities, dihydroxylated product 
5.39a was isolated in trace amount (entry 3). Based on the analysis of the crude material, most of 
the starting material was decomposed. Changing solvent from acetone to tert-butanol did not 
improve the reaction outcome (entry 4). On the other hand, when Narasaka–Sharpless conditions 
were employed, where the dihydroxylation is conducted using n-butylboronic acid as an additive 
under anhydrous conditions in dichloromethane,[114] the formation of the tetrahydroxylated 
product 5.40b was obtained as bis-boronate ester (entry 5), and the dihydroxylated compound was 
not detected. Further increasing the amount of NMO gave much higher conversion to provide the 




























































80 ºC, 20 h;

































 The Narasaka conditions in Table 5-11, entry 6 were then applied to compound 5.38, which 
gave 94% of the tetraol boronate ester 5.41 (Scheme 5-9). Oxidative deprotection of the boronate 
ester moiety proceeded in moderate yield to provide tetraol 5.42, which was then treated under 
basic conditions to remove the Boc group, as well as to hydrolyze the urazole moiety down to 
amine 5.43. However, the latter transformation was not successful.  
5.6 Elaboration of anti-Alzheimer drug memantine 
 The dearomative diamination protocol was then applied to the structural elaboration of 
amine-containing drugs. Specifically, memantine, an FDA-approved drug used for the treatment 
of dementia associated with Alzheimer’s disease,[115] was coupled to naphthalene through the 
standard conditions used in Table 5-6 to give syn-1,4-diaminated product 5.1r in 66% isolated 
yield (Scheme 5-10, A). Moreover, the diaminated product 5.1r was amenable to a variety of 
further diversification. Dissolving metal reduction of 5.1r chemoselectively cleaved the benzylic 






then: memantine (2.0 eq.)
Pd2dba3 (2.5 mol%)
dppf (6.0 mol%)




















(±)-5.45: 57% (±)-5.46: 80%
MeOH (0.1 M)
-20 °C, 16 h
1 M aq. HCl (0.1 M)
MeCN (0.1 M)
rt, 5 min(±)-5.44: 64%
K2CO3 (5.0 eq.)
DCM (0.1 M)
























80 ºC, 20 h;




























MTAD (1.57a, 1.0 eq.)























C–N(urazole) bond to give 1,4-hydroaminated naphthalene 5.44, whereas the chemoselective 
hydrogenation of the olefin, followed by oxidation of the urazole afforded aminoketone 5.46 
(Scheme 5-10, B). Diaminated product 5.1r could also be converted diaminodiol 5.49 in three-step 
procedure: alkylation of urazole (5.47), Upjohn dihydroxylation (5.48), and subsequent hydrolysis. 
5.7 Initial results for dearomative syn-1,2-diamination 
 In order to alter the selectivity observed for the dearomative diamination, other potential 
nitrogen nucleophiles were considered. Isocyanate was an intriguing candidate, as it was expected 
to first react as an electrophile with the urazole leaving group, formed upon oxidative addition, 
which would reveal a nitrogen-based nucleophilic site.[116] This should allow the nucleophilic 
attack to be directed to occur adjacent to urazole, resulting in the formation of a 1,2-diamine. Thus, 
phenyl isocyanate was chosen as a substrate, and the reaction was conducted with the benzene–
cycloadduct, formed in situ in dichloromethane, in the presence of Pd(PPh3)4 as the catalyst (Table 
5-12). When the mixture was slowly warmed from –50 ºC to 0 ºC over 5 h, although the desired 
product 5.50 was not observed, high yields of the tetra-aminated product 5.51 were formed (entry 
1, stereochemistry assigned by 2D NMR). The formation of 5.51 is presumably due to a Diels-
Alder cycloaddition between 5.50 and MTAD (1.57a), generated in situ through retrocycloaddition 
of the unreacted cycloadduct. Keeping the reaction temperature for the substitution step to –20 ºC  
 
Table 5-12: Initial optimization for dearomative syn-1,2-diamination.  
entry R additivea temp. (ºC) time (h) 5.50:5.51b yield (%)b 
1 Ph – –50 to 0 5 1:>20 5.51: 50 
2 Ph – –20 12 3.5:1 – 
3 Ph 1,3-CHD –20 12 >20:1 5.50: 53 (52) 
4 Ts 1,3-CHD –20 12 –– <5 
5 Et 1,3-CHD –20 12 –– <5 
a1,3-Cyclohexadiene (1,3-CHD) was added after the cyclocloaddition step. bDetermined by 1H 





MTAD (1.57a, 1.0 eq.)
visible light, -78 ºC

























for 12 h resulted in a mixture of 5.50 and 5.51 (entry 2). In order to prevent a such side reaction, 
1,3-cyclohexadiene was added at the substitution step as MTAD scavenger, which successfully 
shut down the undesired pathway, and afforded the syn-diamine 5.50 selectively with a 52% 
isolated yield (entry 3). Other isocyanate sources, such as tosyl isocyanate and ethyl isocyanate 
were also tested; however, the formation of the product was not observed (entry 4 and 5). 
Nonetheless, the concept of using isocyanate to change the selectivity was demonstrated; the 
dearomative diamination protocol with amines and isocyanate provided selective access to both 
syn-1,2-diamine and syn-1,4-diamine. 
5.8 Conclusion  
 Arenophile-mediated palladium-catalyzed dearomative diamination was developed. This 
is the first example of a dearomative aminofunctionalization strategy to promote coupling between 
simple arene and heteroatom-based nucleophiles. In this process, a variety of amines and arenes 
provided products with exclusive syn-1,4-selectivity, which is in accordance with the expected 
outcome. The corresponding dearomatized products were further derivatized to showcase unique 
and facile ways to access highly functionalized alicyclic structures. Furthermore, the synthetic 
value of the method was also demonstrated by selective elaboration of memantine, an anti-
Alzheimer drug, into new analogues. Overall, this novel dearomatization reaction offers rapid and 






Chapter 6: Palladium-Catalyzed Dearomative syn-1,4-Oxyamination 
6.1 Background and significance 
 The aim of this chapter is to further explore the scope of heteroatom-nucleophiles for the 
palladium-catalyzed dearomative aminofunctionalization strategy. Besides nitrogen-based 
nucleophiles that provide diaminocyclohexane derivatives, incorporation of oxygen-based 
nucleophiles would enable facile synthesis of aminocyclohexanol derivatives. Such a process 
would greatly expand the accessible bioactive motifs, as many natural products and biologically 
active compounds possess such structures (Figure 6-1).[117] 
 Dearomative oxidations (limited to reactions that install oxygen functionality to the 
dearomatized core) of simple arenes have been studied for decades, and some unique 
transformations have been developed. For example, arene epoxidation, either enzymatic or 
chemical, has long been known; however, in most cases the resulting epoxide itself cannot be 
directly isolated due to a spontaneous NIH shift which rearomatize the ring to form an 









































































hydroxylated arene (Scheme 6-1, A)[118]. Photo-oxygenation of simple polynuclear arenes is 
another powerful method to install oxygen functionality directly to the arene core (Scheme 6-1, 
B).[119] In this process, singlet oxygen (1O2) formed in situ undergoes a [4+2] cycloaddition with 
an arene to afford endoperoxide. On the other hand, dearomative 1,4-addition of alcohol to 1-
naphthalene derivative mediated by N-phenyl-1,2,4-triazoline-3,5-dione (PTAD) is a unique 
example that enable direct formation of a ketal group (Scheme 6-1, C).[120] Finally, the arenophile-
mediated dearomative dihydroxylation method has demonstrated the feasibility of concomitant 
dearomatization of simple arenes using arenophiles, and dihydroxylation of the resulting 
cycloadduct (Scheme 6-1, D).[26]  
 Despite several enabling dearomative oxidations being established, there still remain ample 
room for developing novel dearomative oxidation processes that expand the toolbox of synthetic 
organic chemistry. Based on the outcomes of the palladium-catalyzed aminofunctionalization 
described in prior chapters, as well as precedent for the catalytic allylic substitution with oxygen 
nucleophiles,[44,45] arenophile-mediated dearomative oxyamination was anticipated to provide 




























6.2 Reaction optimization with naphthalene 
 Condition screening for the dearomative oxyamination began with finding suitable oxygen-
based nucleophiles. It has been reported that reagents ranging from carboxylates,[121] 
phenols/alcohols,[122] silanolates,[123] aminoalcohols,[124] to oximes[125] are amenable to palladium-
catalyzed allylic substitution. Thus, the initial investigation was conducted using naphthalene as 
the model substrate, Pd(PPh3)4 as the catalyst, and a variety of oxygen nucleophiles in the presence 
of potassium tert-butoxide as a base. As shown in Table 6-1, among all the nucleophiles tested, 
only acetophenone oxime provided a trace amount of desired product 6.1a. Nonetheless, this result 
proved that the dearomative oxyamination was feasible. As expected based on the pKa of the 
oximes, the stereochemistry of the product 6.1a was syn-1,4-product, and no other isomers were 
observed (see Table 6-5 for x-ray crystal structure). 
 To optimize the reaction conditions, the choice of base was investigated first (Table 6-2). 
Although a trace amount of product 6.1a was formed using potassium tert-butoxide by pre-mixing 
the base with acetophenone oxime in THF, the mixture was a suspension, which most likely 
attenuated the reactivity (entry 1). The reaction did not proceed when the base was changed to 
sodium ethoxide or sodium hydride (entries 2–3). However, when the deprotonation was 
conducted with strong lithium bases to irreversibly form the lithiated oxime, the reaction 
proceeded smoothly to give good conversion (entries 4–6). Using these lithium-based bases, the 
mixture of the oxime and the base in THF was consistently a solution. Other strong bases such as 
NaHMDS, KHDMS, or MeMgBr were less effective, and no reaction occurred in the absence of 
base (entries 7–10). Thus, n-BuLi was selected as the optimal base (entry 6). 
  
Table 6-1: Initial screening of oxygen-based nucleophile. 
then: O-nucleophile (2.0 eq.)
KOtBu (2.0 eq.)
Pd(PPh3)4 (5.0 mol%)
CH2Cl2/THF, –50 to 0 ºC, 5 h
MTAD (1.57a, 1.0 eq.)



























entry base oxime+base/THFa yield (%)b 
1 KOtBu suspension 5 
2 NaOEt suspension <5 
3 NaH suspension <5 
4 LDA solution 39 
5 LiHMDS solution 35 
6 nBuLi solution 42 
7 NaHMDS suspension 30 
8 KHMDS solution <5 
9 MeMgBr suspension <5 
10 – solution <5 
aPhysical state of premixed oxime and base in THF at –78 ºC. For KOtBu, NaOEt, and 
NaH, deprotonation was done at 0 ºC. bDetermined by 1H NMR analysis. 
 
 Next, to improve the conversion of the cycloadduct in the substitution step, the effect of 
solvent was tested (Table 6-3). By conducting the cycloaddition in dichloromethane and pre-
forming the lithiated oxime in THF, 42% yield of 6.1a was obtained (entry 1). Replacing the 
solvent for cycloaddition with acetone or ethyl acetate had a detrimental effect on the reaction 
outcome, whereas in propionitrile an improvement in yield was observed (entries 2–4). On the 
other hand, etheric solvents other than THF for the deprotonation of the oxime were less successful, 
so as in propionitrile and DMF (entries 5–9). However, when toluene was used, the yield of 6.1a 
significantly improved to give a 70% isolated yield, despite the insolubility of lithiated species in 
toluene (entry 10). With these conditions, full conversion of the naphthalene cycloadduct was 
observed. Thus, further optimization was conducted using propionitrile and toluene as the solvents.  
 Finally, the effect of palladium source and ligand were explored. In the presence of PPh3 
as the ligand, both Pd(OAc)2 and Pd2(dba)3 afforded 6.1a (Table 6-4). Some representative 
monodentate and bidentate phosphine ligands were tested, which showed that Pd(PPh3)4 provided 
the highest yield. Thus, the conditions in entry 1 were chosen as the optimized conditions.  
Table 6-2: Base screening.  
then: acetophenone-oxime (2.0 eq.)
base (2.0 eq.)
Pd(PPh3)4 (5.0 mol%)
CH2Cl2/THF, –50 to 0 ºC, 5 h
MTAD (1.57a, 1.0 eq.)















entry solvent 1 solvent 2a yield (%)b 
1 CH2Cl2 THF 42 
2 acetone THF 21 




5 Et2O 43 
6 nBu2O <5 
7 MTBE 8 
8 EtCN 26 
9 DMF <5 
10 PhMe 71 (70) 
aSolvent used to preform lithium-oxime complex. bDetermined by 1H NMR analysis. 
Isolated yield shown in parenthesis. 
  
 
entry [Pd] ligand yield (%)a 
1 Pd(PPh3)4 – 71 (70) 
2 Pd(MeCN)2Cl2 PPh3 4 




5 P(p-MeOC6H4)3 53 
6 dpppb 5 
7 dppbb 42 
8 dppfb 40 
aDetermined by 1H NMR analysis. Isolated yield shown in parenthesis. b6.0 mol% ligand used. 
Table 6-3: Solvent screening. 
then: acetophenone-oxime (2.0 eq.)
nBuLi (1.9 eq.)
Pd(PPh3)4 (5.0 mol%)
solvent 1/solvent 2, –50 to 0 ºC, 5 h
MTAD (1.57a, 1.0 eq.)













Table 6-4: Catalyst optimization.  




EtCN/PhMe, –50 to 0 ºC, 5 h
MTAD (1.57a, 1.0 eq.)















6.3 Scope of the dearomative syn-1,4-diamination for polynuclear arenes 
 With optimized conditions in hand, the oxime scope of the dearomative oxyamination 
using the naphthalene cycloadduct was explored. As shown in Table 6-5, a variety of para-
substituted acetophenone oxime derivatives with different substituents were amenable to give high 
yield of the syn-1,4-oxyamianted products (6.1a–g). Likewise, the reactions with ortho-substituted 
analogues, which are more sterically demanding, proceeded smoothly (6.1h–j). Other oximes 
derived from aromatic ketones were also viable substrates for this transformation (6.1k–m). 
Furthermore, an aliphatic ketone derived oxime (6.1n), as well as (E)-4-phenylbut-3-en-2-one-
derived oxime (6.1o), gave high yields of the desired products. Finally, the dearomative 
oxyamination process was scalable for a gram-scale synthesis; the reaction with acetophenone 
oxime on an 8.8 mmol scale proceeded without much loss of productivity (6.1a). 
 At this point, other oxygen-based nucleophiles were re-examined, and it was found that 
under the optimized conditions for oxime, benzyl alcohol derivatives were also viable nucleophiles 
(Table 6-6). For example, benzyl alcohols with a variety of para-substituents were compatible 
with forming syn-1,4-oxyaminated product (6.2a–f). The stereochemistry of the product was 
confirmed by x-ray analysis to be syn-1,4-products (see x-ray structure for 6.2d). Likewise, the 
ortho-substituted benzyl alcohols afforded the desired product (6.2g–h), and a gram-scale 
[x-ray of 6.1a] 
Table 6-5: Oxime scope of dearomative oxyamination with naphthalene. 
MTAD (1.57a, 1.0 eq.)
visible light, EtCN, –50 ºC;
Pd(PPh3)4 (5 mol%)
oxime (2.0 eq.), nBuLi (1.9 eq.)

































(±)-6.1a (R = H):
(±)-6.1b (R = NMe2):
(±)-6.1c (R = OMe):
(±)-6.1d (R = CF3):
(±)-6.1e (R = F):
(±)-6.1f (R = Cl):















Reaction was run on 0.5 mmol scale. Isolated yield shown after flash chromatography.  aReaction was conducted on a gram-scale.
(±)-6.1h (R = Me):
(±)-6.1i (R = OMe):






synthesis was feasible without much loss of yield (6.2b).  
 As for the polynuclear arene scope using acetophenone oxime as the nucleophile, the yields 
of the products were generally much lower than that were observed for other nucleophiles. As 
shown in Table 6-7, although some conversion was observed for many of the polynuclear arenes 
tested under the optimized conditions, majority of the substitution reactions did not reach full 
conversion the cycloadduct (6.3–6.9). Furthermore, substrates that worked well for other 
palladium-catalyzed dearomative aminofunctionalization proved to be not competent for the 












(±)-6.2a: 62% (±)-6.2d: 51%(±)-6.2b: 53%, 45%a (±)-6.2c: 56%
(±)-6.2f: 58% (±)-6.2h: 65%(±)-6.2g: 51%(±)-6.2e: 70%
MTAD (1.57a, 1.0 eq.)
visible light, EtCN, –50 ºC;
Pd(PPh3)4 (5 mol%)
ArCH2OH (2.0 eq.), nBuLi (1.9 eq.)









Reaction was run on 0.5 mmol scale. Isolated yield shown after flash chromatography.  aReaction was conducted on a gram-scale.
R
[x-ray of 6.2d] 
Table 6-6: Dearomative oxyamination using benzyl alcohol derivatives.  
Table 6-7: Polynuclear arene scope of dearomative oxyamination. 
(±)-6.4: 45%(±)-6.3: 24% (±)-6.9: 26% (1.2:1)
then: acetophenone-oxime (2.0 eq.)
nBuLi (1.9 eq.)
Pd(PPh3)4 (5.0 mol%)
EtCN/PhMe, –50 to 0 ºC, 5 h
MTAD (1.57a, 1.0 eq.)




















(±)-6.5 (R = 4-CF3C6H4):
(±)-6.6 (R = 3,5-CF3C6H4):
(±)-6.7 (R = CF3):



























6.4 Development of asymmetric variants for dearomative syn-1,4-oxyamination 
 Enantioselective dearomative syn-1,4-oxyamination on a meso-cycloadduct with oxygen 
nucleophiles was also attempted (Table 6-8). Thus, taking the isolated naphthalene–cycloadduct 
1.48, chiral ligands such as Phospherrox (L9) and BINAP (L2), which provided high yields as 
well as high enantioselectivities for other nucleophiles, were tested with Pd2(dba)3 as the palladium 
source; however, no conversion was observed (entries 1–2). Other chiral bidentate 
diarylalkylphosphines gave some conversion, albeit with low enantiomeric excess (entries 3–4). 
In contrast, the (S,S)-DACH-Ph Trost ligand (L20)[126] turned out to be highly effective, 
 
entry [Pd] ligand yield (%)a erb 
1 
Pd2(dba)3 
(R,Rp)-iPr-Phosferrox (L9) 6 – 
 (S)-BINAP (L2) <5 – 
2 (R,R)-DIOP (L19) 36 52:48 
3 (S,S)-BDPP (L1) 45 62:38 
4 Pd2(dba)3 
(S,S)-DACH-Ph Trost ligand 
(L20) 
(50) 98:2 
5 [Pd(allyl)Cl]2 8 – 
6 Pd(MeCN)2Cl2 <5 – 
7 Pd(OAc)2 <5 – 





















(S,S)-DACH-Ph Trost Ligand (L20)















Table 6-8: Optimization of chiral ligand for asymmetric dearomative syn-1,4-oxyamination. 
ArCH2OH (2.0 eq.), nBuLi (1.9 eq.)











chiral ligand (6.0 mol%)
100 
 
affording 50% isolated yield of 6.2a with 98:2 enantiomeric ratio (entry 4). Other palladium 
complexes were examined, and concluded that the conditions in entry 4 to be optimal (entries 4–
7). 
 The asymmetric dearomative syn-1,4-oxyamination was conducted with representative 
benzyl alcohol derivatives (Table 6-9). Reactions under conditions A were employed using the 
naphthalene–cycloadduct 1.48 formed in situ with propionitrile as the solvent, whereas the 
conditions B employed isolated cycloadduct in toluene. For both benzyl alcohol and para-
fluorobenzyl alcohol, conditions B gave slightly improved yields with excellent enantioselectivity 
(6.2a, 6.2e). Under the same conditions, oximes were also viable oxygen nucleophiles to provide 
the desired oxyaminated products in high enantioselectivity (6.1e, 6.1h, 6.1n). Similar to benzyl 
alcohol, the reactions with oximes conducted under conditions B gave much higher yield compared 
to the conditions A.  
Table 6-9: Scope of asymmetric dearomative syn-1,4-oxyamination. 
X
Pd2(dba)3 (2.5 mol%)
(S,S)-DACH-Ph Trost Ligand (L20, 6.0 mol%)
O-nucleophile (2.0 eq.), nBuLi (1.9 eq.)













(S,S)-DACH-Ph Trost Ligand (L20)
Conditions A: MTAD (1.57a, 1.0 eq), naphthalene (1.2a, 2.0 eq.), EtCN (0.1 M), visible light, –50 ºC; then substitution step.
Conditions B: naphthalene–cycloadduct (1.0 eq.), PhMe (0.1 M) directly used for substitution step.





Cond. A: 41% yield, 98:2 er
Cond. B: 50% yield, 98:2 er
Cond. A: 44% yield, 98.5:1.5 er










Cond. A: 65% yield, >99:1 er












Cond. A: 54% yield, 98:2 er
Cond. B: 85% yield, 98.5:1.5 er
Cond. A: 48% yield, 98:2 er




6.5 Product elaboration 
 The oxyaminated products derived from naphthalene and para-methoxybenzyl alcohol 
could readily be converted to syn-1,4-oxyaminated tetrahydronaphthalene 6.11 through a three-
step protocol: chemoselective hydrogenation of the olefin moiety in the presence of the benzylic 
C–N bond and the bis-benzyl protected alcohol, followed by alkylation of the urazole, and 
subsequent base hydrolysis (Scheme 6-3; top).[85] On the other hand, osmium-catalyzed 
dihydroxylation of 6.2b, followed by urazole oxidation afforded trihydroxyketone 6.13 (Scheme 
6-3; bottom). 




















2. KOH (10 eq.)
    MeOH (0.1 M)
    80 ºC, 24 h;
    then 160 ºC, 12 h, 95%
1. α-Br-acetophenone (1.5 eq.)
    NaH (1.1 eq.)
    THF (0.1 M)
    0 to rt ºC, 12 h, 85%


















































    MeCN/H2O/AcOH
    rt, 5 min, 60%
1. Zn, AcOH, 80%
Scheme 6-4: Elaboration of 6.1a. 
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the urazole using tert-butyl hypochlorite under anhydrous conditions provided a-chloro-g-
hydroxytetralone 6.15, while the oxidation in aqueous conditions gave oxime-protected g-
hydroxytetralone 6.16. The oxime protecting group could be easily cleaved using zinc as a 
reductant, and subsequent oxidation of urazole under aqueous conditions provided g-
hydroxytetralone 2.19. Compared to the synthesis of g-hydroxytetralone 2.19 described in Scheme 
2-5, this new method is much more facile, and importantly g-hydroxytetralone 2.19 could be 
synthesized with high enantiopurity when employing the asymmetric dearomative syn-1,4-
oxyamination.  
 The oxime functionality serves not only as a protecting group for the benzyl alcohol, but 
also as a directing group in the installation of functional groups on the aromatic C-H bond. Using 
acetoxime-derived compound 6.17, which was prepared by hydrogenation of the olefin and 
methylation of the urazole moiety, the oxime ether directed palladium-catalyzed C–H bond 
activation/functionalization via an exo-cyclopalladated intermediate[127] with PIDA as a 
stoichiometric oxidant to successfully incorporated an acetyl group to provide 6.18 (Scheme 6-5, 
top).[128] Similarly, oxidation using tert-butyl hydrogen peroxide (TBHP) in the presence of 
benzaldehyde enabled direct ortho-aroylation to afford 6.19 (Scheme 6-5, bottom).[129]  
6.6 Preliminary results for optimization of dearomative syn-1,4-oxyamination with benzene 
 In addition to polynuclear arenes, benzene was examined as a representative substrate for 
mononuclear arenes. Forming the benzene-cycloadduct 1.68 in dichloromethane at cryogenic 














    CH2Cl2, 35 ºC, 12 h
    80%
1. Rh/Al2O3 (5.0 mol%)
    H2 (1 atm)
    EtOAc (0.1 M)




















100 ºC, 12 h
Pd(OAc)2 (1.0 mol%)
PIDA (1.5 eq.)








temperature, and subsequently subjecting it to palladium-catalyzed substitution with lithiated 
acetophenone-oxime and Pd(PPh3)4, 40% of the desired syn-1,4-oxiaminated product 6.20 was 
obtained (Scheme 6-6). Based on this preliminary result, further optimization is expected to deliver 
the benzene-derived syn-1,4-oxiaminated in high efficiency. 
6.7 Conclusion and outlook 
 Palladium-catalyzed dearomative syn-1,4-oxyamination was developed based on the 
arenophile-mediated palladium-catalyzed aminofunctionalization strategy. Both oximes and 
benzyl alcohol derivatives were viable oxygen-nucleophiles in this transformation, and both 
racemic and enantioselective processes have been established using polynuclear arene substrates. 
Although it is still a preliminary result, benzene was also amenable towards syn-1,4-oxyamination. 
Further derivatization of the products demonstrates the feasibility of facile preparations of highly 
oxidized alicyclic motifs from simple non-activated arenes. As many bioactive compounds possess 
poly-oxygenated cyclohexane structures, this novel method is expected to find application in the 
synthesis of natural products and medicinally-relevant compounds. 
 
Scheme 6-6: Preliminary results for dearomative syn-1,4-oxyamination with benzene. 
then: acetophenone-oxime (2.0 eq.)
nBuLi (1.9 eq.)
Pd(PPh3)4 (5.0 mol%)
CH2Cl2/THF, –20 ºC, 20 h
MTAD (1.57a, 1.0 eq.)

















Chapter 7: Experimental 
7.1 General experimental 
Unless otherwise noted, all reactions were carried out under an ambient atmosphere. All 
chemicals were purchased from commercial suppliers and used as received. Potassium 
azodicarboxylate was prepared based on the literature procedure.[130] PhSi(Oi-Pr)H2 was prepared 
according to the reported procedure.[61] Bis(dibenzylideneacetone)palladium(0) (Pddba2) was 
purchased from Sigma Aldrich, tris(dibenzylideneacetone)dipalladium(0) (Pd2dba3) was 
purchased from Acros Organics, and tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4) and 
(R)-DTBM-SEGPHOS were purchased from Strem Chemicals, Inc. Tri(o-tolyl)phosphine (P(o-
MeC6H4)3), 1,4-bis(diphenylphosphino)butane (dppb) and 1,1’-bis(diphenylphosphino)ferrocene 
(dppf) were purchased from Oakwood Chemical. Bis[(2-diphenylphosphino)phenyl] ether 
(DPEphos) was purchased from AK Scientific, Inc.. PhMgBr (3.0 M in Et2O), (allyl)MgBr (1.0 M 
in Et2O), MeMgBr (3.0 M in Et2O), and (cyclopentyl)MgBr (3.0 M in Et2O) were purchased from 
Sigma Aldrich. Vinylmagnesiumbromide (0.7 M in THF) was purchased from Acros Organics. N-
methyl-1,2,4-triazoline-3,5-dione (MTAD) was prepared based on the literature procedures[42] and 
was sublimed before use. Tert-butyl hypochlorite was prepared based on the literature 
procedure.[131] (S, Sp)-tBu-phosferrox was prepared based on the literature procedure from the 
corresponding L-tert-leucinol, and the 1H and 13C spectra were in accordance with the reported 
values.[132] Propionitrile (EtCN) was purchased from Acros Organics, and freshly distilled over 
CaH, then degassed with nitrogen gas before use. Ethyl acetate (EtOAc) was purchased from 
Sigma Aldrich, and freshly distilled over CaH2, then degassed with nitrogen gas before use. Dry 
dichloromethane (CH2Cl2) and tetrahydrofuran (THF) were obtained by passing commercially 
available anhydrous, oxygen-free formulations through activated alumina columns. For methanol, 
acetone, and acetonitrile commercially available anhydrous solvents were used without further 
purification. Analytical thin-layer chromatography was performed on Merck silica gel 60 F254 glass 
plates. Visualization was accomplished with UV light and/or potassium permanganate (KMnO4) 
solutions. Retention factor (Rf) values reported were measured using a 5 × 2 cm TLC plate in a 
developing chamber containing the solvent system described. Flash column chromatography was 
performed using Silicycle SiliaFlash® P60 (SiO2, 40-63 µm particle size, 230-400 mesh). 1H and 
13C NMR spectra were recorded on Varian Unity Inova 500 (500 MHz, 1H; 125 MHz, 13C) MHz
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or Bruker 500 (500 MHz, 1H; 125 MHz, 13C) spectrometers. Spectra are referenced to residual 
chloroform (δ = 7.26 ppm, 1H; 77.16 ppm, 13C), residual methanol (δ = 3.31 ppm, 1H; 49.0 ppm, 
13C) residual acetone (δ = 2.05 ppm, 1H; 29.84 ppm, 13C), residual benzene (δ = 7.16 ppm, 1H; 
128.06 ppm, 13C), and residual dimethyl sulfoxide (δ = 2.50 ppm, 1H; 39.5 ppm, 13C). Chemical 
shifts are reported in parts per million (ppm). Multiplicities are indicated by s (singlet), d (doublet), 
t (triplet), q (quartet), m (multiplet), and br (broad). Coupling constants J are reported in Hertz 
(Hz). Mass spectrometry (MS) was performed by the University of Illinois Mass Spectrometry 
Laboratory. Electron Impact (EI+) spectra were performed at 70 eV using methane as the carrier 
gas, with time-of-flight (TOF) mass analyzer. Chemical Ionization (CI+) spectra were performed 
with methane reagent gas, with either a double focusing sector field (DFSF) or time-of-flight 
(TOF) mass analyzer. Electrospray ionization (ESI+) spectra were performed using a time-of-flight 
(TOF) mass analyzer. Data are reported in the form of m/z. For several compounds, Waters Q-
TOF Ultima ESI and Agilent 6230 ESI TOF LC/MS spectrometers were used to obtain the high 
resolution mass spectra. Infrared spectra were measured neat on a Perkin-Elmer spectrum BX FT-
IR spectrometer. Peaks are reported in cm−1 with indicated relative intensities: s (strong, 0–33% 
T); m (medium, 34–66% T), w (weak, 67–100% T), and br (broad). Visible-light spectrum of LED 
was recorded using an Avantes Sensline Avaspec-ULS TEC Spectrometer. Melting points were 
measured on a Buchi B-540 melting point apparatus and are uncorrected. Optical rotations were 
recorded on a Jasco P-2000 polarimeter at 589 nm and are reported in units of 10−1 (deg cm2 g−1). 
HPLC was performed on a Shimadzu Prominence HPLC system with SPD-M20A UV/VIS 
Photodiode array detector. The x-ray diffraction experiments were conducted using Bruker D8 
Venture/Photon 100 diffractometer or Bruker APEX-II CCD diffractometer. Using Olex2[133] the 
structure was solved with ShelXT[134] structure solution program using intrinsic phasing solution 







7.2 Experimental set-up 
7.2.1 LED light source 
Generic cool white light LED corn bulbs were used for the photochemical experiments. 
These can be obtained from several manufactures over amazon.com and proved to give consistent 




LED Chip: 48 LEDs SMD 2835 
Consume wattage: 4W 
Input voltage: AC / DC 12V 
Beam degree: 360 degrees 
Color temperature: 6500K (Cool White) 
       Initial Lumens (lm): 290 
 























7.2.2. Set-up for small scale reactions (up to 2.0 mmol scale) 
Five 4-W LED corn bulbs (12V, cool white light 6500K) were wired to a suitable 12V 
power supply, then sealed into test tubes and capped with septa (Picture S1). Lights and reaction 
tubes were arranged in a merry-go-round fashion for maximal exposure of each reaction vessel to 
light source and were submerged in a −78 °C bath. Generally, up to four 0.2-2.0 mmol scale 
reactions can be run in the same bath using five 4 W lamps positioned around them.  
 
Picture 7-1: Assembly of LED bulbs for small-scale photochemical reactions. 
7.2.3 Set-up for large scale reactions (up to 10 mmol scale) 
Eight 4 W LED corn bulbs (12V, cool white light 6500K) were wired to a suitable 12V 
power supply, then sealed into test tubes and capped with septa (see Picture S1). Lights were 
arranged in a merry-go-round fashion around a 500 mL clear borosilicate glass bottle (Picture S2). 
A normal reagent or media bottle can be used. The whole set-up was kept submerged in a −50 °C 
bath during the photochemical reaction.  
Picture 7-2: Photochemical set-up for large scale reactions.  
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7.3 Experimental procedures for Chapter 2 
7.3.1 Dearomative cycloaddition/diimide reduction of mononuclear arenes 
General procedure 2A for the synthesis of compound 2.1 (Table 2-2, Scheme 2-1) 
 
MTAD (1.57a, 113.1 mg, 1.0 mmol, 1.0 eq.) was placed in a test tube. Ethyl acetate (10 mL, 0.1 
M) was added to the test tube at – 78 ºC, followed by the addition of arene (10 mmol, 10 eq.). The 
mixture was then stirred under the irradiation with LED lights at –78 ºC until full decolorization 
of the reaction mixture was observed (pink to colorless solution). Then the lights were turn off and 
potassium azodicarboxylate (582.7 mg, 3.0 mmol, 3.0 eq.) was added in one portion, followed by 
the addition of acetic acid (0.86 mL, 15 mmol, 15 eq.) in ethyl acetate (4.0 mL) at –78 ºC. After 
stirring the resulting suspension at –50 ºC for 5 h, the reaction was warmed up to rt in a water bath, 
then quenched with water (2.0 mL). Saturated aqueous sodium bicarbonate solution (7.5 mL) was 
added, and then the organic phase was separated. The aqueous phase was extracted with ethyl 
acetate (3 × 10 mL). The combined organic layer was washed with saturated aqueous sodium 
chloride solution (15 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. 
After a short column of the crude material to remove the excess arene, the ratio of 2.1 to 2.1 was 
determined by 1H NMR analysis.  The mixture of compound 2.1 and 2.1 was then isolated by 
flash column chromatography (SiO2, hexanes/EtOAc mixture). For the spectroscopic 
characterizations of compound 2.1, column-inseparable mixtures of solid products 2.1 and 2.1 
were further purified by recrystallization from n-hexane/EtOAc mixtures, and only the major 
product 3 was characterized. For column-separable mixtures, both products 2.1 and 2.1 were 




Synthesis of 2.1a (Table 2-2): Following the general procedure 2A, the title compound 
was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) as a white solid 
(131.3mg, 68%).  
Rf = 0.18 (n-hexane:EtOAc = 2:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 6.42 (dd, J = 4.3, 3.1 Hz, 2H), 4.85 (ddd, J = 4.3, 3.1, 1.8 Hz, 2H), 
3.00 (s, 3H), 2.20 – 2.11 (m, 2H), 1.56 (ddd, J = 11.2, 3.5, 1.8 Hz, 2H).  
13C NMR: (126 MHz, CDCl3) δ 158.1, 130.4, 50.2, 25.4, 22.1.  
HRMS: (ESI-TOF, m/z) calcd. For C9H11KN3O2 [M+K]+ calc.: 232.0483; found: 232.0474.  
IR: (ATR, neat, cm-1) 2945 (w), 1771 (m), 1697 (s), 1459 (s), 1435 (s), 1385 (m), 1197 (s), 1175 
(m), 909 (m), 851 (m), 769 (s), 727 (s), 697 (s), 645 (w), 554 (s).  
m.p.: 105 – 106 ºC. 
 
Synthesis of 2.1b (Table 2-2): The reaction was conducted following the general 
procedure 2A, except the acetic acid was added with methanol (4.0 mL), and the 
reaction was then slowly warmed up to rt. The title compound was isolated by flash 
chromatography (SiO2, hexanes:EtOAc = 4:1) as a light yellow solid (94.0 mg, 45%, 2.1b:2.1b = 
5:1).  
Rf = 0.24 (SiO2, hexanes:EtOAc = 2:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 5.96 (dd, J = 5.8, 1.8 Hz, 1H), 4.77 – 4.68 (m, 1H), 4.60 (ddd, J = 
3.8, 2.1, 1.7 Hz, 1H), 2.96 (s, 3H), 2.07 – 2.09 (m, 2H), 1.84 (d, J = 1.7 Hz, 3H), 1.54 – 1.43 (m, 
2H). 
13C NMR: (126 MHz, CDCl3) δ 158.3, 158.2, 140.4, 122.3, 54.6, 51.1, 25.4, 23.2, 21.7, 19.5. 
HRMS: (ESI-TOF, m/z) calcd. For C10H13N3NaO2 [M+Na]+ calc.: 230.0900; found: 230.0904. 
IR: (ATR, neat, cm-1) 2947 (w), 1770 (m), 1694 (s), 1456 (s), 1392 (m), 1208 (s), 1022 (w), 712 
(s), 876 (m), 334 (s), 511 (m). 




Synthesis of 2.1c (Table 2-2): Following the general procedure 2A, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 4:1) as 
a light yellow solid (150.3 mg, 52%, 2.1c:2.1c > 20:1).  
Rf = 0.70 (SiO2, hexanes:EtOAc = 1:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 5.95 (dd, J = 5.6, 1.7 Hz, 1H), 4.77 (dd, J = 5.6, 2.6 Hz, 1H), 4.64 
(dd, J = 2.6 Hz, 1H), 2.97 (s, 3H), 2.18 – 2.03 (m, 4H), 1.54 – 1.48 (m, 2H), 1.44 – 1.33 (m, 2H), 
1.32 – 1.14 (m, 8H), 0.86 (t, J = 6.9 Hz, 3H).  
13C NMR: (126 MHz, CDCl3) δ 158.2, 157.9, 144.7, 121.6, 53.9, 51.0, 33.4, 31.9, 29.13, 29.07, 
26.7, 25.4, 23.2, 22.7, 22.3, 14.2.  
HRMS: (ESI-TOF, m/z) calcd. For C16H25N3NaO2 [M+Na]
+ calc.: 314.1839; found: 314.1830.  
IR: (ATR, neat, cm-1) 2926 (m), 2855 (w), 1772 (m), 1701 (s), 1451 (s), 1393 (m), 1203 (m), 1013 
(m), 912 (w), 766 (m).  
m.p.: 40 – 42 ºC. 
 
Synthesis of 2.1d (Table 2-2): Following the general procedure 2A, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 4:1) as a 
light yellow solid (192.0 mg, 77%, 2.1d:2.1d > 20:1).  
Rf = 0.60 (SiO2, hexanes:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 5.99 (dd, J = 5.9, 2.5 Hz, 1H), 4.92 (dt, J = 2.5, 2.5 Hz, 1H), 4.81 
(dt, J = 5.9, 3.0 Hz, 1H), 2.97 (s, 3H), 2.19 (ddt, J = 12.5, 9.4, 2.5 Hz, 1H), 2.11 (ddt, J = 12.5, 9.4, 
3.0 Hz, 1H), 1.53 (tt, J = 12.1, 3.0 Hz, 1H), 1.43 (tt, J = 12.1, 2.5 Hz, 1H), 1.04 (s, 9H). 
13C NMR: (126 MHz, CDCl3) δ 157.6, 156.7, 153.1, 119.0, 51.0, 50.4, 33.4, 28.0, 25.3, 23.4, 23.2. 
HRMS: (ESI-TOF, m/z) calcd. For C13H20N3O2 [M+H]+ calc.: 250.1556; found: 250.1548. 
IR: (ATR, neat, cm-1) 2968 (w), 1769 (m), 1699 (s), 1630 (w), 1462 (m), 1396 (m), 1366 (m), 
1216 (m), 1165 (w), 1024 (w), 923 (w), 856 (w), 764 (m), 697 (w), 573 (w) 




Synthesis of 2.1e (Table 2-2): Following the general procedure 2A, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) 
as a colorless oil (194.2 mg, 66%, 2.1e:2.1e > 20:1).  
Rf = 0.45 (SiO2, hexanes:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 6.19 (dd, J = 6.0, 2.1 Hz, 1H), 4.89 – 4.86 (m, 2H), 3.67 (s, 3H), 
2.98 (s, 3H), 2.21 – 2.09 (m, 2H), 1.64 – 1.51 (m, 2H), 1.34 (s, 3H), 1.32 (s, 3H). 
13C NMR: (126 MHz, CDCl3) δ 175.0, 157.3, 156.5, 146.8, 122.3, 52.4, 51.7, 50.1, 45.0, 25.2, 
24.3, 23.4, 23.1, 22.9.  
HRMS: (ESI-TOF, m/z) calcd. For C14H19N3O4 [M+H]
+ calc.: 294.1446; found: 294.1454.  
IR: (ATR, neat, cm-1): 2946 (w), 1769 (m), 1696 (s), 1450 (m), 1392 (m), 1210 (m), 1019 (w), 
913 (m), 727 (s), 571 (m).  
m.p.: 105 – 106 ºC.  
 
Synthesis of 2.1f (Table 2-2): Following the general procedure 2A, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) as 
a light yellow solid (190.0 mg, 67%, 2.1f:2.1f > 20:1).  
Rf = 0.55 (SiO2, hexanes:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 6.14 (dd, J = 6.0, 2.1 Hz, 1H), 4.89 – 4.83 (m, 2H), 3.51 (d, J = 
11.1 Hz, 1H), 3.42 (d, J = 11.1 Hz, 1H), 2.97 (s, 3H), 2.25 – 2.06 (m, 2H), 1.64 – 1.48 (m, 2H), 
1.15 (s, 3H), 1.14 (s, 3H). 
13C NMR: (126 MHz, CDCl3) δ 157.7, 157.2, 147.2, 123.5, 52.3, 50.4, 50.3, 38.4, 25.2, 24.0, 23.8, 
23.1, 22.6.  
HRMS: (ESI-TOF, m/z) calcd. For C13H18N3O2Cl [M]+ calc.: 283.1088; found: 283.1088.  
IR: (ATR, neat, cm-1) 2946 (w), 1769 (m), 1696 (s), 1450 (m), 1392 (m), 1210 (m), 1019 (w), 913 
(m), 830 (m), 727 (s), 571 (m).  
m.p.: 97 – 98 ºC. 
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Synthesis of 2.1g (Table 2-2): Following the general procedure 2A the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) as 
a light yellow solid (165.9 mg, 59%, 2.1g:2.1g = 10:1). 
Gram-scale synthesis of 2.1g: MTAD (1.57a, 2.00 g, 17.7 mmol, 1.0 eq.) was placed in a 500 
mL borosilicate bottle. Ethyl acetate (150 mL, 0.12 M) was added to the test tube at – 78 ºC, 
followed by the addition of phenethyl acetate (28.1 mL, 176.9 mmol, 10 eq.). The mixture was 
then stirred under irradiation with LED lights at –78 ºC until full decolorization of the reaction 
mixture was observed (pink to colorless solution). The lights were turned off and potassium 
azodicarboxylate (10.3 g, 53.1 mmol, 3.0 eq.) was added in one portion at –78 ºC, followed by the 
addition of acetic acid (15.2 mL, 265.3 mmol, 15 eq.) in ethyl acetate (30.0 mL) over 20 
minutes. After stirring the resulting suspension at –50 ºC for 12 h, the reaction was warmed up 
to rt in water bath, then slowly quenched with water (50 mL). The organic phase was separated, 
and the aqueous phase was extracted with ethyl acetate (3 × 200 mL). The combined organic layer 
was washed with saturated aqueous sodium chloride solution (200 mL), dried over anhydrous 
magnesium sulfate, and concentrated in vacuo. The product was purified by column 
chromatography (SiO2, hexanes/EtOAc = 2:1) to yield the desired product 2.1g (3.36 g, 68%, 
2.1g:2.1g = 10:1). 
 
Rf = 0.17 (SiO2, hexanes:EtOAc = 1:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 6.12 (d, J = 5.6 Hz, 1H), 4.85 (dt, J = 5.6, 2.5 Hz, 1H), 4.77 (dt, J 
= 2.3, 2,3 Hz, 1H), 4.28 (dt, J = 11.1, 6.1 Hz, 1H), 4.12 (ddd, J = 11.1, 7.7, 5.8 Hz, 1H), 3.04 (s, 
3H), 2.59 – 2.44 (m, 2H), 2.24 – 2.14 (m, 2H), 2.06 (s, 3H), 1.63 – 1.54 (m, 2H). 
13C NMR: (126 MHz, CDCl3) δ 170.6, 158.0, 157.8, 140.4, 124.3, 61.5, 53.4, 50.7, 32.4, 25.2, 
22.7, 21.9, 20.8. 
HRMS: (ESI-TOF, m/z) calcd. For C13H18N3O4 [M+H]+ calc.: 280.1297; found: 280.1293. 
IR: (ATR, neat, cm-1) 2954 (w), 1738 (s), 1702 (s), 1464 (m), 1450 (m), 1386 (m), 1250 (s), 1220 
(s), 1182 (m), 1028 (m), 963 (m), 857 (w), 764 (w), 530 (w), 460 (w). 
m.p.: 66 – 68 ºC.  
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Synthesis of 2.1h (Table 2-2): Following the general procedure 2A, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) 
as a yellow oil (196.2 mg, 67%, 2.1h:2.1h = 7.7:1).  
Rf = 0.17 (SiO2, hexanes:EtOAc = 2:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 6.00 (dd, J = 5.5, 1.7 Hz, 1H), 4.80 (dt, J = 5.5, 2.6 Hz, 1H), 4.70 
– 4.65 (m, 1H), 4.11 (q, J = 7.2 Hz, 2H), 2.99 (s, 3H), 2.52 – 2.32 (m, 4H), 2.19 – 2.07 (m, 2H), 
1.62 – 1.47 (m, 2H), 1.24 (t, J = 7.2 Hz, 3H). 
13C NMR: (126 MHz, CDCl3) δ 172.3, 158.3, 158.2, 143.0, 122.4, 60.8, 53.8, 50.9, 31.6, 28.3, 
25.5, 23.1, 22.1, 14.4. 
HRMS: (ESI-TOF, m/z) calcd. For C14H19KN3O4 [M+K]+ calc.: 332.1007; found: 332.0997. 
IR: (ATR, neat, cm-1) 2942 (w), 1701 (s), 1698 (s), 1449 (s), 1393 (m), 1191 (m), 1175 (m), 1162 
(m), 1044 (m), 1021 (m), 918 (w), 854 (w), 767 (s), 581 (w), 547 (m). 
 
Synthesis of 2.1j (Table 2-2): Following the general procedure 2A, using 
dichloromethane instead of ethyl acetate as solvent and 3 eq. of starting arene, 
the title compound was isolated by flash chromatography (SiO2, hexanes:EtOAc 
= 2:1) as a white solid (165  mg, 45%, 2.1j:2.1j > 20:1).  
Rf = 0.09 (SiO2, hexanes:EtOAc = 2:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.82 (dd, J = 5.5, 3.1 Hz, 2H), 7.71 (dd, J = 5.5, 3.1 Hz, 2H), 6.06 
(ddd, J = 5.9, 1.6 Hz, 1H), 4.78 – 4.73 (m, 2H), 3.84 (ddd, J = 13.7, 8.2, 7.1 Hz, 1H), 3.67 (ddd, J 
= 13.7, 8.2, 5.7 Hz, 1H), 2.97 (s, 3H), 2.62 – 2.46 (m, 2H), 2.17 – 2.05 (m, 2H), 1.68 – 1.58 (m, 
1H), 1.45 (ddd, J = 11.9, 9.1, 2.6 Hz, 1H).  
13C NMR: (126 MHz, CDCl3) δ 168.1, 158.1, 157.9, 140.8, 134.2, 132.0, 124.2, 123.4, 53.7, 50.9, 
35.8, 32.1, 25.5, 22.9, 22.1.  
HRMS: (ESI-TOF, m/z) calcd. For C19H18N4O4 [M]+ calc.: 366.1328; found: 366.1329. 
IR: (ATR, neat, cm-1) 2944 (w), 1770 (m), 1702 (s), 1398 (m), 1199 (m), 1010 (m), 769 (m), 723 
(s), 531 (m). 
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m.p.: 186 – 188 ºC.  
 
Synthesis of 2.1m diastereomer 1 (Table 2-2): Following the general 
procedure 2A, the title compound was isolated as a mixture with 2.1m 
diastereomer 1 and 2 by flash chromatography (SiO2, hexanes:EtOAc 
= 1:1) as a colorless oil (355.7 mg, 72%, diastereomer 1:diasteromer 
2 = 1.1:1). The isomers were further separated by flash chromatography (SiO2, hexanes:EtOAc = 
1:1) for analytical purposes. 
Rf = 0.41 (SiO2, n-hexane:EtOAc = 1:1, KMnO4) 
1H NMR (500 MHz, CDCl3) δ 6.09 (ddd, J = 5.8, 1.6, 1.6 Hz, 1H), 5.11 (dd, J = 8.8, 6.2 Hz, 1H), 
4.85 – 4.71 (m, 2H), 3.73 (s, 3H), 3.09 – 3.00 (m, 1H), 2.99 (s, 3H), 2.73 (ddd, J = 15.2, 8.9, 1.3 
Hz, 1H), 2.20 – 2.07 (m, 2H), 1.65 (dtt, J = 11.7, 5.4, 2.9 Hz, 1H), 1.51 (s, 18H), 1.46 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ 170.5, 158.7, 158.4, 152.1, 140.2, 124.9, 83.7, 55.7, 53.8, 52.5, 
51.3, 34.4, 28.1, 25.4, 23.0, 22.0. 
HRMS (ESI-TOF, m/z) calcd. For C23H34N4O8Na [M+Na]+ calc.: 517.2274; found: 517.2273. 
IR (ATR, neat, cm-1): 2977 (w), 2866 (w), 1749 (m), 1710 (s), 1455 (w), 1367 (m), 1134 (s), 1138 
(w), 771 (w). 
 
2.1m diastereomer 2 
Rf = 0.38 (SiO2, n-hexane:EtOAc = 1:1, KMnO4) 
1H NMR (500 MHz, CDCl3) δ 6.11 (ddd, J = 5.9, 1.6 Hz, 1H), 4.93 
(dd, J = 8.4, 5.6 Hz, 1H), 4.78 (dt, J = 5.3, 2.4 Hz, 1H), 4.69 (q, J = 2.2 Hz, 1H), 3.70 (s, 3H), 3.07 
(ddd, J = 15.5, 5.6, 1.5 Hz, 1H), 2.99 (s, 3H), 2.65 (ddd, J = 15.5, 8.5, 1.5 Hz, 1H), 2.14 – 2.04 (m, 
2H), 1.49 (s, 18H), 1.49 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 170.5, 158.2, 158.0, 152.1, 140.6, 124.6, 83.7, 56.6, 54.2, 52.6, 
50.9, 34.2, 28.1, 25.5, 22.9, 22.0. 
HRMS (ESI-TOF, m/z) calcd. For C23H34N4O8Na [M+Na]+ calc.: 517.2274; found: 517.2274. 
115 
 
IR (ATR, neat, cm-1): 2980 (w), 1711 (w), 1456 (w), 1368 (s), 1138 (w), 768 (w). 
 
Synthesis of 2.1n (Table 2-2): Following the general procedure 2A, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 1:1) as 
a light yellow solid (160.2 mg, 60%, 2.1n:2.1n = 10:1).  
Rf = 0.40 (SiO2, hexanes:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 6.28 (ddd, J = 5.9, 1.6 Hz, 1H), 4.86 (ddt, J = 5.9, 3.0, 1.2 Hz, 
1H), 4.80 (dd, J = 1.6 Hz, 1H), 4.66 (dd, J = 13.6, 1.6 Hz, 1H), 4.55 (dd, J = 13.6, 1.5 Hz, 1H), 
2.99 (s, 3H), 2.18 (t, J = 2.6 Hz, 1H), 2.17 – 2.14 (m, 1H), 2.09 (s, 3H), 1.59 – 1.52 (m, 2H). 
13C NMR: (126 MHz, CDCl3) δ 170.6, 158.2, 158.0, 138.8, 125.4, 62.7, 51.4, 50.5, 25.3, 22.6, 
22.1, 20.8. 
HRMS: (ESI-TOF, m/z) calcd. For C12H15N3O4 [M]+ calc.: 265.1063; found: 265.1060. 
IR: (ATR, neat, cm-1) 2944 (w), 1740 (m), 1699 (s), 1451 (m), 1393 (w), 1218 (s), 1027 (m), 912 
(m), 767 (m), 729 (s). 
m.p.: 57 – 58 ºC.  
 
Synthesis of 2.1o (Table 2-2): Following the general procedure 2A, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) as 
a light yellow solid (183.0 mg, 64%, 2.1o:2.1o = 10:1).  
Rf = 0.27 (SiO2, hexanes:EtOAc = 2:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 6.30 (dt, J = 6.1, 1.6 Hz, 1H), 4.83 (m, 2H), 3.99 (dd, J = 10.8, 
1.6 Hz, 1H), 3.90 (dd, J = 10.8, 0.8 Hz, 1H), 2.95 (s, 3H), 2.22 – 2.14 (m, 2H), 1.66 – 1.54 (m, 
2H). 
13C NMR: (126 MHz, CDCl3) δ 157.9, 157.7, 139.5, 126.0, 53.1, 50.9, 30.5, 25.4, 22.9, 22.8. 
HRMS: (ESI-TOF, m/z) calcd. For C10H12N3O2Br [M]+ calc.: 285.0113; found: 285.0112. 
IR: (ATR, neat, cm-1) 2944 (w), 2249 (w), 1771 (m), 1695 (s), 1450 (s), 1392 (m), 1202 (m), 1016 
(w), 912 (m), 765 (m), 728 (m). 
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m.p.: 108 – 110 ºC. 
 
Rf = 0.41 (SiO2, n-hexane:EtOAc = 1:2) 
1H NMR (500 MHz, CDCl3) δ 6.31 (dd, J = 5.7, 1.4 Hz, 1H), 4.87 – 4.84 (m, 2H), 
4.12 (dd, J = 12.5, 1.4 Hz, 1H), 4.04 (dd, J = 12.5, 1.1 Hz, 1H), 2.97 (s, 3H), 2.25 
– 2.09 (m, 2H), 1.71 – 1.44 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 158.2, 157.8, 139.5, 125.8, 52.4, 50.8, 43.5, 25.5, 22.8, 22.7. 
HRMS (ESI-TOF, m/z) calcd. For C10H12ClN3O2 [M]+ calc.: 241.0613; found: 241.0619. 
IR (ATR, neat, cm-1): 2946 (w), 1772 (w), 1695 (s), 1450 (s), 1392 (m), 1202 (m), 1017 (m), 766 
(m), 698 (m), 543 (w). 
m.p.: 105 – 106 °C 
 
Synthesis of 2.1q (Table 2-2): Following the general procedure 2A using racemic 
1-phenylethyl acetate, the title compound was isolated by flash chromatography 
(SiO2, hexanes:EtOAc = 2:1) as a light yellow solid (162.4 mg, 58%, 2.1q:2.1q > 
20:1, dr = 1.7:1).  
Rf = 0.24 (SiO2, hexanes:EtOAc = 1:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 6.15 (m, 1H major, 1H minor), 5.28 (qd, J = 6.6, 1.3 Hz, 1H major), 
5.15 (qd, J = 6.8, 1.2 Hz, 1H minor), 4.83 – 4.69 (m, 2H major, 2 H minor), 2.91 (s, 3H major), 
2.87 (s, 3H minor), 2.21 – 2.00 (m, 2H major, 2H minor), 1.98 (d, J = 0.9 Hz, 3H major, 3H minor), 
1.57 – 1.31 (m, 2H major, 2H minor), 1.24 (dd, J = 6.7, 0.9 Hz, 3H major, 3H minor). 
13C NMR: (126 MHz, CDCl3) δ 170.1 (major), 170.1 (minor), 158.1 (minor), 158.0 (major), 157.7 
(minor), 157.5 (major), 143.4 (minor), 143.0 (major), 123.4 (major), 123.4 (minor), 69.1 (minor), 
68.4 (major), 50.8 (major), 50.6 (minor), 50.3 (minor), 50.2 (major), 25.2 (major), 25.1 (minor), 
22.8 (minor), 22.5 (major), 22.5 (minor), 22.4 (major), 21.1 (minor), 20.9 (major), 19.1 (minor), 
18.3 (major). 
HRMS: (ESI-TOF, m/z) calcd. For C13H17N3O4 [M+H]+ calc.: 279.1219; found: 279.1218. 
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IR: (ATR, neat, cm-1) 2968 (w), 1769 (m), 1699 (s), 1630 (w), 1462 (m), 1396 (m), 1366 (m), 
1216 (m), 1165 (w), 1024 (w), 923 (w), 856 (w), 764 (m), 697 (w), 573 (w). 
m.p.: 86 – 88 ºC  
 
Synthesis of 2.1s (Table 2-2): Following the general procedure 2A, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) as 
a yellow oil (128.1 mg, 48%, 2.1s:2.1s > 20:1).  
Rf = 0.14 (SiO2, hexanes:EtOAc = 1:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 6.31 (dt, J = 5.9, 1.6 Hz, 1H), 4.84 – 4.82 (m, 2H), 4.70 (d, J = 
1.4 Hz, 1H), 3.24 (s, 3H), 3.17 (s, 3H), 2.91 (s, 3H), 2.12 – 2.07 (m, 2H), 1.53 – 1.47 (m, 2H). 
13C NMR: (126 MHz, CDCl3) δ 157.9, 157.5, 140.5, 125.9, 101.5, 54.2, 53.2, 50.5, 50.4, 25.5, 
22.9, 22.5. 
HRMS: (ESI-TOF, m/z) calcd. For C12H17N3O4Na [M+Na]+ calc.: 290.1117; found: 290.1113. 
IR: (ATR, neat, cm-1) 2942 (w), 2832 (w), 1774 (m), 1699 (s), 1447 (m), 1392 (m), 1193 (m), 
1018 (m), 1053 (m), 909 (w), 766 (m), 547 (m). 
 
Synthesis of 2.1t (Table 2-2): Following the general procedure 2A, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) as 
a light yellow oil (164.0 mg, 58%, 2.1t:2.1t > 20:1).  
Rf = 0.24 (SiO2, hexanes:EtOAc = 1:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 6.43 (dd, J = 5.4, 1.9 Hz, 1H), 4.99 (d, J = 2.4 Hz, 1H), 4.92 (dt, 
J = 5.4, 2.2 Hz, 1H), 3.14 (s, 3H), 3.12 (s, 3H), 2.99 (s, 3H), 2.23 – 2.13 (m, 2H), 1.60 – 1.54 (m, 
2H), 1.37 (s, 3H). 
13C NMR: (126 MHz, CDCl3) δ 157.4, 156.9, 144.4, 125.5, 99.5, 50.6, 50.1, 49.3, 49.1, 25.4, 23.0, 
22.8, 22.6. 
HRMS: (ESI-TOF, m/z) calcd. For C13H23N4O4 [M+NH4]+ calc.: 299.1714; found: 299.1716. 
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IR: (ATR, neat, cm-1) 2944 (w), 1767 (m), 1699 (s), 1449 (s), 1393 (s), 1188 (s), 1143 (s), 1106 
(m), 1033 (s), 873 (m), 856 (m), 765 (s), 696 (m), 557 (m). 
 
Synthesis of 2.1u (Table 2-2): Following the general procedure 2A, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) as 
a light yellow oil (159.3 mg, 54%, 2.1u:2.1u > 20:1).  
Rf = 0.14 (SiO2, hexanes:EtOAc = 1:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 6.52 (dd, J = 5.9, 1.8 Hz, 1H), 4.97 (dd, J = 2.2 Hz, 1H), 4.90 (dt, 
J = 5.9, 2.4 Hz, 1H), 3.08 (s, 9H), 2.93 (s, 3H), 2.13 (m, 2H), 1.56 – 1.50 (m, 2H). 
13C NMR: (126 MHz, CDCl3) δ 156.6, 155.9, 138.6, 129.3, 112.7, 50.0, 49.9, 49.4, 25.3, 23.1, 
22.6. 
HRMS: (ESI-TOF, m/z) calcd. For C13H19N3O5Na [M+Na]+ calc.: 320.1220; found: 320.1222. 
IR: (ATR, neat, cm-1): 2947 (w), 1772 (w), 1709 (s), 1446 (m), 1394 (m), 1211 (m), 1086 (s), 
1068 (s), 920 (w), 871 (w), 763 (m), 543 (w). 
 
Synthesis of 2.1v (Table 2-2): Following the general procedure 2A using 
dichloromethane instead of ethyl acetate as a solvent, the title compound was isolated 
by flash chromatography (SiO2, hexanes:EtOAc = 4:1) as a light yellow solid (116.3 
mg, 43%, 2.1v:2.1v > 20:1).  
Rf = 0.39 (SiO2, hexanes:EtOAc = 2:1, UV, KMnO4). 
1H NMR (500 MHz, CDCl3) δ 6.53 (dd, J = 6.1, 2.2 Hz, 1H), 4.90 (ddd, J = 5.2, 2.8 Hz, 1H), 4.85 
(dt, J = 5.9, 2.8 Hz, 1H), 2.99 (s, 3H), 2.27 – 2.05 (m, 2H), 1.83 – 1.70 (m, 1H), 1.64 – 1.51 (m, 
1H). 
13C NMR (125 MHz, CDCl3) δ 157.7, 157.4, 129.4, 118.9, 58.2, 52.3, 25.3, 22.4, 22.3. 
HRMS (ESI-TOF, m/z) calcd. For C9H11N3O2Br [M+H]+ calc.: 272.0035; found: 272.0035. 




Synthesis of 2.1w (Table 2-2): Following the general procedure 2A using 
dichloromethane instead of ethyl acetate as a solvent, the title compound was isolated 
by flash chromatography (SiO2, hexanes:EtOAc = 4:1) as a light yellow solid (94.5 
mg, 42%, 2.1w:2.1w > 20:1).  
Rf = 0.39 (SiO2, hexanes:EtOAc = 2:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 6.29 (dd, J = 6.2, 2.2 Hz, 1H), 4.88 (dt, J = 5.9, 2.8 Hz, 1H), 4.84 
– 4.82 (m, 1H), 2.99 (s, 3H), 2.22 – 2.09 (m, 2H), 1.75 (m, 1H), 1.58 (m, 1H). 
13C NMR: (126 MHz, CDCl3) δ 157.7, 157.4, 131.8, 124.6, 56.8, 51.7, 25.3, 22.6, 22.3. 
HRMS: (ESI-TOF, m/z) calcd. For C9H10N3O2Cl [M]+ calc.: 227.0462; found: 227.0467. 
IR: (ATR, neat, cm-1) 3076 (w), 2943 (w), 1768 (m), 1714 (s), 1610 (m), 1444 (s), 1013 (m), 849 
(m), 766 (s), 533 (m), 521 (m). 
m.p.: 110 – 111 ºC. 
 
Synthesis of 2.1x (Table 2-2): Following the general procedure 2A, the title 
compound was isolated as a mixture with 2.1x by flash chromatography (SiO2, 
hexanes:EtOAc = 2:1) as a light yellow solid (184.0 mg, 69%, 2.1x:2.1x = 1.3:1). 
The isomers were further separated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) for 
analytical purposes. 
Rf = 0.50 (SiO2, hexanes:EtOAc = 1:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 6.57 (dd, J = 5.5, 1.4 Hz, 1H), 4.83 (td, J = 2.9, 1.4 Hz, 1H), 4.78 
(dt, J = 5.5, 2.8 Hz, 1H), 2.97 (s, 3H), 2.24 – 2.04 (m, 2H), 1.60 – 1.45 (m, 1H), 1.44 – 1.31 (m, 
1H), 0.09 (s, 9H). 
13C NMR: (126 MHz, CDCl3) δ 158.2, 157.8, 146.0, 137.1, 52.4, 50.4, 25.4, 22.1, 22.0, –2.5. 
HRMS: (ESI-TOF, m/z) calcd. For C12H19N3O2Si [M]+ calc.: 265.1247; found: 265.1243. 
IR: (ATR, neat, cm-1) 2953 (w), 1706 (s), 1451 (s), 1388 (m), 1262 (m), 1202 (s), 1037 (m), 871 
(m), 831 (s), 809 (m), 768 (m), 753 (s), 603 (m), 563 (m), 498 (m). 




Rf = 0.40 (SiO2, hexanes:EtOAc = 1:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 6.48 (ddd, J = 8.1, 5.7, 1.5 Hz, 1H), 6.33 (ddd, J = 8.1, 5.7, 1.5 
Hz, 1H), 4.84 (ddd, J = 5.7, 2.8, 1.5 Hz, 1H), 4.77 (ddd, J = 5.7, 1.7, 1.6 Hz, 1H), 2.96 (s, 3H), 
2.04 (ddd, J = 13.0, 5.0, 1.7 Hz, 1H), 1.63 (ddd, J = 13.0, 11.8, 2.8 Hz, 1H), 0.83 (ddd, J = 11.8, 
5.0, 1.6 Hz, 1H), 0.09 (s, 9H). 
13C NMR: (126 MHz, CDCl3) δ 158.3, 157.9, 132.5, 128.5, 51.4, 50.8, 25.4, 24.4, 21.5, –2.6. 
HRMS: (ESI-TOF, m/z) calcd. For C12H19N3O2Si [M]+ calc.: 265.1247; found: 265.1250. 
IR: (ATR, neat, cm-1) 2952 (w), 1766 (m), 1698 (s), 1454 (m), 1393 (m), 1249 (m), 1212 (m), 885 
(m), 831 (s), 766 (s), 753 (s), 709 (m), 685 (s), 529 (m). 
m.p.: 77 – 80 ºC. 
Stereochemistry was assigned based on the structural analysis of 2.8x'. 
 
Synthesis of 2.1y (Table 2-2): Following the general procedure 2A using 
dichloromethane instead of ethyl acetate as solvent, the title compound was isolated 
by flash chromatography (SiO2, hexanes:EtOAc = 4:1) as a light yellow solid (94.5 
mg, 42%, 2.1y:2.1y >1:20). Stereochemistry of 2.1y was assigned in analogy to 2.1x'. 
Rf = 0.25 (n-hexane:EtOAc = 1:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 6.44 (ddd, J = 8.0, 5.7, 1.7 Hz, 1H), 6.36 (ddd, J = 8.0, 5.9, 1.7 
Hz, 1H), 4.94 (ddd, J = 5.7, 1.9, 1.7 Hz, 1H), 4.83 (dddd, J = 5.9, 3.0, 2.8, 1.7 Hz, 1H), 2.97 (s, 
3H), 2.35 (ddd, J = 13.0, 4.4, 3.0 Hz, 1H), 1.60 (ddd, J = 13.0, 11.8, 2.8 Hz, 1H), 1.25 (s, 12H), 
1.21 – 1.16 (m, 1H). 
13C NMR: (125 MHz, CDCl3) δ 158.15, 158.08, 131.4, 129.6, 84.3, 52.4, 50.5, 25.4, 25.1, 24.6, 
24.2, 18.8. The carbon signal bound to the boron was not observed due to quadrupolar relaxation.  
11B NMR: (160 MHz, CDCl3) δ 33.4. 
HRMS: (ESI-TOF, m/z) calcd. For C15H23BN3O5 [M+H]+ calc.: 320.1782; found: 320.1782.  
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IR: (ATR, neat, cm-1): 1761 (w), 1697 (s), 1390 (w), 1366 (m), 1330 (m), 1261 (w), 1216 (w), 
1206 (w), 1139 (m), 974 (w), 851 (m), 766 (m), 733 (w), 556 (s). 
m.p.: 194–195 ºC. 
 
Synthesis of 2.4b (Scheme 2-1): Following the general procedure 2A, the title 
compound was isolated as a mixture with 2.5b by flash chromatography (SiO2, 
hexanes:EtOAc = 2:1) as a colorless oil (215.0 mg, 66%, 2.4b:2.5b = 1.9:1).  The 
constitutional isomers were further separated by flash chromatography (SiO2, 
hexanes:EtOAc = 2:1). 
Rf = 0.21 (SiO2, hexanes:EtOAc = 2:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.74 (dd, J = 7.7, 0.9 Hz, 1H), 7.49 (dd, J = 7.6, 1.4 Hz, 1H), 7.36 
(dd, J = 7.7, 1.4 Hz, 1H), 7.28 – 7.25 (m, 1H), 6.20 (dd, J = 6.0, 1.9 Hz, 1H), 5.00 (dt, J = 4.4, 2.2 
Hz, 1H), 4.93 (dd, J = 5.7, 2.7 Hz, 1H), 3.81 (s, 3H), 3.02 (s, 3H), 2.26 – 2.20 (m, 2H), 2.07 – 2.01 
(m, 1H), 1.69 (ddd, J = 10.6, 6.0, 3.1 Hz, 1H). 
13C NMR: (126 MHz, CDCl3) δ 168.3, 158.2, 157.9, 142.8, 137.2, 132.0, 130.3, 130.1, 129.3, 
128.3, 125.5, 55.0, 52.3, 51.0, 25.5, 22.7, 22.4.  
HRMS: (ESI-TOF, m/z) calcd. For C17H17N3O4Na [M+Na]+ calc.: 350.1117; found: 350.1111.  
IR: (ATR, neat, cm-1) 2949 (w), 2252 (w), 1772 (m), 1699 (s), 1447 (m), 1393 (m), 1269 (m), 911 
(m), 756 (m), 727 (m), 545 (w).  
 
2.5b 
Rf = 0.25 (SiO2, hexanes:EtOAc = 2:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.41 – 7.35 (m, 5H), 5.47 (t, J = 2.8 Hz, 1H), 
5.08 (t, J = 2.8 Hz, 1H), 3.65 (s, 3H), 3.03 (s, 3H), 2.33 – 2.24 (m, 2H), 1.81 – 1.64 (m, 2H).  
13C NMR: (126 MHz, CDCl3) δ 164.0, 157.7, 157.5, 150.6, 134.3, 129.5, 128.4, 128.4, 125.7, 
56.4, 52.2, 51.6, 25.7, 22.6, 21.9.  
HRMS: (ESI-TOF, m/z) calcd. For C17H17N3O4Na [M+Na]+ calc.: 350.1117; found: 350.1110.  
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IR: (ATR, neat, cm-1) 2950 (w), 2254 (w), 1770 (m), 1703 (s), 1446 (m), 1393 (m), 1225 (m), 916 
(m), 768 (m), 698 (m), 577 (m).  
 
Synthesis of 2.4c (Scheme 2-1): Following the general procedure 2A, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) 
as a white solid (91.5 mg, 34%, 2.4c:2.5c > 20:1) 
Rf = 0.55 (SiO2, n-hexane:EtOAc = 1:2, KMnO4), column 2:1 H/E to 1:1 
1H NMR (500 MHz, CDCl3) δ 7.89 – 7.81 (m, 2H), 7.56 – 7.49 (m, 1H), 7.50 – 7.43 (m, 2H), 6.15 
(t, J = 2.5 Hz, 1H), 5.39 (t, J = 2.8 Hz, 1H), 2.96 (s, 3H), 2.33 (ddt, J = 12.4, 9.6, 2.6 Hz, 1H), 2.27 
(ddt, J = 12.4, 9.6, 2.6 Hz, 1H), 1.73 (tt, J = 12.4, 2.9 Hz, 1H), 1.65 (tt, J = 12.4, 2.9 Hz, 1H). 
13C NMR (125 MHz, CDCl3) δ 171.1, 157.9, 157.5, 133.3, 132.1, 129.1, 126.9, 67.1, 48.8, 25.6, 
21.4, 20.0. 
HRMS (EI-TOF, m/z) calcd. For C14H15N4O2 [M+H]+ calc.: 271.1186; found: 271.1195. 
IR (ATR, neat, cm-1): 2946 (w), 1776 (m), 1702 (s), 1595 (m), 1568 (m), 1446 (s), 1392 (m), 1364 
(m), 1194 (m), 1060 (m), 1025 (m), 1013 (m), 916 (m), 793 (m), 764 (m), 718 (s), 690 (m), 645 
(m), 576 (m), 555 (m).  
m.p.: 162.4 – 163.5 °C. 
 
7.3.2 Cycloreversion of reduced cycloadduct 2.1 for the synthesis of 1,3-cyclohexadiene 
General procedure 2B for the synthesis of compound 2.6 and 2.7b (Table 2-3)  
 
Compound 2.1 (0.4 mmol, 1.0 eq.) and potassium hydroxide (248.9 mg, 90% w/w, 4.0 mmol, 10.0 
eq.) in 2-propanol (2.0 mL, 0.2 M) were stirred at 100 ºC under a nitrogen atmosphere until full 
conversion of 2.1 was observed by TLC analysis. Reaction was then cooled to 0 ºC, and acetic 
acid 0.23 mL (4.0 mmol, 10.0 eq.) was added dropwise to neutralize to pH 6. Volatiles were then 
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removed in vacuo, and the resulting residue was dissolved in distilled water (1.0 mL). An aqueous 
solution of CuCl2 (1.0 M, 0.4 mL, 1.0 eq.) was added, and the mixture was stirred for one minute. 
Aqueous ammonium hydroxide (5.0 M, 1.5 mL) was then added to the resulting brown solution, 
and the color of the solution turned dark blue. After adding diethyl ether (for 2.6b and 2.6d) or 
ethyl acetate (for other products) (5.0 mL), the mixture was transferred to a separatory funnel. The 
organic layer was separated, and the aqueous layer was extracted with diethyl ether (for 2.6b and 
2.6d) or ethyl acetate (for other products) (3 × 5.0 mL). The combined organic layers were washed 
with saturated aqueous sodium chloride solution (10 mL), dried over magnesium sulfate, and 
concentrated in vacuo. For most of the cases, the desired compound 2.6 was obtained in 
analytically pure form without further purification. Otherwise, the crude mixture was purified by 
flash chromatography (SiO2, hexanes:EtOAc mixtures). For 2.6b and 2.6d, the yield was 
determined by 1H NMR analysis with crude material using internal standard (2.6b: 1,3,5-
trimethoxybenzene, 2.6d: nitromethane). 
 
Synthesis of 2.6b (Table 2-3): Following the general procedure 2B, the title 
compound was synthesized and confirmed by NMR analysis (yellow oil, 53% yield 
based on 1H NMR analysis using 1,3,5-trimethoxybenzene as an internal standard).  
1H NMR: (500 MHz, CDCl3) δ 5.85 – 5.70 (m, 2H), 5.50 – 5.35 (m, 1H), 2.11 – 2.04 (m, 4H), 
1.71 (s, 3H).  
13C NMR: (126 MHz, CDCl3) δ 131.6, 128.3, 126.6, 120.6, 31.7, 22.8, 22.6.  
The analytical data was in accordance with previously reported values.[136]  
 
Synthesis of 2.6c (Table 2-3): Following the general procedure 2B using 2.1e (55.4 
mg, 0.34 mmol, 1.0 eq.), the title compound was isolated by flash chromatography 
(SiO2, hexanes) as a colorless oil (55.1 mg, 78%). 
Rf = 0.91 (SiO2, n-hexane/EtOAc = 10:1, KMnO4) 
1H NMR (500 MHz, CDCl3) δ 5.84 – 5.82 (m, 2H), 5.47 – 5.45 (m, 1H), 2.11 – 2.08 (m, 4H), 2.00 
(t, J = 7.6 Hz, 2H), 1.39 (p, J = 7.6 Hz, 2H), 1.34 – 1.20 (m, 8H), 0.89 (t, J = 6.7 Hz, 3H). 
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13C NMR (126 MHz, CDCl3) δ 136.2, 127.5, 126.6, 120.0, 35.8, 32.0, 29.4, 28.6, 22.8, 22.6, 22.5, 
14.3. 
HRMS (EI-TOF, m/z) calcd. For C13H22K [M+K]+ calc.: 217.1353; found: 217.1347. 
IR (ATR, neat, cm-1): 2924 (s), 2854 (m), 1654 (w), 1465 (m), 1377 (w), 1164 (w), 947 (w), 809 
(w), 734 (m), 588 (m). 
 
Synthesis of 2.6d (Table 2-3): Following the general procedure 2B, the title 
compound was synthesized and confirmed by NMR analysis (yellow oil, 90% yield 
based on 1H NMR analysis using MeNO2 as an internal standard). 
Rf = 0.77 (SiO2, hexanes:EtOAc = 10:1, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 6.07 (dd, J = 9.7, 1.9 Hz, 1H), 5.86 (dtd, J = 9.7, 4.5, 0.9 Hz, 1H), 
5.54 (tdd, J = 4.5, 1.9, 0.9 Hz, 1H), 2.14 – 2.07 (m, 2H), 2.06 – 1.98 (m, 2H), 1.04 (s, 9H).  
13C NMR: (126 MHz, CDCl3) δ 144.1, 126.6, 125.2, 116.5, 34.0, 29.0, 22.7, 22.4.  
HRMS: (ESI-TOF, m/z) calcd. For C10H16Na [M+Na]
+ calc.: 159.1144; found: 159.1147. 
IR: (ATR, neat, cm-1) 2955 (w), 2924 (w), 2856 (w), 1717 (w), 1462 (w).  
 
Synthesis of 2.6e (Table 2-3): Following the general procedure 2B using 2.1e 
(99.7 mg, 0.34 mmol, 1.0 eq.), the title compound was isolated by flash 
chromatography (SiO2, hexanes:EtOAc = 6:1) as a colorless oil (55.1 mg, 97%). 
Rf = 0.47 (SiO2, hexanes:EtOAc = 2:1, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 11.33 (br, 1H), 5.93 (d, J = 9.8 Hz, 1H), 5.87 (dt, J = 9.8, 4.2 Hz, 
1H), 5.70 (t, J = 4.2 Hz, 1H), 2.26 – 2.19 (m, 2H), 2.17 – 2.09 (m, 2H), 1.34 (s, 6 H).  
13C NMR: (126 MHz, CDCl3) δ 185.3 (detected from HMBC), 138.2, 127.5, 124.6, 119.8, 47.6 
(detected from HMBC), 24.5, 22.6, 22.0.  
HRMS: (ESI-TOF, m/z) calcd. For C10H14O2 [M]
+ calc.: 166.0994; found: 166.0991. 
IR: (ATR, neat, cm-1) 3039 (w), 2917 (s), 2875 (m), 2859 (m), 1356 (w), 1240 (w), 1095 (m), 
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1066 (m), 821 (w), 734 (w).  
 
Synthesis of 2.6f (Table 2-3): Following the general procedure 2B, the title 
compound was isolated as a colorless oil (54.4 mg, 90%). 
Rf = 0.70 (SiO2, hexanes:EtOAc = 10:1, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 5.98 (dd, J = 9.7, 2.1 Hz, 1H), 5.90 (dt, J = 9.7, 4.2 Hz, 1H), 5.65 
(t, J = 4.5 Hz, 1H), 3.44 (s, 2H), 2.19 – 2.11 (m, 2H), 2.10 – 2.02 (m, 2H), 1.14 (s, 6H).  
13C NMR: (126 MHz, CDCl3) δ 139.5, 127.6, 123.9, 120.4, 54.6, 39.2, 24.6, 22.7, 22.1.  
HRMS: (ESI-TOF, m/z) calcd. For C10H15Cl [M]
+ calc.: 170.0862; found: 170.0861.  
IR: (ATR, neat, cm-1) 3042 (w), 2974 (w), 2933 (w), 2875 (w), 2829 (w), 1466 (w), 1366 (w), 
1281 (w), 1061 (w), 814 (w), 746 (w), 711 (m), 600 (m).  
 
Synthesis of 2.6g (Table 2-3): Following the general procedure 2B, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 4:1) as a 
colorless oil (42.3 mg, 85%). 
Synthesis of 2.6g on a large scale: Following the general procedure 2B using compound 2.1g 
(881.0 mg, 3.15 mmol, 1.0 eq.), the title compound was isolated by flash chromatography (SiO2, 
hexanes:EtOAc = 4:1) as a colorless oil (300.0 mg, 77%). 
 
Rf = 0.30 (SiO2, hexanes:EtOAc = 2:1, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 5.92 – 5.85 (m, 1H), 5.83 (dd, J = 9.7, 1.5 Hz, 1H), 5.60 (tt, J = 
4.0, 1.5 Hz, 1H), 3.67 (t, J = 6.2 Hz, 2H), 2.29 (td, J = 6.2, 1.4 Hz, 2H), 2.20 – 2.07 (m, 4H), 1.41 
(br, 1H).  
13C NMR: (126 MHz, CDCl3) δ 133.1, 128.0, 126.7, 123.4, 61.2, 39.1, 22.6, 22.5.  
HRMS: (ESI-TOF, m/z) calcd. For C8H12O [M]
+ calc.: 124.0883; found: 124.0880.  
IR: (ATR, neat, cm-1): 3338 (br, m), 3033 (w), 2931 (m), 2873 (m), 2822 (m), 1426 (w), 1359 (w), 




Synthesis of 2.6h (Table 2-3): Following the general procedure 2B, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 4:1) as 
a yellow oil (58.2 mg, 96%). 
Rf = 0.47 (SiO2, hexanes:EtOAc = 2:1, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 5.88 – 5.83 (m, 1H), 5.80 (ddd, J = 9.9, 2.1, 1.3 Hz, 1H), 5.52 (td, 
J = 3.9, 3.5, 2.1 Hz, 1H), 2.48 (t, J = 7.7 Hz, 2H), 2.36 (t, J = 7.7 Hz, 2H), 2.14 – 2.06 (m, 4H).  
13C NMR: (126 MHz, CDCl3) δ 179.8, 134.0, 127.5, 126.6, 121.0, 33.3, 30.4, 22.4, 22.4.  
HRMS: (ESI-TOF, m/z) calcd. For C9H12KO2 [M+K]
+ calc.: 191.0469; found: 191.0473.  
IR: (ATR, neat, cm-1) 3031 (w), 2931 (w), 1704 (s), 1425 (m), 1295 (m), 1211 (m), 938 (m), 817 
(m), 727 (w), 650 (w).  
Synthesis of 2.6j (Table 2-3): Compound 2.1j (100.0 mg, 0.27 mmol, 1.0 eq.) 
was refluxed in anhydrous hydrazine (0.17 mL, 5.5 mmol, 20 eq.) at 100 ºC for 
20 h. Volatiles were removed in vacuo, and the residue was taken up in THF:H2O 
(2:1, 1.5 mL). Sodium bicarbonate (114.6 mg, 1.36 mmol, 5.0 eq.) and di-tert-butyl dicarbonate 
(119.1 mg, 0.55 mmol, 2.0 eq.) were added, and the reaction mixture was stirred at 50 ºC for 2 h. 
CuCl2 (0.8 mL, 1.0 M in H2O, 3.0 eq.) was then added at rt, and the mixture was further stirred for 
one minute. After adding ethyl acetate (5.0 mL), the mixture was transferred to a separatory funnel. 
The organic layer was separated, and the aqueous later extracted with ethyl acetate (3 × 5.0 mL). 
The combined organic layers were washed with saturated aqueous sodium chloride solution (10 
mL), dried over magnesium sulfate, and concentrated in vacuo. The crude mixture was purified by 
flash chromatography (SiO2, hexanes:EtOAc mixtures) to provide the desired compound 2.6j as a 
colorless oil (42.0 mg, 69%). 
 
Rf = 0.42 (SiO2, hexanes:EtOAc = 10:1, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 5.90 – 5.76 (m, 2H), 5.53 (ddt, J = 5.4, 3.7, 1.4 Hz, 1H), 4.52 (s, 
1H), 3.21 – 3.17 (m, 2H), 2.20 – 2.17 (m, 2H), 2.13 – 2.09 (m, 4H), 1.44 (s, 9H). 




HRMS: (ESI-TOF, m/z) calcd. For C13H21NO2 [M]
+ calc.: 223.1572; found: 223.1568.  
IR: (ATR, neat, cm-1) 3355 (w), 2976 (w), 2930 (w), 2873 (w), 1690 (s), 1505 (m), 1365 (m), 
1249 (m), 1166 (s), 736 (w).  
 
Synthesis of 2.6n (Table 2-3): Following the general procedure 2B, the title 
compound was isolated as a colorless oil (36.9 mg, 84%).  
Rf = 0.42 (SiO2, hexanes:EtOAc = 2:1, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 6.00 (dd, J = 9.8, 1.6 Hz, 1H), 5.97 – 5.88 (m, 1H), 5.77 (tt, J = 
3.9, 1.6 Hz, 1H), 4.12 (d, J = 1.6 Hz, 2H), 2.27 – 2.14 (m, 4H), 1.42 (s, 1H).  
13C NMR: (126 MHz, CDCl3) δ 135.7, 127.8, 124.6, 122.3, 65.8, 22.4, 22.2.  
HRMS: (ESI-TOF, m/z) calcd. For C7H11O [M+H]
+ calc.: 111.0804; found: 111.0809.  
IR: (ATR, neat, cm-1) 3324 (br, m), 2930 (m), 2871 (m), 2823 (m), 1426 (m), 1014 (s), 995 (s), 
820 (m), 725 (s), 663 (s).  
 
Synthesis of 2.6o (Table 2-3): Following the general procedure 2B, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 20:1) as 
a colorless oil (35.6 mg, 58%). 
Rf = 0.49 (SiO2, hexanes:EtOAc = 10:1, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 5.94 (ddd, J = 8.2, 1.5 Hz, 1H), 5.89 – 5.83 (m, 1H), 5.71 (ddt, J 
= 4.2, 2.8, 1.5 Hz, 1H), 3.90 (d, J = 1.5 Hz, 2H), 3.59 (sept, J = 6.1 Hz, 1H), 2.25 – 2.05 (m, 4H), 
1.15 (d, J = 6.1 Hz, 6H).  
13C NMR: (126 MHz, CDCl3) δ 133.6, 127.2, 125.2, 123.0, 72.2, 70.6, 22.4, 22.3, 22.2.  
HRMS: (ESI-TOF, m/z) calcd. For C10H16O [M]
+ calc.: 152.1196; found: 152.1197.  
IR: (ATR, neat, cm-1) 3039 (w), 2917 (s), 2875 (m), 2859 (m), 1356 (w), 1240 (w), 1095 (m), 
1066 (m), 821 (w), 734 (w).  
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Synthesis of 2.6q (Table 2-3): Following the general procedure 2B, the title 
compound was isolated as a yellow oil (47.2 mg, 95%). 
Rf = 0.42 (SiO2, hexanes:EtOAc = 2:1, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 5.99 (dt, J = 9.9, 1.5 Hz, 1H), 5.88 (dtd, J = 9.9, 3.6, 1.5 Hz, 1H), 
5.68 (dtd, J = 5.0, 3.6, 1.5 Hz, 1H), 4.25 (q, J = 6.4 Hz, 1H), 2.18 – 2.07 (m, 4H), 1.78 (br, 1H), 
1.26 (d, J = 6.4 Hz, 3H).  
13C NMR: (126 MHz, CDCl3) δ 139.7, 127.7, 123.5, 120.1, 70.3, 22.5, 22.2, 22.1.  
HRMS: (ESI-TOF, m/z) calcd. For C8H12O [M]
+ calc.: 124.0888; found: 124.0888.  
IR: (ATR, neat, cm-1) 3339 (br), 2971 (m), 2872 (m), 2872 (m), 2823 (m), 1426 (m), 1066 (s), 945 
(m), 819 (m), 598 (s).  
 
Synthesis of 2.6s (Table 2-3): The reaction was conducted following the general 
procedure 2B, except the neutralization after the hydrolysis of urazole moiety was 
not conducted. The title compound was isolated by flash chromatography (SiO2, 
hexanes:EtOAc = 20:1) as a colorless oil (44.1 mg, 71%). 
Rf = 0.27 (SiO2, hexanes:EtOAc = 10:1, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 5.98 (d, J = 9.8 Hz, 1H), 5.93 – 5.89 (m, 1H), 5.88 – 5.86 (m, 1H), 
4.65 (s, 1H), 3.30 (s, 6H), 2.25 – 2.18 (m, 2H), 2.19 – 2.10 (m, 2H).  
13C NMR: (126 MHz, CDCl3) δ 133.2, 127.6, 124.7, 122.9, 104.4, 53.3, 22.3, 22.0.  
HRMS: (ESI-TOF, m/z) calcd. For C9H15O2 [M+H]
+ calc.: 155.1067; found: 155.1064.  
IR: (ATR, neat, cm-1) 2933 (w), 2825 (w), 1367 (w), 1193 (w), 1098 (m), 1075 (m), 1051 (s), 
1000 (w), 945 (w), 813 (w).  
 
Synthesis of 2.6t (Table 2-3): The reaction was conducted following the general 
procedure 2B, except the neutralization after the hydrolysis of urazole moiety was 
not conducted. The title compound was isolated as a colorless oil (63.2 mg, 94%). 
Rf = 0.47 (SiO2, hexanes:EtOAc = 10:1, KMnO4). 
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1H NMR: (500 MHz, CDCl3) δ 5.99 – 5.92 (m, 2H), 5.86 (ddt, J = 9.5, 5.0, 2.5 Hz, 1H), 3.14 (s, 
6H), 2.25 – 2.13 (m, 2H), 2.13 – 2.02 (m, 2H), 1.33 (s, 3H).  
13C NMR: (126 MHz, CDCl3) δ 136.8, 127.1, 123.7, 123.1, 100.8, 48.8, 23.1, 22.2, 22.1.  
HRMS: (ESI-TOF, m/z) calcd. For C10H16O2 [M+Na]
+ calc.: 191.1043; found: 191.1036.  
IR: (ATR, neat, cm-1) 2937 (w), 2827 (w), 1272 (m), 1190 (m), 1142 (s), 1066 (s), 1051 (s), 1031 
(s), 872 (s), 629 (m).  
 
Synthesis of 2.6u (Table 2-3): The reaction was conducted following the general 
procedure 2B, except the neutralization after the hydrolysis of urazole moiety was 
not conducted. The title compound was isolated by flash chromatography (SiO2, 
hexanes:EtOAc = 20:1) as a colorless oil (65.3 mg, 89%). 
Rf = 0.31 (SiO2, hexanes:EtOAc = 10:1, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 6.13 (tt, J = 4.3, 1.5 Hz, 1H), 5.96 (dt, J = 9.8, 1.5 Hz, 1H), 5.87 
(dtd, J = 9.8, 4.3, 1.0 Hz, 1H), 3.13 (s, 9H), 2.25 – 2.20 (m, 2H), 2.17 – 2.07 (m, 2H).  
13C NMR: (126 MHz, CDCl3) δ 131.3, 127.3, 127.3, 123.1, 114.2, 49.5, 22.1, 22.0.  
HRMS: (ESI-TOF, m/z) calcd. For C10H20NO3 [M+NH4]
+ calc.: 202.1438; found: 202.1433.  
IR: (ATR, neat, cm-1) 2942 (w), 2823 (w), 1437 (w), 1270 (m), 1183 (w), 1088 (s), 1061 (s), 1038 
(m), 833 (w), 748 (w).  
 
Synthesis of 2.6x (Table 2-3): Following the general procedure 2B, the title 
compound was isolated as a colorless oil (48.3 mg, 79%). 
Rf = 0.87 (SiO2, hexanes:EtOAc = 10:1, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 6.10 (tt, J = 4.3, 1.2 Hz, 1H), 6.01 (ddt, J = 9.6, 1.9, 1.2 Hz, 1H), 
5.81 (ddt, J = 9.6, 4.3, 1.2 Hz, 1H), 2.18 – 2.01 (m, 4H), 0.07 (s, 9H).  
13C NMR: (126 MHz, CDCl3) δ 136.1, 135.1, 126.4, 125.4, 23.3, 22.0, –1.8.  
HRMS: (ESI-TOF, m/z) calcd. For C9H16Si [M]
+ calc.: 152.1016; found: 152.1014.  
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IR: (ATR, neat, cm-1) 2953 (m), 2925 (m), 2859 (w), 1710 (w), 1679 (w), 1455 (w), 1248 (m), 
838 (s), 753 (w).  
 
Synthesis of 2.6x' (Table 2-3): Following the general procedure 2B, the title 
compound was isolated as a colorless oil (55.3 mg, 91%). 
Rf = 0.87 (SiO2, hexanes:EtOAc = 10:1, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 5.84 – 5.70 (m, 3H), 5.60 (ddt, J = 7.5, 5.1, 3.9, 1.1 Hz, 1H), 2.48 
(dddd, J = 17.0, 10.2, 3.9, 2.1 Hz, 1H), 2.18 (dddd, J = 17.0, 7.8, 5.1, 1.6 Hz, 1H), 1.64 (dddd, J = 
10.2, 7.8, 4.8, 1.6 Hz, 1H), 0.02 (s, 9H).  
13C NMR: (126 MHz, CDCl3) δ 129.1, 124.7, 124.5, 122.3, 24.0, 23.2, –2.7.  
HRMS: (ESI-TOF, m/z) calcd. For C9H16Si [M]
+ calc.: 152.1016; found: 152.1018.  
IR: (ATR, neat, cm-1) 2953 (m), 2923 (m), 1679 (m), 1541 (m), 1462 (m), 1413 (w), 1248 (s), 
1104 (w), 836 (s), 752 (m).  
 
Synthesis of 2.7b (Table 2-3): Following the general procedure 2B, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 1:1) as 
an off-white oil (48.8 mg, 61%).  
1H NMR: (500 MHz, CDCl3) δ 11.55 (br, 1H), 7.90 (dd, J = 7.7, 1.4 Hz, 1H), 7.49 (td, J = 7.7, 
1.4 Hz, 1H), 7.34 (td, J = 7.7, 1.4 Hz, 1H), 7.29 (dd, J = 7.7, 1.4 Hz, 1H), 5.95 (dd, J = 9.7, 1.7 
Hz, 1H), 5.92 – 5.84 (m, 1H), 5.83 – 5.76 (m, 1H), 2.32 (m, 2H), 2.22 (m, 2H). 
13C NMR: (126 MHz, CDCl3) δ 172.7, 143.7, 137.4, 132.8, 130.6, 130.0, 130.1, 127.3, 127.0, 
126.1, 124.0, 23.6, 22.9.  






7.3.3 Arenophile fragmentations of reduced cycloadduct 2.1 for the synthesis of 1,4-
diaminocyclohex-2-ene 
General procedure 2C for the synthesis of compound 2.8 (Table 2-6)  
 
Compound 2.1 (0.2 mmol, 1.0 eq.) and potassium hydroxide (125.0 mg, 90% w/w, 2.0 mmol, 10 
eq.) in 2-propanol (0.7 mL, 0.3 M) were stirred at 100 ºC under a nitrogen atmosphere until full 
conversion of 2.1 was observed by TLC analysis. After cooling the reaction mixture to 0 ºC, water 
(0.7 mL) and benzoyl chloride (0.12 mL, 1.0 mmol, 5.0 eq.) were added, and the resulting mixture 
was further stirred at rt for 4 h. Then water (1.0 mL) was added, and the mixture was extracted 
with ethyl acetate (3 × 2.0 mL). The combined organic layer was washed with saturated aqueous 
sodium chloride solution (10 mL), dried over anhydrous magnesium sulfate, and concentrated in 
vacuo. The crude residue was passed through a short column (SiO2, hexanes:EtOAc mixture), and 
used directly for the next step. The product was then dissolved in mehtanol (3.0 mL), degassed 
with ultra sound under nitrogen atmosphere for 10 minutes, and cooled to 0 ºC. SmI2 (0.08 M THF 
solution)138 was added dropwise to the mixture at 0 ºC until the solution turned from colorless to 
blue, then further stirred for 30 min upon warming up to rt. The mixture was diluted with ethyl 
acetate (3.0 mL), then saturated aqueous ammonium chloride solution (1.5 mL) and water (1.5 
mL) were added, and the organic phase was separated. The aqueous layer was extracted with ethyl 
acetate (3 × 2.0 mL), and the combined organic layer was washed with saturated aqueous sodium 
chloride solution (10 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. 
The crude residue was purified by flash column chromatography (SiO2, hexanes:EtOAc mixture) 




Synthesis of 2.8a (Table 2-6): Following the general procedure 2C, the title compound 
was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) as a white solid 
(41.8 mg, 65%). 
Rf = 0.26 (SiO2, hexanes:EtOAc = 1:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.83 – 7.72 (m, 4H), 7.55 – 7.48 (m, 2H), 7.47 – 7.39 (m, 4H), 
6.25 (d, J = 8.0 Hz, 2H), 5.95 (d, J = 1.3 Hz, 2H), 4.69 (tdd, J = 8.0, 3.2, 1.3 Hz, 2H), 2.11 – 1.98 
(m, 2H), 1.89 – 1.77 (m, 2H). 
13C NMR: (126 MHz, CDCl3) δ 167.0, 134.9, 131.7, 131.4, 128.8, 127.1, 45.1, 26.6. 
HRMS: (ESI-TOF, m/z) calcd. For C20H20N2NaO2 [M+Na]+ calc.: 343.1417; found: 343.1419. 
IR: (ATR, neat, cm-1) 3311 (br), 2951 (w), 1651 (w), 1621 (m), 1575 (w), 1519 (s), 1488 (s), 1340 
(w), 1327 (w), 1138 (w), 1081 (w), 933 (w), 897 (w), 805 (w), 748 (w), 700 (s), 666 (m). 
m.p.: 236 – 237 ºC. 
 
Synthesis of 2.8b (Table 2-6): Following the general procedure 2C, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) as a 
white solid (37.6 mg, 56%). 
Rf = 0.32 (SiO2, hexanes:EtOAc = 1:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.80 (ddd, J = 8.3, 6.5, 1.4 Hz, 4H), 7.55 – 7.48 (m, 2H), 7.47 – 
7.35 (m, 4H), 6.36 (d, J = 8.9 Hz, 1H), 6.31 (d, J = 8.0 Hz, 1H), 5.66 (dt, J = 3.6, 1.5 Hz, 1H), 4.67 
– 4.59 (m, 1H), 4.55 (dt, J = 8.9, 4.9 Hz, 1H), 2.10 – 2.03 (m, 1H), 2.02 – 1.94 (m, 2H), 1.79 (s, 
3H), 1.78 – 1.67 (m, 1H). 
13C NMR: (126 MHz, CDCl3) δ 167.2, 167.0, 137.7, 134.7, 134.6, 131.7, 131.6, 128.74, 128.69, 
127.05, 127.03, 126.98, 48.0, 46.1, 27.3, 25.8, 21.0. 
HRMS: (ESI-TOF, m/z) calcd. For C21H23N2O2 [M+H]+ calc.: 335.1754; found: 335.1767. 
IR: (ATR, neat, cm-1) 3317 (w), 2936 (w), 1652 (m), 1622 (m), 1613 (m), 1575 (m), 1520 (s), 
1486 (s), 1461 (m), 1340 (m), 1326 (m), 1092 (w), 878 (w), 694 (s), 665 (m).  
m.p.: 185 – 187 ºC. 
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Synthesis of 2.8c (Table 2-6): Following the general procedure 2C, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 1:1) 
as a light yellow solid (60.3 mg, 72%). 
Rf = 0.26 (hexanes:EtOAc = 1:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.90 – 7.72 (m, 4H), 7.57 – 7.49 (m, 2H), 7.50 – 7.39 (m, 4H), 
6.55 (d, J = 8.5 Hz, 1H), 6.42 (d, J = 8.0 Hz, 1H), 5.66 (d, J = 3.0 Hz, 1H), 4.70 – 4.63 (m, 2H), 
2.19 – 2.00 (m, 4H), 1.94 (dddd, J = 13.8, 11.5, 4.7, 2.7 Hz, 1H), 1.81 – 1.71 (m, 1H), 1.59 – 1.48 
(m, 1H), 1.48 – 1.37 (m, 1H), 1. 36 – 1.21 (m, 8H), 0.89 (t, J = 6.9 Hz, 3H). 
13C NMR: (126 MHz, CDCl3) 167.1, 167.0, 141.5, 134.7, 134.6, 131.64, 131.63, 128.70, 128.67, 
127.1, 127.0, 126.4, 46.4, 46.2, 34.5, 31.9, 29.4, 29.2, 27.8, 27.7, 25.5, 22.8, 14.2. 
 
Synthesis of 2.8d (Table 2-6): Following the general procedure 2C, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) as a 
white solid (64.5 mg, 85%). 
Rf = 0.46 (SiO2, hexanes:EtOAc = 1:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.94 – 7.90 (m, 2H), 7.81 – 7.68 (m, 2H), 7.53 (d, J = 8.0 Hz, 1H), 
7.50 – 7.44 (m, 2H), 7.43 – 7.35 (m, 4H), 6.70 (d, J = 8.0 Hz, 1H), 5.63 (d, J = 3.2 Hz, 1H), 4.91 
– 4.84 (m, 1H), 4.47 – 4.36 (m, 1H), 2.09 – 1.84 (m, 3H), 1.72 – 1.59 (m, 1H), 1.08 (s, 9H). 
13C NMR: (126 MHz, CDCl3) δ 167.2, 166.2, 148.5 134.8, 134.7, 131.7, 11.4, 128.7, 128.6, 127.3, 
127.0, 124.0, 48.2, 43.0, 35.9, 29.5, 29.4, 23.5. 
HRMS: (ESI-TOF, m/z) calcd. For C24H29N2O2 [M+H]+ calc.: 377.2229; found: 377.2222. 
IR: (ATR, neat, cm-1) 3301 (br), 2952 (w), 1622 (m), 1576 (w), 1520 (s), 1486 (m), 1445 (w), 
1315 (w), 1268 (w), 1086 (w), 916 (w), 845 (w), 803 (w), 692 (s), 667 (m), 556 (w). 




Synthesis of 2.8e (Table 2-6): Following the general procedure 2C, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) 
as a white solid (39.6 mg, 49%). 
Rf = 0.59 (SiO2, hexanes:EtOAc = 1:4, UV, KMnO4). 
1H NMR: (500 MHz, acetone-d6) δ 10.79 (br, 1H), 7.93 – 7.88 (m, 4H), 7.86 (d, J = 7.7 Hz, 1H), 
7.70 (d, J = 8.7 Hz, 1H), 7.55 – 7.50 (m, 2H), 7.50 – 7.41 (m, 4H), 5.87 (d, J = 3.2 Hz, 1H), 4.86 
(dt, J = 7.7, 3.4 Hz, 1H), 4.65 – 4.55 (m, 1H), 2.16 – 2.07 (m, 1H), 2.05 – 1.97 (m, 2H), 1.85 – 
1.72 (m, 1H), 1.37 (s, 3H), 1.36 (s, 3H). 
13C NMR: (126 MHz, acetone-d6) δ 178.0, 167.2, 166.1, 142.9, 136.2, 136.1, 132.2, 132.0, 129.33, 
129.28, 128.9, 128.2, 128.1, 48.0, 47.4, 44.8, 29.9, 25.7, 25.1, 24.3. 
HRMS: (ESI-TOF, m/z) calcd. For C24H27N2O4 [M+H]+ calc.: 407.1971; found: 407.1964. 
IR: (ATR, neat, cm-1) 3310 (br), 2936 (w), 1697 (w), 1622 (m), 1574 (w), 1509 (m), 1479 (m), 
1269 (w), 1086 (w), 875 (w), 698 (s), 563 (m), 523 (w). 
m.p.: 218 – 219 ºC. 
 
Synthesis of 2.8f (Table 2-6): Following the general procedure 2C, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 1:1) as 
a light white solid (43.0 mg, 52%). 
Rf = 0.45 (hexanes:EtOAc = 1:1, UV, KMnO4) 
1H NMR: (500 MHz, CDCl3) δ 7.99 – 7.90 (m, 2H), 7.81 – 7.73 (m, 2H), 7.55 – 7.46 (m, 3H), 
7.45 – 7.36 (m, 4H), 6.59 (d, J = 8.0 Hz, 1H), 5.72 (d, J = 3.1 Hz, 1H), 4.84 (dt, J = 8.0, 3.1 Hz, 
1H), 4.52 (dt, J = 11.5, 4.3, 3.7 Hz, 1H), 3.49 (d, J = 1.2 Hz, 2H), 2.13 – 1.98 (m, 2H), 1.99 – 1.85 
(m, 1H), 1.77 – 1.66 (m, 1H), 1.19 (s, 3H), 1.18 (s, 3H). 
13C NMR: (126 MHz, CDCl3) δ 167.3, 166.2, 143.0, 134.6, 134.3, 131.8, 131.6, 128.7, 128.64, 
128.57, 127.3, 127.0, 54.4, 48.0, 42.7, 41.1, 29.4, 25.8, 25.6, 23.5. 
HRMS: (ESI-TOF, m/z) calcd. For C24H27ClN2NaO2 [M+Na]+ calc.: 433.1653; found: 433.1673. 
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IR: (ATR, neat, cm-1) 3280 (w), 2938 (w), 1661 (w), 1623 (m), 1575 (w), 1536 (w), 1511 (m), 
1480 (m), 1342 (w), 1270 (w), 1085 (w), 1028 (w), 973 (w), 844 (w), 803 (w), 700 (s), 677 (w), 
543 (w). 
m.p.: 165 – 167 ºC. 
 
Synthesis of 2.8h (Table 2-6): Following the general procedure 2C, the title 
compound was isolated by flash chromatography (SiO2, CH2Cl2:MeOH = 15:1) 
as a white solid (34.3 mg, 44%). 
Rf = 0.14 (CH2Cl2:MeOH = 9:1, UV, KMnO4) 
1H NMR: (500 MHz, acetone-d6) δ 10.60 (br, 1H), 7.94 – 7.79 (m, 4H), 7.64 (d, J = 8.2 Hz, 1H), 
7.56 – 7.48 (m, 3H), 7.48 – 7.40 (m, 4H), 5.74 – 5.71 (m, 1H), 4.70 – 4.51 (m, 2H), 2.57 (ddd, J = 
15.9, 8.2, 6.3 Hz, 1H), 2.49 (dt, J = 15.9, 7.7 Hz, 1H), 2.39 (m, 2H), 2.09 – 2.05 (m, 1H), 2.02 – 
1.84 (m, 3H). 
13C NMR: (126 MHz, acetone-d6) δ 174.4, 167.3, 167.0, 140.2, 136.2, 136.1, 132.12, 132.08, 
129.30, 129.29, 128.2, 128.1, 127.8, 47.2, 47.0, 32.7, 29.8 (detected from HSQC), 28.4, 25.9. 
HRMS: (ESI-TOF, m/z) calcd. For C23H25N2O4 [M+H]+ calc.: 393.1814; found: 393.1808. 
IR: (ATR, neat, cm-1) 3238 (br), 1702 (m), 1603 (s), 1553 (s), 1489 (w), 1439 (w), 1350 (w), 1300 
(m), 1225 (w), 1210 (w), 1105 (w), 1079 (w), 969 (w), 727 (m), 702 (s), 669 (m), 570 (w). 
m.p.: 119 – 120 ºC. 
 
Synthesis of 2.8j (Table 2-6): Following the general procedure 2C, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 1:1) 
as a colorless solid (66.0 mg, 71%). 
Rf = 0.25 (SiO2, hexanes:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, acetone-d6) δ 8.64 (d, J = 7.8 Hz, 1H), 8.15 – 8.07 (m, 2H), 8.02 (t, J = 6.2 
Hz, 1H), 7.96 – 7.86 (m, 2H), 7.60 – 7.41 (m, 7H), 7.40 – 7.32 (m, 4H), 6.87 (d, J = 7.7 Hz, 1H), 
5.72 (d, J = 3.5 Hz, 1H), 4.69 (dt, J = 7.7, 3.5 Hz, 1H), 4.57 – 4.46 (m, 1H), 3.82 (dddd, J = 13.6, 
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9.6, 7.8, 5.2 Hz, 1H), 3.41 (dd, J = 13.6, 5.3 Hz, 1H), 2.45 – 2.30 (m, 2H), 2.05 – 1.96 (m, 1H), 
1.95 – 1.73 (m, 3H). 
13C NMR: (126 MHz, acetone-d6) δ 168.6, 166.9, 166.8, 137.4, 135.9, 135.8, 135.7, 132.2, 132.0, 
131.9, 130.7, 129.3, 129.23, 129.17, 128.3, 128.1, 127.9, 48.3, 47.2, 39.8, 37.4, 28.9, 25.5.  
HRMS: (ESI-TOF, m/z) calcd. For C29H30N3O3 [M+H]+ calc.: 468.2287; found: 468.2284. 
IR: (ATR, neat, cm-1) 3288 (w), 2935 (w), 1633 (m), 1602 (w), 1577 (w), 1520 (m), 1486 (m), 
1446 (w), 1312 (w), 1271 (w), 1149 (w), 1077 (w), 1028 (w), 802 (w), 692 (s), 666 (m). 
m.p.: 100 – 101 ºC. 
 
Synthesis of 2.8o (Table 2-6): Following the general procedure 2C, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 1:1) as 
a colorless oil (34.1 mg, 43%). 
Rf = 0.34 (hexanes:EtOAc = 1:1, UV, KMnO4) 
1H NMR: (500 MHz, CDCl3) δ 7.86 – 7.72 (m, 4H), 7.53 – 7.47 (m, 2H), 7.48 – 7.35 (m, 4H), 
6.93 (d, J = 7.2 Hz, 1H), 6.37 (d, J = 8.1 Hz, 1H), 6.03 – 5.81 (m, 1H), 4.77 – 4.68 (m, 1H), 4.65 
– 4.58 (m, 1H), 4.00 – 3.91 (m, 2H), 3.58 (sept, J = 6.1 Hz, 1H), 2.15 – 1.94 (m, 3H), 1.83 – 1.74 
(m, 1H), 1.16 (d, J = 6.1 Hz, 3H), 1.07 (d, J = 6.1 Hz, 3H). 
13C NMR: (126 MHz, CDCl3) δ 167.1, 167.0, 138.1, 134.53, 134.50, 131.7, 131.6, 130.2, 128.7, 
128.6, 127.07, 127.06, 72.1, 70.5, 46.9, 45.7, 27.0, 25.9, 22.2, 22.1. 
HRMS: (ESI-TOF, m/z) calcd. For C24H32N3O3 [M+NH4]+ calc.: 410.2438; found: 410.2422. 
IR: (ATR, neat, cm-1) 3314 (br), 2922 (w), 1633 (m), 1578 (w), 1523 (m), 1487 (m), 1332 (w), 
1262 (w), 1073 (m), 928 (w), 802 (w), 693 (s), 601 (s). 
 
Synthesis of 2.8q (Table 2-6): Following the general procedure 2C, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) 
as a white solid (39.3 mg, 54%, dr = 1.7:1). 
Rf = 0.34 (hexanes:EtOAc = 1:1, UV, KMnO4) 
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1H NMR: (500 MHz, CDCl3) δ 7.82 – 7.76 (m, 2H major, 2H minor), 7.75 – 7.72 (m, 2H major, 
2H minor), 7.49 – 7.40 (m, 2H major, 2H minor), 7.39 – 7.31 (m, 4H major, 4H minor), 7.26 (d, J 
= 7.8 Hz, 1H  minor), 7.23 (d, J = 8.2 Hz, 1H major), 6.76 (d, J = 7.8 Hz, 1H major), 6.66 (d, J = 
8.2 Hz, 1H minor), 5.92 (d, J = 3.1 Hz, 1H major), 5.80 (d, J = 3.4 Hz, 1H minor), 4.78 (dt, J = 
8.2, 4.8 Hz, 1H minor), 4.66 (dt, J = 7.8, 3.8 Hz, 1H major), 4.61 – 4.51 (m, 1H minor), 4.56 – 
4.50 (m, 1H major), 4.33 – 4.21 (m, 1H major, 1H minor), 3.66 (br, 1H minor), 3.08 (br, 1H major), 
2.05 – 1.91 (m, 2H major, 3 H minor), 1.86 – 1.75 (m, 2H major, 1H minor), 1.32 – 1.24 (m, 3H 
major, 3H minor). 
13C NMR: (126 MHz, CDCl3) δ 167.6 (minor), 167.2 (major), 167.2 (major), 167.1 (minor), 144.5 
(major), 143.4 (minor), 134.5 (major), 134.5 (minor), 134.4 (major), 134.2 (minor), 131.9, 131.8, 
128.8, 128.7, 127.5 (minor), 127.2, 127.0, 127.0, 125.9 (major), 69.6 (minor), 68.7 (major), 46.7 
(major), 46.0 (minor), 44.6 (major), 44.5 (minor), 28.0 (major), 27.4 (minor), 25.7 (minor), 25.1 
(major), 23.3 (major), 20.7 (minor).  
Overlapping peaks were observed in the aromatic regions for the 1H and 13C NMR spectra for the 
major and minor isomers, therefore these peaks could not be assigned to specific isomers. 
HRMS: (ESI-TOF, m/z) calcd. For For C22H25N2O3 [M+H]+ calc.: 365.1860; found: 365.1851. 
IR: (ATR, neat, cm-1) 3301 (br), 2933 (w), 1626 (m), 1577 (w), 1521 (s), 1487 (m), 1333 (w), 
1314 (w), 1266 (w), 1077 (w), 909 (w), 692 (s), 645 (m), 615 (w). 
m.p.: 85 – 89 ºC. 
 
Synthesis of 2.8v (Table 2-6): Following the general procedure 2C, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) as a 
white solid (25.3 mg, 36%). 
Rf = 0.29 (SiO2, hexanes:EtOAc = 1:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.85 – 7.79 (m, 4H), 7.55 – 7.49 (m, 2H), 7.47 – 7.39 (m, 4H), 
6.73 (d, J = 8.1 Hz, 1H), 6.65 (d, J = 6.8 Hz, 1H), 6.15 (d, J = 4.1 Hz, 1H), 4.85 – 4.74 (m, 1H), 
4.63 (dd, J = 6.8, 5.6 Hz, 1H), 2.23 (dddd, J = 10.8, 8.5, 5.6, 3.2 Hz, 1H), 2.15 – 2.07 (m, 1H), 
2.04 (dddd, J = 13.5, 8.5, 5.1, 3.3 Hz, 1H), 1.82 (dddd, J = 13.5, 9.9, 7.0, 3.2 Hz, 1H). 
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13C NMR: (126 MHz, CDCl3) δ 167.5, 167.0, 135.5, 134.4, 134.3, 132.1, 132.0, 129.9, 128.92, 
128.87, 127.25, 127.24, 50.7, 46.6, 27.4, 25.7. 
HRMS: (ESI-TOF, m/z) calcd. For C20H20ClN2O2 [M+H]+ calc.: 355.1213; found: 355.1205. 
IR: (ATR, neat, cm-1) 3331 (w), 1652 (m), 1623 (m), 1516 (s), 1487 (s), 1334 (w), 1313 (w), 1259 
(w), 1090 (w), 971 (w), 850 (w), 713 (w), 692 (m), 675 (w), 665 (w), 622 (w), 599 (w), 574 (w), 
540 (w). 
m.p.: 248 – 249 ºC. 
 
Synthesis of 2.8x (Table 2-6): Following the general procedure 2C, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) as 
a colorless solid (42.5 mg, 54%). 
Rf = 0.48 (SiO2, hexanes:EtOAc = 1:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.85 – 7.75 (m, 4H), 7.53 – 7.47 (m, 2H), 7.47 – 7.39 (m, 4H), 
6.45 (d, J = 8.5 Hz, 1H), 6.31 (d, J = 8.3 Hz, 1H), 6.14 (d, J = 2.8 Hz, 1H), 4.84 – 4.78 (m, 1H), 
4.63 – 4.54 (m, 1H), 2.12 – 1.98 (m, 2H), 1.93 – 1.82 (m, 1H), 1.74 (ddd, J = 12.6, 9.6, 2.9 Hz, 
1H), 0.11 (s, 9H). 
13C NMR: (126 MHz, CDCl3) δ 167.1, 166.3, 142.2, 141.0, 134.63, 134.62, 131.8, 131.7, 128.78, 
128.76, 127.05, 127.03, 47.4, 44.9, 28.1, 25.0, –1.3. 
HRMS: (ESI-TOF, m/z) calcd. For C23H28N2NaO2Si [M+Na]+ calc.: 415.1812; found: 415.1821. 
IR: (ATR, neat, cm-1) 3312 (w), 2951 (w), 1627 (m), 1577 (w), 1520 (s), 1486 (s), 1247 (w), 1086 
(w), 834 (s), 802 (w), 753 (w), 691 (s), 666 (w), 635 (w), 562 (w). 
m.p.: 92 – 93 ºC. 
 
Synthesis of 2.8x' (Table 2-6): Following the general procedure 2C, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) as a 




Rf = 0.47 (SiO2, hexanes:EtOAc = 1:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.82 – 7.75 (m, 4H), 7.54 – 7.46 (m, 2H), 7.47 – 7.37 (m, 4H), 
6.33 (d, J = 9.4 Hz, 1H), 6.26 (d, J = 9.4 Hz, 1H), 6.03 (ddd, J = 9.9, 5.1, 2.3 Hz, 1H), 5.76 (d, J = 
9.9 Hz, 1H), 4.92 (dt, J = 9.4, 4.3 Hz, 1H), 4.64 (dtt, J = 9.4, 6.1, 2.3 Hz, 1H), 2.24 (dd, J = 13.9, 
6.1 Hz, 1H), 1.61 – 1.47 (m, 1H), 1.35 (ddd, J = 13.9, 4.4, 2.3 Hz, 1H), 0.06 (s, 9H). 
13C NMR: (126 MHz, CDCl3) δ 167.2, 166.1 134.6, 134.5, 131.8, 131.7, 131.5, 131.2, 128.78, 
128.76, 127.02, 127.00, 48.0, 43.7, 27.0, 26.8, –2.4. 
HRMS: (ESI-TOF, m/z) calcd. For C23H29N2O2Si [M+H]+ calc.: 393.1998; found: 393.1986. 
IR: (ATR, neat, cm-1) 3313 (br), 2949 (w), 1629 (m), 1577 (w), 1517 (m), 1485 (m), 1331 (w), 
1074 (w), 835 (s), 749 (w), 691 (s), 661 (m), 599 (w). 
m.p.: 75 – 76 ºC. 
 
7.3.4 Arenophile fragmentations of reduced cycloadduct 2.1 for the synthesis of 1-
aminocyclohex-3-ene 
General procedure 2D for the synthesis of compound 2.10 (Table 2-8)  
 
Compound 2.1 (50.0 mg, 0.20 mmol, 1.0 eq.) and Mn(dpm)3 (6.1 mg, 0.010 mmol, 5.0 mol%) 
were placed in a vial under nitrogen atmosphere, and 2-propanl (0.5 mL, 0.4 M, degassed) was 
added. At rt, PhSi(OiPr)H2 (47 µL, 0.20 mmol, 1.0 eq.) was dropwisely added, and the resulting 
mixture was stirred at rt for 8 h. Then saturated aqueous sodium chloride solution (1.0 mL) was 
added, and the aqueous phase was extracted with EtOAc (3 × 1 mL). Combined organic layer was 
washed with saturated aqueous sodium chloride solution (2 mL), dried over anhydrous magnesium 
sulfate, and concentrated in vacuo. The resulting residue was purified by flash chromatography 
(SiO2, n-hexane:EtOAc = 2:1).  
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Synthesis of 2.10d (Table 2-8): Following the general procedure 2D, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) to 
afford a mixture of compound 2.10d and 2.11d as a white solid (24.6 mg, 49%, 
2.10d:2.11d = 7.1:1). The mixture was further separated by flash chromatography 
(SiO2, hexanes:EtOAc = 2:1) for analytical purposes. 
Rf = 0.22 (n-hexane:EtOAc = 1:1, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 5.50 – 5.45 (m, 1H), 4.22 (dddd, J = 11.6, 9.7, 5.0, 3.1 Hz, 1H), 
3.10 (s, 3H), 2.34 – 2.14 (m, 4H), 1.88 – 1.80 (m, 1H), 1.69 (ddd, J = 20.1, 11.8, 8.2 Hz, 1H), 1.03 
(s, 9H). 
13C NMR: (125 MHz, CDCl3) δ 155.8, 154.4, 143.5, 117.2, 53.9, 35.5, 29.1, 27.6, 26.0, 25.4, 24.8. 
HRMS: (ESI-TOF, m/z) calcd. For C13H22N3O2 [M+H]+ calc.: 252.1712; found: 252.1713.  
IR: (ATR, neat, cm-1): 3136 (w), 2964 (w), 1760 (m), 1680 (s), 1483 (m), 1016 (w), 840 (w), 806 
(w), 769 (m), 734 (w), 700 (m), 663 (w), 610 (w). 
m.p.: 168–169 ºC. 
 
7.3.5 Derivatizations of 1,4-diamino-2-cyclohexane 2.8c 
Synthesis of Compound 2.12 (Table 2-9): 
 
Compound 2.8c (20.0 mg, 0.048 mmol, 1.0 eq.) and Pd/C (0.3 mg, 10 wt%, 0.0024 mmol, 5.0 mol) 
in methanol (0.5 mL, 0.1 M) were stirred at 50 ºC under hydrogen atmosphere for 30 h. The 
resulting mixture was passed through a plug of silica, and then concentrated in vacuo to give 
mixture of diastereomers (19.7 mg, 98%). The diastereomeric ratio was determined based on crude 
1H NMR (dr = 5.5:1), and each diastereoisomer was separated by flash column chromatography 
(SiO2, hexanes:EtOAc = 2:1). Both isomers were isolated as a colorless oil. 
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 2.12 (major isomer) 
Rf = 0.33 (SiO2, hexanes:EtOAc = 1:1, UV). 
1H NMR: (500 MHz, CDCl3) δ 7.80 – 7.73 (m, 4H), 7.51 (t, J = 7.5 Hz, 2H), 
7.44 (t, J = 7.5 Hz, 4H), 6.18 (d, J = 7.5 Hz, 1H), 6.03 (d, J = 8.7 Hz, 1H), 4.44 – 4.28 (m, 1H), 
3.91 (ddd, J = 8.7, 3.9, 3.9 Hz, 1H), 2.11 – 1.96 (m, 2H), 1.90 – 1.78 (m, 2H), 1.71 – 1.62 (m, 1H), 
1.64 – 1.53 (m, 3H), 1.45 – 1.35 (m, 1H), 1.35 – 1.28 (m, 1H), 1.29 – 1.16 (m, 9H), 0.84 (t, J = 
6.8 Hz, 3H). 
13C NMR: (126 MHz, CDCl3) δ 167.1, 167.0, 135.0, 135.0, 131.6 (2 peaks based on HSQC), 128.7 
(2 peaks based on HSQC), 127.0, 126.9, 51.6, 44.7, 38.2, 34.3, 31.9, 30.0, 29.3, 29.0, 27.7, 26.8, 
22.8, 14.2. 
HRMS: (ESI-TOF, m/z) calcd. For C27H37N2O2 [M+H]+ calc.: 421.2850; found: 421.2851. 
IR: (ATR, neat, cm-1) 3301 (br), 2926 (w), 2855 (w), 1633 (m), 1603 (w), 1578 (w), 1520 (m), 
1487 (m), 1464 (w), 1327 (w), 1276 (w), 1148 (w), 1074 (w), 1028 (w), 801 (w), 692 (m), 667 
(w), 570 (w). 
  
2.12' (minor isomer) 
Rf = 0.47 (SiO2, hexanes:EtOAc = 1:1, UV). 
1H NMR: (500 MHz, CDCl3) δ 7.81 – 7.70 (m, 4H), 7.54 – 7.48 (m, 2H), 7.49 – 
7.38 (m, 4H), 6.14 (d, J = 7.7 Hz, 1H), 6.01 (d, J = 8.0 Hz, 1H), 4.41 (ddd, J = 7.7, 3.7, 3.7 Hz, 
1H), 4.04 (ddd, J = 12.3, 8.0, 4.3 Hz, 1H), 2.21 – 2.09 (m, 2H), 2.05 – 1.97 (m, 1H), 1.88 – 1.77 
(m, 1H), 1.70 (ddd, J = 14.0, 3.7, 3.7 Hz, 1H), 1.45 – 1.28 (m, 4H), 1.28 – 1.19 (m, 9H), 1.10 (q, 
J = 12.3 Hz, 1H), 0.85 (t, J = 6.8 Hz, 3H). 
13C NMR: (126 MHz, CDCl3) δ 167.3, 166.9, 135.3, 134.8, 131.6, 131.6, 128.8, 128.7, 126.9 (2 
peaks based on HSQC), 48.8, 46.5, 39.1, 34.9, 33.1, 31.9, 29.9, 29.8, 29.3, 27.8, 26.9, 22.8, 14.2.  
HRMS: (ESI-TOF, m/z) calcd. For C27H37N2O2 [M+H]+ calc.: 421.2850; found: 421.2856.  
IR: (ATR, neat, cm-1) 3314 (br), 2924 (w), 2854 (w), 1630 (m), 1603 (w), 1578 (w), 1520 (m), 
1488 (m), 1464 (w), 1322 (w), 1075 (w), 709 (m), 692 (m), 663 (w), 615 (w), 580 (w). 
142 
 





Synthesis of compound 2.13 (Scheme 2-3): 
 
Compound 2.8c (25.0 mg, 0.06 mmol, 1.0 eq.) and 4-methylmorpholine N-oxide (14.0 mg, 0.12 
mmol, 2.0 eq.) were dissolved in acetone (0.6 mL, 0.1 M), and then water (22 µL, 1.2 mmol, 20 
eq.) was added. To this solution was added dropwise osmium tetroxide (15 µL, 0.2 M solution in 
acetonitrile, 0.003 mmol, 5.0 mol%), and the resulting solution was stirred at rt for 3 h. Then the 
reaction was quenched with saturated aqueous sodium thiosulfate solution (0.2 mL), and diluted 
with ethyl acetate (1.0 mL) and water (1.0 mL). The organic phase was separated, and the aqueous 
layer was extracted with ethyl acetate (3 × 1.0 mL), and the combined organic layer was washed 
with saturated aqueous sodium chloride solution (5.0 mL), dried over anhydrous magnesium 
sulfate, and concentrated in vacuo. The crude residue was purified by flash column 
chromatography (SiO2, EtOAc) to afford the titled compound 2.13 (24.8 mg, 92%) as a white solid. 
 
Rf = 0.47 (SiO2, hexanes:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.78 – 7.73 (m, 4H), 7.57 – 7.50 (m, 2H), 7.48 – 
7.42 (m, 4H), 6.17 (d, J = 6.3 Hz, 1H), 6.09 (d, J = 8.3 Hz, 1H), 4.86 (br, 1H), 
4.52 (dt, J = 8.3, 3.4 Hz, 1H), 4.29 – 4.18 (m, 1H), 3.57 (d, J = 9.0 Hz, 1H), 2.71 
(br, 1H), 2.18 (tt, J = 13.9, 3.7 Hz, 1H), 1.99 (dd, J = 13.1, 4.3 Hz, 1H), 1.94 – 1.84 (m, 2H), 1.65 
(dd, J = 13.1, 3.7 Hz, 1H), 1.52 – 1.46 (m, 2H), 1.43 – 1.38 (m, 1H), 1.29 – 1.10 (m, 8H), 0.80 (t, 
J = 6.8 Hz, 3H). 
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13C NMR: (126 MHz, CDCl3) δ 170.0, 167.1, 135.1, 134.0, 132.2, 131.8, 128.9 (2 peaks based on 
HSQC), 127.2, 127.0, 77.6, 75.8, 53.2, 50.3, 35.6, 31.9, 30.3, 29.2, 25.6, 24.7, 22.7, 22.2, 14.1. 
HRMS: (ESI-TOF, m/z) calcd. For C27H37N2O4 [M+H]+ calc.: 453.2748; found: 453.2740. 
IR: (ATR, neat, cm-1) 3333 (br), 2927 (w), 1628 (m), 1578 (w), 1528 (m), 1489 (w), 1340 (w), 
1112 (w), 1073 (w), 1027 (w), 854 (w), 801 (w), 711 (w), 692 (m), 616 (w), 552 (w). 
m.p.: 100 – 101 ºC. 






Synthesis of compound 2.14 (Scheme 2-3): 
 
Compound 2.8c (25.0 mg, 0.06 mmol, 1.0 eq.), m-chloroperoxybenzoic acid (15.5 mg, 70% w/w, 
0.09 mmol, 1.5 eq.), and sodium bicarbonate (8.5 mg, 0.1 mmol, 1.7 eq.) in dichloromethane (0.6 
mL, 0.1 M) were stirred at rt for 12 h. The resulting crude mixture was diluted with 
dichloromethane (1.0 mL) and water (1.0 mL), and the organic phase was separated. The aqueous 
layer was extracted with dichloromethane (3 × 1.0 mL), and the combined organic layer was 
washed with saturated aqueous sodium chloride solution (5.0 mL), dried over anhydrous 
magnesium sulfate, and concentrated in vacuo. The crude residue was purified by flash column 
chromatography (SiO2, hexanes:EtOAc = 1:1) to afford the titled compound 2.14 (25.2 mg, 97%) 




Rf = 0.37 (SiO2, hexanes:EtOAc = 1:1, UV). 
1H NMR: (500 MHz, acetone-d6) δ 7.94 – 7.86 (m, 4H), 7.59 – 7.43 (m, 7H), 
7.19 (d, J = 9.2 Hz, 1H), 4.62 (ddd, J = 9.2, 4.9, 4.9 Hz, 1H), 4.53 (ddd, J = 7.9, 
2.7, 2.7 Hz, 1H), 3.41 (d, J = 2.7 Hz, 1H), 1.89 – 1.81 (m, 1H), 1.79 – 1.73 (m, 
1H), 1.71 – 1.62 (m, 3H), 1.55 – 1.39 (m, 3H), 1.37 – 1.15 (m, 8H), 0.85 (t, J = 6.8 Hz, 3H). 
13C NMR: (126 MHz, acetone-d6) δ 167.2, 167.0, 136.0, 135.9, 132.25, 132.21, 129.4, 129.3, 
128.3, 128.1, 65.2, 62.2, 47.2, 46.4, 36.0, 32.6, 30.5, 30.1, 27.8, 25.5, 23.5, 23.4, 14.5. 
HRMS: (ESI-TOF, m/z) calcd. For C27H38N3O3 [M+NH4]+ calc.: 452.2908; found: 452.2887. 
IR: (ATR, neat, cm-1) 3301 (br), 2926 (w), 2855 (w), 1636 (m), 1579 (w), 1511 (m), 1483 (m), 
1445 (w), 1315 (w), 1271 (w), 1074 (w), 899 (w), 710 (m), 692 (m), 660 (w), 623 (w). 





Synthesis of compound 2.15 (Scheme 2-3): 
 
To a mixture of compound 2.8c (30.0 mg, 0.07 mmol, 1.0 eq.) and Co(acac)2 (3.7 mg, 0.014 mmol, 
20 mol%) in tetrahydrofuran (0.36 mL, 0.2 M) was added PhSi(Oi-Pr)H2 (26.5 µL, 0.14 mmol, 
2.0 eq.), and the reaction was stirred at rt under oxygen atmosphere for 20 h. The resulting mixture 
was concentrated in vacuo, and the crude residue was purified by flash column chromatography 




Rf = 0.17 (SiO2, hexanes:EtOAc = 1:1, UV, KMnO4). 
1H NMR: (500 MHz, acetone-d6) δ 7.86 – 7.78 (m, 4H), 7.54 – 7.38 (m, 6H), 
7.22 (d, J = 8.3 Hz, 1H), 7.07 (d, J = 9.5 Hz, 1H), 4.41 (ddd, J = 12.2, 8.3, 4.6 Hz, 
1H), 4.30 (d, J = 9.5 Hz, 1H), 3.73 (s, 1H), 2.30 – 2.19 (m, 1H), 2.03 – 1.97 (m, 
1H), 1.94 – 1.87 (m, 1H), 1.84 (d, J = 13.0 Hz, 1H), 1.78 – 1.70 (m, 2H), 1.67 (td, J = 13.7, 12.7, 
4.2 Hz, 1H), 1.56 – 1.43 (m, 3H), 1.29 – 1.13 (m, 8H), 0.81 (t, J = 6.8 Hz, 3H). 
13C NMR: (126 MHz, acetone-d6) δ 167.3, 166.7, 136.8, 136.6, 132.0, 131.9, 129.3, 129.2, 128.2, 
128.1, 74.3, 51.5, 46.0, 41.1, 40.3, 32.7, 31.1, 27.7, 30.2, 26.7, 23.5, 22.9, 14.5.  
HRMS: (ESI-TOF, m/z) calcd. For C27H40N3O3 [M+NH4]+ calc.: 454.3064; found: 454.3072. 
IR: (ATR, neat, cm-1) 3358 (br), 2925 (w), 1632 (m), 1578 (w), 1526 (m), 1489 (m), 1326 (w), 
1156 (w), 1037 (w), 710 (m), 689 (m), 671 (w), 582 (w). 
m.p.: 148 – 150 ºC. 





Synthesis of compound 2.16 (Scheme 2-3):  
 
To a mixture of compound 2.8c (30.0 mg, 0.07 mmol, 1.0 eq.) and Fe(acac)3 (3.7 mg, 0.014 mmol, 
20 mol%) in dichloromethane/ethylene glycol=1:1 (0.1 mL each, 0.2 M) was added PhSi(Oi-Pr)H2 
(27 µL, 0.14 mmol, 2.0 eq.), then methyl acrylate (32 µL, 0.36 mmol, 5.0 eq.). The resulting 
mixture was stirred at rt under argon atmosphere for 20 h, then concentrated in vacuo, and passed 
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through short column (SiO2, hexanes:EtOAc = 2:1) to separate the unreacted silane. 
Diastereomeric ratio was then determined based on the crude 1H NMR (dr = 1.2:1), and the 
diastereoisomers were separated by flash column chromatography (SiO2, hexanes:EtOAc = 2:1). 
Both isomers were isolated as a colorless oil (2.16: 15.6 mg, 43%, 2.16': 13.1 mg, 36%). 
  
2.16 (major isomer) 
Rf = 0.27 (SiO2, hexanes:EtOAc = 1:1, UV, KMnO4). 
1H NMR: (500 MHz, benzene-d6) δ 8.04 – 7.97 (m, 2H), 7.83 – 7.75 (m, 2H), 
7.16 – 7.09 (m, 6H), 6.44 (d, J = 9.4 Hz, 1H), 5.77 (d, J = 7.1 Hz, 1H), 4.39 – 
4.31 (m, 1H), 3.86 (dq, J = 11.9, 7.1 Hz, 1H), 3.42 (s, 3H), 2.52 (ddd, J = 16.1, 11.6, 5.1 Hz, 1H), 
2.22 (ddd, J = 16.1, 11.6, 5.1 Hz, 1H), 1.91 (ddd, J = 16.6, 11.6, 5.1 Hz, 1H), 1.79 – 1.68 (m, 2H), 
1.66 – 1.58 (m, 2H), 1.54 – 1.45 (m, 1H), 1.43 – 1.33 (m, 1H), 1.30 – 1.01 (m, 13H), 0.85 (t, J = 
6.8 Hz, 3H). 
13C NMR: (126 MHz, benzene-d6) δ 173.7, 166.5, 166.1, 135.1, 135.7, 131.43, 131.38, 128.9, 
128.7, 127.4, 127.3, 51.3, 49.0, 45.2, 39.6, 37.2, 36.4, 32.2, 30.8, 29.6, 28.4, 28.0, 26.5, 25.9, 23.0, 
22.5, 14.3. 
HRMS: (ESI-TOF, m/z) calcd. For C31H43N2O4 [M+H]+ calc.: 507.3217; found: 507.3217. 
IR: (ATR, neat, cm-1) 3321 (br), 2929 (w), 1735 (w), 1631 (m), 1603 (w), 1578 (w), 1521 (m), 
1488 (m), 1465 (w), 1326 (w), 1154 (w), 1074 (w), 710 (m), 692 (m), 666 (w), 553 (w). 







2.16' (minor isomer) 
Rf = 0.43 (SiO2, hexanes:EtOAc = 1:1, UV, KMnO4). 
1H NMR: (500 MHz, benzene-d6) δ 8.00 – 7.91 (m, 2H), 7.87 – 7.76 (m, 2H), 
7.15 – 7.07 (m, 6H), 6.42 (d, J = 9.5 Hz, 1H), 5.83 (d, J = 7.6 Hz, 1H), 4.34 – 
4.23 (m, 1H), 4.16 – 4.04 (m, 1H), 3.24 (s, 3H), 2.54 (ddd, J = 16.3, 11.6, 4.5 Hz, 1H), 2.16 (ddd, 
J = 16.3, 11.6, 5.3 Hz, 1H), 1.80 (td, J = 13.2, 11.6, 4.5 Hz, 1H), 1.74 – 1.52 (m, 5H), 1.41 – 1.04 
(m, 13H), 1.03 – 0.90 (m, 3H), 0.94 – 0.86 (m, 1H). 
13C NMR: (126 MHz, benzene-d6) δ 174.1, 166.8, 166.3, 136.2, 135.7, 131.4, 131.3, 128.8, 128.7, 
127.44, 127.42, 51.2, 49.1, 44.7, 39.8, 37.4, 32.8, 32.4, 31.5, 30.8, 29.7, 28.1, 27.2, 26.0, 23.2, 
23.1, 14.5. 
HRMS: (ESI-TOF, m/z) calcd. For C31H43N2O4 [M+H]+ calc.: 507.3217; found: 507.3229. 
IR: (ATR, neat, cm-1) 3323 (br), 2928 (w), 1737 (w), 1634 (m), 1579 (w), 1520 (m), 1488 (m), 
1464 (m), 1329 (w), 1155 (w), 1075 (w), 801 (w), 710 (m), 692 (m), 666 (m). 
 
7.3.6 Dearomative bis-1,4-hydroamination of polynuclear arenes  
General procedure 2D for the synthesis of compound 2.17 (Table 2-10)  
 
MTAD (1.57a, 113.1 mg, 1.0 mmol, 1.0 eq.) was placed in a test tube. Ethyl acetate (10 mL, 0.1 
M) was added to the test tube at –78 ºC, followed by the addition of compound 1.2 (2.0 mmol, 2.0 
eq.). If compound 1.2 was a solid, ethyl acetate (5.0 mL) was added to MTAD at –78 ºC, and 
compound 1.2 was added as a solution in ethyl acetate (5.0 mL). The mixture was then stirred 
under the irradiation with LED lights at –78 ºC until full decolorization of the reaction mixture 
was observed (pink to colorless solution). After turning the lights off, potassium azodicarboxylate 
(582.7 mg, 3.0 mmol, 3.0 eq.) was added in one portion, followed by the addition of acetic acid 
(0.86 mL, 15 mmol, 15 eq.) in ethyl acetate (4.0 mL) at –78 ºC. After stirring the resulting 
suspension at –50 ºC for 5 h, the reaction was warmed up to rt in water bath, then quenched with 
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water (2.0 mL). Saturated aqueous sodium bicarbonate solution (7.5 mL) was added, and then the 
organic phase was separated. The aqueous phase was extracted with ethyl acetate (3 × 10 mL). 
The combined organic layer was washed with saturated aqueous sodium chloride solution (15 mL), 
dried over anhydrous magnesium sulfate, and concentrated in vacuo. The crude mixture was 
purified by flash column chromatography (SiO2, hexanes/EtOAc mixture) to provide compound 
2.17. 
 
General procedure 2E for the synthesis of compound 2.18 (Table 2-10)  
 
A mixture of cycloadduct 2.17 (0.2 mmol, 1.0 eq.) and anhydrous hydrazine (0.125 mL, 4.0 mmol, 
20 eq.) was stirred at 100 °C until full conversion of the cycloadduct was observed. The reaction 
was then cooled to 50 °C, and ethanol (1.0 mL) was added under a hydrogen atmosphere (balloon). 
Raney®-Nickel (0.1 mL, W.R. Grace and Co. Raney® 2400, slurry, in H2O) was added, and the 
resulting mixture was stirred under a hydrogen atmosphere at 50 °C for 8 h, then filtered through 
a plug of Celite. The product was purified by column chromatography (SiO2, 5% NH4OH (5.0 M, 
aq) in MeOH) to provide compound 2.18. 
 
Synthesis of 2.17a (Table 2-10): Following the general procedure 2D, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 1:1) as a 
white solid (212.1 mg, 87%).  
Synthesis of 2.17a on gram-scale: Naphthalene (1.2a, 2.56 g, 20.0 mmol, 2.0 eq.) and MTAD 
(1.57a, 1.13 g, 10.0 mmol, 1.0 eq.) were placed in a 500 mL borosilicate bottle, and ethyl acetate 
(100 mL, 0.10 M) was added at –78 ºC. The mixture was then stirred under irradiation with LED 
lights at –78 ºC until full decolorization of the reaction mixture was observed (pink to colorless 
solution). The lights were turned off and potassium azodicarboxylate (5.83 g, 30.0 mmol, 3.0 eq.) 
was added in one portion at –78 ºC, followed by the addition of acetic acid (8.85mL, 150 mmol, 
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15 eq.) in ethyl acetate (20.0 mL) over 15 minutes. The resulting suspension was immediately 
placed out of the cold bath and stirred at ambient temperature for 5 hours. Water (50 mL) was 
added and the phases were separated. The aqueous phase was extracted with ethyl acetate (3 × 100 
mL) and the combined organic layer was washed with saturated aqueous sodium chloride solution 
(100 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The product was 
purified by column chromatography (SiO2, hexanes/EtOAc = 5:1 → 1:1). The obtained pale yellow 
solid was recrystallized from diethylether/hexanes to yield the desired product 7a (2.00 g, 82%). 
 
Rf = 0.35 (SiO2, hexanes:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.35 (dd, J = 5.4, 3.3 Hz, 2H), 7.29 (dd, J = 5.4, 3.3 Hz, 2H), 5.30 
– 5.28 (m, 2H), 2.84 (s, 3H), 2.42 – 2.36 (m, 2H), 1.73 – 1.68 (m, 2H).  
13C NMR: (126 MHz, CDCl3) δ 156.9, 134.9, 128.8, 123.4, 53.8, 25.2, 23.5.  
HRMS: (ESI-TOF, m/z) calcd. For C13H13N3O2 [M]
+ calc.: 243.1007; found: 243.1008.  
IR: (ATR, neat, cm-1) 2942 (w), 1764 (m), 1698 (s), 1458 (s), 1436 (s), 1395 (s), 1237 (m), 1204 
(s), 1165 (m), 1069 (w), 1037 (m), 988 (m), 946 (m), 915 (m), 753 (s), 593 (m), 538 (s).  
m.p.: 190 – 191 ºC. 
 
Synthesis of 2.18a (Table 2-10): Following the general procedure 2E, the title 
compound was isolated by flash chromatography (SiO2, 5% NH4OH (5 M, aq) in 
MeOH) as a brown oil (25.0 mg, 77%). 
Rf = 0.26 (SiO2, 5% NH4OH (5 M, aq) in MeOH, ninhydrin). 
1H NMR: (500 MHz, CDCl3) δ 7.40 (dd, J = 5.7, 3.4 Hz, 2H), 7.24 (dd, J = 5.7, 3.4 Hz, 2H), 3.94 
(t, J = 5.5 Hz, 2H), 2.03 – 1.97 (m, 2H), 1.91 (br, 4H), 1.85 – 1.78 (m, 2H).  
 13C NMR: (126 MHz, CDCl3) δ 140.9, 127.9, 127.4, 49.8, 30.2.  
HRMS: (ESI-TOF, m/z) calcd. For C10H14KN2 [M+K]
+ calc.: 201.0789; found: 201.0785.  
IR: (ATR, neat, cm-1) 3277 (br, m), 2928 (m), 1571 (s), 1449 (s), 1370 (m), 1350 (m), 940 (w), 
771 (m), 722 (w). 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Synthesis of 2.17b (Table 2-10): Following the general procedure 2D, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1, 
1% Et3N) as a white solid (220.0 mg, 66%). 
Rf = 0.57 (SiO2, hexanes:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.56 (dd, J = 8.1, 1.3 Hz, 1H), 7.30 (dd, J = 8.1, 7.3 Hz, 1H), 7.21 
(dd, J = 7.3, 1.3 Hz, 1H), 6.16 (t, J = 2.5 Hz, 1H), 5.27 (t, J = 2.3 Hz, 1H), 3.25 (s, 3H), 3.23 (s, 
3H), 2.87 (s, 3H), 2.37 – 2.34 (m, 2H), 1.73 – 1.68 (m, 2H), 1.67 (s, 3H).  
13C NMR: (126 MHz, CDCl3) δ 156.3, 155.6, 138.0, 136.1, 133.5, 128.0, 127.5, 123.4, 102.1, 
53.7, 50.5, 49.2, 49.2, 26.0, 25.3, 23.8, 23.4.  
HRMS: (ESI-TOF, m/z) calcd. For C17H21N3O4Na [M+Na]+ calc.: 354.1430; found: 354.1428.  
IR: (ATR, neat, cm-1) 2945 (w), 2249 (w), 1764 (m), 1700 (s), 1453 (m), 1394 (m), 1275 (m), 
1206 (m), 1146 (m), 1038 (m), 876 (m), 762 (m), 729 (m), 562 (m).  
m.p.: 168 – 169 ºC. 
 
Synthesis of 2.18b (Table 2-10): Following the general procedure 2E, the title 
compound was isolated by flash chromatography (SiO2, 5% NH4OH (5 M, aq) in 
MeOH) as a brown oil (29.4 mg, 59%). 
Rf = 0.10 (SiO2, 5% NH4OH (5 M, aq) in MeOH, ninhydrin). 
1H NMR: (500 MHz, CDCl3) δ 7.41 – 7.33 (m, 2H), 7.21 (t, J = 7.7 Hz, 1H), 4.46 (d, J = 3.2 Hz, 
1H), 4.00 (t, J = 7.5 Hz, 1H), 3.35 (s, 3H), 3.15 (s, 3H), 2.10 – 2.08 (m, 5H), 2.06 – 1.97 (m, 1H), 
1.95 – 1.85 (m, 1H), 1.80 – 1.70 (m, 1H), 1.54 (s, 3H).  
 13C NMR: (126 MHz, CDCl3) δ 142.3, 141.1, 140.2, 128.8, 127.1, 126.5, 104.1, 51.0, 49.7, 48.7, 
46.1, 30.1, 27.8, 26.0.  
HRMS: (ESI-TOF, m/z) calcd. For C14H22N2NaO2 [M+Na]
+ calc.: 273.1573; found: 273.1562.  
IR: (ATR, neat, cm-1) 3360 (br, w), 2933 (m), 1580 (m), 1460 (m), 1371 (m), 1265 (m), 1143 (s), 




Synthesis of 2.17c (Table 2-10): Following the general procedure 2D, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) 
as a white solid (136.4 mg, 43%). 
Rf = 0.53 (SiO2, hexanes:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.61 – 7.54 (m, 3H), 7.51 (d, J = 1.8 Hz, 1H), 7.47 – 7.41 (t, J = 
7.6 Hz, 2H), 7.36 (dt, J = 7.6, 3.5 Hz, 2H), 5.37 – 3.33 (m, 2H), 2.86 (s, 3H), 2.45 – 2.41 (m, 2H), 
1.77 – 1.73 (m, 2H).  
13C NMR: (126 MHz, CDCl3) δ 157.1, 157.1, 142.1, 140.3, 135.6, 133.9, 129.0, 127.9, 127.6, 
127.3, 124.0, 122.4, 54.1, 53.7, 25.4, 23.8, 23.8.  
HRMS: (ESI-TOF, m/z) calcd. For C19H18N3O2 [M+H]
+ calc.: 320.1399; found: 320.1396.  
IR: (ATR, neat, cm-1) 2944 (w), 1763 (m), 1700 (s), 1480 (m), 1453 (m), 1393 (m), 1212 (w), 
1027 (w), 916 (w), 760 (m), 730 (m), 699 (m), 535 (w).  
m.p.: 234 – 235 ºC. 
 
Synthesis of 2.18c (Table 2-10): Following the general procedure 2E, the title 
compound was isolated by flash chromatography (SiO2, 5% NH4OH (5 M, aq) 
in MeOH) as a brown oil (30.4 mg, 65%). 
Rf = 0.26 (SiO2, 5% NH4OH (5 M, aq) in MeOH, ninhydrin). 
1H NMR: (500 MHz, CDCl3) δ 7.66 (d, J = 1.8 Hz, 1H), 7.62 – 7.57 (m, 2H), 7.53 – 7.46 (m, 2H), 
7.43 (t, J = 7.6 Hz, 2H), 7.34 (t, J = 7.4 Hz, 1H), 4.08 – 3.88 (m, 2H), 2.10 – 2.00 (m, 2H), 1.92 – 
1.82 (m, 2H), 1.70 (br, 4H).  
13C NMR: (126 MHz, CDCl3) δ 141.2, 141.1, 140.3, 139.9, 128.9, 128.4, 127.4, 127.2, 126.6, 
126.1, 49.8, 49.5, 30.3, 30.2.  
HRMS: (ESI-TOF, m/z) calcd. For C16H19N2 [M+H]
+ calc.: 239.1543; found: 239.1533.  
IR: (ATR, neat, cm-1) 3353 (w), 2924 (m), 2885 (m), 1599 (m), 1482 (s), 904 (m), 830 (s), 766 




Synthesis of 2.17d (Table 2-10): Following the general procedure 2D, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) as 
a white solid (150.9 mg, 51%). 
Rf = 0.54 (SiO2, hexanes:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 8.15 (d, J = 8.2 Hz, 1H), 7.88 (d, J = 8.2 Hz, 1H), 7.85 (d, J = 8.2 
Hz, 1H), 7.62 (ddt, J = 8.2, 6.8, 1.1 Hz, 1H), 7.54 (ddt, J = 8.2, 6.8, 1.1 Hz, 1H), 7.43 (d, J = 8.2 
Hz, 1H), 6.09 (t, J = 2.7 Hz, 1H), 5.45 (t, J = 2.7 Hz, 1H), 2.77 (s, 3H), 2.59 – 2.42 (m, 2H), 1.79 
– 1.65 (m, 2H).  
13C NMR: (126 MHz, CDCl3) δ 157.5, 157.3, 133.4, 132.4, 131.0, 128.8, 128.7, 127.7, 127.4, 
126.3, 122.1, 121.5, 54.3, 49.4, 25.2, 23.7, 23.2.  
HRMS: (ESI-TOF, m/z) calcd. For C17H16N3O2 [M+H]
+ calc.: 294.1243; found: 294.1242.  
IR: (ATR, neat, cm-1) 2943 (w), 2250 (w), 1767 (m), 1699 (s), 1451 (s), 1393 (s), 1207 (m), 1024 
(m), 914 (m), 819 (m), 765 (m), 728 (s), 595 (m).  
m.p.: 167 – 168 ºC. 
 
Synthesis of 2.18d (Table 2-10): Following the general procedure 2E, the title 
compound was isolated by flash chromatography (SiO2, 5% NH4OH (5 M, aq) in 
MeOH) as a brown oil (41.4 mg, 97%). 
Rf = 0.26 (SiO2, 5% NH4OH (5 M, aq) in MeOH, ninhydrin). 
1H NMR: (500 MHz, CDCl3) δ 8.19 (d, J = 8.6 Hz, 1H), 7.81 (dd, J = 8.1, 1.4 Hz, 1H), 7.75 (d, J 
= 8.6 Hz, 1H), 7.68 (d, J = 8.6 Hz, 1H), 7.54 (ddd, J = 8.6, 6.8, 1.4 Hz, 1H), 7.46 (dd, J = 8.1, 6.8 
Hz, 1H), 4.74 (t, J = 3.2 Hz, 1H), 4.04 (dd, J = 10.2, 5.9 Hz, 1H), 2.17 – 2.09 (m, 1H), 2.09 – 2.02 
(m, 2H), 2.00 – 1.90 (m, 1H), 1.85 (br s, 4H).  
13C NMR: (126 MHz, CDCl3) δ 138.1, 134.9, 133.0, 131.7, 128.8, 127.9, 126.7, 125.4, 125.3, 
123.7, 50.9, 45.0, 31.0, 29.0.  
HRMS: (ESI-TOF, m/z) calcd. For C14H20N3 [M+NH4]
+ calc.: 230.1652; found: 230.1661.  
IR: (ATR, neat, cm-1) 3276 (br, w), 2924 (m), 2856 (m), 1597 (m), 1507 (m), 1198 (w), 906 (m), 
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817 (s), 751 (s), 732 (s).  
 
Synthesis of 2.17e (Table 2-10): Following the general procedure 2D, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 2:1) as 
a white solid (224.7 mg, 92%). 
Rf = 0.10 (SiO2, n-hexane:EtOAc = 1:2, KMnO4), column 1:4 H/E to EtOAc 
1H NMR (500 MHz, CDCl3) δ 8.58 (dd, J = 5.1, 1.6 Hz, 1H), 7.65 (dd, J = 7.6, 1.6 Hz, 1H), 7.34 
(dd, J = 7.6, 5.1 Hz, 1H), 5.50 (t, J = 2.8 Hz, 1H), 5.40 (t, J = 2.8 Hz, 1H), 2.91 (s, 3H), 2.55 – 
2.41 (m, 2H), 1.91 – 1.82 (m, 1H), 1.79 – 1.70 (m, 1H). 
13C NMR (125 MHz, CDCl3) δ 156.8, 156.5, 154.6, 149.7, 131.2, 129.8, 124.1, 55.6, 53.2, 25.4, 
23.5, 22.8. 
HRMS (EI-TOF, m/z) calcd. For C12H13N4O2 [M+H]+ calc.: 245.1033; found: 245.1039. 
IR (ATR, neat, cm-1): 2946 (w), 1769 (m), 1700 (s), 1581 (w), 1455 (s), 1394 (m), 1217 (m), 1029 
(w), 983 (w), 800 (w), 762 (m), 594 (w), 544 (w). 
m.p.: 158.8 - 159.6 °C 
 
Synthesis of 2.18f (Teble 2-10): Following the general procedure 2E, the title 
compound was isolated by flash chromatography (SiO2, 5% NH4OH (5 M, aq) in 
MeOH) as a brown oil (22.8 mg, 70%). 
Rf = 0.09 (5% NH3 (5 M, aq) in MeOH, ninhydrin) 
1H NMR (500 MHz, CDCl3) δ 8.47 (dd, J = 4.8, 1.7 Hz, 1H), 7.74 (dd, J = 7.8, 1.7 Hz, 1H), 7.16 
(dd, J = 7.8, 4.7 Hz, 1H), 4.02 – 3.94 (m, 2H), 2.11 (dddd, J = 13.2, 8.4, 5.3, 3.3 Hz, 1H), 2.03 
(dddd, J = 13.2, 9.9, 5.3, 3.3 Hz, 1H), 1.95 – 1.85 (m, 1H), 1.84 (tdd, J = 8.4, 5.3, 2.6 Hz, 1H), 
1.77 (br s, 4H). 
13C NMR (125 MHz, CDCl3) δ 159.3, 148.3, 136.4, 135.5, 122.4, 51.5, 49.5, 30.3, 27.7. 
IR (ATR, neat, cm-1): 3349 (m), 3275 (m), 2927 (m), 2857 (w), 1574 (s), 1437 (s), 1372 (m), 942 
(m), 808 (m), 728 (m). 
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HRMS (EI-TOF, m/z) calcd. For C9H17N4 [M+NH4]+ calc.: 181.1448; found: 181.1445. 
 
Synthesis of 2.17f (Table 2-10): Following the general procedure 2D, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 1:2) as 
a yellow solid (284.1 mg, 88%). 
Rf = 0.39 (SiO2, hexanes:EtOAc = 1:4, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 8.61 (d, J = 2.1 Hz, 1H), 7.77 (d, J = 2.1 Hz, 1H), 5.43 (t, J = 2.7 
Hz, 1H), 5.33 (t, J = 2.7 Hz, 1H), 2.88 (s, 3H), 2.52 – 2.35 (m, 2H), 1.85 – 1.74 (m, 1H), 1.75 – 
1.63 (m, 1H).  
13C NMR: (126 MHz, CDCl3) δ 156.8, 156.5, 153.0, 150.8, 133.9, 131.0, 121.0, 55.1, 52.9, 25.6, 
23.4, 22.7.  
HRMS: (ESI-TOF, m/z) calcd. For C12H11BrN4O2 [M]
+ calc.: 322.0060; found: 322.0063.  
IR: (ATR, neat, cm-1) 2946 (w), 1765 (w), 1702 (s), 1448 (m), 1392 (m), 1214 (w), 986 (w), 764 
(w), 729 (w), 629 (w).  
m.p.: 165– 166 ºC. 
 
Synthesis of 2.18f (Table 2-10): Following the general procedure 2E, the title 
compound was isolated by flash chromatography (SiO2, 5% NH4OH (5 M, aq) in 
MeOH) as a brown oil (26.0 mg, 54%). 
Rf = 0.03 (SiO2, 5% NH4OH (5 M, aq) in MeOH, ninhydrin). 
1H NMR: (500 MHz, CDCl3) δ 8.51 (d, J = 2.2 Hz, 1H), 7.94 (d, J = 2.2 Hz, 1H), 4.03 – 3.73 (m, 
2H), 2.10 (dddd, J = 14.2, 9.0, 5.8, 3.3 Hz, 1H), 2.05 – 1.97 (m, 1H), 1.92 – 1.86 (m, 1H), 1.86 – 
1.78 (m, 1H), 1.69 (br, 4H).  
13C NMR: (126 MHz, CDCl3) δ 157.8, 149.2, 138.7, 137.5, 119.1, 51.0, 49.5, 30.2, 27.7.  
HRMS: (ESI-TOF, m/z) calcd. For C9H12BrN3 [M]
+ calc.: 241.0209; found: 241.0212.  
IR: (ATR, neat, cm-1) 3349 (w), 2934 (m), 2856 (m), 1685 (m), 1588 (m), 1437 (s), 899 (s), 858 
(m), 781 (m), 625 (w). 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Synthesis of 2.17g (Table 2-10): Following the general procedure 2D, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 1:4 to 
EtOAc) as a yellow solid (201.3 mg, 82%). 
Rf = 0.14 (SiO2, hexanes:EtOAc = 1:4, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 8.46 (s, 2H), 5.49 – 5.46 (m, 2H), 2.82 (s, 3H), 2.49 – 2.43 (m, 
2H), 1.81 – 1.75 (m, 2H).  
13C NMR: (126 MHz, CDCl3) δ 155.9, 149.7, 144.7, 54.8, 25.4, 22.8.  
HRMS: (ESI-TOF, m/z) calcd. For C11H11N5O2 [M]
+ calc.: 245.0913; found: 245.0913.  
IR: (ATR, neat, cm-1) 2948 (w), 1764 (m), 1701 (s), 1454 (m), 1392 (m), 1233 (w), 1207 (w), 
1134 (m), 985 (m), 854 (w), 762 (m), 729 (m), 595 (m).  
m.p.: 172– 173 ºC. 
 
Synthesis of 2.18g (Table 2-10):  Following the general procedure 2E, the title 
compound was isolated by flash chromatography (SiO2, 5% NH4OH (5 M, aq) in 
MeOH) as a brown oil (17.4 mg, 53%). 
Rf = 0.12 (SiO2, 5% NH4OH (5 M, aq) in MeOH, ninhydrin). 
1H NMR: (500 MHz, CDCl3) δ 8.44 (s, 2H), 4.13 – 4.01 (m, 2H), 2.19 – 2.09 (m, 2H), 1.99 – 1.91 
(m, 2H), 1.84 (br, 4H).  
13C NMR: (126 MHz, CDCl3) δ 154.7, 143.1, 51.3, 27.7  
HRMS: (ESI-TOF, m/z) calcd. For C8H12N4Na [M+Na]
+ calc.: 187.0954; found: 187.0954.  
IR: (ATR, neat, cm-1) 3352(s), 3284 (s), 2944 (w), 1594 (m), 1407 (m), 1375 (w), 1151 (w), 1069 
(w), 947 (m), 629 (w). 
 
Synthesis of 2.17h (Table 2-10): Following the general procedure 2D, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 1:2) 
as a brown solid (179.5 mg, 61%). 
Rf = 0.33 (SiO2, hexanes:EtOAc = 1:4, UV, KMnO4). 
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1H NMR: (500 MHz, CDCl3) δ 8.13 (dt, J = 8.5, 0.9 Hz, 1H), 8.05 (s, 1H), 7.85 (dd, J = 8.1, 1.4 
Hz, 1H), 7.77 (ddd, J = 8.5, 6.9, 1.4 Hz, 1H), 7.60 (ddd, J = 8.1, 6.9, 0.9 Hz, 1H), 5.56 (t, J = 2.8 
Hz, 1H), 5.49 (t, J = 2.8 Hz, 1H), 2.85 (s, 3H), 2.62 – 2.47 (m, 2H), 2.02 – 1.93 (m, 1H), 1.87 – 
1.77 (m, 1H).  
13C NMR: (126 MHz, CDCl3) δ 156.7, 156.2, 155.0, 147.8, 130.6, 130.3, 129.8, 128.3, 128.2, 
127.7, 127.4, 56.0, 53.4, 25.5, 24.2, 23.1.  
HRMS: (ESI-TOF, m/z) calcd. For C16H15N4O2 [M+H]
+ calc.: 295.1190; found: 295.1185.  
IR: (ATR, neat, cm-1) 2945 (w), 1699 (s), 1452 (m), 1392 (m), 1209 (w), 1025 (w), 861 (w), 762 
(m), 732 (m), 542 (m).  
m.p.: 183– 184 ºC. 
 
Synthesis of 2.18h (Table 2-10): Following the general procedure 2E, the title 
compound was isolated by flash chromatography (SiO2, 5% NH4OH (5 M, aq) in 
MeOH) as a brown oil (31.8 mg, 75%). 
Rf = 0.41 (SiO2, 5% NH4OH (5 M, aq) in MeOH, ninhydrin). 
1H NMR: (500 MHz, CDCl3) δ 8.20 (s, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.78 (dd, J = 8.1, 1.4 Hz, 
1H), 7.66 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H), 7.48 (dd, J = 8.1, 6.8 Hz, 1H), 4.21 – 4.16 (m, 1H), 4.13 
(dd, J = 8.0, 5.7 Hz, 1H), 2.23 (dddd, J = 13.3, 7.5, 5.7, 4.0 Hz, 1H), 2.13 (ddd, J = 13.3, 9.1, 4.0 
Hz, 1H), 1.98 (br, 4H), 1.97 – 1.85 (m, 2H).  
 13C NMR: (126 MHz, CDCl3) δ 160.7, 147.2, 134.9, 134.2, 129.3, 128.7, 127.7, 127.5, 126.3, 
52.0, 49.7, 30.4, 27.9.  
HRMS: (ESI-TOF, m/z) calcd. For C13H15N3Na [M+Na]
+ calc.: 236.1158; found: 236.1164.  
IR: (ATR, neat, cm-1) 3350 (m), 2937 (w), 1597 (m), 1491 (m), 1446 (w), 1374 (w), 918 (m), 793 




Synthesis of 2.17i (Table 2-10): Following the general procedure 2D, the title 
compound was isolated by flash chromatography (SiO2, hexanes:EtOAc = 1:2) 
as a yellow solid (157.7 mg, 54%). 
Rf = 0.33 (SiO2, hexanes:EtOAc = 1:4, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.98 (dd, J = 4.2, 1.8 Hz, 1H), 8.15 (dd, J = 8.2, 1.8 Hz, 1H), 7.80 
(d, J = 8.2 Hz, 1H), 7.49 (d, J = 8.2 Hz, 1H), 7.42 (dd, J = 8.2, 4.2 Hz, 1H), 6.63 (t, J = 2.6 Hz, 
1H), 5.48 (t, J = 2.6 Hz, 1H), 2.75 (s, 3H), 2.54 – 2.42 (m, 2H), 1.76 – 1.67 (m, 2H).  
13C NMR: (126 MHz, CDCl3) δ 157.3, 156.9, 151.5, 142.4, 136.4, 135.9, 132.9, 128.4, 128.1, 
122.2, 121.7, 53.9, 48.4, 25.3, 23.8, 23.0.  
HRMS: (ESI-TOF, m/z) calcd. For C16H14KN4O2 [M+K]
+ calc.: 333.0748; found: 333.0764.  
IR: (ATR, neat, cm-1) 2942 (w), 1764 (m), 1698 (s), 1451 (s), 1393 (m), 1209 (m), 1158 (w), 1024 
(w), 840 (m), 764 (m).  
m.p.: 220– 221 ºC. 
 
Synthesis of 2.18i (Table 2-10): Following the general procedure 2E, the title 
compound was isolated by flash chromatography (SiO2, 5% NH4OH (5 M, aq) in 
MeOH) as a brown oil (24.8 mg, 58%). 
Rf = 0.20 (SiO2, 5% NH4OH (5 M, aq) in MeOH, ninhydrin). 
1H NMR: (500 MHz, CDCl3) δ 8.91 (dd, J = 4.2, 1.8 Hz, 1H), 8.11 (dd, J = 8.2, 1.8 Hz, 1H), 7.75 
(d, J = 8.6 Hz, 1H), 7.70 (d, J = 8.6 Hz, 1H), 7.38 (dd, J = 8.2, 4.2 Hz, 1H), 4.98 (t, J = 4.3 Hz, 
1H), 4.06 (dd, J = 9.2, 4.7 Hz, 1H), 2.15 – 2.06 (m, 3H), 2.01 – 1.95 (m, 1H), 1.94 (br, 4H).  
 13C NMR: (126 MHz, CDCl3) δ 149.6, 147.1, 141.7, 137.5, 136.4, 127.4, 126.8, 126.6, 120.8, 
51.0, 45.2, 30.1, 29.4.  
HRMS: (ESI-TOF, m/z) calcd. For C13H15N3 [M]
+ calc.: 213.1260; found: 213.1251.  
IR: (ATR, neat, cm-1) 3347 (w), 2927 (m), 2857 (w), 1595 (m), 1498 (m), 1455 (m), 1370 (w), 




Synthesis of 2.17j (Scheme 2-4): Following the general procedure 2D, the title 
compound was isolated as a mixture with 2.17j’ by flash chromatography (SiO2, 
hexanes:EtOAc = 2:1) as a white solid (194.2 mg, 68%, 2.17j:2.17j’ = 3.3:1). 
Rf = 0.57 (SiO2, 1exanes:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.58 (dd, J = 7.3, 2.0 Hz, 1H), 7.30 (s, 1H), 7.30 – 7.21 (m, 1H), 
5.79 (t, J = 2.5 Hz, 1H), 5.27 (t, J = 2.5 Hz, 1H), 2.90 (s, 3H), 2.50 – 2.37 (m, 2H), 1.81 – 1.65 (m, 
2H). 
13C NMR: (126 MHz, CDCl3) δ 157.1, 156.9, 137.0, 135.0, 132.5, 130.1, 122.7, 119.0, 53.8, 52.9, 
25.5, 23.3, 22.9. 
HRMS: (ESI-TOF, m/z) calcd. C13H12N3O2Br [M+H]+ calc.: 321.0113; found: 321.0128. 
IR: (ATR, neat, cm-1) 2944 (w), 1771 (m), 1707 (s), 1566 (w), 1455 (m), 1392 (m), 1209 (w), 
1027 (w), 918 (w), 759 (m), 602 (w), 571 (w). 
m.p.: 164 – 165 ºC. 
 
2.17j’ 
Rf = 0.64 (SiO2, 1exanes:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.69 (d, J = 7.7 Hz, 1H), 7.44 (dt, J = 7.7, 1.4 Hz, 
2H), 7.40 (dt, J = 7.7, 1.4 Hz, 2H), 7.25 (dd, J = 7.7, 1.4 Hz, 1H), 5.33 (dd, J = 3.6, 2.3 Hz, 1H), 
2.92 (ddd, J = 13.3, 10.3, 4.4 Hz, 1H), 2.80 (s, 3H), 2.50 (ddt, J = 13.1 10.3, 3.6 Hz, 1H), 2.23 
(ddd, J = 13.4, 11.7, 3.6 Hz, 1H), 1.77 (dddd, J = 13.4, 11.7, 4.4, 2.3 Hz, 1H). 
13C NMR: (126 MHz, CDCl3) δ 156.8, 156.2, 135.9, 133.7, 130.0, 129.5, 124.7, 123.3, 70.5, 54.8, 
37.6, 26.7, 25.5. 
HRMS: (ESI-TOF, m/z) calcd. C13H12N3O2Br [M+H]+ calc.: 321.0113; found: 321.0111. 
IR: (ATR, neat, cm-1) 2947 (w), 2251 (w), 1774 (m), 1707 (s), 1446 (s), 1391 (m), 1187 (m), 1163 
(m), 1005 (m), 901 (m), 757 (s), 728 (m), 603 (m), 545 (s). 




7.3.7 Derivatizations of naphthalene-derived cycloadduct 2.17a 
Synthesis of compound 2.19 (Scheme 2-5): 
Compound 2,17a (50.0 mg, 0.21 mmol, 1.0 eq.) and anhydrous hydrazine (0.125 mL, 4.11 mmol, 
20.0 eq.) under a nitrogen atmosphere was heated at 100 ºC for 8 h. Reaction was then cooled to 
rt, and hydrazine was removed at 50 ºC in vacuo. Dichloromethane (10 mL) was added to dissolve 
the residue, and oxygen gas was bubble through the reaction at rt for 15 minutes. After stirring the 
mixture under oxygen atmosphere for 4 h, 1,8-diazabicyclo[5.4.0]undec-7-ene (92 µL, 0.62 mmol, 
3.0 eq.) was added, and the reaction was further stirred for 45 minutes. The reaction was quenched 
with aqueous saturated ammonium chloride solution (5.0 mL) and extracted with ethyl acetate (3 
× 5.0 mL). The combined organic layers were washed with saturated aqueous sodium chloride 
solution (10 mL), dried over magnesium sulfate, and concentrated in vacuo. The crude mixture 
was purified by column chromatography (SiO2, hexanes/EtOAc = 1:1) to afford the titled 
compound 2.19 as a brown oil (20.1 mg, 60%).  
 
1H NMR: (500 MHz, CDCl3) δ 8.04 – 7.97 (m, 1H), 7.64 – 7.55 (m, 2H), 7.41 (ddd, 
J = 8.1, 5.1, 3.4 Hz, 1H), 4.98 (dd, J = 7.8, 3.9 Hz, 1H), 2.93 (ddd, J = 17.4, 7.8, 4.5 
Hz, 1H), 2.59 (ddd, J = 17.4, 9.6, 4.5 Hz, 1H), 2.40 (ddt, J = 13.0, 7.8, 4.5 Hz, 1H), 
2.35 (br, 1H), 2.18 (dddd, J = 13.0, 9.6, 7.8, 4.5 Hz, 1H). 
13C NMR: (126 MHz, CDCl3) δ 197.7, 145.5, 134.2, 131.2, 128.5, 127.3, 127.2, 68.0, 35.3, 32.2. 





Synthesis of compound 2.24 (Scheme 2-6): 
 
Cycloreversion and nitroso Diels-Alder reaction: Compound 2.17a (49.0 mg, 0.20 mmol, 1.0 eq.) 
was refluxed in hydrazine (0.2 mL) at 100 °C for 12 h. Volatiles were removed in vacuo and the 
residue was dissolved in dry tetrahydrofuran (1.0 mL). Nitrosobenzene (66.0 mg, 0.61 mmol, 3.0 
eq.) was added and the reaction mixture was stirred at 60 °C for 30 min. The crude product was 
purified by flash chromatography (SiO2; hexane:EtOAc = 20:1) to provide the title compound S1.1 
(43.0 mg, 91%) as a colorless solid. 
Oxidative N–O cleavage: Copper(I) chloride (12.5 mg, 0.13 mmol, 1.0 eq.) was added to a stirring 
solution of S1.1 (30.0 mg, 0.13 mmol, 1.0 eq.) in methanol (1.2 mL) and stirred at 70 °C for 16 h. 
The crude mixture was purified by flash chromatography (SiO2; hexanes:EtOAc = 20:1 to 10:1) 
to provide the title compound 2.24 (23.0 mg, 76%) as a colorless solid. 
 
Rf = 0.22 (SiO2, hexanes:EtOAc = 9:1, CAM). 
1H NMR: (500 MHz, CDCl3) δ 7.35 – 7.27 (m, 2H), 7.22 (dd, J = 7.2, 1.8 Hz, 1H), 
7.13 – 7.08 (m, 2H), 7.00 (dd, J = 7.4, 1.1 Hz, 1H), 6.88 – 6.82 (m, 3H), 5.25 (dd, 
J = 4.1, 1.5 Hz, 1H), 4.78-4.77 (m, 1H), 2.68 – 2.46 (m, 2H), 1.76 (ddd, J = 12.1, 
9.2, 3.2 Hz, 1H), 1.54 (ddd, J = 12.5, 3.4, 1.4 Hz, 1H).  
13C NMR: (126 MHz, CDCl3) δ 151.9, 137.9, 135.2, 128.3, 128.0, 127.6, 124.2, 122.8, 122.3, 
117.4, 73.0, 60.6, 25.1, 22.9.  
HRMS: (ESI-TOF, m/z) calcd. For C16H16NO [M+H]+ calc.: 238.1226; found: 238.1216. 
IR: (ATR, neat, cm-1) 2966 (w), 2938 (w), 1596 (m), 1488 (m), 1240 (w), 965 (m), 854 (m), 754 
(s), 692 (m).  




Rf = 0.14 (SiO2, hexanes:EtOAc = 4:1, UV). 
1H NMR: (500 MHz, CDCl3) δ 7.52 (dd, J = 7.5, 1.5 Hz, 1H), 7.48 – 7.40 (m, 1H), 
7.31 (ddd, J = 20.7, 7.5, 1.5 Hz, 2H), 7.22 (dd, J = 8.5, 7.2 Hz, 2H), 6.77 – 6.71 
(m, 1H), 6.71 – 6.66 (m, 2H), 4.80 – 4.77 (m, 1H), 4.61 – 4.59 (m, 1H), 3.92 (s, 
1H), 2.19 – 1.98 (m, 4H), 1.93 (s, 1H).  
13C NMR: (126 MHz, CDCl3) δ 147.5, 139.5, 138.4, 129.6, 128.8, 128.3, 128.1, 128.0, 117.5, 
113.0, 68.3, 51.4, 29.4, 25.3.  
HRMS: (ESI-TOF, m/z) calcd. For C16H18NO [M+H]+ calc.: 240.1383; found: 240.1394. 
IR: (ATR, neat, cm-1) 3399 (w), 2926 (w), 2857 (w), 1600 (s), 1503 (s), (s), 1499 (s), 1405 (m), 
1309 (m), 1072 (m), 748 (s), 693 (s).  
m.p.: 106 – 108 ºC. 
 
7.4 Experimental procedures for Chapter 3 
7.4.1 Dearomative syn-1,4-carboamination of naphthalene with ketone/ester-derived 
enolates 
General procedure 3A for the dearomative syn-1,4-carboamination of naphthalene with 
ketone/ester-derived enolates (Table 3-6) 
MTAD (1.57a, 113 mg, 1.0 mmol, 1.0 eq.) and naphthalene (1.2a, 256 mg, 2.0 mmol, 2.0 eq.) 
were placed in a test tube with a septum as the cap under nitrogen atmosphere. Propionitrile (8.0 
mL) was added to the test tube at rt, and the mixture was stirred until both MTAD and the 
naphthalene were completely dissolved. Then the resulting pink solution was stirred under 
irradiation with LED lights at –50 ºC until the solution became white suspension (about 6 hours). 
In a separate flask, a fresh solution of LDA was prepared from diisopropylamine (0.28 mL, 2.0 
mmol, 2.0 eq.) in THF (1.0 mL) and n-BuLi (1.2 mL, 1.9 mmol, 1.9 eq., 1.6 M solution in hexane) 
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under nitrogen atmosphere at 0 ºC. After stirring for 15 min, the LDA solution was cooled to –78 
ºC, and the ketone or ester (2.0 mmol, 2.0 eq.) dissolved in THF (1.0 mL) was added dropwise. 
The resulting enolate solution was stirred at –78 ºC for 40 min and then cannulated into the solution 
of cycloadduct (at this point the LED lights were turned off). For enolates that became a suspension 
at –78 ºC, the mixture was warmed up in an ice bath until it became a solution, which was added 
to the solution of cycloadduct. After the addition of enolate, a solution of Pd(dba)2 (14.4 mg, 0.025 
mmol, 2.5 mol%) and dppb (12.8 mg, 0.03 mmol, 3.0 mol%) in THF (2.0 mL, pre-stirred at rt until 
both Pd(dba)2 and dppb completely dissolved) was added, and the resulting mixture was warmed 
from –50 ºC to 0 ºC over 5 h. The reaction was then quenched with saturated aqueous NH4Cl (3.0 
mL), and EtOAc (10 mL) and water (10 mL) were added. Aqueous HCl solution (1 M, 3.0 mL) 
was added to acidify the solution to pH~5 and the organic phase was separated. The aqueous phase 
was extracted with EtOAc (3 × 10 mL), then the combined organic extracts were washed with 
saturated aqueous sodium chloride solution (10 mL), dried over anhydrous magnesium sulfate, 
and concentrated under reduced pressure. The product was purified by flash column 
chromatography (SiO2, n-hexane:EtOAc mixture).  
 
Synthesis of ()-3.1a (Table 3-6): Following the general procedure 3A, 
the title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (360.3 mg, 92%).  
Rf = 0.27 (n-hexane:EtOAc = 1:2, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.51 (s, 1H), 7.93 – 7.86 (m, 2H), 7.43 – 
7.34 (m, 1H), 7.29 – 7.12 (m, 3H), 6.91 – 6.81 (m, 2H), 6.31 (ddd, J = 
10.1, 4.0, 1.4 Hz, 1H), 5.94 – 5.90 (m, 1H), 5.85 (ddd, J = 10.1, 4.2, 1.6 Hz, 1H), 4.07 – 3.99 (m, 
1H), 3.85 (s, 3H), 3.57 (dd, J = 17.6, 7.8 Hz, 1H), 3.44 (dd, J = 17.6, 4.1 Hz, 1H), 2.99 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 196.9, 164.0, 154.0, 153.9, 139.0, 135.5, 131.2, 130.6, 129.7, 
129.0, 128.6, 127.6, 127.3, 121.8, 113.9, 55.6, 52.4, 44.9, 34.4, 25.2.  
HRMS: (ESI-TOF, m/z) calcd. For C22H25N4O4 [M+NH4]+ calc.: 409.1870; found: 409.1869.  
IR: (ATR, neat, cm-1): 3071 (w), 1675 (s), 1602 (w), 1477 (m). 1354 (w), 1250 (w), 1208 (w), 
1182 (m), 986 (w), 924 (w), 775 (m), 754 (s), 732 (m), 601 (m). 
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m.p.: 155–157 ºC. 
 
Synthesis of ()-3.1b (Table 3-6): Following the general procedure 3A, the 
title compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc 
= 2:1 to 1:1) as a white solid (294.5 mg, 81%).  
Rf = 0.40 (n-hexane:EtOAc = 1:2, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.48 (br, 1H), 7.89 (dd, J = 8.4, 1.4 Hz, 2H), 
7.52 (tt, J = 7.4, 1.4 Hz, 1H), 7.44 – 7.39 (m, 1H), 7.34 (dd, J = 8.4, 7.4 Hz, 
2H), 7.31 – 7.22 (m, 3H), 6.37 (ddd, J = 10.1, 4.1, 1.3 Hz, 1H), 5.96 – 5.90 (m, 1H), 5.86 (ddd, J 
= 10.1, 4.2, 1.6 Hz, 1H), 4.13 – 4.04 (m, 1H), 3.62 (dd, J = 18.0, 8.2 Hz, 1H), 3.47 (dd, J = 18.0, 
4.1 Hz, 1H), 2.93 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 198.3, 154.3, 153.9, 139.1, 136.6, 135.7, 133.7, 131.3, 129.1, 
128.8, 128.7, 128.2, 127.7, 127.4, 121.8, 52.5, 45.8, 34.2, 25.2. 
HRMS: (ESI-TOF, m/z) calcd. For C21H20KN3O3 [M+H]+ calc.: 362.1499; found: 365.1514.  
IR: (ATR, neat, cm-1): 3041 (w), 1679 (s), 1477 (m), 1449 (m), 1199 (m), 1013 (m), 750 (s), 738 
(m), 689 (m), 660 (w), 648 (w), 614 (m), 569 (m). 
m.p.: 157–159 ºC. 
 
Synthesis of ()-3.1c (Table 3-6): Following the general procedure 3A, the 
title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (354.7 mg, 73%).  
Rf = 0.41 (n-hexane:EtOAc = 1:2, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.07 (br, 1H), 7.78 (d, J = 8.5 Hz, 2H), 7.62 
(d, J = 8.5 Hz, 2H), 7.41 (dd, J = 7.4, 1.9 Hz, 1H), 7.32 – 7.17 (m, 3H), 6.31 
(ddd, J = 10.2, 4.0, 1.4 Hz, 1H), 5.95 – 5.90 (m, 1H), 5.88 (ddd, J = 10.2, 4.2, 1.6 Hz, 1H), 4.08 – 
4.02 (m, 1H), 3.57 (dd, J = 18.0, 7.9 Hz, 1H), 3.44 (dd, J = 18.0, 4.1 Hz, 1H), 3.03 (s, 3H). 
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13C NMR: (125 MHz, CDCl3) δ 197.8, 154.3, 154.0, 138.7, 138.1, 135.9, 135.3, 131.2, 129.6, 
129.1, 128.8, 127.6, 127.5, 122.1, 101.9, 52.6, 45.5, 34.2, 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C21H19N3O3I [M+H]+ calc.: 488.0471; found: 488.0459.  
IR: (ATR, neat, cm-1): 3051 (w), 2903 (w), 1683 (s), 1580 (m), 1480 (m), 1397 (m), 1203 (m), 
1008 (m), 983 (m), 974 (m), 808 (m), 776 (m), 752 (s), 651 (m), 630 (m), 489 (w). 
m.p.: 197–198 ºC. 
 
Synthesis of ()-3.1d (Table 3-6): The reaction was conducted following 
the general procedure 3A, except after the addition of the enolate and 
catalyst solution to the cycloadduct, the mixture was stirred at –30 ºC for 12 
h. The title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (346.7 mg, 79%).  
Rf = 0.52 (n-hexane:EtOAc = 1:2, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.26 (br, 1H), 7.78 (d, J = 7.7 Hz, 2H), 7.56 (d, J = 7.7 Hz, 2H), 
7.43 (d, J = 7.3 Hz, 1H), 7.36 – 7.22 (m, 3H), 6.35 (dd, J = 10.1, 4.0 Hz, 1H), 5.97 – 5.93 (m, 1H), 
5.90 (dd, J = 10.1, 4.2 Hz, 1H), 4.08 (ddd, J = 8.1, 4.3, 4.0 Hz, 1H), 3.59 (dd, J = 17.9, 8.1 Hz, 
1H), 3.46 (dd, J = 17.9, 4.0 Hz, 1H), 3.01 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 197.4, 154.4, 154.0, 138.8, 135.34, 135.31, 132.1, 131.2, 129.8, 
129.1, 129.0, 127.8, 127.7, 127.5, 122.0, 52.6, 45.7, 34.2, 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C21H19N3O3Br [M+H]+ calc.: 440.0610; found: 440.0613.  
IR: (ATR, neat, cm-1): 3086 (w), 2885 (w), 1771 (w), 1683 (s), 1583 (m), 1475 (m), 1399 (m), 
1351 (w), 1289 (w), 1173 (w), 1070 (w), 986 (m), 923 (w), 813 (m), 778 (m), 760 (s), 563 (m), 
492 (w). 




Synthesis of ()-3.1e (Table 3-6): Following the general procedure 3A, the 
title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (316.6 mg, 80%).  
Rf = 0.52 (n-hexane:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 8.29 (br, 1H), 7.85 – 7.81 (m, 2H), 7.40 
(dd, J = 7.5, 1.7 Hz, 1H), 7.37 – 7.33 (m, 2H), 7.31 – 7.26 (m, 2H), 7.27 – 
7.20 (m, 1H), 6.33 (ddd, J = 10.1, 4.2, 1.3 Hz, 1H), 5.93 – 5.90 (m, 1H), 5.87 (ddd, J = 10.1, 4.2, 
1.5 Hz, 1H), 4.10 – 4.01  (m, 1H), 3.57 (dd, J = 17.9, 8.1 Hz, 1H), 3.44 (dd, J = 17.9, 4.1 Hz, 1H), 
2.97 (s, 3H).  
13C NMR: (125 MHz, CDCl3) δ 197.2, 154.4, 154.0, 140.2, 138.8, 135.4, 134.9, 131.2, 129.7, 
129.10, 129.09, 128.8, 127.7, 127.5, 122.0, 52.6, 45.7, 34.2, 25.2.  
HRMS: (ESI-TOF, m/z) calcd. For C21H18NaN3O3 [M+Na]+ calc.: 418.0934; found: 418.0922.  
IR: (ATR, neat, cm-1): 3090 (w), 1683 (s), 1476 (m), 1401 (m), 1289 (w), 1203 (m), 1090 (w), 
987 (m), 924 (w), 816 (m), 780 (m), 762 (s), 709 (w), 648 (m). 
m.p.: 202–203 ºC. 
 
Synthesis of ()-3.1f (Table 3-6): Following the general procedure 3A, 
the title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (341.4 mg, 80%).  
Rf = 0.61 (n-hexane:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 8.04 (d, J = 8.4 Hz, 2H), 7.73 (br, 1H), 
7.71 (d, J = 8.4 Hz, 2H), 7.42 (dd, J = 7.4, 1.8 Hz, 1H), 7.32 – 7.19 (m, 
3H), 6.32 (ddd, J = 10.1, 4.1, 1.2 Hz, 1H), 5.94 (dd, J = 4.2, 4.1 Hz, 1H), 5.90 (ddd, J = 10.0, 4.2, 
1.5 Hz, 1H), 4.12 – 4.03 (m, 1H), 3.65 (dd, J = 18.0, 7.8 Hz, 1H), 3.53 (dd, J = 18.0, 4.0 Hz, 1H), 
3.06 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 197.5, 154.5, 154.1, 139.2, 138.7, 135.1, 134.95 (q, J = 32.8 Hz), 
131.2, 129.1, 128.8, 128.6 (overlap of 2 peaks detected by HSQC), 127.7, 127.6, 125.9 (q, J = 3.7 
Hz), 123.58 (q, J = 272.9 Hz), 52.7, 46.1, 34.2, 25.3. 
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19F NMR: (471 MHz, CDCl3) δ –63.2. 
HRMS: (ESI-TOF, m/z) calcd. For C22H19FN3O3 [M+H]+ calc.: 430.1373; found: 430.1392.  
IR: (ATR, neat, cm-1): 3035 (w), 689 (s), 1478 (m), 1324 (m), 1202 (w), 1128 (m), 1065 (m), 988 
(w), 922 (w), 825 (w), 781 (w), 736 (w), 646 (w), 614 (w). 
m.p.: 197–198 ºC. 
 
Synthesis of ()-3.1g (Table 3-6): (Table 2): Following the general procedure 
3A, the title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (317.3 mg, 85%).  
Rf = 0.50 (n-hexane:EtOAc = 1:2, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.01 (br, 1H), 7.62 (d, J = 7.8 Hz, 1H), 7.43 – 
7.34 (m, 2H), 7.32 – 7.27 (m, 2H), 7.28 – 7.17 (m, 3H), 6.31 (ddd, J = 10.1, 
4.0, 1.3 Hz, 1H), 5.98 – 5.93 (m, 1H), 5.89 (ddd, J = 10.1, 4.1, 1.7 Hz, 1H), 4.08 – 3.97 (m, 1H), 
3.56 (dd, J = 17.9, 7.7 Hz, 1H), 3.45 (dd, J = 17.9, 4.1 Hz, 1H), 3.06 (s, 3H), 2.44 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 202.0, 154.6, 153.9, 139.3, 138.5, 137.0, 135.8, 132.1, 131.8, 
131.2, 128.9, 128.7, 128.5, 127.7, 127.1, 125.6, 121.5, 52.5, 49.0, 34.2, 24.9, 21.6. 
HRMS: (ESI-TOF, m/z) calcd. For C22H22N3O3 [M+H]+ calc.: 376.1655; found: 376.1655.  
IR: (ATR, neat, cm-1): 3074 (w), 1688 (s), 1667 (s), 1476 (m), 1459 (m), 1342 (w), 1268 (w), 
1207 (w), 1166 (w), 977 (w), 763 (s), 756 (s), 725 (m), 711 (m), 607 (m), 556 (w). 
m.p.: 138–139 ºC. 
 
Synthesis of ()-3.1h (Table 3-6): Following the general procedure 3A, the 
title compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc 
= 2:1 to 1:1) as a white solid (342.8 mg, 91%, dr>20:1).  
Rf = 0.36 (n-hexane:EtOAc = 1:2, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.04 (d, J = 7.6 Hz, 2H), 7.63 (t, J = 7.3 Hz, 
1H), 7.54 (dd, J = 7.6, 7.3 Hz, 2H), 7.48 (d, J = 7.8 Hz, 1H), 7.42 (d, J = 7.8 
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Hz, 1H), 7.37 (dd, J = 7.8, 7.5 Hz, 1H), 7.31 (dd, J =7.8, 7.5 Hz, 1H), 6.96 – 6.71 (br, 1H), 6.18 
(dd, J = 10.3, 3.6 Hz, 1H), 5.97 (dd, J = 10.3, 3.7 Hz, 1H), 5.94 – 5.89 (m, 1H), 4.14 (td, J = 6.8, 
6.7 Hz, 1H), 4.04 – 3.98 (m, 1H), 3.15 (s, 3H), 1.10 (d, J = 6.8 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 203.0, 155.5, 155.0, 137.6, 136.4, 133.3, 132.4, 131.6, 129.0, 
128.65, 128.60, 128.4, 127.8, 127.5, 123.8, 53.0, 46.9, 39.5, 25.4, 12.9. 
HRMS: (ESI-TOF, m/z) calcd. For C22H21KN3O3 [M+K]+ calc.: 414.1214; found: 414.1196.  
IR: (ATR, neat, cm-1): 3029 (w), 1704 (m), 1680 (s), 1471 (m), 1235 (m), 1208 (m), 969 (m), 806 
(w), 767 (m), 747 (m), 733 (s), 693 (m), 650 (m), 576 (m), 545 (w). 
m.p.: 173–174 ºC.  
Stereochemistry determined by X-ray (see page S319 for details):  
 
 
Synthesis of ()-3.1i (Table 3-6): Following the general procedure 3A, the 
title compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc 
= 2:1 to 1:1) as a white solid (223.0 mg, 57%).  
Rf = 0.39 (n-hexane:EtOAc = 1:2, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.63 – 7.55 (m, 2H), 7.49 (t, J = 7.4 Hz, 1H), 
7.44 – 7.37 (m, 3H), 7.30 – 7.27 (m, 1H), 7.25 – 7.20 (m, 2H), 6.68 (br, 1H), 
6.28 (ddd, J = 10.4, 4.1, 1.6 Hz, 1H), 5.98 (ddd, J = 10.4, 4.0, 1.6 Hz, 1H), 5.90 – 5.86 (m, 1H), 
4.47 – 4.36 (m, 1H), 3.12 (s, 3H), 1.33 (s, 3H), 1.25 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 209.6, 155.1, 155.0, 138.8, 137.1, 133.0, 131.6, 131.4, 129.3, 
129.0, 128.4, 128.1, 127.9, 127.6, 124.2, 53.7, 53.4, 44.4, 26.3, 25.5, 24.7. 
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HRMS: (ESI-TOF, m/z) calcd. For C23H24N3O2 [M+H]+ calc.: 390.1812; found: 390.1798.  
IR: (ATR, neat, cm-1): 1771 (w), 1690 (s), 1660 (m), 1467 (m), 1401 (w), 1227 (w), 1018 (w), 950 
(w), 758 (s), 716 (m), 688 (m), 653 (m), 606 (m). 
m.p.: 176–177 ºC.  
 
Synthesis of ()-3.1j (Table 3-6): The reaction was conducted following 
the general procedure 3A, except after the addition of the enolate and 
catalyst solution to the cycloadduct, the mixture was stirred at –30 ºC for 
12 h. The title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (353.6 mg, 86%).  
Rf = 0.48 (n-hexane:EtOAc = 1:2, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.45 (s, 1H), 8.40 (br, 1H), 7.99 (d, J = 8.6 Hz, 1H), 7.93 (d, J = 
8.1 Hz, 1H), 7.88 – 7.83 (m, 2H), 7.61 (dd, J = 7.4, 7.3 Hz, 1H), 7.55 (dd, J = 7.4, 7.3 Hz, 1H), 
7.42 (d, J = 7.4 Hz, 1H), 7.31 – 7.27 (m, 3H), 6.35 (dd, J = 10.1, 4.0 Hz, 1H), 6.00 – 5.94 (m, 1H), 
5.89 (dd, J = 10.1, 3.2 Hz, 1H), 4.11 (ddd, J = 7.9, 4.3, 4.0 Hz, 1H), 3.80 (dd, J = 17.7, 7.9 Hz, 
1H), 3.64 (dd, J = 17.7, 4.3 Hz, 1H), 3.03 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 198.4, 154.3, 154.0, 139.0, 135.8, 135.5, 134.0, 132.5, 131.2, 
130.2, 129.7, 129.0, 128.9, 128.72, 128.67, 127.9, 127.7, 127.4, 127.1, 123.7, 121.9, 52.6, 45.7, 
34.4, 25.2. 
HRMS: (ESI-TOF, m/z) calcd. For C25H22N3O3 [M+H]+ calc.: 412.1655; found: 412.1644.  
IR: (ATR, neat, cm-1): 3057 (w), 1675 (s), 1469 (m), 1357 (w), 1277 (w), 1216 (w), 1183 (w), 
1017 (w), 755 (s), 730 (m), 607 (w), 556 (m), 475 (m). 




Synthesis of ()-3.1k (Table 3-6): Following the general procedure 3A, the 
title compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc 
= 2:1 to 1:1) as a white solid (197.5 mg, 56%).  
Rf = 0.32 (n-hexane:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.88 (br, 1H), 7.55 – 7.49 (m, 1H), 7.39 (d, J 
= 7.6, 1H), 7.31 – 7.21 (m, 3H), 7.19 (d, J = 3.5 Hz, 1H), 6.50 (dd, J = 3.6, 1.7 
Hz, 1H), 6.30 (ddd, J = 10.1, 4.1, 1.3 Hz, 1H), 5.96 – 5.90 (m, 1H), 5.87 (ddd, J = 10.1, 4.2, 1.6 
Hz, 1H), 4.02 (ddd, J = 7.3, 4.4, 4.1 Hz, 1H), 3.47 (dd, J = 17.1, 7.8 Hz, 1H), 3.35 (dd, J = 17.1, 
4.4 Hz, 1H), 3.07 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 187.7, 154.2, 154.1, 152.8, 146.9, 138.6, 135.3, 131.2, 129.1, 
128.7, 127.8, 127.4, 122.1, 117.9, 112.7, 52.5, 45.1, 34.3, 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C19H21N4O4 [M+NH4]+ calc.: 369.1557; found: 369.1564.  
IR: (ATR, neat, cm-1): 3041 (w), 1758 (w), 1674 (s), 1482 (m), 1392 (w), 1276 (w), 1251 (w), 
1027 (m), 757 (s), 714 (m), 631 (m), 615 (m), 595 (m), 555 (m).  
m.p.: 173–174 ºC. 
 
Synthesis of ()-3.1l (Table 3-6): Following the general procedure 3A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 
to 1:1) as a white solid (182.0 mg, 58%).  
Rf = 0.16 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.11 (br, 1H), 7.36 (d, J = 7.6 Hz, 1H), 7.31 – 
7.25 (m, 1H), 7.26 – 7.19 (m, 1H), 7.16 (d, J = 7.6 Hz, 1H), 6.21 (ddd, J = 10.2, 
4.0, 1.4 Hz, 1H), 5.94 – 5.88 (m, 1H), 5.84 (ddd, J = 10.2, 4.1, 1.6 Hz, 1H), 3.88 – 3.80 (m, 1H), 
3.08 (s, 3H), 3.01 (dd, J = 17.7, 7.6 Hz, 1H), 2.91 (dd, J = 17.7, 4.1 Hz, 1H), 2.41 – 2.22 (m, 2H), 
0.99 (t, J = 7.3 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 210.4, 154.1, 154.0, 138.5, 135.1, 131.1, 129.0, 128.7, 127.43, 
127.38, 122.0, 52.4, 48.6, 36.9, 34.1, 25.3, 7.7. 
HRMS: (ESI-TOF, m/z) calcd. For C17H20N3O3 [M+H]+ calc.: 314.1499; found: 314.1501.  
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IR: (ATR, neat, cm-1): 3055 (w), 1760 (w), 1686 (s), 1474 (m), 1397 (w), 1221 (w), 1006 (w), 763 
(m), 725 (m), 607 (m), 550 (w). 
m.p.: 119–120 ºC. 
 
Synthesis of ()-3.1m (Table 3-6): Following the general procedure 3A, 
the title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (253.2 mg, 69%).  
Rf = 0.26 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.95 (br, 1H), 7.36 (d, J = 7.0 Hz, 1H), 
7.32 – 7.20 (m, 2H), 7.16 (d, J = 8.0 Hz, 1H), 6.18 (ddd, J = 10.2, 4.0, 1.4 
Hz, 1H), 5.95 – 5.89 (m, 1H), 5.85 (ddd, J = 10.2, 4.1, 1.7 Hz, 1H), 5.02 – 4.94 (m, 1H), 3.86 – 
3.78 (m, 1H), 3.10 (s, 3H), 3.04 (dd, J = 17.9, 7.4 Hz, 1H), 2.92 (dd, J = 17.9, 4.1 Hz, 1H), 2.44 – 
2.30 (m, 2H), 2.26 – 2.16 (m, 2H), 1.66 (s, 3H), 1.58 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 209.7, 154.1, 154.0, 138.5, 135.1, 133.2, 131.1, 129.0, 128.6, 
127.4, 127.3, 122.4, 121.9, 52.4, 49.3, 43.6, 34.0, 25.8, 25.3, 22.6, 17.8. 
HRMS: (ESI-TOF, m/z) calcd. For C21H25KN3O3 [M+K]+ calc.: 406.1528; found: 406.1531.  
IR: (ATR, neat, cm-1): 3226 (w), 2928 (w), 1763 (m), 1693 (s), 1474 (m), 1457 (m), 1418 (w), 
1372 (m), 1344 (m) ,1180 (w), 1018 (m), 980 (m), 939 (w), 779 (m), 768 (s), 601 (m), 570 (m). 
m.p.: 108–109 ºC.  
 
Synthesis of ()-3.1n (Table 3-6): The reaction was conducted 
following the general procedure 3A, except after the addition of the 
enolate and catalyst solution to the cycloadduct, the mixture was stirred 
at –30 ºC for 12 h. The title compound was isolated by flash 
chromatography (SiO2, n-hexane:EtOAc = 2:1 to 1:1) as a light-yellow 
oil (306.6 mg, 67%).  
Rf = 0.44 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
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1H NMR: (500 MHz, CDCl3) δ 7.88 (br, 1H), 7.40 – 7.33 (m, 1H), 7.32 – 7.24 (m, 1H), 7.27 – 
7.20 (m, 1H), 7.19 – 7.16 (m, 1H), 6.19 (ddd, J = 10.1, 3.9, 1.4 Hz, 1H), 5.95 – 5.89 (m, 1H), 5.87 
– 5.82 (m, 1H), 3.86 – 3.77 (m, 1H), 3.59 – 3.53 (m, 2H), 3.14 – 3.04 (m, 4H), 2.97 (dd, J = 17.9, 
4.0 Hz, 1H), 2.54 – 2.36 (m, 2H), 1.77 – 1.69 (m, 2H), 0.87 (s, 9H), 0.02 (s, 6H). 
13C NMR: (125 MHz, CDCl3) δ 209.9, 154.0, 153.9, 138.3, 135.0, 131.1, 129.0, 128.7, 127.38, 
127.36, 122.0, 62.0, 52.3, 48.9, 40.1, 34.0, 26.7, 26.1, 25.3, 18.4, -5.2. 
HRMS: (ESI-TOF, m/z) calcd. For C24H35KN3O4Si [M+K]+ calc.: 496.2028; found: 496.2017.  
IR: (ATR, neat, cm-1): 2928 (w), 1765 (w), 1693 (s), 1471 (m), 1250 (m), 1093 (m), 1017 (w), 
833 (m), 774 (m), 757 (m), 606 (w). 
 
Synthesis of ()-3.1o (Table 3-6): Following the general procedure 3A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 
to 1:1) as a white solid (282.6 mg, 86%).  
Gram-scale synthesis of ()-3.1o (Table 3-6): MTAD (1.57a, 1.0 g, 8.8 mmol, 
1.0 eq.) and naphthalene (2.3 g, 17.7 mmol, 2.0 eq.) were placed in a 500 mL 
clear borosilicate glass bottle (see Picture S2) with a septum as the cap under 
nitrogen atmosphere. Propionitrile (71 mL) was added to the bottle at rt, and the mixture was 
stirred until both MTAD and the naphthalene were completely dissolved. Then the resulting pink 
solution was stirred under irradiation with LED lights at –50 ºC until the solution became white 
suspension (about 24 hours). In a separate flask, a fresh solution of LDA was prepared from 
diisopropylamine (2.5 mL, 17.7 mmol, 2.0 eq.) in THF (9.0 mL) and n-BuLi (10.5 mL, 16.8 mmol, 
1.9 eq., 1.6 M solution in hexane) under nitrogen atmosphere at 0 ºC. After stirring for 30 min, the 
LDA solution was cooled to –78 ºC, and the 3-methylbutan-2-one (1.9 mL, 17.7 mmol, 2.0 eq.) 
dissolved in THF (9.0 mL) was added dropwise. The resulting enolate solution was stirred at –78 
ºC for 60 min and then cannulated into the solution of cycloadduct (at this point the LED lights 
were turned off). Then a solution of Pd(dba)2 (127 mg, 0.22 mmol, 2.5 mol%) and dppb (113 mg, 
0.27 mmol, 3.0 mol%) in THF (18 mL, pre-stirred at rt for 60 min until both Pd(dba)2 and dppb 
completely dissolved) was added, and the resulting mixture was warmed from –50 ºC to 0 ºC over 
5 h. The reaction was then quenched with saturated aqueous NH4Cl (15 mL), and EtOAc (50 mL) 
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and water (50 mL) were added. Aqueous HCl solution (1 M, 15 mL) was added to acidify the 
solution to pH~5 and the organic phase was separated. The aqueous phase was extracted with 
EtOAc (3 × 50 mL), then the combined organic extracts were washed with saturated aqueous 
sodium chloride solution (30 mL), dried over anhydrous magnesium sulfate, and concentrated 
under reduced pressure. The product was isolated by flash column chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (2.37 g, 82%).  
 
Rf = 0.32 (n-hexane:EtOAc = 1:2, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.95 (br, 1H), 7.37 (dd, J = 7.5, 1.5 Hz, 1H), 7.30 – 7.26 (m, 1H), 
7.27 – 7.20 (m, 1H), 7.18 – 7.14 (m, 1H), 6.18 (ddd, J = 10.1, 4.0, 1.4 Hz, 1H), 5.94 – 5.89 (m, 
1H), 5.84 (ddd, J = 10.1, 4.1, 1.7 Hz, 1H), 3.84 (dq, J = 7.1, 4.0 Hz, 1H), 3.10 (dd, J = 18.0, 7.4 
Hz, 1H), 3.09 (s, 3H), 2.97 (dd, J = 18.0, 4.1 Hz, 1H), 2.52 (hept, J = 6.9 Hz, 1H), 1.06 (d, J = 6.9 
Hz, 3H), 1.02 (d, J = 6.9 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 213.6, 154.0, 153.9, 138.5, 135.1, 131.1, 129.0, 128.7, 127.4, 
127.3, 122.0, 52.3, 46.7, 41.5, 34.0, 25.3, 18.2, 18.1. 
HRMS: (ESI-TOF, m/z) calcd. For C18H25N4O3 [M+NH4]+ calc.: 345.1921; found: 345.1909.  
IR: (ATR, neat, cm-1): 2971 (w), 1758 (m), 1690 (s), 1476 (m), 1399 (m), 1275 (w), 1217 (m), 
1016 (m), 762 (m), 728 (m), 647 (w), 610 (m). 
m.p.: 149–150 ºC. 
 
Synthesis of ()-3.1p (Table 3-6): Following the general procedure 3A, the 
title compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc 
= 2:1 to 1:1) as a white solid (319.1 mg, 87%).  
Rf = 0.47 (n-hexane:EtOAc = 1:2, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.91 (br, 1H), 7.37 (dd, J = 7.6, 1.6 Hz, 1H), 
7.28 (dd, J = 7.4, 1.6 Hz, 1H), 7.28 – 7.20 (m, 1H), 7.16 (dd, J = 7.6, 1.6 Hz, 
1H), 6.16 (ddd, J = 10.1, 3.9, 1.4 Hz, 1H), 5.94 – 5.90 (m, 1H), 5.84 (ddd, J = 10.1, 4.1, 1.8 Hz, 
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1H), 3.86 – 3.78 (m, 1H), 3.11 (dd, J = 18.1, 7.2 Hz, 1H), 3.10 (s, 3H). 2.97 (dd, J = 18.1, 4.0 Hz, 
1H), 2.33 – 2.21 (m, 1H), 1.84 – 1.72 (m, 4H), 1.68 – 1.58 (m, 1H), 1.37 – 1.11 (m, 5H). 
13C NMR: (125 MHz, CDCl3) δ 213.0, 153.9, 153.7, 138.5, 135.1, 131.1, 129.0, 128.6, 127.33, 
127.30, 121.9, 52.2, 51.4, 46.9, 33.9, 28.4, 28.3, 25.8, 25.6 (overlap of 2 peaks detected by 
HMBC), 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C21H25KN3O3 [M+K]+ calc.:406.1528; found: 406.1539.  
IR: (ATR, neat, cm-1): 2935 (w), 2852 (w), 1681 (s), 1474 (m), 1449 (m), 1398 (w), 1218 (w), 
1142 (w), 1005 (w), 924 (w), 783 (m) 752 (m), 647 (w), 612 (m), 550 (m), 497 (w). 
m.p.: 155–157 ºC. 
 
Synthesis of ()-3.1q (Table 3-6): Following the general procedure 3A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 
to 1:2) as a white solid (253.8 mg, 78%, dr = 1.2:1, column-inseparable mixture).  
Rf = 0.32 (n-hexane:EtOAc = 1:4, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.35 (br, 1H major), 7.39 – 7.27 (m, 3H major, 
4H minor), 7.18 – 7.14 (m, 1H major), 6.55 (br, 1H minor), 6.12 (ddd, J = 10.2, 
3.8, 1.5 Hz, 1H major), 5.99 – 5.95 (m, 1H major), 5.91 (ddd, J = 10.2, 4.0, 1.7 Hz, 1H major), 
5.89 – 5.81 (m, 3H minor), 4.16 – 4.02 (m, 1H minor), 3.87 – 3.73 (m, 1H major), 3.13 (s, 3H 
major, 3H minor), 2.84 – 2.75 (m, 1H major, 1H minor), 2.47 – 2.26 (m, 2H major, 1H minor), 
2.15 – 1.97 (m, 2H major, 2H minor), 1.91 – 1.69 (m, 2H major, 3H minor). 
13C NMR: (125 MHz, CDCl3) δ 220.6 (major), 219.5 (minor), 155.3 (minor), 154.8 (minor), 153.6 
(major), 153.4 (major), 137.5 (minor), 137.1 (major), 132.3 (major), 131.6 (minor), 131.1 (major), 
130.7 (minor), 128.7 (major), 128.4 (major, minor. Overlap of 2 peaks detected by HSQC), 128.2 
(minor), 127.7 (major), 127.17 (major), 127.15 (minor), 127.0 (minor), 123.8 (minor), 123.4 
(major), 55.2 (major), 55.1 (minor), 52.8 (minor), 51.8 (major), 39.1 (major), 38.8 (minor), 37.4 
(major), 36.9 (minor), 27.2 (major), 25.13 (minor), 25.07 (major), 24.8 (minor), 20.4 (major), 20.3 
(minor).  
HRMS: (ESI-TOF, m/z) calcd. For C18H23N4O2 [M+NH4]+ calc.: 343.1764; found: 343.1778.  
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IR: (ATR, neat, cm-1): 3140 (w), 2970 (w), 1734 (m), 1682 (s), 1476 (m), 1397 (m), 1274 (w), 
1151 (w), 1016 (w), 929 (w), 802 (m), 778 (m), 762 (s), 735 (m), 702 (m), 630 (m), 607 (m), 594 
(m), 563 (w). 
m.p.: 162–163 ºC. 
 
Synthesis of ()-3.1r (Table 3-6): Following the general procedure 3A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 
to 1:2) as a white solid (276.9 mg, 82%, dr = 2.6:1, column-inseparable 
mixture).  
Rf = 0.42 (n-hexane:EtOAc = 1:4, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 9.33 (br, 1H, major), 7.39 – 7.33 (m, 1H, 
major), 7.34 – 7.27 (m, 1H, minor), 7.26 – 7.18 (m, 2H major, 1H minor), 7.19 – 7.10 (m, 1H 
major), 6.46 (br, 1H), 6.24 – 6.10 (m, 1H major, 1H minor), 6.04 – 5.97 (m, 1H, major), 5.91 (ddd, 
J = 10.3, 4.0, 2.1 Hz, 1H, major), 5.91 – 5.85 (m, 1H minor), 5.84 (ddd, J = 10.3, 3.6, 1.8 Hz, 1H 
minor), 4.19 (ddd, J = 5.2, 2.6, 2.6 Hz, 1H minor), 3.52 – 3.40 (m, 1H, major), 3.20 – 3.13 (m, 1H 
major), 3.14 (s, 3H, major), 3.12 (s, 3H minor), 2.93 – 2.86 (m, 1H minor), 2.50 (ddt, J = 14.6, 
4.2, 2.2 Hz, 1H minor), 2.42 – 2.18 (m, 2H major, 3H minor), 2.14 – 2.05 (m, 1H major), 2.03 (dt, 
J = 13.2, 4.0 Hz, 1H major), 1.95 – 1.83 (m, 1H major), 1.86 – 1.73 (m, 1H major, 1H minor), 1.72 
– 1.43 (m, 2H major, 3H minor). 
13C NMR: (125 MHz, CDCl3) δ 212.4 (major), 211.1 (minor), 155.5 (minor), 154.8 (minor), 152.9 
(major), 152.5 (major), 137.8 (minor), 137.4 (major), 133.1 (minor), 131.9 (minor), 131.8 (major), 
131.5 (major), 129.0 (major), 128.5 (minor), 128.25 (major), 128.21 (minor), 127.12 (minor), 
127.07 (major, minor. Overlap of 2 peaks detected by HSQC), 127.0 (major), 123.1 (major), 122.7 
(minor), 56.0 (minor), 55.5 (minor), 52.8 (minor), 51.3 (major), 42.8 (major), 42.2 (minor), 38.8 
(major), 36.4 (minor), 32.5 (major), 28.2 (minor), 27.5 (major), 27.1 (minor), 25.6 (major), 25.3 
(minor), 25.2 (major), 25.0 (major). 
HRMS: (ESI-TOF, m/z) calcd. For C19H21KN3O3 [M+K]+ calc.: 378.1215; found: 378.1224.  
IR: (ATR, neat, cm-1): 2942 (w), 1683 (s), 1477 (m), 1452 (m), 1218 (w), 1013 (w), 887 (w), 764 
(m), 756 (s), 609 (m), 564 (w), 488 (w). 
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m.p.: 183–184 ºC.  
 
Synthesis of ()-3.1s (Table 3-6): Following the general procedure 3A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 
to 1:1) as a white solid (225.2 mg, 64%, dr = 10:1, column-inseparable 
mixture). Recrystallization from n-hexane/EtOAc mixture gave 22 as a single 
diastereoisomer. 
Rf = 0.45 (n-hexane:EtOAc = 1:4, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.82 (br, 1H), 7.34 (dd, J = 7.6, 1.3 Hz, 1H), 7.29 – 7.12 (m, 3H), 
6.24 (ddd, J = 10.3, 3.8, 1.5 Hz, 1H), 5.97 – 5.92  (m, J = 4.1 Hz, 1H), 5.87 (ddd, J = 10.3, 4.2, 2.0 
Hz, 1H), 3.59 – 3.54 (m, 1H), 3.31 (ddd, J = 11.3, 4.2, 2.9 Hz, 1H), 3.11 (s, 3H), 2.47 – 2.27 (m, 
2H), 2.17 – 2.00 (m, 2H), 2.00 – 1.91 (m, 1H), 1.91 – 1.82 (m, 1H), 1.76 – 1.65 (m, 1H), 1.65 – 
1.46 (m, 2H), 1.29 (dtt, J = 14.6, 12.1, 2.8 Hz, 1H). 
13C NMR: (125 MHz, CDCl3) δ 216.6, 153.1, 152.5, 137.6, 131.5, 131.5, 129.3, 128.5, 127.3, 
126.8, 123.4, 56.7, 51.4, 44.8, 41.8, 30.6, 29.9, 29.6, 25.3, 24.1. 
HRMS: (ESI-TOF, m/z) calcd. For C20H23KN3O3 [M+K]+ calc.: 392.1371; found: 392.1375.  
IR: (ATR, neat, cm-1): 3087 (w), 2944 (w), 1765 (m), 1681 (s), 1454 (m), 1400 (m), 1354 (m), 
1280 (w), 1177 (w), 1155 (w), 1023 (m), 850 (w), 799 (m), 757 (s), 541 (m), 490 (m). 
m.p.: 153–154 ºC. 





Synthesis of ()-3.1t (Table 3-6): Following the general procedure 3A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 
to 1:1) as a white solid (338.7 mg, 92%, dr = 5:1, column-inseparable mixture). 
Recrystallization from n-hexane/EtOAc mixture gave ()-3.1t as a single 
diastereoisomer. 
Rf = 0.30 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.45 (br, 1H), 7.39 – 7.26 (m, 3H), 7.26 – 7.15 (m, 1H), 6.40 (ddd, 
J = 10.3, 3.9, 1.5 Hz, 1H), 5.96 – 5.90 (m, 1H), 5.88 (ddd, J = 10.3, 4.2, 1.5 Hz, 1H), 3.67 – 3.59 
(m, 1H), 3.59 – 3.53 (m, 1H), 3.11 (s, 3H), 2.21 – 2.09 (m, 1H), 2.09 – 1.97 (m, 2H), 1.92 – 1.69 
(m, 4H), 1.69 – 1.53 (m, 2H), 1.50 – 1.39 (m, 2H), 1.14 – 1.00 (m, 1H). 
13C NMR: (125 MHz, CDCl3) δ 221.8, 153.4, 152.6, 136.7, 132.5, 132.0, 129.4, 128.4, 127.6, 
127.2, 122.7, 54.0, 51.5, 46.0, 41.7, 34.2, 28.3, 25.8, 25.3, 24.9, 23.4. 
HRMS: (ESI-TOF, m/z) calcd. For C21H26N3O3 [M+H]+ calc.: 368.1974; found: 368.1981.  
IR: (ATR, neat, cm-1): 2929 (w), 1762 (w), 1686 (s), 1472 (m), 1397 (w), 1016 (w), 909 (m), 758 
(m), 725 (s), 646 (m), 555 (w), 522 (w). 
m.p.: 123 – 124 ºC.  








Synthesis of ()-3.1u (Table 3-6): Following the general procedure 3A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 
to 1:1) as a white solid (305.8 mg, 75%, dr = 6.3:1, column-inseparable mixture). 
Recrystallization from n-hexane/EtOAc mixture gave ()-3.1u as a single 
diastereoisomer. 
Rf = 0.24 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.31 (br, 1H), 7.43 – 7.27 (m, 9H), 6.04 – 5.95 (m, 2H), 5.90 (ddd, 
J = 10.4, 4.1, 1.8 Hz, 1H), 4.43 (d, J = 6.0 Hz, 1H), 4.02 (qd, J = 7.1, 3.1 Hz, 2H), 3.90 – 3.81 (m, 
1H), 3.13 (s, 3H), 1.02 (t, J = 7.1 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 172.7, 153.4, 152.6, 135.9, 135.8, 132.1, 131.8, 129.1, 128.9, 
128.8, 128.3, 128.0, 127.8, 127.7, 123.6, 61.5, 56.4, 51.6, 42.1, 25.3, 14.0. 
HRMS: (ESI-TOF, m/z) calcd. For C23H24N3O4 [M+H]+ calc.: 406.1761; found: 406.1753.  
IR: (ATR, neat, cm-1): 3247 (w), 2934 (w), 1766 (w), 1714 (m), 1689 (s), 1479 (m), 1453 (m), 
1377 (w), 1250 (m), 1192 (m), 1174 (m), 1160 (m), 1032 (m), 751 (s), 725 (m), 608 (m). 
m.p.: 117–118 ºC. 
Stereochemistry determined by X-ray (see page S323 for details):  
 
Synthesis of ()-3.1v (Table 3-6): Following the general procedure 3A, the title 
compound was initially isolated as a mixture of ()-3.1v and a minor isomers 
()-3.1t' by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 to 1:1) as a 
white solid (289.4 mg, 54%). The isomers were further separated by careful 
flash chromatography (SiO2, n-hexane:EtOAc = 2:1 to 1:1).  
Rf = 0.52 (n-hexane:EtOAc = 1:2, UV, KMnO4). 
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1H NMR: (500 MHz, CDCl3) δ 9.60 (br, 1H), 7.54 – 7.47 (m, 1H), 7.45 – 7.37 (m, 3H), 7.35 – 
7.31 (m, 1H), 7.31 – 7.27 (m, 2H), 7.24 – 7.18 (m, 2H), 7.09 – 7.02 (m, 3H), 6.92 – 6.83 (m, 2H), 
6.40 (ddd, J = 10.1, 4.5, 1.0 Hz, 1H), 6.10 (ddd, J = 10.1, 4.9, 1.3 Hz, 1H), 6.03 – 5.98 (m, 1H), 
4.59 (d, J = 4.5 Hz, 1H), 4.20 – 4.12 (m, 1H), 2.97 (s, 3H), 1.50 (s, 9H). 
13C NMR: (125 MHz, CDCl3) δ 175.8, 169.4, 153.3, 151.5, 139.2, 137.0, 136.1, 134.2, 132.2, 
130.7, 129.5, 129.3, 128.8, 128.7, 128.4, 128.3, 127.8, 127.7, 127.4, 125.5, 82.6, 70.3, 51.4, 42.1, 
28.2, 25.1. 
HRMS: (ESI-TOF, m/z) calcd. For C32H36N5O4 [M+NH4]+ calc.: 554.2762; found: 554.2776.  
IR: (ATR, neat, cm-1): 2990 (w), 1378 (m), 1710 (s), 1608 (w), 1466 (m), 1455 (m), 1367 (w), 
1231 (w), 1140 (s), 1023 (w), 845 (w), 784 (w), 774 (w), 747 (s), 709 (s), 700 (s), 560 (m). 
m.p.: 174–175 ºC. 










Rf = 0.64 (n-hexane:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.67 – 7.60 (m, 2H), 7.48 – 7.30 (m, 7H), 7.26 
– 7.22 (m, 2H), 7.16 (td, J = 7.6, 1.6 Hz, 1H), 7.01 (d, J = 7.7 Hz, 1H), 6.90 – 
6.83 (m, 2H), 6.54 (ddd, J = 10.0, 4.3, 1.2 Hz, 1H), 5.95 – 5.85 (m, 2H), 4.34 
(d, J = 6.4 Hz, 1H), 3.94 – 3.86 (m, 1H), 3.07 (s, 3H), 1.39 (s, 9H). 
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13C NMR: (125 MHz, CDCl3) δ 171.6, 170.2, 1554.0, 152.7, 139.0, 136.3, 136.1, 132.9, 131.9, 
130.8, 129.19, 129.15, 129.04, 128.96, 128.7, 128.3, 127.8, 127.5, 127.4, 123.8, 82.6, 71.5, 52.5, 
42.2, 28.1, 25.2. 
HRMS: (ESI-TOF, m/z) calcd. For C32H32NaN4O4 [M+Na]+ calc.: 559.2316; found: 559.2342.  
IR: (ATR, neat, cm-1): 3004 (w), 1726 (m), 1682 (s), 1486 (m), 1449 (w), 1366 (w), 1264 (w), 
1142 (m), 1018 (w), 850 (w), 760 (s) ,734 (m), 701 (s), 692 (s). 
m.p.: 175–176 ºC.  
 
Synthesis of ()-3.1w (Table 3-6): The reaction was conducted following the 
general procedure 3A, except after the addition of the enolate and catalyst 
solution to the cycloadduct, the mixture was stirred at –30 ºC for 12 h. The title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 
to 1:1) as a white solid (247.8 mg, 72%).  
Rf = 0.43 (n-hexane:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.37 (dd, J = 7.3, 1.9 Hz, 1H), 7.32 – 7.26 (m, 1H), 7.27 – 7.22 
(m, 1H), 7.15 (d, J = 7.6 Hz, 1H), 7.11 (br, 1H), 6.24 (dd, J = 10.3, 4.2 Hz, 1H), 5.94 (dd, J = 10.3, 
4.0 Hz, 1H), 5.87 (s, J = 4.4, 4.3 Hz, 1H), 3.87 – 3.80 (m, 1H), 3.70 (s, 3H), 3.13 (m, 3H), 1.31 (s, 
3H), 1.18 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 178.2, 154.9, 154.8, 136.5, 132.4, 131.6, 129.0, 128.8, 127.9, 
127.5, 124.2, 53.5, 52.3, 48.0, 44.8, 25.35, 25.28, 22.8. 
HRMS: (ESI-TOF, m/z) calcd. For C18H25N4O4 [M+NH4]+ calc.: 361.1870; found: 361.1872.  
IR: (ATR, neat, cm-1): 3090 (w), 2976 (w), 1718 (m), 1679 (s), 1453 (m), 1434 (w), 1251 (m), 
1146 (m), 1025 (w), 951 (w), 856 (w), 815 (w), 778 (s). 




Synthesis of ()-3.1x (Table 3-6): Following the general procedure 3A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 
to 1:1) as a white solid (290.5 mg, 76%).  
Rf = 0.54 (n-hexane:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 8.11 (br, 1H), 7.39 – 7.32 (m, 1H), 7.31 – 7.25 
(m, 3H), 6.35 (ddd, J = 10.3, 4.7, 1.5 Hz, 1H), 5.93 (ddd, J = 10.3, 4.4, 1.3 Hz, 
1H), 5.90 – 5.83 (m, 1H), 3.56 – 3.50 (m, 1H), 3.44 (s, 3H), 3.14 (s, 3H), 2.46 – 2.38 (m, 1H), 2.30 
– 2.20 (m, 1H), 1.71 (dd, J = 10.5, 6.1 Hz, 2H), 1.64 – 1.60 (m, 1H), 1.50 (td, J = 12.5, 3.6 Hz, 
2H), 1.31 – 1.14 (m, 3H). 
13C NMR: (125 MHz, CDCl3) δ 176.6, 154.4, 153.7, 135.6, 132.7, 132.2, 129.8, 129.2, 127.5, 
127.2, 124.1, 54.1, 53.0, 51.8, 46.8, 34.5, 33.2, 25.4, 25.3, 23.84, 23.76. 
HRMS: (ESI-TOF, m/z) calcd. For C21H26N3O4 [M+H]+ calc.: 384.1918; found: 384.1910.  
IR: (ATR, neat, cm-1): 2949 (w), 1725 (m), 1681 (s), 1480 (m), 1451 (m), 1397 (w), 1208 (m), 
1126 (m), 1016 (w), 999 (w), 959 (w), 896 (w), 833 (w), 723 (s), 664 (m). 
m.p.: 154–155 ºC.  
 
Synthesis of ()-3.1y (Table 3-6): The reaction was conducted following the 
general procedure 3A, except that: 1) CH2Cl2 was used as the solvent instead of 
propionitrile, 2) LiCl (84.8 mg, 2.0 mmol, 2.0 eq.) was added with 
diisopropylamine for the formation of LDA, and 3) Pd(dba)2 (28.8 mg, 0.05 
mmol, 5.0 mol%) and rac-BINAP (37.0 mg, 0.06 mmol, 6.0 mol%) were used 
as the catalyst.   The title compound was isolated by flash chromatography 
(SiO2, n-hexane:EtOAc = 2:1 to 1:1) as a white solid (196.4 mg, 55%).  
Rf = 0.50 (n-hexane:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 8.13 (br, 1H), 7.37 – 7.34 (m, 1H), 7.34 – 7.27 (m, 1H), 7.27 – 
7.21 (m, 2H), 6.22 (ddd, J = 10.2, 3.9, 1.4 Hz, 1H), 5.98 – 5.92 (m, 1H), 5.89 (ddd, J = 10.2, 4.0, 
1.8 Hz, 1H), 3.81 – 3.71 (m, 1H), 3.10 (s, 3H), 2.85 (ddd, J = 16.1, 7.1, 2.8 Hz, 1H), 2.77 (dd, J = 
16.1, 3.6 Hz, 1H), 1.36 (s, 9H). 
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13C NMR: (125 MHz, CDCl3) δ 171.6, 153.6, 153.2, 137.5, 134.6, 131.3, 128.9, 128.6, 127.6, 
127.5, 122.6, 82.0, 51.8, 41.5, 34.8, 28.2, 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C19H24N3O4 [M+H]+ calc.: 358.1761; found: 358.1773.  
IR: (ATR, neat, cm-1): 3220 (w), 2987 (w), 1718 (m), 1689 (s), 1476 (m), 1353 (w), 1220 (w), 
1145 (s), 1003 (w), 852 (w), 757 (s), 650 (w), 599 (m), 560 (w). 
m.p.: 98–99 ºC. 
 
7.4.2 Dearomative syn-1,4-carboamination of arenes with p-methoxyacetophenone 
General procedure 3B for the dearomative syn-1,4-carboaminations of naphthalene 
derivatives with p-methoxyacetophenone (Table 3-7) 
 
For solid arene: MTAD (1.57a, 113 mg, 1.0 mmol, 1.0 eq.) and arene (1.2, 2.0 mmol, 2.0 eq.) were 
placed in a test tube with a septum as the cap under nitrogen atmosphere. Propionitrile (8.0 mL) 
was added to the test tube at rt, and the mixture was stirred until both MTAD and the naphthalene 
were completely dissolved.  
For liquid arene: MTAD (1.57a, 113 mg, 1.0 mmol, 1.0 eq.) was dissolved in propionitrile (6.0 
mL) at rt under nitrogen atmosphere. Then a solution of arene (1.2, 2.0 mmol, 2.0 eq.) in 
propionitrile (2.0 mL) was added. 
The resulting pink solution was stirred under irradiation with LED lights at –50 ºC until the 
solution became white suspension or colorless solution. In a separate flask, a fresh solution of LDA 
was prepared from diisopropylamine (0.28 mL, 2.0 mmol, 2.0 eq.) in THF (1.0 mL) and n-BuLi 
(1.2 mL, 1.9 mmol, 1.9 eq., 1.6 M solution in hexane) under nitrogen atmosphere at 0 ºC. After 
stirring for 15 min, the LDA solution was cooled to –78 ºC, and p-methoxyacetophenone (300 mg, 
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2.0 mmol, 2.0 eq.) dissolved in THF (1.0 mL) was added dropwise. The resulting solution was 
stirred at –78 ºC for 10 min, then at 0 ºC for 30 min until the white suspension became light-yellow 
solution, and cannulated into the solution of cycloadduct (at this point the LED lights were turned 
off). A solution of Pd(dba)2 (28.8 mg, 0.05 mmol, 5.0 mol%) and dppb (25.6 mg, 0.06 mmol, 6.0 
mol%) in THF (2.0 mL, pre-stirred at rt until both Pd(dba)2 and dppb completely dissolved and 
became orange solution) were then added, and the resulting mixture was warmed up from –50 ºC 
to 0 ºC over 5 h. The reaction was then quenched with saturated aqueous NH4Cl (3.0 mL), and 
EtOAc (10.0 mL) and water (10 mL) were added. Aqueous HCl solution (1 M, 3.0 mL) was added 
to acidify the solution to pH~5 and the organic phase was separated. The aqueous phase was 
extracted with EtOAc (3 × 10 mL), then the combined organic extracts were washed with saturated 
aqueous sodium chloride solution (10 mL), dried over anhydrous magnesium sulfate, and 
concentrated under reduced pressure. The product was purified by flash column chromatography 
(SiO2, n-hexane:EtOAc mixture).  
 
Synthesis of ()-3.2 (Table 3-7): Following the general procedure 
3B, the title compound was isolated by flash chromatography (SiO2, 
n-hexane:EtOAc = 2:1 to 1:1) as a white solid (290.8 mg, 54%).  
Rf = 0.15 (n-hexane:EtOAc = 1:2, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.95 – 7.87 (m, 2H), 7.95 – 7.87 (m, 
2H), 6.93 – 6.87 (m, 2H), 6.73 (br, 1H), 6.46 (dd, J = 9.8, 5.1 Hz, 
1H), 6.17 (dd, J = 5.1, 2.2 Hz, 1H), 5.90 (ddd, J = 9.8, 5.1, 1.4 Hz, 1H), 5.67 (s, 1H), 5.42 (s, 1H), 
4.55 – 4.46 (m, 1H), 3.85 (s, 3H), 3.53 (dd, J = 17.7, 10.0 Hz, 1H), 3.48 (d, J = 2.7 Hz, 1H), 3.44 
(s, 3H), 3.29 (s, 3H), 3.27 (s, 3H), 3.28 – 3.23 (m, 3H), 3.09 – 3.04 (m, 3H). 
13C NMR: (125 MHz, CDCl3) δ 196.8, 163.9, 155.9, 155.4, 140.5, 137.9, 137.0, 136.5, 130.5, 
129.8, 128.3, 127.3, 125.6, 119.8, 114.0, 101.5, 100.4, 55.6, 55.4, 54.8, 54.7, 52.6, 51.7, 47.2, 31.7, 
25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C28H37N4O8 [M+NH4]+ calc.: 557.26065; found: 557.2631.  
183 
 
IR: (ATR, neat, cm-1): 2944 (w), 1756 (w), 1682 (s), 1599 (m), 1485 (m), 1468 (m), 1349 (w), 
1252 (m), 1225 (w), 1192 (m) ,1167 (m), 1110 (m), 1097 (m), 1082 (m), 1041 (m), 1026 (m), 981 
(m), 964 (w), 920 (w), 820 (w), 597 (m). 
m.p.: 197–195 ºC. 
 
Synthesis of ()-3.3 (Table 3-7): Following the general procedure 3B, 
the title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a light-yellow oil (259.6 mg, 44%).  
Rf = 0.32 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.89 (d, J = 8.8 Hz, 2H), 7.10 (d, J = 8.7 
Hz, 1H), 6.95 (d, J = 8.7 Hz, 1H), 6.89 (br, 1H), 6.88 (d, J = 8.8 Hz, 2H), 
6.42 (dd, J = 9.9, 4.8 Hz, 1H), 5.85 (dd, J = 9.9, 4.7 Hz, 1H), 5.81 (dd, J = 4.8, 2.6 Hz, 1H), 4.12 
(dddd, J = 10.7, 4.8, 2.7, 2.6 Hz, 1H), 3.83 (s, 3H), 3.45 (dd, J = 17.4, 10.7 Hz, 1H), 3.30 (dd, J = 
17.4, 2.7 Hz, 1H), 3.01 (s, 3H), 1.34 (s, 9H), 1.26 (s, 9H). 
13C NMR: (125 MHz, CDCl3) δ 196.3, 178.5, 177.0, 163.9, 156.03, 155.98, 147.1, 146.1, 136.1, 
135.6, 130.5, 129.8, 124.3, 123.8, 121.9, 119.3, 114.0, 55.6, 50.8, 45.4, 39.5, 39.4, 30.9, 27.3, 
27.15, 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C32H38N3O8 [M+H]+ calc.: 592.2653; found: 592.2668.  
IR: (ATR, neat, cm-1): 2981 (w), 1750 (m), 1704 (s), 1599 (m), 1472 (m) ,1398 (w), 1259 (m), 
1216 (m), 1169 (m), 1099 (s), 1027 (m), 999 (w), 831 (w), 758 (m), 602 (w). 
 
Synthesis of ()-3.4 (Table 3-7): Following the general procedure 
3B, the title compound was isolated by flash chromatography (SiO2, 
n-hexane:EtOAc = 2:1 to 1:1) as a white solid (355.2 mg, 60%).  
Gram-scale synthesis of ()-3.4 (Table 3-7): MTAD (1.57a, 1.0 g, 
8.8 mmol, 1.0 eq.) and naphthalene-2,3-diyl-bis(2,2-
dimethylpropanoate) (5.8 g, 17.7 mmol, 2.0 eq.) were placed in a 500 
mL clear borosilicate glass bottle (see Picture S2) with a septum as the cap under nitrogen 
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atmosphere. Propionitrile (71 mL) was added to the bottle at rt, and the mixture was stirred until 
both MTAD and the naphthalene were completely dissolved. Then the resulting pink solution was 
stirred under irradiation with LED lights at –50 ºC until the solution became white suspension 
(about 24 hours). In a separate flask, a fresh solution of LDA was prepared from diisopropylamine 
(2.5 mL, 17.7 mmol, 2.0 eq.) in THF (9.0 mL) and n-BuLi (10.5 mL, 16.8 mmol, 1.9 eq., 1.6 M 
solution in hexane) under nitrogen atmosphere at 0 ºC. After stirring for 30 min, the LDA solution 
was cooled to –78 ºC and p-methoxyacetophenone (2.7 g, 17.7 mmol, 2.0 eq.) dissolved in THF 
(9.0 mL) was added dropwise. The resulting solution was stirred at –78 ºC for 10 min, then at 0 ºC 
for 30 min until the white suspension became light-yellow solution and cannulated into the solution 
of cycloadduct (at this point the LED lights were turned off). A solution of Pd(dba)2 (254 mg, 0.44 
mmol, 5.0 mol%) and dppb (226 mg, 0.54 mmol, 6.0 mol%) in THF (18 mL, pre-stirred at rt for 
60 min until both Pd(dba)2 and dppb completely dissolved) was then added, and the resulting 
mixture was warmed from –50 ºC to 0 ºC over 5 h. The reaction was then quenched with saturated 
aqueous NH4Cl (15 mL), and EtOAc (50 mL) and water (50 mL) were added. Aqueous HCl 
solution (1 M, 15 mL) was added to acidify the solution to pH~5 and the organic phase was 
separated. The aqueous phase was extracted with EtOAc (3 × 50 mL), then the combined organic 
extracts were washed with saturated aqueous sodium chloride solution (30 mL), dried over 
anhydrous magnesium sulfate, and concentrated under reduced pressure. The product was isolated 
by flash column chromatography (SiO2, n-hexane:EtOAc = 2:1 to 1:1) as a white solid (2.71 g, 
52%).  
 
Rf = 0.28 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.05 (br, 1H), 7.92 (d, J = 8.3 Hz, 2H), 7.19 (s, 1H), 7.04 (s, 1H), 
6.92 (d, J = 8.3 Hz, 2H), 6.26 (dd, J = 9.9, 4.0 Hz, 1H), 5.89 – 5.83 (m, 1H), 5.82 (dd, J = 9.9, 4.2 
Hz, 1H), 4.09 – 3.95 (m, 1H), 3.86 (s, 3H), 3.52 (dd, J = 17.5, 7.8 Hz, 1H), 3.42 (d, J = 17.5 Hz, 
1H), 3.07 (s, 3H), 1.33 (s, 9H), 1.31 (s, 9H). 
13C NMR: (125 MHz, CDCl3) δ 196.6, 175.9, 175.7, 163.7, 154.8, 154.5, 142.6, 141.3, 138.2, 
135.4, 130.4, 129.5, 129.3, 123.7, 122.5, 120.8, 113.7, 55.4, 52.7, 45.9, 39.08, 39.06, 34.1, 27.2, 
27.1, 25.0. 
HRMS: (ESI-TOF, m/z) calcd. For C32H37N3NaO8 [M+Na]+ calc.: 614.2473; found: 614.2460.  
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IR: (ATR, neat, cm-1): 2971 (w), 1758 (m), 1689 (m), 1599 (w), 1476 (m), 1353 (w), 1257 (m), 
1172 (m), 1108 (s), 1028 (m), 892 (w), 769 (m), 759 (m), 700 (w). 
m.p.: 194–195 ºC.  
 
Synthesis of ()-3.5 (Table 3-7): Following the general procedure 3B, 
the title compound was initially isolated as a mixture of 3.5 and a 
minor isomers 3.5' by flash chromatography (SiO2, n-hexane:EtOAc 
= 2:1 to 1:1) as a white solid (353.0 mg, 62%). The isomers were 
further separated by careful flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1). 
Rf = 0.37 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.93 (dd, J = 9.0, 1.9 Hz, 2H), 7.51 (br, 1H), 7.29 (d, J = 8.4 Hz, 
1H), 7.09 (d, J = 8.4 Hz, 1H), 6.92 (d, J = 9.0, 1.9 Hz, 2H), 6.24 (dd, J = 9.9, 4.2 Hz, 1H), 5.99 – 
5.94 (m, 1H), 5.92 (ddd, J = 9.9, 4.7, 1.5 Hz, 1H), 4.12 – 4.03 (m, 1H), 3.87 (s, 3H), 3.63 (dd, J = 
17.5, 7.9 Hz, 1H), 3.43 (dd, J = 17.5, 4.1 Hz, 1H), 3.09 (s, 3H), 1.40 (s, 9H). 
13C NMR: (125 MHz, CDCl3) δ 196.8, 176.3, 164.0, 155.2, 154.1, 147.6, 140.2, 134.4, 130.8, 
130.6, 129.6, 128.2, 123.8, 121.2, 119.3, 114.0, 55.6, 54.1, 45.6, 39.4, 35.2, 27.3, 25.2. 
HRMS: (ESI-TOF, m/z) calcd. For C27H28NaN3O6Br [M+Na]+ calc.: 592.1059; found: 592.1055.  
IR: (ATR, neat, cm-1): 2972 (w), 1749 (m), 16969 (s), 1683 (s), 1600 (m), 1482 (w), 1469 (m), 
1253 (m), 1221 (m), 1175 (m), 1107 (s), 730 (w), 603 (w), 509 (w). 
m.p.: 206–207 ºC. 





Rf = 0.22 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.91 (d, J = 8.8 Hz, 2H), 7.77 (br, 
1H), 7.50 (d, J = 8.4 Hz, 1H), 7.04 (d, J = 8.4 Hz, 1H), 6.91 (d, J = 
8.8 Hz, 2H), 6.53 – 6.46 (m, 1H), 5.90 – 5.78 (m, 2H), 4.34 – 4.26 
(m, 1H), 3.87 (s, 3H), 3.68 (dd, J = 17.4, 3.1 Hz, 1H), 3.36 (dd, J = 
17.4, 9.6 Hz, 1H), 3.00 (s, 3H), 1.39 (s, 9H). 
13C NMR: (125 MHz, CDCl3) δ 196.6, 176.2, 164.0, 155.0, 154.8, 149.0, 141.2, 136.9, 131.4, 
130.6, 129.7, 129.6, 122.5, 120.7, 118.1, 114.0, 55.7, 53.8, 44.3, 39.5, 35.9, 27.3, 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C27H28NaN3O6Br [M+Na]+ calc.: 592.1059; found: 592.1050.  
IR: (ATR, neat, cm-1): 2970 (w), 1739 (s), 1597 (m), 1470 (m), 1365 (m), 1217 (s), 1167 (m), 
1099 (m), 1025 (w), 983 (w), 829 (w), 602 (w). 
m.p.: 147–148 ºC.  
 
Synthesis of ()-3.6 (Table 3-7): Following the general procedure 3B, 
the title compound was initially isolated as a mixture of 3.6 and a minor 
isomers 3.6' by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 to 
1:2) as a white solid (332.0 mg, 62%). The isomers were further 
separated by careful flash chromatography (SiO2, n-hexane:EtOAc = 2:1 
to 1:2). 
Rf = 0.26 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.51 (br, 1H), 7.92 (d, J = 8.9 Hz, 2H), 7.65 (d, J = 7.9 Hz, 2H), 
7.41 – 7.33 (m, 3H), 7.35 – 7.29 (m, 1H), 7.09 – 7.03 (m, 1H), 6.91 (d, J = 8.9 Hz, 2H), 6.10 (ddd, 
J = 10.1, 3.9, 1.2 Hz, 1H), 6.06 – 5.98 (m, 1H), 5.86 (ddd, J = 10.1, 4.4, 1.7 Hz, 1H), 4.05 – 3.95 
(m, 1H), 3.86 (s, 3H), 3.78 (dd, J = 18.0, 6.3 Hz, 1H), 3.59 (dd, J = 18.0, 3.8 Hz, 1H), 2.74 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 197.0, 164.2, 153.6, 151.2, 144.1, 141.7, 139.9, 132.3, 130.7, 
129.8 (q, J = 32.5 Hz), 129.6, 128.9, 128.65, 128.56, 127.5, 127.4, 125.3 (q, J = 3.8 Hz), 124.3 (q, 
J = 272.0 Hz), 123.4, 114.0, 55.6, 49.3, 43.7, 35.1, 24.6. 
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19F NMR: (471 MHz, CDCl3) δ –62.8 
HRMS: (ESI-TOF, m/z) calcd. For C29H28F3N4O4 [M+NH4]+ calc.: 553.2057; found: 553.2065.  
IR: (ATR, neat, cm-1): 3202 (w), 1757 (m), 1680 (s), 1602 (w), 1484 (m), 1256 (m), 1226 (w), 
1162 (m), 1108 (w), 1027 (w), 842 (w), 801 (w), 766 (m), 752 (m), 577 (w). 
m.p.: 223–224 ºC.  







Rf = 0.19 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.09 (br, 1H), 7.70 (d, J = 8.0 Hz, 2H), 
7.53 (d, J = 7.4 Hz, 1H), 7.49 – 7.41 (m, 4H), 7.35 (dd, J = 7.6, 7.4 Hz, 
1H), 7.14 (dd, J = 7.6, 1.4 Hz, 1H), 6.80 (d, J = 8.9 Hz, 2H), 6.17 (ddd, J 
= 10.0, 4.7, 1.2 Hz, 1H), 6.08 – 6.02 (m, 1H), 5.93 (ddd, J = 10.0, 4.4, 1.3 
Hz, 1H), 4.25 – 4.16 (m, 1H), 3.84 (s, 3H), 3.12 (s, 3H), 3.01 (dd, J = 
16.3, 3.9 Hz, 1H), 2.77 (dd, J = 16.3, 8.9 Hz, 1H). 
13C NMR: (125 MHz, CDCl3) δ 197.0, 164.0, 154.3, 154.2, 145.0, 139.8, 136.6, 136.0, 132.8, 
130.7, 130.5, 129.9 (q, J = 32.6 Hz), 129.6, 129.5, 129.2, 127.5, 125.8 (q, J = 3.7 Hz), 124.2 (q, J 
= 272.2 Hz), 121.8, 113.9, 55.6, 53.3, 43.5, 32.6, 25.4. 
19F NMR: (471 MHz, CDCl3) δ –62.8 
HRMS: (ESI-TOF, m/z) calcd. For C29H24F3KN3O4 [M+K]+ calc.: 574.1351; found: 574.1328.  
IR: (ATR, neat, cm-1): 2970 (w), 1738 (w), 1692 (m), 1472 (w), 1365 (w), 1323 (s), 1257 (m), 
1216 (m), 1165 (m), 1122 (m), 1107 (m), 1064 (w), 761 (w), 611 (w). 
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m.p.: 191–192 ºC. 
 
Synthesis of ()-3.7 (Table 3-7): Following the general procedure 3B, 
the title compound was initially isolated as a mixture of 3.7 and a minor 
isomers 3.7' by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 to 
1:1) as a white solid (266.0 mg, 54%). The isomers were further 
separated by careful flash chromatography (SiO2, n-hexane:EtOAc = 2:1 
to 1:1). 
Rf = 0.39 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.92 (d, J = 8.9 Hz, 2H), 7.35 (dd, J = 7.8, 7.7 Hz, 1H), 7.21 (d, J 
= 7.8 Hz, 1H), 6.93 (br, 1H), 6.91 (d, J = 8.9 Hz, 2H), 6.87 (d, J = 7.7 Hz, 1H), 6.34 (dd, J = 10.1, 
4.6 Hz, 1H), 5.87 (dd, J = 10.1, 4.6 Hz, 1H), 5.81 (dd, J = 4.6, 3.0 Hz, 1H), 4.19 (ddd, J = 8.6, 4.6, 
4.2 Hz, 1H), 3.85 (s, 3H), 3.49 (dd, J = 17.2, 8.6 Hz, 1H), 3.30 (dd, J = 17.2, 4.2 Hz, 1H), 3.01 (s, 
3H), 1.32 (s, 9H). 
13C NMR: (125 MHz, CDCl3) δ 196.6, 178.6, 163.8, 155.7, 155.6, 149.7, 143.4, 135.8, 130.6, 
129.7, 129.6, 125.2, 122.7, 121.0, 119.9, 114.0, 55.6, 50.3, 47.1, 39.4, 34.7, 27.2, 25.2. 
HRMS: (ESI-TOF, m/z) calcd. For C27H29KN3O6 [M+K]+ calc.: 530.1688; found: 530.1710.  
IR: (ATR, neat, cm-1): 2970 (w), 1704 (s), 1598 (m), 1510 (w), 1466 (m), 1365 (w), 1257 (m), 
1217 (m), 1168 (w), 1112 (m), 1027 (w), 830 (w), 751 (m), 569 (w). 
m.p.: 207–208 ºC. 







Rf = 0.20 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.17 (br, 1H), 7.86 (d, J = 8.8 Hz, 2H), 
7.36 – 7.26 (m, 2H), 6.98 (d, J = 7.6 Hz, 1H), 6.85 (d, J = 8.8 Hz, 2H), 
6.45 (dd, J = 10.2, 4.6 Hz, 1H), 5.88 (dd, J = 4.1, 3.8 Hz, 1H), 5.81 (dd, 
J = 10.2, 4.1 Hz, 1H), 4.10 – 3.99 (m, 1H), 3.84 (s, 3H), 3.43 (dd, J = 
17.9, 9.4 Hz, 1H), 3.37 (dd, J = 17.9, 3.5 Hz, 1H), 2.91 (s, 3H), 1.26 (s, 9H). 
13C NMR: (125 MHz, CDCl3) δ 196.7, 177.0, 164.0, 154.9, 154.5, 148.5, 136.1, 133.4, 132.5, 
130.5, 129.8, 128.0, 126.8, 122.7, 121.0, 114.0, 55.7, 53.3, 44.4, 39.4, 30.7, 27.2, 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C27H29NaN3O6 [M+Na]+ calc.: 514.1949; found: 514.1964.  
IR: (ATR, neat, cm-1): 2970 (w), 1751 (s), 1703 (s), 1670 (m), 1462 (m), 1258 (m), 1216 (m), 
1169 (m), 1111 (s), 1011 (w), 863 (w), 769 (w), 730 (w), 607 (w), 592 (w), 569 (w). 
m.p.: 209–210 ºC.  
 
Synthesis of ()-3.8 (Table 3-7): Following the general procedure 3B, 
the title compound was initially isolated as a mixture of 3.8 and a minor 
isomers 3.8' by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 to 
1:1) as a white solid (338.6 mg, 74%). The isomers were further 
separated by careful flash chromatography (SiO2, n-hexane:EtOAc = 2:1 
to 1:1). 
Rf = 0.57 (n-hexane:EtOAc = 1:2, UV, KMnO4).  
1H NMR: (500 MHz, d6-DMSO) δ 9.93 (br, 1H), 7.92 (d, J = 8.9 Hz, 2H), 7.78 – 7.68 (m, 2H), 
7.57 (t, J = 7.8 Hz, 1H), 7.06 (d, J = 8.9 Hz, 2H), 6.36 (dd, J = 10.0, 4.6 Hz, 1H), 5.98 (dd, J = 5.1, 
2.6 Hz, 1H), 5.74 (dd, J = 10.0, 5.1 Hz, 1H), 4.16 – 4.08 (m, 1H), 3.84 (s, 3H), 3.51 (d, J = 7.0 Hz, 
2H), 2.90 (s, 3H). 
13C NMR: (125 MHz, d6-DMSO) δ 196.4, 163.3, 155.1, 155.0, 143.6, 134.7, 133.5, 130.2, 129.5, 
128.7, 128.2, 127.8 (q, J = 29.5 Hz), 125.6 (q, J = 6.0 Hz), 124.4 (q, J = 249.2 Hz), 120.3, 114.0, 
55.6, 50.3, 46.8, 35.1, 24.8 
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19F NMR: (471 MHz, d6-DMSO) δ 58.1 
HRMS: (ESI-TOF, m/z) calcd. For C23H20F3KN3O4 [M+K]+ calc.: 498.1037; found: 498.1047.  
IR: (ATR, neat, cm-1): 3067 (w), 1764 (w), 1689 (m), 1674 (m), 1575 (m), 1475 (m), 1341 (w), 
1259 (w), 1175 (m), 1116 (s), 1021 (m), 808 (m), 754 (m). 
m.p.: 219–220 ºC.  
 
()-3.8' 
Rf = 0.33 (n-hexane:EtOAc = 1:2, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.44 (br, 1H), 7.85 (d, J = 8.8 Hz, 2H), 
7.74 (d, J = 7.8 Hz, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.41 (dd, J = 7.8, 7.8 
Hz, 1H), 6.85 (d, J = 8.8 Hz, 2H), 6.49 (dd, J = 9.0, 5.4 Hz, 1H), 5.98 – 
5.76 (m, 2H), 4.58 – 4.43 (m, 1H), 3.86 (s, 3H), 3.58 (dd, J = 17.2, 3.5 
Hz, 1H), 3.32 (dd, J = 17.2, 9.8 Hz, 1H), 2.96 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 196.5, 164.0, 155.1, 154.6, 139.7, 137.7, 134.4, 134.1, 130.5, 
129.4, 127.9 (q, J = 29.6 Hz), 127.6 (q, J = 6.4 Hz), 127.4, 124.6 (q, J = 249.2 Hz), 120.6, 114.0, 
55.7, 54.1, 47.4, 32.0, 25.3.  
19F NMR: (471 MHz, CDCl3) δ –58.7. 
HRMS: (ESI-TOF, m/z) calcd. For C23H24F3KN4O4 [M+NH4]+ calc.: 477.1744; found: 477.1743.  
IR: (ATR, neat, cm-1): 2970 (w), 1738 (m), 1685 (s), 1598 (w), 1460 (w), 1307 (m), 1259 (m), 
1217 (m), 1113 (s), 1019 (w), 765 (s), 571 (w). 
m.p.: 197–198 ºC.  







Synthesis of ()-3.9 (Table 3-7): Following the general procedure 3B, the 
title compound was initially isolated as a mixture of 3.9 and a minor 
isomers 3.9' by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 to 
1:1) as a white solid (194.1 mg, 42%). The isomers were further separated 
by careful flash chromatography (SiO2, n-hexane:EtOAc = 2:1 to 1:1). 
Rf = 0.73 (n-hexane:EtOAc = 1:2, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.93 (dd, J = 7.9, 1.1 Hz, 2H), 7.56 (dd, J = 6.3, 2.5 Hz, 1H), 7.36 
– 7.29 (m, 2H), 6.92 (d, J = 9.1 Hz, 2H), 6.39 – 6.31 (m, 1H), 6.23 (br, 1H), 5.97 – 5.86 (m, 2H), 
4.18 (ddd, J = 9.8, 5.1, 4.6 Hz, 1H), 3.86 (s, 3H), 3.50 (dd, J = 17.1, 9.8 Hz, 1H), 3.31 (dd, J = 
17.1, 4.6 Hz, 1H), 3.09 (s, 3H), 0.36 (s, 9H). 
13C NMR: (125 MHz, CDCl3) δ 197.0, 163.8, 155.3, 155.2, 141.0, 140.9, 135.7, 134.6 (overlap 
of 2 peaks detected by HMBC), 130.6, 129.91, 129.88, 128.1, 120.6, 114.0, 55.6, 54.5, 47.3, 36.0, 
25.3, 0.8. 
HRMS: (ESI-TOF, m/z) calcd. For C25H29KN3O4Si [M+K]+ calc.: 502.1559; found: 502.1574.  
IR: (ATR, neat, cm-1): 3163 (w), 2953 (w), 1704 (s), 1651 (m), 1596 (m), 1571 (w), 1470 (m), 
1259 (m), 1223 (m), 1176 (m), 1018 (w), 839 (m), 800 (w), 763 (s), 730 (m), 691 (w). 
m.p.: 110–111 ºC. 








Rf = 0.43 (n-hexane:EtOAc = 1:2, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.04 (br, 1H), 7.82 (d, J = 8.8 Hz, 2H), 
7.60 – 7.52 (dd, J = 7.4, 1.4 Hz, 1H), 7.46 (dd, J = 7.7, 1.4 Hz, 1H), 7.28 
– 7.22 (m, 1H), 6.81 (d, J = 8.8 Hz, 2H), 6.65 (dd, J = 8.9, 5.1 Hz, 1H), 
5.87 – 5.76 (m, 2H), 4.37 – 4.25 (m, 1H), 3.84 (s, 3H), 3.45 (dd, J = 18.1, 
11.1 Hz, 1H), 3.26 (dd, J = 18.1, 2.8 Hz, 1H), 2.85 (s, 3H), 0.30 (s, 9H). 
13C NMR: (125 MHz, CDCl3) δ 196.4, 163.8, 155.5, 154.6, 146.9, 138.9, 138.3, 136.3, 131.1, 
130.6, 130.3, 129.7, 126.5, 120.6, 113.9, 55.6, 55.0, 49.9, 35.1, 25.2, 1.3. 
HRMS: (ESI-TOF, m/z) calcd. For C25H29KN3O4Si [M+K]+ calc.: 502.1559; found: 502.1569.  
IR: (ATR, neat, cm-1): 2951 (w), 1679 (s), 1598 (m), 1476 (m), 1430 (w), 1353 (w), 1250 (m), 
1215 (m), 1166 (m), 1019 (w), 835 (s), 784 (m), 761 (s), 605 (m), 572 (m). 
m.p.: 218–219 ºC.  
 
Synthesis of ()-3.10 (Table 3-7): Following the general procedure 
3B, the title compound was initially isolated as a mixture of 3.10 and 
a minor isomers 3.10' by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (281.9 mg, 57%). The 
isomers were further separated by careful flash chromatography 
(SiO2, n-hexane:EtOAc = 2:1 to 1:1). 
Rf = 0.33 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.04 (br, 1H), 7.95 – 7.89 (m, 2H), 7.25 (d, J = 8.6 Hz, 1H), 7.12 
(d, J = 2.4 Hz, 1H), 7.00 (dd, J = 8.6, 2.4 Hz, 1H), 6.96 – 6.88 (m, 2H), 6.26 (ddd, J = 10.1, 3.9, 
1.3 Hz, 1H), 5.96 – 5.86 (m, 1H), 5.84 (ddd, J = 10.1, 4.1, 1.7 Hz, 1H), 4.06 – 3.95 (m, 1H), 3.87 
(s, 3H), 3.59 (dd, J = 17.6, 7.2 Hz, 1H), 3.46 (dd, J = 17.6, 4.1 Hz, 1H), 3.11 (s, 3H), 1.34 (s, 9H). 
13C NMR: (125 MHz, CDCl3) δ 196.9, 177.2, 164.0, 154.2, 154.1, 149.9, 136.3, 135.4, 132.4, 
130.7, 129.7, 128.7, 122.3, 121.6, 121.5, 114.0, 55.7, 52.6, 44.8, 39.2, 34.1, 27.2, 25.3.  
HRMS: (ESI-TOF, m/z) calcd. For C27H30N3O6 [M+H]+ calc.: 492.2129; found: 492.2126.  
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IR: (ATR, neat, cm-1): 3225 (w), 2970 (w), 1745 (m), 1694 (s), 1671 (m), 1597 (w), 1478 (m), 
1266 (w), 1217 (m), 1164 (w), 1154 (m), 1127 (m), 1114 (m), 983 (w), 826 (w), 768 (m), 601 (m). 
m.p.: 194–195 ºC.  







Rf = 0.27 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.30 (br, 1H), 7.95 – 7.88 (m, 2H), 
7.43 (d, J = 9.2 Hz, 1H), 6.97 – 6.93 (m, 2H), 6.92 – 6.87 (m, 2H), 
6.28 (ddd, J = 10.1, 4.0, 1.4 Hz, 1H), 5.94 – 5.91 (m, 1H), 5.85 (ddd, 
J = 10.1, 4.2, 1.6 Hz, 1H), 4.06 – 3.98 (m, 1H), 3.86 (s, 3H), 3.56 (dd, 
J = 17.7, 7.8 Hz, 1H), 3.46 (dd, J = 17.7, 4.1 Hz, 1H), 3.03 (s, 3H), 1.32 (s, 9H). 
13C NMR: (125 MHz, CDCl3) δ 196.7, 177.2, 164.1, 154.2, 154.1, 151.1, 140.7, 135.2, 130.7, 
130.4, 129.7, 128.6, 121.8, 120.8, 120.4, 114.0, 55.7, 52.2, 45.0, 39.2, 34.6, 27.2, 25.2. 
HRMS: (ESI-TOF, m/z) calcd. For C27H33N4O6 [M+NH4]+ calc.: 509.2394; found: 509.2370.  
IR: (ATR, neat, cm-1): 2970 (w), 1748 (m), 1690 (s), 1598 (m), 1477 (w), 1353 (w), 1252 (w), 
1168 (m), 1108 (s), 1023 (w), 765 (m), 595 (w). 




Synthesis of ()-3.11 (Table 3-7): Following the general procedure 3B, 
the title compound was initially isolated as a mixture of 3.11 and a minor 
isomers 3.11' by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 to 
1:2) as a white solid (203.7 mg, 46%). The isomers were further 
separated by careful flash chromatography (SiO2, n-hexane:EtOAc = 
2:1 to 1:2). 
Rf = 0.47 (n-hexane:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 8.21 (d, J = 8.6 Hz, 1H), 7.97 – 7.91 (m, 2H), 7.86 – 7.79 (m, 2H), 
7.59 (dd, J = 7.6, 7.5 Hz, 1H), 7.51 (dd, J = 7.5, 7.4 Hz, 1H), 7.45 (br, 1H), 7.33 (d, J = 8.6 Hz, 
1H), 6.91 (d, J = 8.8 Hz, 2H), 6.52 (dd, J = 4.6, 4.3 Hz, 1H), 6.37 (dd, J = 9.9, 4.0 Hz, 1H), 5.99 
(ddd, J = 9.9, 4.6, 1.4 Hz, 1H), 4.22 – 4.15 (m, 1H), 3.86 (s, 3H), 3.64 (dd, J = 17.3, 8.2 Hz, 1H), 
3.51 (dd, J = 17.3, 4.0 Hz, 1H), 3.07 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 197.1, 164.0, 154.4, 154.1, 138.6, 134.8, 132.7, 131.2, 130.8, 
129.82, 129.77, 128.8, 127.4, 126.1, 125.7, 124.4, 123.4, 121.6, 114.0, 55.6, 50.7, 44.9, 36.0, 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C26H23NaN3O4 [M+Na]+ calc.: 464.1580; found: 464.1601.  
IR: (ATR, neat, cm-1): 2970 (w), 1738 (s), 1689 (m), 1600 (w), 1365 (m), 1217 (m), 1030 (w), 
740 (w), 528 (w). 
m.p.: 198–199 ºC.  








Rf = 0.37 (n-hexane:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.96 (d, J = 8.1 Hz, 1H), 7.90 – 7.82 
(m, 3H), 7.78 (d, J = 8.5 Hz, 1H), 7.59 – 7.44 (m, 3H), 7.28 (br, 1H), 
6.88 (dd, J = 8.9, 1.0 Hz, 2H), 6.59 (dd, J = 9.9, 4.7 Hz, 1H), 6.01 (dd, 
J = 4.2, 3.9 Hz, 1H), 5.93 (dd, J = 9.9, 4.2 Hz, 1H), 4.91 – 4.78 (m, 
1H),  3.85 (s, 3H), 3.56 (dd, J = 17.6, 2.2 Hz, 1H), 3.46 (dd, J = 17.6, 9.7 Hz, 1H), 2.99 (s, 3H). 
13C NMR: 196.9, 164.0, 155.2, 154.9, 137.0, 136.1, 133.8, 130.7, 130.3, 129.7, 129.3, 128.5, 
128.4, 127.1, 126.5, 126.1, 123.4, 120.8, 114.0, 55.7, 54.7, 46.0, 31.7, 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C26H23KN3O4 [M+K]+ calc.: 480.1320; found: 480.1343.  
IR: (ATR, neat, cm-1): 2970 (w), 1738 (s), 1599 (w), 1366 (m), 1216 (m), 1011 (m), 763 (m). 
m.p.: 180–181 ºC.  
 
General procedure 4C for the dearomative syn-1,4-carboaminations of mononuclear arenes 
with ketones/ester (Table 3) 
 
MTAD (1.57a, 113 mg, 1.0 mmol, 1.0 eq.) was placed in a test tube with a septum as the cap under 
nitrogen atmosphere. Propionitrile (8.0 mL) was added to the test tube at rt, and cooled to –78 ºC. 
Arene (1.1, 10 mmol, 10 eq.) was added dropwise at –78 ºC, and the resulting pink solution was 
stirred under irradiation with LED lights at –78 ºC until the solution became colorless. In a separate 
flask, a fresh solution of LDA was prepared from diisopropylamine (0.28 mL, 2.0 mmol, 2.0 eq.) 
in THF (1.0 mL) and n-BuLi (1.2 mL, 1.9 mmol, 1.9 eq., 1.6 M solution in hexane) under nitrogen 
atmosphere at 0 ºC. After stirring for 15 min, the LDA solution was cooled to –78 ºC, and p-
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methoxyacetophenone (300 mg, 2.0 mmol, 2.0 eq.) dissolved in THF (1.0 mL) was added 
dropwise. The resulting solution was stirred at –78 ºC for 10 min, then at 0 ºC for 30 min until the 
white suspension became light-yellow solution, and cannulated into the solution of cycloadduct 
(at this point the LED lights were turned off). A solution of Pd(dba)2 (28.8 mg, 0.05 mmol, 5.0 
mol%) and dppb (25.6 mg, 0.06 mmol, 6.0 mol%) in THF (2.0 mL, pre-stirred at rt until both 
Pd(dba)2 and dppb completely dissolved and became orange solution) was then added, and the 
resulting mixture was warmed up from –50 ºC to 0 ºC over 5 h. The reaction was then quenched 
with saturated aqueous NH4Cl (3.0 mL), and EtOAc (10.0 mL) and water (10 mL) were added. 
Aqueous HCl solution (1 M, 3.0 mL) was added to acidify the solution to pH~5 and the organic 
phase was separated. The aqueous phase was extracted with EtOAc (3 × 10 mL), then the combined 
organic extracts were washed with saturated aqueous sodium chloride solution (10 mL), dried over 
anhydrous magnesium sulfate, and concentrated under reduced pressure. The product was purified 
by flash column chromatography (SiO2, n-hexane:EtOAc mixture).  
 
Synthesis of ()-3.13a (Table 3-8): Following the general procedure 4C, the 
title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:2) as a white solid (274.6 mg, 80%).  
Rf = 0.32 (n-hexane:EtOAc = 1:2, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.65 (br, 1H), 7.96 – 7.84 (m, 2H), 6.95 – 
6.85 (m, 2H), 6.09 (ddd, J = 10.3, 3.4, 1.6 Hz, 2H), 5.67 (ddd, J = 10.3, 3.6, 
1.8 Hz, 2H), 5.24 (dtt, J = 7.0, 3.6, 1.6 Hz, 1H), 3.86 (s, 3H), 3.44 – 3.32 (m, 1H), 3.14 (d, J = 6.5 
Hz, 2H), 2.96 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 196.7, 163.9, 154.5, 153.8, 135.0, 130.5, 129.8, 122.1, 113.9, 
55.6, 50.2, 42.2, 31.9, 25.1. 
HRMS: (ESI-TOF, m/z) calcd. For C18H19KN3O4 [M+K]+ calc.: 380.1007; found: 380.0997.  
IR: (ATR, neat, cm-1): 2933 (w), 1765 (m), 1671 (S), 1598 (m), 1481 (m), 1399 (m), 1262 (s), 
1210 (m), 1173 (w), 1033 (m), 826 (m), 773 (m), 629 (w), 576 (w). 




Synthesis of ()-3.13b (Table 3-8): Following the general procedure 4C, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 
to 1:2) as a colorless oil (204.6 mg, 74%).  
Rf = 0.32 (n-hexane:EtOAc = 1:2, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.66 (br, 1H), 5.98 (ddd, J = 10.1, 3.4, 1.7 Hz, 
2H), 5.66 (ddd, J = 10.1, 4.0, 1.7 Hz, 2H), 5.23 (dtt, J = 7.5, 3.4, 1.7 Hz, 1H), 
3.25 – 3.16 (m, 1H), 3.09 (s, 3H), 2.68 (d, J = 6.3 Hz, 2H), 2.58 (hept, J = 6.9 Hz, 1H), 1.10 (d, J 
= 6.9 Hz, 6H). 
13C NMR: (125 MHz, CDCl3) δ 213.1, 154.5, 153.9, 134.6, 122.1, 50.2, 44.3, 41.3, 31.4, 25.2, 
18.2. 
HRMS: (ESI-TOF, m/z) calcd. For C14H23N4O3 [M+NH4]+ calc.: 295.1765; found: 295.1772.  
IR: (ATR, neat, cm-1): 3035 (w), 2970 (w), 1682 (s), 1480 (m), 1401 (m), 1231 (w), 1007 (m), 
799 (m), 761 (s), 720 (m), 702 (m), 569 (m). 
 
Synthesis of ()-3.13c (Table 3-8): Following the general procedure 4C, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 
to 1:2) as a white solid (280 mg, 86%, dr>20:1). Stereochemistry was assigned 
in analogy to compound ()-3.1h. 
Rf = 0.43 (n-hexane:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.98 – 7.91 (m, 2H), 7.62 – 7.56 (m, 1H), 7.49 
(dd, J = 7.7, 7.7 Hz, 2H), 7.37 (br, 1H), 6.11 (ddd, J = 10.2, 3.5, 1.9, 1.9 Hz, 1H), 6.04 (dddd, J = 
10.2, 3.6, 1.8, 1.7 Hz, 1H), 5.78 – 5.62 (m, 2H), 5.24 (dtt, J = 8.6, 3.5, 1.7 Hz, 1H), 3.79 – 3.62 
(m, 1H), 3.23 – 3.14 (m, 1H), 3.07 (s, 3H), 1.28 (d, J = 7.1 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 203.1, 154.7, 154.3, 136.3, 133.6, 133.5, 132.6, 129.0, 128.5, 
123.7, 123.1, 50.6, 44.2, 38.1, 25.3, 14.9. 
HRMS: (ESI-TOF, m/z) calcd. For C18H20N3O3 [M+H]+ calc.: 326.1499; found: 326.1513.  
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IR: (ATR, neat, cm-1): 3058 (w), 1701 (s), 1677 (s), 1485 (m), 1447 (w), 1217 (w), 1405 (w), 1030 
(w), 974 (w), 917 (w), 801 (m), 770 (m), 757 (m), 725 (m), 687 (s), 665 (m), 630 (m). 
m.p.: 147–148 ºC.  
 
Synthesis of ()-3.13d (Table 3-8): Following the general procedure 4C, the 
title compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 
2:1 to 1:2) as a white solid (219.8 mg, 75%).  
Rf = 0.44 (n-hexane:EtOAc = 1:2, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.92 (br, 1H), 5.97 (ddd, J = 10.5, 3.2, 1.8 Hz, 
2H), 5.72 (ddd, J = 10.5, 3.5, 2.0 Hz, 2H), 5.22 (dtt, J = 8.7, 3.5, 1.8 Hz, 1H), 
3.70 (s, 3H), 3.06 (s, 3H), 3.07 – 2.99 (m, 1H), 1.21 (s, 6H). 
13C NMR: (125 MHz, CDCl3) δ 177.4, 154.8, 154.4, 131.5, 124.2, 52.3, 50.7, 45.7, 42.9, 25.3, 
23.1. 
HRMS: (ESI-TOF, m/z) calcd. For C14H20N3O4 [M+H]+ calc.: 294.1448; found: 294.1435.  
IR: (ATR, neat, cm-1): 3142 (w), 2947 (w), 1764 (m), 1732 (m), 1691 (s), 1486 (s), 1471 (m), 
1389 (w), 1243 (m), 1190 (m), 1155 (m), 1125 (s), 1101 (m), 1040 (m). 
m.p.: 150–151 ºC. 
 
7.4.3 Asymmetric dearomative syn-1,4-carboamination of arenes with ketones/esters  
General procedure 4D for the asymmetric dearomative syn-1,4-carboamination of arenes 




MTAD (1.57a, 56.6 mg, 0.5 mmol, 1.0 eq.) and naphthalene (1.2a, 128.0 mg, 1.0 mmol, 2.0 eq.) 
were placed in a test tube with a septum as the cap under nitrogen atmosphere. Propionitrile (4.0 
mL) was added to the test tube at rt, and the mixture was stirred until both MTAD and the 
naphthalene were completely dissolved. The resulting pink solution was stirred under irradiation 
with LED lights at –50 ºC until the solution became white suspension. In a separate flask, a fresh 
solution of LDA was prepared from diisopropylamine (0.14 mL, 1.0 mmol, 1.0 eq.) in THF (0.5 
mL) and n-BuLi (0.6 mL, 0.95 mmol, 1.9 eq., 1.6 M solution in hexane) under nitrogen atmosphere 
at 0 ºC. After stirring for 15 min, the LDA solution was cooled to –78 ºC, and ketone/ester (2.0 
mmol, 2.0 eq.) dissolved in THF (0.5 mL) was added dropwise. The resulting solution was stirred 
at –78 ºC for 10 min, then at 0 ºC for 30 min until the white suspension became light-yellow 
solution, and cannulated into the solution of cycloadduct (at this point the LED lights were turned 
off).  
For ketone: Pd(dba)2 (14.4 mg, 0.025 mmol, 5.0 mol%) and (S, SP)-tBu-Phosferrox (14.9 mg, 0.03 
mmol, 6.0 mol%) in THF (1.0 mL) was stirred at rt for 1 h. The resulting orange solution was pre-
cooled to –50 ºC, and then added to the mixture of cycloadduct and enolate. The reaction was then 
warmed from –50 ºC to 0 ºC over 5 h. 
For ester: [Pd(allyl)Cl]2 (4.6 mg, 0.013 mmol, 5.0 mol%) and (R)-DTBM-SEGPHOS (35.4 mg, 
0.03 mmol, 6.0 mol%) in THF (1.0 mL) was stirred at rt for 1 h. The resulting yellow solution was 
pre-cooled to –50 ºC, and then added to the mixture of cycloadduct and enolate. The reaction was 
then warmed from –50 ºC to 0 ºC over 5 h. 
Work-up: The reaction was then quenched with saturated aqueous NH4Cl (3.0 mL), and EtOAc 
(10.0 mL) and water (10 mL) were added. Aqueous HCl solution (1 M, 3.0 mL) was added to 
acidify the solution to pH~5 and the organic phase was separated. The aqueous phase was extracted 
with EtOAc (3 × 10 mL), then the combined organic extracts were washed with saturated aqueous 
sodium chloride solution (10 mL), dried over anhydrous magnesium sulfate, and concentrated 
under reduced pressure. The product was purified by flash column chromatography (SiO2, n-




Synthesis of 3.1a (Table 3-10): Following the general procedure D, the 
title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (146.7 mg, 75%). 
Enantiomeric excess was determined with HPLC analysis using Diacel 
Chiracel® OJ-3 column, 15% iPrOH in n-hexane, 1.5 mL/min. 95:5 er, 
tR(major) = 15.7 min, tR(minor) = 21.8 min. [α]D20 = +2.5 (c = 1.00 in 
CHCl3) 
 
Synthesis of 3.1h (Table 3-10): Following the general procedure D, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 
to 1:1) as a white solid (112.5 mg, 60%, dr>20:1). Enantiomeric excess was 
determined with HPLC analysis using Diacel Chiracel® OJ-3 column, 20% 
iPrOH in n-hexane, 0.5 mL/min. 82:18 er, tR(major) = 26.7 min, tR(minor) = 
29.3 min. [α]D23 = –0.8 (c = 1.00 in CHCl3) 
 
Synthesis of 3.1o (Table 3-10): Following the general procedure D, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 
to 1:1) as a white solid (73.8 mg, 45%). Enantiomeric excess was determined 
with HPLC analysis using Diacel Chiracel® IC-30 column, 20% iPrOH in n-
hexane, 0.8 mL/min. 94:6 er, tR(major) = 13.6 min, tR(major) = 20.5 min. 
[α]D21 = –0.9 (c = 0.38 in CHCl3) 
 
Synthesis of 3.1p (Table 3-10): Following the general procedure D, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 
to 1:1) as a white solid (126.0 mg, 68%). Enantiomeric excess was determined 
with HPLC analysis using Diacel Chiracel® IC-3 column, 20% iPrOH in n-
hexane, 0.8 mL/min. 97:3 er, tR(major) = 14.4 min, tR(minor) = 23.2 min. 
Absolute stereochemistry of the two chiral centers were determined by x-ray 
analysis. [α]D22 = –0.9 (c = 1.00 in CHCl3) 
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Synthesis of 3.1w (Table 3-12): Following the general procedure D, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 
to 1:1) as a white solid (104.7 mg, 61%). Enantiomeric excess was determined 
with HPLC analysis using Diacel Chiracel® IC-30 column, 30% iPrOH in n-
hexane, 0.8 mL/min. 95:5, tR(major) = 10.6 min, tR(major) = 18.6 min. [α]D21 = 
–0.5 (c = 1.00 in CHCl3) 
 
Synthesis of 3.1x (Table 3-12): Following the general procedure D, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 
to 1:1) as a white solid (143.5 mg, 72%). Enantiomeric excess was determined 
with HPLC analysis using Diacel Chiracel® IC-30 column, 20% iPrOH in n-
hexane, 0.8 mL/min. 95:5 er, tR(major) = 11.8 min, tR(minor) = 14.8 min. [α]D22 
= –1.1 (c = 1.00 in CHCl3) 
 
7.4.4 Derivatization of product ()-3.1o 
Synthesis of compound ()-3.18 (Table 3-13): 
 
Compound ()-3.1o (1.0 g, 3.0 mmol, 1.0 eq.) and Rh/Al2O3 (232 mg, 10 wt%, 0.15 mmol, 5.0 
mol%) in EtOAc (30 mL) were stirred at rt under hydrogen atmosphere for 12 h. The mixture was 
passed through a plug of celite, and then concentrated under reduced pressure. The resulting 
residue was purified by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) to afford compound 




Rf = 0.27 (n-hexane:EtOAc = 1:2, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.26 – 7.16 (m, 3H), 7.15 (d, J = 7.5 Hz, 1H), 
7.12 (br, 1H), 5.35 (dd, J = 8.2, 5.8 Hz, 1H), 3.44 – 3.36 (m, 1H), 3.12 (s, 
3H), 3.05 (dd, J = 18.0, 8.9 Hz, 1H), 2.73 (dd, J = 18.0, 4.4 Hz, 1H), 2.57 
(hept, J = 6.9 Hz, 1H), 2.09 – 1.88 (m, 3H), 1.88 – 1.77 (m, 1H), 1.09 (d, J = 
6.9 Hz, 3H), 1.08 (d, J = 6.9 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 213.5, 154.8, 154.3, 141.9, 132.2, 128.9, 128.6, 127.8, 127.1, 
55.2, 46.8, 41.4, 32.5, 25.4, 25.3, 22.9, 18.3, 18.2. 
HRMS: (ESI-TOF, m/z) calcd. For C18H24N3O3 [M+H]+ calc.: 330.1812; found: 330.1827.  
IR: (ATR, neat, cm-1): 2970 (w), 1758 (w), 1682 (s), 1480 (m), 1364 (w), 1275 (w), 1060 (w), 
1009 (w), 809 (w), 762 9m), 749 (m), 716 (m), 630 (w), 601 (w). 
m.p.: 161–162 ºC.  
 
Synthesis of compound ()-3.19 (Table 3-13): 
 
Compound ()-3.1o (33.0 mg, 0.10 mmol, 1.0 eq.) and Pd/C (10.6 mg, 5 wt%, 0.005 mmol, 5.0 
mol%) in methanol (1.0 mL, 0.1 M) were stirred at rt under hydrogen atmosphere for 12 h. The 
mixture was passed through a plug of celite, and then concentrated under reduced pressure. The 
resulting residue was purified by flash chromatography (SiO2, n-hexane:EtOAc = 10:1) to afford 




Rf = 0.38 (n-hexane:EtOAc = 10:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.15 – 7.04 (m, 4H), 3.51 – 3.42 (m, 1H), 
2.85 – 2.68 (m, 4H), 2.58 (hept, J = 6.9 Hz, 1H), 1.93 – 1.84 (m, 1H), 1.84 
– 1.69 (m, 2H), 1.60 – 1.52 (m, 1H), 1.11 (d, J = 6.9 Hz, 3H), 1.10 (d, J = 
6.9 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 213.9, 140.3, 137.3, 129.4, 128.4, 125.9 (overlap of 2 peaks 
detected by HSQC), 48.3, 41.5, 33.1, 29.7, 28.5, 19.8, 18.3, 18.2. 
HRMS: (ESI-TOF, m/z) calcd. For C15H24NO [M+NH4]+ calc.: 234.1852; found: 234.1863.  
IR: (ATR, neat, cm-1): 2930 (m), 2870 (w), 1709 (s), 1490 (m), 1451 (m), 1382 (w), 1356 (w), 
1091 (w), 1043 (m), 1009 (w), 929 (w), 751 (s), 728 (m), 543 (w). 
 
Synthesis of compound ()-3.22 (Table 3-14): 
Compound ()-3.1o (33.0 mg, 0.10 mmol, 1.0 eq.) and 4-methylmorpholine N-oxide (23.0 mg, 
0.20 mmol, 2.0 eq.) were dissolved in acetone (1.0 mL) and water (36 μL, 2.0 mmol, 20 eq.). To 
this solution was dropwise added osmium tetroxide (25 μL, 0.2 M solution in acetonitrile, 0.005 
mmol, 5.0 mol%) and the resulting solution was stirred at rt for 12 h. Then the reaction was 
quenched with saturated aqueous sodium thiosulfate solution (0.5 mL) and diluted with EtOAc 
(2.0 mL) and water (2.0 mL). Aqueous HCl solution (1 M) was added to acidify the solution to 
pH~5 and the organic phase was separated. The aqueous layer was extracted with EtOAc (3 × 2.0 
mL), the combined organic extracts were washed with saturated aqueous sodium chloride solution 
(5.0 mL), dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The 
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crude residue was purified by flash column chromatography (SiO2, CH2Cl2:MeOH=15:1 to 10:1) 
to afford the compound ()-3.23 as a white solid (31.5 mg, 87%).  
 
Rf = 0.21 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CD3OD) δ 7.26 – 7.21 (m, 3H), 7.22 – 7.15 (m, 1H), 
5.44 (d, J = 9.9 Hz, 1H), 4.21 (dd, J = 9.9, 2.2 Hz, 1H), 4.00 (dd, J = 2.5, 2.2 
Hz, 1H), 3.67 (ddd, J = 8.4, 5.5, 2.5 Hz, 1H), 3.10 (s, 3H), 2.89 (dd, J = 18.0, 
8.4 Hz, 1H), 2.81 (dd, J = 18.0, 5.5 Hz, 1H), 2.64 (hept, J = 6.9 Hz, 1H), 1.10 
(d, J = 6.9 Hz, 3H), 1.07 (d, J = 6.9 Hz, 3H). 
13C NMR: (125 MHz, CD3OD) δ 214.5, 157.0, 156.0, 139.9, 133.3, 130.7, 129.3, 127.9, 127.6, 
74.2, 68.0, 59.8, 47.9, 42.6, 42.1, 25.4, 18.5, 18.3. 
HRMS: (ESI-TOF, m/z) calcd. For C18H24N3O5 [M+H]+ calc.: 362.1711; found: 362.1702.  
IR: (ATR, neat, cm-1): 3364 (w), 1711 (m), 1713 (m), 1668 (s), 1489 (m), 1242 (w), 1050 (w), 
1021 (m), 759 (m), 731 (m), 639 (m), 544 (m). 
m.p.: 183–184 ºC.  





Synthesis of compound ()-3.24 (Table 3–15): 
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To a solution of Et2Zn (0.31 mL, 0.31 mmol, 2.0 eq., 1.0 M solution in hexane) in DCM (0.8 mL) 
was added the chloroiodomethane (45 µL, 0.61 mmol, 4.0 eq.) at –10 ºC, and stirred at –10 ºC for 
15 min. Then, compound ()-3.1o (50.0 mg, 0.15 mmol, 1.0 eq.) in DCM (0.8 mL) was dropwisely 
added to the resulting white suspension, and further stirred at –10 ºC for 24 h. The reaction was 
quenched with saturated aqueous NH4Cl (2.0 mL). The aqueous HCl solution (1 M, 0.5 mL) was 
added to acidify the solution to pH~5, then the organic phase was separated. The aqueous phase 
was extracted with EtOAc (3 × 10 mL), then the combined organic layer was washed with saturated 
aqueous sodium chloride solution (10 mL), dried over anhydrous magnesium sulfate, and 
concentrated in vacuo. The resulting residue was purified by flash chromatography (SiO2, n-
hexane:Et2O = 5:1 to Et2O) to afford compound ()-3.24 as a white solid (33.4 mg, 64%). 
 
Rf = 0.24 (Et2O, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.27 – 7.19 (m, 2H), 7.07 (d, J = 7.7 Hz, 1H), 
7.02 (d, J = 7.2 Hz, 1H),  5.76 (d, J = 3.9 Hz, 1H), 3.68 (ddd, J = 8.6, 4.5, 4.5 
Hz, 1H), 3.21 – 3.13 (m, 4H), 2.82 (dd, J = 17.1, 8.6 Hz, 1H), 2.75 (hept, J = 
7.0 Hz, 1H), 1.52 – 1.43 (m, 1H), 1.45 – 1.36 (m, 1H), 1.20 (d, J = 7.0 Hz, 3H), 
1.19 (d, J = 7.0 Hz, 3H), 0.49 (td, J = 8.0, 5.3 Hz, 1H), 0.31 (q, J = 5.1 Hz, 1H). 
13C NMR: (125 MHz, CDCl3) δ 213.8, 154.9, 153.8, 136.3, 130.4, 128.1, 127.0, 126.1, 125.3, 
54.2, 44.6, 41.6, 31.4, 25.3, 18.4, 18.3, 13.6, 13.5, 2.1 
HRMS: (ESI-TOF, m/z) calcd. For C19H24N3O3 [M+H]+ calc.: 342.1818; found: 342.1819.  
IR: (ATR, neat, cm-1): 1760 (w), 1702 (w), 1676 (s), 1485 (w), 1464 (w), 1451 (w), 1367 (w), 
1023 (w), 821 (w), 756 (m), 733 (w), 723 (m), 623 (w). 
m.p.: 178–179 ºC. 
 





Synthesis of compound ()-3.26 (Scheme 3-6): 
 
A mixture of ()-3.18 (50.0 mg, 0.15 mmol, 1.0 eq.), ethylene glycol (25 µL, 0.43 mmol, 3.0 eq.), 
p-toluenesulfonic acid monohydrate (2.9 mg, 0.015 mmol, 10 mol%) in toluene (1.5 mL) was 
refluxed for 5 h. After cooling the mixture to rt, saturated aqueous sodium bicarbonate solution (1 
mL) and water (2.0 mL) were added, and organic phase was separated. Aqueous layer was 
extracted with EtOAc (3 × 2.0 mL), the combined organic extracts were washed with saturated 
aqueous sodium chloride solution (3.0 mL), dried over anhydrous magnesium sulfate, and 
concentrated under reduced pressure. The resulting residue was purified by flash chromatography 
(SiO2, n-hexane:EtOAc = 1:1) to afford compound ()-3.26 as a white solid (48.0 mg, 85%). 
 
Rf = 0.47 (n-hexane:EtOAc = 1:2, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.26 – 7.22 (m, 3H), 7.20 – 7.15 (m, 1H), 6.58 
(br, 1H), 5.33 (dd, J = 10.1, 6.5 Hz, 1H), 4.08 – 3.80 (m, 4H), 3.12 (s, 3H), 
3.08 – 2.99 (m, 1H), 2.20 – 2.11 (m, 1H), 2.08 – 1.93 (m, 4H), 1.89 – 1.81 (m, 
2H), 0.99 (d, J = 6.8 Hz, 3H), 0.94 (d, J = 6.8 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.1, 154.7, 144.5, 132.3, 130.3, 128.3, 
126.7, 126.6, 114.0, 65.4, 65.1, 55.6, 39.8, 34.7, 32.5, 25.6, 25.3, 21.4, 17.7, 17.2. 
HRMS: (ESI-TOF, m/z) calcd. For C20H31N4O4 [M+NH4]+ calc.: 391.2339; found: 391.2333.  
IR: (ATR, neat, cm-1): 2950 (w), 1765 (w), 1674 (s), 1486 (w), 1364 (w), 1211 (w), 1107 (w), 
1083 (w), 1030 (w), 1008 (w), 948 (w), 760 (m), 744 (w), 711 (w), 617 (w). 
m.p.: 210–211 ºC. 
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Synthesis of compound ()-3.28 (Scheme 3-7): 
 
Alkylation of urazole: NaH (21.2 mg, 0.88 mmol, 1.1 eq., 95% purity) was suspended in DMF 
(4.0 mL) under nitrogen atmosphere at 0 ºC and a solution of compound ()-3.26 (300 mg, 0.80 
mmol, 1.0 eq.) in DMF (2.0 mL) was added dropwise. After stirring at 0 ºC for 1 h, a solution of 
2-bromoacetophenone (240 mg, 1.2 mmol, 1.5 eq.) in DMF (2.0 mL) was added, and the reaction 
was further stirred at rt for 12 h. The mixture was then quenched with saturated aqueous NH4Cl 
(2.0 mL) and water (20 mL). The resulting solution was extracted with Et2O (3 × 20 mL), the 
combined organic extracts were washed with saturated aqueous sodium chloride solution (20 mL), 
dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The crude 
residue was purified by flash column chromatography (SiO2, n-hexane:EtOAc = 3:1) to afford the 
compound ()-3.27 as a white solid (306.1 mg, 78%). 
Hydrolysis of urazole: A degassed mixture of compound ()-3.27 (100 mg, 0.20 mmol, 1.0 eq.) 
and potassium hydroxide (285 mg, 2.0 mmol, 10 eq., 90% purity) in methanol (2.0 mL, 0.1 M) in 
a pressure tube was heated at 80 ºC for 24 h and then at 160 ºC for 12 h under nitrogen atmosphere. 
After cooling the reaction to rt, water (2.0 mL) was added. The resulting solution was extracted 
with CH2Cl2 (3 × 2 mL), the combined organic extracts were washed with saturated aqueous 
sodium chloride solution (3 mL), dried over anhydrous magnesium sulfate, and concentrated under 
reduced pressure. The crude residue was purified by flash column chromatography (SiO2, 




Rf = 0.24 (n-hexane:EtOAc = 2:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.51 (t, J = 7.5 Hz, 1H), 7.39 (d, J = 
7.5 Hz, 2H), 7.32 (t, J = 7.5 Hz, 2H), 7.16 – 7.09 (m, 2H), 6.90 (t, J = 
7.4 Hz, 1H), 6.57 (dd, J = 7.5, 7.4 Hz, 1H), 5.51 – 5.38 (m, 1H), 4.72 
(d, J = 18.1 Hz, 1H), 4.13 (d, J = 18.1 Hz, 1H), 4.07 – 3.89 (m, 4H), 
3.23 (s, 3H), 3.06 – 2.94 (m, 1H), 2.22 – 2.00 (m, 4H), 1.94 – 1.79 (m, 
3H), 1.04 (d, J = 6.9 Hz, 3H), 0.97 (d, J = 6.8 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 191.8, 157.4, 156.3, 143.2, 134.1, 134.0, 133.7, 129.8, 128.7, 
127.8, 127.7, 127.5, 126.7, 113.8, 65.5, 65.3, 56.3, 52.7, 39.6, 34.6, 32.6, 26.0, 25.6, 20.9, 17.8, 
17.1. 
HRMS: (ESI-TOF, m/z) calcd. For C28H37N4O5 [M+NH4]+ calc.: 509.2758; found: 509.2741.  
IR: (ATR, neat, cm-1): 2939 (w), 1710 (s), 1694 (s), 1449 (m), 1226 (m), 1060 (w), 1001 (w), 755 
(m), 729 (m), 717 (m), 687 (m), 592 (m), 467 (w). 
 
Rf = 0.30 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.48 – 7.42 (m, 1H), 7.27 – 7.21 (m, 1H), 7.23 
– 7.13 (m, 2H), 4.06 – 3.91 (m, 5H), 3.02 – 2.90 (m, 1H), 2.36 (br, 2H), 2.05 – 
1.93 (m, 5H), 1.94 – 1.84 (m, 1H), 1.74 – 1.67 (m, 1H), 1.00 (d, J = 6.9 Hz, 3H), 
0.95 (d, J = 6.9 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 142.2, 140.3, 129.1, 127.4, 127.1, 126.1, 114.2, 65.4, 65.2, 50.1, 
40.6, 34.8, 33.1, 30.2, 26.2, 17.7, 17.2. 
HRMS: (ESI-TOF, m/z) calcd. For C17H29N2O2 [M+NH4]+ calc.: 293.2223; found: 293.2215.  
IR: (ATR, neat, cm-1): 2877 (br), 1738 (m), 1511 (w), 1366 (s), 1216 (m), 1159 (w), 1074 (s), 949 






Synthesis of compound ()-3.29 (Table 3-16): 
 
To a suspension of compound ()-3.28 (50.0 mg, 0.13 mmol, 1.0 eq.) in MeCN (2.7 mL, 0.05 M) 
was added bleach (1.0 mL) and the mixture was stirred for 5 min at 0 ºC. The reaction was 
quenched with saturated aqueous sodium thiosulfate solution (0.5 mL) and then diluted with 
EtOAc (2.0 mL) and water (2.0 mL). The organic phases were separated and the aqueous layer 
was extracted with EtOAc (3 × 2.0 mL). The combined organic extracts were washed with 
saturated aqueous sodium chloride solution (3.0 mL), dried over anhydrous magnesium sulfate, 
and concentrated under reduced pressure. The crude residue was purified by flash column 
chromatography (SiO2, n-hexane:EtOAc = 8:1) to afford the comound ()-3.29 (19.5 mg, 53%) as 
a colorless oil. 
 
Rf = 0.32 (n-hexane:EtOAc = 4:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.00 (dd, J = 7.5, 1.4 Hz, 1H), 7.49 (ddd, J = 
7.5, 7.4, 1.4 Hz, 1H), 7.33 (d, J = 7.5 Hz, 1H), 7.29 (ddd, J = 7.5, 7.4, 1.1 Hz, 
1H), 4.12 – 3.91 (m, 4H), 3.23 – 3.15 (m, 1H), 2.78 (ddd, J = 17.6, 12.0, 5.2 
Hz, 1H), 2.59 (ddd, J = 17.6, 4.7, 4.7 Hz, 1H), 2.32 – 2.17 (m, 2H), 2.10 – 2.00 
(m, 2H), 1.92 (dd, J = 15.0, 3.4 Hz, 1H), 1.00 (d, J = 6.9 Hz, 3H), 0.96 (d, J = 6.9 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 198.8, 149.5, 133.8, 132.1, 128.6, 127.3, 126.7, 113.8, 65.5, 65.1, 
37.5, 35.0, 34.6, 33.5, 27.3, 17.7, 17.1. 
HRMS: (ESI-TOF, m/z) calcd. For C17H26NO3 [M+NH4]+ calc.: 292.1907; found: 292.1914.  
IR: (ATR, neat, cm-1): 2963 (w), 1682 (s), 1597 (w), 1453 (w), 1286 (w), 1194 (w), 1157 (w), 
1089 (m), 1030 (w), 1009 (w), 764 (m), 734 (w). 
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Synthesis of compound ()-3.30 (Table 3-16): 
 
To a suspension of compound ()-3.29 (50.0 mg, 0.13 mmol, 1.0 eq.) in MeCN (2.7 mL, 0.05 M) 
was added t-butyl hypochlorite (38 µL, 2.5 eq.) and the resulting orange solution was stirred for 5 
min at rt. A solution of saturated aqueous sodium bicarbonate (1 mL) was added and the mixture 
was further stirred for 5 min. The reaction was quenched with saturated aqueous sodium thiosulfate 
solution (0.5 mL) and then diluted with EtOAc (2.0 mL) and water (2.0 mL). The organic phase 
was separated. The aqueous layer was extracted with EtOAc (3 × 2.0 mL), the combined organic 
extracts were washed with saturated aqueous sodium chloride solution (3.0 mL), dried over 
anhydrous magnesium sulfate, and concentrated under reduced pressure. The crude residue was 
purified by flash column chromatography (SiO2, n-hexane:EtOAc =8:1) to afford the compound 
()-3.30 as a colorless oil (31.7 mg, 77%, dr>20:1). 
 
Rf = 0.50 (n-hexane:EtOAc = 4:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.06 (dd, J = 7.9, 1.5 Hz, 1H), 7.58 – 7.52 (m, 
1H), 7.38 – 7.31 (m, 2H), 4.83 (dd, J = 10.6, 4.4 Hz, 1H), 4.13 – 3.89 (m, 4H), 
3.45 – 3.36 (m, 1H), 2.69 (ddd, J = 13.7, 4.8, 4.4 Hz, 1H), 2.59 (ddd, J = 13.7, 
10.6, 4.6 Hz, 1H), 2.13 – 1.95 (m, 3H), 1.01 (d, J = 6.9 Hz, 3H), 0.96 (d, J = 
6.9 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 191.6, 148.2, 134.5, 130.4, 128.5, 128.4, 127.1, 113.6, 65.6, 65.1, 
58.5, 38.1, 37.7, 34.7, 32.4, 17.7, 17.2. 
HRMS: (ESI-TOF, m/z) calcd. For C17H22O3Cl [M+H]+ calc.: 309.1257; found: 309.1269.  
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IR: (ATR, neat, cm-1): 2963 (w), 1695 (s), 1598 (w), 1452 (w), 1225 (m), 1158 (w), 1110 (m), 
1089 (s), 1014 (m), 948 (w), 860 (w), 803 (w), 782 (w), 753 (m), 620 (m), 527 (m). 






Synthesis of compound ()-3.31 (Scheme 3-9): 
 
Compound ()-3.18 (50.0 mg, 0.15 mmol, 1.0 eq.) was dissolved in a mixture of MeCN (1.5 mL), 
water (1.5 mL), and acetic acid (0.5 mL) at rt, and t-butyl hypochlorite (34 µL, 0.30 mmol, 2.0 
eq.) was added dropwise. The resulting yellow solution was stirred for 5 min, then quenched with 
saturated aqueous sodium thiosulfate solution (0.5 mL), and then diluted with EtOAc (2.0 mL) and 
water (2.0 mL). The organic phase was separated and the aqueous layer was extracted with EtOAc 
(3 × 2.0 mL), the combined organic extracts were washed with saturated aqueous sodium chloride 
solution (3.0 mL), dried over anhydrous magnesium sulfate, and concentrated under reduced 
pressure. The crude residue was purified by flash column chromatography (SiO2, n-hexane:EtOAc 




Rf = 0.29 (n-hexane:EtOAc = 4:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.03 (dd, J = 7.8, 1.4 Hz, 1H), 7.48 (dd, J = 
7.8, 7.5, 1.5 Hz, 1H), 7.32 (ddd, J = 7.8, 7.5, 1.4 Hz, 1H), 7.23 (d, J = 7.8 Hz, 
1H), 3.65 (ddd, J = 11.8, 6.8, 4.9 Hz, 1H), 2.87 – 2.83 (m, 2H), 2.75 – 2.52 (m, 
3H), 2.32 – 2.20 (m, 1H), 2.03 – 1.91 (m, 1H), 1.11 (d, J = 6.9 Hz, 3H), 1.08 
(d, J = 6.9 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 212.8, 198.0, 147.2, 133.9, 132.2, 128.0, 127.6, 127.1, 45.4, 41.6, 
35.3, 33.3, 27.7, 18.3, 18.1. 
HRMS: (ESI-TOF, m/z) calcd. For C15H18KO2 [M+K]+ calc.: 269.0938; found: 269.0942.  
IR: (ATR, neat, cm-1): 2967 (w), 2931 (w), 1707 (m), 1682 (s), 1598 (m), 1453 (m), 1361 (w), 
1287 (m), 1236 (w), 1032 (m), 951 (w), 765 (m), 562 (m). 
 
Synthesis of compound ()-3.33 (Scheme 3-9): 
 
Compound ()-S3.22 (40.0 mg, 0.11 mmol, 1.0 eq.) was dissolved in MeCN (2.2 mL, 0.05 M) at 
rt and bleach (1.0 mL) was added dropwise. After stirring the yellow solution for 5 min, the 
reaction was quenched with saturated aqueous sodium thiosulfate solution (0.5 mL), and then 
diluted with EtOAc (2.0 mL) and water (2.0 mL). The organic phase was separated. The aqueous 
layer was extracted with EtOAc (3 × 2.0 mL), the combined organic extracts were washed with 
saturated aqueous sodium chloride solution (3.0 mL), dried over anhydrous magnesium sulfate, 
and concentrated under reduced pressure. The crude residue was purified by flash column 
chromatography (SiO2, n-hexane:EtOAc = 10:1) to afford the compound ()-3.33 as a colorless 
oil (11.6 mg, 40%). 
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Rf = 0.30 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.01 (dd, J = 7.6, 1.3 Hz, 1H), 7.56 (ddd, J = 
7.6, 7.5, 1.3 Hz, 1H), 7.36 (dd, J = 7.6, 7.5 Hz, 1H), 7.30 (d, J = 7.5 Hz, 1H), 
4.57 (d, J = 2.6 Hz, 1H), 4.36 (dd, J = 2.6, 2.6 Hz, 1H), 4.03 (ddd, J = 7.9, 6.2, 
2.6 Hz, 1H), 3.94 (br, 1H), 2.95 (dd, J = 17.8, 7.9 Hz, 1H), 2.81 (dd, J = 17.8, 
6.2 Hz, 1H), 2.63 – 2.52 (m, 2H), 1.12 (d, J = 6.9 Hz, 3H), 1.08 (d, J = 6.9 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 211.2, 197.6, 144.3, 135.3, 129.9, 129.5, 127.5, 127.3, 74.3, 73.3, 
45.0, 41.5, 39.0, 18.3, 18.2. 
HRMS: (ESI-TOF, m/z) calcd. For C15H18NaO4 [M+Na]+ calc.: 285.1103; found: 285.1095.  
IR: (ATR, neat, cm-1): 3439 (br, w), 2969 (w), 1693 (s), 1601 (w), 1457 (w), 1280 (w), 1236 (w), 
1132 (m), 1092 (s), 1044 (m), 1000 (s), 936 (m), 762 (s), 723 (w), 578 (m). 
 
Synthesis of compound ()-3.34 (Scheme 3–9): 
 
To a suspension of compound ()-3.24 (25.0 mg, 0.06 mmol, 1.0 eq.) in MeCN (1.2 mL, 0.05 M) 
was added bleach (1.0 mL) and the mixture was stirred for 5 min at 0 ºC. The reaction was 
quenched with saturated aqueous sodium thiosulfate solution (0.5 mL) and then diluted with 
EtOAc (2.0 mL) and water (2.0 mL). The organic phases were separated and the aqueous layer 
was extracted with EtOAc (3 × 2.0 mL). The combined organic extracts were washed with 
saturated aqueous sodium chloride solution (3.0 mL), dried over anhydrous magnesium sulfate, 
and concentrated under reduced pressure. The crude residue was purified by flash column 
chromatography (SiO2, n-hexane:EtOAc = 4:1) to afford the compound ()-3.34 (5.8 mg, 33%) as 
a colorless oil. 
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Rf = 0.48 (n-hexane:EtOAc = 2:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.85 (dd, J = 7.6, 1.6 Hz, 1H), 7.43 (ddd, J = 7.8, 
7.7 1.6 Hz, 1H), 7.26 (ddd, J = 7.7, 7.6, 1.1 Hz, 1H), 7.07 (dd, J = 7.8, 1.1 Hz, 
1H), 3.87 (ddd, J = 9.1, 8.6, 4.7 Hz, 1H), 3.17 (dd, J = 17.4, 4.7 Hz, 1H), 2.88 
(dd, J = 17.4, 8.6 Hz, 1H), 2.70 (hept, J = 7.2 Hz, 1H), 2.14 (ddd, J = 9.1, 7.6, 
4.3 Hz, 1H), 1.92 (ddd, J = 7.6, 6.3, 4.9 Hz, 1H), 1.15 (d, J = 7.2 Hz, 3H), 1.14 (d, J = 7.2 Hz, 3H) 
1.04 (dd, J = 6.7, 5.6 Hz, 1H), 0.68 (dd, J = 6.7, 6.3, 4.3 Hz, 1H).  
13C NMR: (125 MHz, CDCl3) δ 213.3, 197.7, 140.7, 133.5, 131.0, 127.8, 127.2, 126.1, 44.8, 41.7, 
30.7, 26.0, 19.3, 18.5, 18.3, 11.5. 
HRMS: (ESI-TOF, m/z) calcd. For C16H19O2 [M+H]+ calc.: 243.1385; found: 243.1385.  
IR: (ATR, neat, cm-1): 2968 (w), 1709 (m), 1668 (s), 1454 (w), 1356 (w), 1290 (w), 1265 (w), 
1088 (w), 958 (w), 757 (m), 727 (m), 542 (w). 





7.5 Experimental procedures for Chapter 4 
7.5.1 Dearomative syn-1,4-carboamination of mononuclear arenes with Grignard reagents 
General procedure 4A for the dearomative syn-1,4-carboamination of benzene with 




MTAD (1.57a, 56.7 mg, 0.5 mmol, 1.0 eq.) was placed in a test tube with a septum as the cap 
under nitrogen atmosphere. Dichloromethane (2.5 mL, 0.2 M) was added to the test tube at rt, and 
cooled to –78 ºC. Benzene (1.1a, 0.45 mL, 5.0 mmol, 10 eq.) was added dropwise at –78 ºC, and 
the resulting pink solution was stirred under irradiation with LED lights at –78 ºC until the solution 
became colorless (approximately 12 h). To this solution were added Grignard reagent (0.75 mmol, 
1.5 eq., see below for detail) and a solution of Pd(dba)2 (14.4 mg, 0.025 mmol, 5.0 mol%) and P(o-
MeC6H4)3 (18.3 mg, 0.06 mmol, 12 mol%) in THF (1.0 mL, pre-stirred at rt until completely 
dissolved), and the resulting mixture was warmed from –50 ºC to 15 ºC over 10 h. The reaction 
was then quenched with saturated aqueous NH4Cl (3.0 mL), and DCM (5 mL) and water (5 mL) 
were added. Aqueous HCl solution (1 M, 3.0 mL) was added to acidify the solution to pH~5, and 
the organic phase was separated. The aqueous phase was extracted with DCM (3 × 5 mL), then 
the combined organic extracts were washed with saturated aqueous sodium chloride solution (5 
mL), dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The 
product was purified by flash column chromatography (SiO2, n-hexane:EtOAc mixture). 
 
For mono-substituted benzene, DPEPhos (16.2 mg, 0.03 mmol, 6.0 mol%) was used as ligand 
instead of P(o-MeC6H4)3 with otherwise identical conditions. 
For the following Grignard reagents, commercially available solutions were used.  
 • PhMgBr (3.0 M in Et2O) 
 • Vinylmagnesiumbromide (0.7 M in THF) 
 • Allylmagnesiumbromide (1.0 M in Et2O) 
 • methylmagnesiumbromide (3.0 M in Et2O) 
 • cyclopentylmagnesiumbromide (2.0 M in Et2O) 
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Other Grignard reagents were prepared according to the following procedure:  
 Magnesium (2.0 eq.) was placed in a flask equipped with reflux condenser under nitrogen, 
and small amount of I2 was added. Upon adding dibromoethane (50 µL) and THF (2 mL, 2.0 M), 
organobromide (1.0 eq.) was dropwisely added while keeping the reaction mixture close to 
refluxing, then further stirred at 70 ºC for 1 h. After cooling down to rt, the resulting Grignard 
reagent (2.0 M in THF, 1.5 eq.) was added to the solution of cycloadduct at –78 ºC. 
 
Synthesis of 4.2a (Table 4-4): Following the general procedure 4A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) 
as a white solid (100.9 mg, 75%).  
Rf = 0.34 (n-hexane:EtOAc = 1:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.33 (s, 1H), 7.32 – 7.16 (m, 5H), 6.11 (ddd, J = 
10.3, 3.4, 1.9 Hz, 2H), 5.74 (ddd, J = 10.3, 3.4, 2.0 Hz, 2H), 5.30 (dtt, J = 8.6, 
3.4, 1.9 Hz, 1H), 3.98 (dtt, J = 8.6, 3.4, 2.0 Hz, 1H), 3.00 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.6, 154.7, 141.7, 134.8, 128.8, 128.2, 127.1, 121.4, 50.6, 42.3, 
25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C15H15N3O2Na [M+Na]+ calc.: 292.1062; found: 292.1068.  
IR: (ATR, neat, cm-1): 1755 (w), 1683 (s), 1482 (m), 1453 (w), 1398 (w), 1028 (w), 847 (w), 764 
(m), 750 (s), 699 (s), 672 (w), 627 (w), 590 (w), 531 (w). 
m.p.: 153–154 ºC. 
 
Synthesis of 4.2b (Table 4-4): Following the general procedure 4A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) 
as a white solid (95.3 mg, 61%).  
Rf = 0.26 (n-hexane:EtOAc = 1:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.16 – 7.08 (m, 3H), 6.70 (d, J = 8.5 Hz, 2H), 
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6.10 (ddd, J = 10.2, 3.4, 1.7 Hz, 2H), 5.68 (ddd, J = 10.2, 3.4, 1.8 Hz, 2H), 5.32 – 5.24 (m, 1H), 
3.94 – 3.85 (m, 1H), 3.08 (s, 3H), 2.93 (s, 6H). 
13C NMR: (125 MHz, CDCl3) δ 155.3, 154.9, 149.9, 135.8, 129.3, 128.7, 120.7, 113.1, 50.7, 41.4, 
40.8, 25.4. 
HRMS: (ESI-TOF, m/z) calcd. For C17H21N4O2 [M+H]+ calc.: 313.1665; found: 313.1656.  
IR: (ATR, neat, cm-1): 1765 (w), 1680 (s), 1517 (m), 1479 (m), 1400 (w), 1218 (m), 1141 (m), 
906 (w), 859 (w), 823 (m), 768 (s), 721 (w), 670 (w), 609 (w), 556 (m), 534 (m), 503 (w). 
m.p.: 184–185 ºC. 
 
Synthesis of 4.2c (Table 4-4): Following the general procedure 4A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) 
as a white solid (61.3 mg, 41%).  
Rf = 0.30 (n-hexane:EtOAc = 1:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.21 (s, 1H), 7.16 (d, J = 8.6 Hz, 2H), 6.81 (d, J 
= 8.6 Hz, 2H), 6.08 (ddd, J = 10.2, 3.4, 1.9 Hz, 2H), 5.71 (ddd, J = 10.2, 3.4, 1.9 
Hz, 2H), 5.28 (dtt, J = 8.5, 3.4, 1.9 Hz, 1H), 3.96 – 3.86 (m, 2H), 3.76 (s, 3H), 
3.02 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 158.8, 155.5, 154.8, 135.2, 133.7, 129.1, 121.1, 114.3, 55.4, 50.7, 
41.5, 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C16H18N3O3 [M+H]+ calc.: 300.1348; found: 300.1350.  
IR: (ATR, neat, cm-1): 1770 (w), 1678 (s), 1509 (w), 1473 (s), 1448 (w), 1222 (w), 1029 (w), 909 
(w), 860 (m), 839 (m), 827 (w), 773 (m), 757 (s), 725 (m), 707 (w), 673 (w), 613 (m), 562 (m), 
507 (w). 




Synthesis of 4.2d (Table 4-4): Following the general procedure 4A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) 
as a white solid (94.5 mg, 67%).  
Rf = 0.40 (n-hexane:EtOAc = 1:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.20 – 7.07 (m, 5H), 6.09 (ddd, J = 10.3, 3.4, 1.8 
Hz, 2H), 5.76 (ddd, J = 10.3, 3.4, 1.8 Hz, 2H), 5.30 (dtt, J = 8.5, 3.4, 1.8 Hz, 1H), 
4.39 – 4.07 (m, 1H), 3.08 (s, 3H), 2.41 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.3, 154.9, 139.6, 135.4, 134.3, 130.8, 128.2, 127.1, 126.8, 
121.7, 50.6, 38.2, 25.4, 19.5. 
HRMS: (ESI-TOF, m/z) calcd. For C16H18N3O2 [M+H]+ calc.: 284.1399; found: 284.1398.  
IR: (ATR, neat, cm-1): 1765 (w), 1683 (s), 1480 (m), 1395 (w), 1346 (w), 1236 (w), 1035 (w), 909 
(w), 846 (m), 795 (w), 767 (m), 757 (s), 734 (m), 722 (m), 695 (w), 684 (m), 659 (w), 613 (m), 
556 (w), 456 (m). 
m.p.: 178–179 ºC. 
 
Synthesis of 4.2e (Table 4-4): Following the general procedure 4A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) 
as a white solid (119.5 mg, 71%).  
Rf = 0.43 (n-hexane:EtOAc = 1:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.99 (s, 1H), 7.64 (d, J = 7.9 Hz, 1H), 7.52 – 7.45 
(m, 2H), 7.37 – 7.30 (m, 1H), 6.34 (dd, J = 9.6, 5.5 Hz, 1H), 6.11 (ddd, J = 9.7, 
5.4, 1.6 Hz, 1H), 5.84 (dd, J = 9.6, 4.6 Hz, 1H), 5.72 – 5.59 (m, 1H), 5.20 – 4.94 (m, 1H), 4.08 – 
3.94 (m, 1H), 3.03 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.2, 153.4, 139.7, 132.5, 129.5, 129.4, 128.4, 127.8 (q, J = 29.5 
Hz), 127.5, 126.2 (q, J = 5.9 Hz), 124.5 (q, J = 274.0 Hz), 122.4, 120.7, 55.3, 39.8, 25.3. 
19F NMR: (471 MHz, CDCl3) δ –58.5. 
HRMS: (ESI-TOF, m/z) calcd. For C16H13F3N3O2 [M-H]+ calc.: 336.0906; found: 336.0953.  
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IR: (ATR, neat, cm-1): 1699 (s), 1452 (w), 1370 (w), 1310 (m), 1217 (w), 1160 (w), 1110 (s), 1036 
(m), 764 (m). 
m.p.: 101–102 ºC. 
 
Synthesis of 4.2f (Table 4-4): Following the general procedure 4A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) 
as a white solid (108.3 mg, 69%).  
Rf = 0.25 (n-hexane:EtOAc = 1:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.41 (s, 1H), 6.78 – 6.72 (m, 2H), 6.73 – 6.66 (m, 
1H), 6.07 (ddd, J = 10.3, 3.4, 1.8 Hz, 2H), 5.93 (s, 2H), 5.71 (ddd, J = 10.3, 3.4,  
1.8 Hz, 2H), 5.27 (dtt, J = 8.4, 3.4, 1.8 Hz, 1H), 3.90 (dtt, J = 8.6, 3.4, 1.8 Hz, 1H), 3.08 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.5, 155.0, 148.1, 146.7, 135.6, 135.0, 121.4, 121.2, 108.6 
(overlap of two peaks detected by HSQC), 101.2, 50.7, 41.9, 25.4.  
HRMS: (ESI-TOF, m/z) calcd. For C16H15NaN3O4 [M+Na]+ calc.: 336.0960; found: 336.0971.  
IR: (ATR, neat, cm-1): 3031 (w), 1764 (w), 1698 (s), 147 (m), 1440 (w), 1248 (w), 1222 (m), 1154 
(w), 1029 (m), 925 (w), 805 (w), 758 (m), 693 (w), 626 (w), 562 (w). 
m.p.: 222–223 ºC. 
 
Synthesis of 4.2g (Table 4-4): Following the general procedure 4A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) 
as a white solid (108.3 mg, 68%).  
Rf = 0.27 (n-hexane:EtOAc = 1:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.12 (d, J = 8.4 Hz, 1H), 7.88 (d, J = 8.0 Hz, 1H), 
7.85 (br, 1H), 7.73 (d, J = 7.6 Hz, 1H), 7.56 (ddd, J = 8.4, 6.8, 1.5 Hz, 1H), 7.51 (ddd, J = 8.1, 6.8, 
1.3 Hz, 1H), 7.43 – 7.35 (m, 2H), 6.27 (ddd, J = 10.2, 3.3, 1.9 Hz, 2H), 5.82 (ddd, J = 10.2, 3.4, 
2.0 Hz, 2H), 5.35 (dtt, J = 8.5, 3.4, 1.8 Hz, 1H), 4.85 – 4.76 (m, 1H), 2.99 (s, 3H). 
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13C NMR: (125 MHz, CDCl3) δ 155.4, 154.8, 137.5, 134.5, 134.2, 131.2, 129.3, 127.7, 126.5, 
125.9, 125.8 (overlap of two peaks detected from HSQC), 122.9, 121.9, 50.7, 37.5 (peak confirmed 
by HSQC), 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C19H17NaN3O2 [M+Na]+ calc.: 342.1218; found: 342.1215.  
IR: (ATR, neat, cm-1): 1765 (w), 1682 (s), 1484 (m), 1396 (w), 1250 (w), 1038 (w), 853 (w), 791 
(m), 780 (m), 760 (s), 719 (m), 695 (w), 659 (w), 614 (m), 598 (m), 566 (w), 547 (m). 
m.p.: 211–212 ºC. 
 
Synthesis of 4.2h (Table 4-4): Following the general procedure 4A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) 
as a white solid (56.5 mg, 46%).  
Rf = 0.48 (n-hexane:EtOAc = 1:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.30 (s, 1H), 5.93 (ddd, J = 10.2, 3.6, 1.6 Hz, 
2H), 5.61 (ddd, J = 10.2, 3.5, 1.7 Hz, 2H), 5.19 (dtt, J = 7.2, 3.5, 1.6 Hz, 1H), 4.89 – 4.79 (m, 1H), 
3.58 (dtt, J = 7.2, 3.6, 1.7 Hz, 1H), 3.08 (s, 3H), 1.71 (s, 3H), 1.70 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.1, 154.6, 135.3, 134.1, 124.1, 120.7, 50.5, 35.6, 25.8, 25.3, 
18.1. 
HRMS: (ESI-TOF, m/z) calcd. For C13H17NaN3O2 [M+Na]+ calc.: 270.1218; found: 270.1217.  
IR: (ATR, neat, cm-1): 1754 (w), 1702 (s), 1677 (s), 1487 (m), 1467 (m), 1404 (w), 1218 (w), 1031 
(w), 1000 (w), 899 (w), 766 (s), 727 (m), 699 (m), 684 (w), 629 (w), 603 (w), 589 (m). 
m.p.: 138–139 ºC. 
 
Synthesis of 4.2i (Table 4-4): Following the general procedure 4A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) 
as a white solid (65.5 mg, 56%).  
Rf = 0.37 (n-hexane:EtOAc = 1:1, KMnO4).  
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1H NMR: (500 MHz, CDCl3) δ 7.53 (br, 1H), 5.99 (ddd, J = 10.3, 3.3, 1.7 Hz, 2H), 5.69 (ddd, J 
= 10.3, 3.5, 1.9 Hz, 2H), 5.23 (dtt, J = 8.7, 3.5, 1.8 Hz, 1H), 4.86 – 4.83 (m, 2H), 3.42 – 3.25 (m, 
1H), 3.07 (s, 3H), 1.72 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.3, 154.7, 145.4, 134.2, 134.1, 122.3 (overlap of two peaks 
observed by HSQC), 112.8, 50.7, 44.0, 25.3, 20.6. 
HRMS: (ESI-TOF, m/z) calcd. For C12H16N3O2 [M+H]+ calc.: 234.1243; found: 234.1236.  
IR: (ATR, neat, cm-1): 1758 (m), 1693 (s), 1645 (m), 1478 (m), 1438 (w), 1400 (w), 1350 (w), 
1247 (w), 1164 (w), 1002 (w), 905 (s), 839 (m), 760 (s), 688 (m), 659 (w), 624 (m), 545 (s). 
m.p.: 167–168 ºC. 
 
Synthesis of 4.2j (Table 4-4): Following the general procedure 4A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) 
as a white solid (69.6 mg, 60%).  
Rf = 0.45 (n-hexane:EtOAc = 1:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 6.61 (s, 1H), 6.04 (ddd, J = 10.1, 3.3, 1.7 Hz, 
2H), 5.81 (ddt, J = 17.3, 10.2, 7.1 Hz, 1H), 5.64 (ddd, J = 10.1, 3.5, 1.9 Hz, 2H), 5.29 – 5.19 (m, 
1H), 5.17 – 5.04 (m, 2H), 3.09 (s, 3H), 2.89 – 2.80 (m, 1H), 2.33 – 2.23 (m, 2H). 
13C NMR: (125 MHz, CDCl3) δ 154.7, 154.5, 135.5, 135.4, 121.9, 117.8, 50.9, 39.1, 35.4, 25.4. 
HRMS: (ESI-TOF, m/z) calcd. For C12H15NaN3O2 [M+Na]+ calc.: 256.1062; found: 256.1067.  
IR: (ATR, neat, cm-1): 3157 (w), 1760 (w), 1685 (s), 1481 (s), 1401 (m), 1341 (w), 1220 (w), 1012 
(w), 912 (w), 828 (w), 790 (w), 750 (s), 703 (w), 675 (m), 618 (w), 588 (m), 524 (w). 




Synthesis of 4.2k (Table 4-4): Following the general procedure A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) 
as a white solid (74.8 mg, 72%).  
Rf = 0.33 (n-hexane:EtOAc = 1:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.69 (br, 1H), 6.01 (ddd, J = 10.2, 3.6, 1.7 Hz, 
2H), 5.58 (ddd, J = 10.2, 2.9, 1.7 Hz, 2H), 5.20 (ddt, J = 7.3, 3.6, 1.7 Hz, 1H), 3.07 (s, 3H), 2.87 – 
2.72 (m, 1H), 1.15 (d, J = 7.3 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.1, 154.5, 137.3, 120.7, 50.8, 30.7, 25.3, 20.5. 
HRMS: (ESI-TOF, m/z) calcd. For C10H13NaN3O2 [M+Na]+ calc.: 230.0905; found: 230.0915.  
IR: (ATR, neat, cm-1): 2965 (w), 1764 (w), 1677 (s), 1479 (m), 1397 (w), 1233 (w), 1018 (w), 904 
(w), 814 (m), 770 (m), 758 (s), 720 (w), 699 (w), 624 (m), 544 (m), 503 (w). 
m.p.: 124–125 ºC. 
 
Synthesis of 4.2l (Table 4-5): Following the general procedure 4A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) 
as a white solid (104.2 mg, 75%).  
Rf = 0.49 (n-hexane:EtOAc = 1:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.50 – 7.27 (br, 1H), 6.09 – 5.91 (m, 2H), 5.61 
(ddd, J = 10.3, 3.7, 1.6 Hz, 2H), 5.21 (dtt, J = 6.7, 3.2, 1.6 Hz, 1H), 3.07 (s, 3H), 2.81 – 2.46 (m, 
1H), 1.53 – 1.46 (m, 2H), 1.41 – 1.32 (m, 2H), 1.32 – 1.24 (m, 6H), 0.88 (t, J = 6.6 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.0, 154.5, 136.2, 121.3, 51.2, 35.6, 35.1, 31.9, 29.5, 26.9, 25.3, 
22.8, 14.2. 
HRMS: (ESI-TOF, m/z) calcd. For C15H23NaN3O2 [M+Na]+ calc.: 300.1688; found: 300.1686.  
IR: (ATR, neat, cm-1): 2924 (w), 1762 (w), 1693 (s), 1479 (m), 1400 (w), 1136 (w), 1124 (w), 
1020 (w), 762 (m), 718 (w), 690 (w), 629 (w), 565 (m), 528 (m), 490 (w). 




Synthesis of 4.2m (Table 4-4): Following the general procedure 4A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) 
as a white solid (70.5 mg, 54%).  
Rf = 0.48 (n-hexane:EtOAc = 1:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.32 (br, 1H), 6.09 (ddd, J = 10.4, 3.4, 1.7 Hz, 
2H), 5.63 (ddd, J = 10.4, 3.5, 1.8 Hz, 2H), 5.26 – 5.13 (m, 1H), 3.08 (s, 3H), 2.65 – 2.56 (m, 1H), 
1.87 – 1.73 (m, 3H), 1.61 (d, J = 6.3 Hz, 2H), 1.56 – 1.45 (m, 2H), 1.34 – 1.23 (m, 2H). 
13C NMR: (125 MHz, CDCl3) δ 155.1, 154.5, 135.5, 121.6, 51.3, 45.0, 40.5, 30.5, 25.5, 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C14H19NaN3O2 [M+Na]+ calc.: 284.1375; found: 284.1375.  
IR: (ATR, neat, cm-1): 2943 (w), 1763 (w), 1693 (s), 1477 (m), 1399 (w), 1226 (w), 1029 (w), 913 
(w), 797 (w), 766 (s), 725 (m), 671 (w), 628 (m), 525 (w). 
m.p.: 141–142 ºC. 
 
Synthesis of ()-4.4 (Table 4-5): Following the general procedure 4A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) 
as a white solid (99.2 mg, 61%).  
Rf = 0.56 (n-hexane:EtOAc = 1:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.37 (br, 1H), 7.32 – 7.25 (m, 4H), 7.24 – 7.20 
(m, 1H), 6.16 – 6.06 (m, 2H), 5.70 (ddd, J = 10.2, 4.0, 1.8 Hz, 1H), 5.54 – 5.49 
(m, 1H), 4.20 – 3.89 (m, 1H), 3.01 (s, 3H), 1.18 (s, 9H). 
13C NMR: (125 MHz, CDCl3) δ 150.0, 154.1, 141.7, 138.2, 133.2, 130.2, 128.9, 128.1, 126.9, 
122.7, 50.7, 43.6, 35.5, 30.3, 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C19H24N3O2 [M+H]+ calc.: 326.1869; found: 326.1880.  
IR: (ATR, neat, cm-1): 3029 (w), 2956 (w), 1761 (w), 1684 (s), 1457 (m), 1453 (w), 1215 (w), 
1019 (w), 887 (w), 818 (w), 770 (m), 755 (m), 716 (w), 704 (w), 693 (m), 666 (w), 623 (w). 
m.p.: 187–188 ºC. 
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Synthesis of ()-4.5 (Table 4-5): Following the general procedure 4A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) 
as a white solid (71.2 mg, 46%).  
Rf = 0.50 (n-hexane:EtOAc = 1:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.47 (br, 1H), 7.32 – 7.25 (m, 4H), 7.22 – 7.14 
(m, 1H), 6.17 – 6.03 (m, 1H), 5.98 – 5.84 (m, 1H), 5.71 (ddd, J = 10.0, 3.5, 2.0 
Hz, 1H), 5.46 – 5.32 (m, 1H), 4.17 – 3.81 (m, 1H), 2.98 (s, 3H), 2.29 (hept, J = 6.9 Hz, 1H), 1.12 
(d, J = 6.9 Hz, 3H), 1.10 (d, J = 6.9 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.4, 154.3, 142.3, 137.4, 134.1, 128.7, 128.2, 127.5, 126.9, 
122.0, 51.4, 43.2, 30.0, 25.2, 22.5, 20.5. 
HRMS: (ESI-TOF, m/z) calcd. For C18H22N3O2 [M+H]+ calc.: 312.1712; found: 312.1721.  
IR: (ATR, neat, cm-1): 2961 (w), 1764 (w), 1687 (s), 1478 (m), 1397 (w), 1266 (w), 1025 (w), 929 
(w), 764 (m), 733 (w), 700 (w), 609 (w). 
m.p.: 154–155 ºC. 







Synthesis of ()-4.6 (Table 4-5): Following the general procedure 4A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) 
as a white solid (95.0 mg, 53%).  
Rf = 0.58 (n-hexane:EtOAc = 1:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.66 (br, 1H), 7.35 – 7.26 (m, 4H), 7.21 (ddd, J 
= 8.5, 4.5, 2.7 Hz, 1H), 6.15 (dd, J = 4.4, 1.7 Hz, 1H), 6.11 (ddd, J = 9.8, 3.5, 
1.6 Hz, 1H), 5.63 (ddd, J = 9.8, 4.1, 1.8 Hz, 1H), 5.51 – 5.44 (m, 1H), 4.27 – 3.96 (m, 2H), 3.67 
(d, J = 11.0 Hz, 1H), 3.57 (d, J = 11.0 Hz, 1H), 3.00 (s, 3H), 1.31 (s, 3H), 1.27 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.1, 154.8, 141.2, 133.7, 133.3, 133.2, 128.8, 128.1, 127.0, 
122.0, 55.0, 51.2, 43.8, 40.8, 26.7, 25.8, 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C19H23N3O2Cl [M+H]+ calc.: 360.1479; found: 360.1489.  
IR: (ATR, neat, cm-1): 1766 (w), 1689 (s), 1478 (w), 1399 (w), 1215 (w), 1028 (w), 885 (w), 765 
(m), 729 (w), 702 (m), 614 (w), 485 (w). 
m.p.: 169–170 ºC. 






Synthesis of ()-4.7 (Table 4-5): Following the general procedure 4A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) 
as a white solid (94.8 mg, 55%).  
Rf = 0.48 (n-hexane:EtOAc = 1:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 9.03 (br, 1H), 7.29 (dd, J = 5.3, 2.0 Hz, 4H), 
7.24 (ddd, J = 7.0, 3.6, 2.0 Hz, 1H), 6.17 – 6.08 (m, 1H), 5.97 – 5.92 (m, 1H), 
5.75 (ddd, J = 10.0, 3.5, 2.0 Hz, 1H), 5.37 – 5.25 (m, 1H), 4.12 – 3.87 (m, 1H), 3.62 – 3.46 (m, 
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2H), 2.99 (s, 3H), 2.36 – 2.24 (m, 1H), 2.24 – 2.16 (m, 1H), 2.11 – 2.03 (m, 1H), 2.02 – 1.91 (m, 
1H). 
13C NMR: (125 MHz, CDCl3) δ 155.5, 154.4, 141.8, 134.1, 130.7, 130.1, 128.6, 128.2, 126.9, 
121.6, 52.0, 44.5, 43.1, 30.5, 29.8, 25.2. 
HRMS: (ESI-TOF, m/z) calcd. For C18H21N3O2Cl [M+H]+ calc.: 346.1322; found: 346.1331.  
IR: (ATR, neat, cm-1): 3027 (w), 2955 (w), 1685 (s), 1478 (m), 1452 (w), 1398 (w), 1026 (w), 761 
(m), 734 (w), 700 (m), 609 (w). 
m.p.: 127–128 ºC. 






Synthesis of ()-4.8 (Table 4-5): Following the general procedure 4A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 
3:1) as a white solid (122.0 mg, 65%).  
Rf = 0.10 (n-hexane:EtOAc = 3:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.64 (br, 1H), 7.31 – 7.23 (m, 4H), 7.25 – 7.18 
(m, 1H), 6.10 (ddd, J = 11.7, 3.4, 1.7 Hz, 1H), 6.00 – 5.94 (m, 1H), 5.70 (ddd, 
J = 10.0, 3.5, 2.0 Hz, 1H), 5.27 (ddd, J = 9.3, 3.4, 1.7 Hz, 1H), 4.07 – 4.02 (m, 1H), 3.64 – 3.50 
(m, 2H), 2.98 (s, 3H), 2.67 (dt, J = 14.4, 6.2 Hz, 1H), 2.59 (dt, J = 14.4 7.9 Hz, 1H). 
13C NMR: (125 MHz, CDCl3) δ 155.5, 154.6, 141.5, 134.2, 132.7, 128.8, 128.6, 128.2, 127.1, 
121.4, 51.9, 43.1, 36.6, 30.3, 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C17H19N3O2Br [M+H]+ calc.: 376.0661; found: 376.0656.  
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IR: (ATR, neat, cm-1): 3166 (w), 1761 (w), 1692 (s), 1473 (m), 1452 (m), 1398 (w), 1333 (w), 
1215 (W), 1122 (w), 1002 (w), 932 (w), 915 (w), 904 (w), 805 (w), 781 (w), 765 (s), 731 (m), 700 
(m), 689 (m), 606 (m), 591 (w). 
m.p.: 224–225 ºC. 







Synthesis of ()-4.9 (Table 4-5): Following the general procedure 4A, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) 
as a white solid (124.1 mg, 73%).  
Rf = 0.41 (n-hexane:EtOAc = 1:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.64 (br, 1H), 7.34 – 7.28 (m, 2H), 7.26 – 7.21 
(m, 3H), 6.37 (dd, J = 3.6, 1.8 Hz, 1H), 6.08 (ddd, J = 10.1, 3.6, 1.7 Hz, 1H), 
5.74 – 5.68 (m, 1H), 5.40 (ddd, J = 8.1, 3.3, 17 Hz, 1H), 4.05 – 3.68 (m, 1H), 3.02 (s, 3H), 0.12 (s, 
9H). 
13C NMR: (125 MHz, CDCl3) δ 155.1, 154.3, 144.0, 141.7, 133.4, 132.5, 128.94, 128.92, 128.29, 
128.27, 127.1, 122.5, 52.1, 43.1, 25.3, –1.4. 
HRMS: (ESI-TOF, m/z) calcd. For C14H19NaN3O2Si [M+Na]+ calc.: 364.1441; found: 364.1458.  
IR: (ATR, neat, cm-1): 1764 (w), 1685 (s), 1472 (m), 1247 (w), 1239 (w), 1017 (w), 840 (s), 820 
(w), 763 (m), 752 (m), 729 (w), 701 (m), 621 (m), 595 (w), 578 (w). 
m.p.: 127–128 ºC. 
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7.5.2 Dearomative syn-1,4-carboamination of polynuclear arenes with PhMgBr 
General procedure 4B for the dearomative syn-1,4-carboamination of naphthalene 
derivatives with PhMgBr (Table 4-6) 
 
For solid arene: MTAD (1.57a, 56.7 mg, 0.5 mmol, 1.0 eq.) and arene (1.2, 1.0 mmol, 2.0 eq.) 
were placed in a test tube with a septum as the cap under nitrogen atmosphere. Dichloromethane 
(5.0 mL, 0.1 M) was added to the test tube at rt, and the mixture was stirred until both MTAD and 
the naphthalene were completely dissolved.  
For liquid arene: MTAD (1.57a, 56.7 mg, 0.5 mmol, 1.0 eq.)  was dissolved in dichloromethane 
(4.0 mL) at rt under nitrogen atmosphere. Then a solution of arene (1.2, 1.0 mmol, 2.0 eq.) in 
dichloromethane (1.0 mL) was added. 
 
The resulting pink solution was stirred under irradiation with LED lights at –50 ºC until the 
solution became white suspension or colorless solution. To this solution were PhMgBr (3.0 M in 
Et2O, 0.75 mmol, 1.5 eq.) and a solution of Pd(dba)2 (14.4 mg, 0.025 mmol, 5.0 mol%) and dppf 
(16.6 mg, 0.03 mmol, 6.0 mol%) in THF (1.0 mL, pre-stirred at rt until completely dissolved), and 
the resulting mixture was warmed from –50 ºC to 15 ºC over 10 h. The reaction was then quenched 
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with saturated aqueous NH4Cl (3.0 mL), and DCM (5 mL) and water (5 mL) were added. Aqueous 
HCl solution (1 M, 3.0 mL) was added to acidify the solution to pH~5, and the organic phase was 
separated. The aqueous phase was extracted with DCM (3 × 5 mL), then the combined organic 
extracts were washed with saturated aqueous sodium chloride solution (5 mL), dried over 
anhydrous magnesium sulfate, and concentrated under reduced pressure. The product was purified 
by flash column chromatography (SiO2, n-hexane:EtOAc mixture). 
 
Synthesis of ()-4.3a (Table 4-6): Following the general procedure 4B, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 2:1) 
as a white solid (80.1 mg, 50%).  
Rf = 0.21 (n-hexane:EtOAc = 1:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.42 (dd, J = 7.7, 1.5 Hz, 1H), 7.31 – 7.23 (m, 
2H), 7.22 – 7.17 (m, 4H), 7.08 – 6.93 (m, 2H), 6.23 (ddd, J = 10.2, 3.6, 1.8 Hz, 
1H), 6.01 – 5.94 (m, 1H), 5.85 (ddd, J = 10.2, 3.6, 2.1 Hz, 1H), 4.66 – 4.51 (m, 1H), 3.07 (s, 10H). 
13C NMR: (125 MHz, CDCl3) δ 155.3, 155.0, 143.8, 138.5, 135.6, 130.4, 130.3, 128.91, 128.90, 
128.6, 127.9, 127.5, 127.0, 120.8, 52.9, 45.2, 25.4. 
HRMS: (ESI-TOF, m/z) calcd. For C19H18N3O2 [M+H]+ calc.: 320.1399; found: 320.1400.  
IR: (ATR, neat, cm-1): 3021 (w), 1758 (w), 1681 (s), 1483 (m), 1450 (m), 1266 (w), 1021 (w), 768 
(m), 747 (s), 703 (m), 628 (m), 605 (w), 565 (w), 507 (w). 
m.p.: 211–212 ºC. 
 
Synthesis of ()-4.14 (Table 4-6): Following the general procedure 4B, 
the title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 4:1) as a white solid (132.6 mg, 50%).  
Rf = 0.28 (n-hexane:EtOAc = 4:1, UV, KMnO4).  
1H NMR: 7.86 (s, 1H), 7.71 (s, 2H), 7.33 (t, J = 7.6 Hz, 1H), 7.28 (d, J = 
8.5 Hz, 2H), 7.25 (d, J = 1.4 Hz, 2H), 7.24 – 7.19 (m, 2H), 7.11 (d, J = 7.6 
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Hz, 1H), 7.06 (br, 1H), 6.23 (ddd, J = 10.2, 3.7, 1.6 Hz, 1H), 6.01 – 5.88 (m, 1H), 5.76 (ddd, J = 
10.2, 4.0, 1.9 Hz, 1H), 4.71 (dd, J = 4.2 Hz, 1H), 2.72 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.2, 152.1, 143.4, 142.8, 140.0, 139.6, 134.1, 131.8 (q, J = 33.3 
Hz), 131.1, 129.4, 129.1 (overlap of two peaks detected by HSQC), 128.82, 128.79, 128.51, 127.3, 
126.9, 123.4 (q, J = 272.8 Hz), 121.5 (q, J = 3.8 Hz), 120.8, 49.9, 45.6, 24.9. 
19F NMR: (470 MHz, CDCl3) δ –63.2. 
HRMS: (ESI-TOF, m/z) calcd. For C27H20N3O2F6 [M+H]+ calc.: 532.1460; found: 372.532.1454.  
IR: (ATR, neat, cm-1): 1764 (w), 1692 (s), 1482 (w), 1271 (s), 1189 (m), 1179 (w), 1166 (m), 1130 
(s), 1106 (w), 897 (w), 794 (m), 766 (w), 752 (w), 706 (s), 679 (w). 
m.p. 227–228 ºC. 




7.5.3 Synthesis of Sertraline (+)-4.22 
Synthesis of compound ()-4.3b (Scheme 4–5): 
 
Following the general procedure 4B, except Pd2(dba)3 (2.5 mol%) and DPEPhos (6 mol%) were 
used instead, the title compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 




Rf = 0.30 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.43 (d, J = 7.7 Hz, 1H), 7.37 – 7.27 (m, 4H), 
7.23 (dd, J = 7.7, 1.7 Hz, 1H), 7.05 (dd, J = 8.2, 2.1 Hz, 1H), 6.98 (d, J = 7.7 
Hz, 1H), 6.16 (ddd, J = 10.0, 3.5, 1.7 Hz, 1H), 5.99 – 5.79 (m, 2H), 4.64 – 4.48 
(m, 1H), 3.04 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.5, 155.2, 144.1, 137.3, 134.3, 132.9, 131.2, 
131.0, 130.8, 130.3, 130.1, 128.8, 128.3, 128.1, 128.0, 121.8, 52.9, 44.4, 25.4. 
HRMS: (ESI-TOF, m/z) calcd. For C19H16N3O2Cl2 [M+H]+ calc.: 388.0620; found: 388.0613.  
IR: (ATR, neat, cm-1): 3060 (w), 1679 (s), 1468 (m), 1028 (w), 981 (w), 800 (w), 776 (m), 756 
(s), 681 (w), 641 (m), 570 (w), 542 (w), 497 (w). 
m.p.: 100–101 ºC. 
 
Synthesis of compound ()-4.20 (Scheme 4–5): 
 
Hydrogenation: Compound (±)-4.3b (582.0 mg, 1.5 mmol, 1.0 eq.) and 5 wt% Rh/Al2O3 (233.0 
mg, 0.075 mmol, 5.0 mol%) in EtOAc (15 mL, 0.1 M) were stirred at rt under hydrogen 
atmosphere for 12 h. The mixture was passed through a plug of celite, and then concentrated under 
reduced pressure. The resulting residue was purified by flash chromatography (SiO2, n-
hexane:EtOAc = 1:1) to afford compound (±)-S4.1 as a white solid (585.4 mg, 98%). 
Alkylation: To a stirred solution of compound (±)-S4.1 (585.4 mg, 1.5 mmol, 1.0 equiv.) in CH2Cl2 
(15 mL, 0.1 M) under ambient atmosphere was added K2CO3 (1.04 g, 7.5 mmol, 5.0 equiv.) and 
2-bromoacetophenone (896.3 mg, 4.5 mmol, 3.00 equiv.). The resulting suspension was stirred 
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until full conversion (TLC monitoring) at 50 ºC. Upon completion, the mixture was added with 
NaHCO3 (sat. aq. 10 mL), and the organic phase was separated. The aqueous phase was extracted 
with CH2Cl2 (3 × 5 mL). The combined organic extracts were washed with brine (15 mL), dried 
over MgSO4, filtered and concentrated under reduced pressure. The resulting residue was purified 
by flash chromatography (SiO2, n-hexane:EtOAc = 4:1) to give the desired compound (±)-4.20 as 
a white solid (633.0 mg, 1.25 mmol, 83%). 
 
Rf = 0.18 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.45 (br, 1H), 7.37 (dd, J = 7.9, 1.2 Hz, 1H), 
7.33 – 7.28 (m, 2H), 7.25 – 7.22 (m, 1H), 7.16 (d, J = 2.1 Hz, 1H), 6.96 (dd, J 
= 7.9, 1.0 Hz, 1H), 6.87 (dd, J = 8.2, 2.1 Hz, 1H), 5.45 – 5.37 (m, 1H), 4.18 – 
4.11 (m, 1H), 3.07 (s, 3H), 2.28 – 2.17 (m, 1H), 2.08 – 1.99 (m, 1H), 2.01 – 1.88 
(m, 2H). 
13C NMR: (125 MHz, CDCl3) δ 155.5, 54.8, 146.3, 139.4, 133.2, 132.6, 131.1, 
130.9, 130.6, 130.4, 128.7, 128.3, 128.0, 127.5, 55.2, 43.5, 29.5, 25.4, 22.1. 
HRMS: (ESI-TOF, m/z) calcd. For C19H18N3O2Cl2 [M+ H]+ calc.: 390.0776; found: 390.0778.  
IR: (ATR, neat, cm-1): 3061 (w), 1765 (w), 1680 (s), 1468 (m), 1451 (m), 1396 (w), 1027 (w), 
1019 (w), 907 (w), 816 (w), 764 (w), 725 (s), 649 (w), 603 (w).  
m.p.: 103–104 ºC. 
 
Rf = 0.32 (n-hexane:EtOAc = 2:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.64 – 7.54 (m, 3H), 7.45 – 7.39 (m, 
3H), 7.28 (d, J = 7.9 Hz, 1H), 7.07 (s, 1H), 7.05 – 6.98 (m, 2H), 6.92 (d, 
J = 7.6 Hz, 1H), 6.78 (t, J = 7.8 Hz, 1H), 5.54 – 5.35 (m, 1H), 4.87 (d, J 
= 18.1 Hz, 1H), 4.32 (d, J = 18.1 Hz, 1H), 4.16 (dd, J = 4.7, 4.6 Hz, 1H), 
3.23 (s, 3H), 2.32 – 2.21 (m, 1H), 2.20 – 2.11 (m, 1H), 2.04 – 1.91 (m, 
1H), 1.89 – 1.79 (m, 1H). 
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13C NMR: (125 MHz, CDCl3) δ 191.5, 157.4, 156.3, 146.1, 137.6, 134.7, 134.1, 134.0, 132.4, 
130.9, 130.6, 130.6, 128.8 (two peaks overlap detected by HSQC), 127.9 (two peaks overlap 
detected by HSQC), 127.9, 127.7, 127.6 (three peaks overlap detected by HSQC), 56.3, 53.1, 42.9, 
29.6, 25.9, 22.0. 
HRMS: (ESI-TOF, m/z) calcd. For C27H24N3O3Cl2 [M+ H]+ calc.: 508.1195; found: 508.1182.  
IR: (ATR, neat, cm-1): 2940 (w), 1771 (m), 1711 (s), 1692 (s), 1467 (s), 1396 (m), 1224 (s), 1028 
(w), 990 (w), 747 (m), 735 (m), 686 (m).  
m.p.: 107–108 ºC. 
 
Synthesis of (±)-4.21 (Scheme 4–5): 
 
To a stirred solution of product (±)-4.20 (100.0 mg, 0.20 mmol, 1.0 equiv.) in isopropanol (0.7 
mL) under ambient atmosphere was added 40% KOH solution (0.7 mL, 2.0 mmol, 10.0 equiv). 
The resulting suspension was stirred at 80 ºC for 20 h. After cooling down to rt, NH4Cl (sat. aq. 2 
mL) was added. The organic phase was separated, and the aqueous phase was extracted with 
CH2Cl2 (3 × 2 mL). The combined organic extracts were washed with brine (10 mL), dried over 
MgSO4, filtered and concentrated under reduced pressure. The resulting residue was purified by 
flash chromatography (SiO2, n-hexane:EtOAc = 1:1 to 1:2) to give the desired compound (±)-4.21 




Rf = 0.23 (n-hexane:EtOAc = 1:2, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.41 (d, J = 7.8 Hz, 1H), 7.35 (d, J = 8.3 Hz, 
1H), 7.21 (t, J = 7.4 Hz, 1H), 7.17 – 7.11 (m, 2H), 6.94 (dd, J = 8.3, 1.8 Hz, 
1H), 6.81 (d, J = 7.8 Hz, 1H), 5.06 – 4.99 (m, 1H), 4.71 (d, J = 7.5 Hz, 1H), 
4.37 (q, J = 5.0 Hz, 1H), 4.02 (dd, J = 7.5, 7.0 Hz, 1H), 2.79 (d, J = 5.0 Hz, 
3H), 2.20 – 2.03 (m, 1H), 1.99 – 1.83 (m, 3H). 
13C NMR: (125 MHz, CDCl3) δ 158.2, 147.1, 138.6, 138., 132.5, 130.7, 
130.4, 130.4, 130.0, 129.3, 128.4, 127.8, 127.3, 48.6, 44.8, 29.4, 28.2, 27.4. 
HRMS: (ESI-TOF, m/z) calcd. For C18H19N2OCl [M+ H]+ calc.: 349.0874; found: 349.0868.  
IR: (ATR, neat, cm-1): 3292 (w), 2933 (w), 1739 (w), 1626 (s), 1567 (s), 1466 (m), 1254 (m), 1129 
(m), 1028 (m), 741 (m), 527 (w), 474 (w).  
m.p.: 224–225 ºC. 
 
Synthesis of sertraline (±)-4.22 (Scheme 4–5): 
 
LiAl(OMe)3H was prepared by adding MeOH (0.43 mL, 45.0 equiv.) to a suspension of LiAlH4 
(134.5 mg, 3.5mmol, 15.0 equiv.) in THF (15 mL) at 0 ºC under nitrogen atmosphere, and then 
stirred at rt for 3 h. To this solution was added compound (±)-4.21 (82.5 mg, 0.24 mmol, 1.0 equiv.) 
dissolved in THF (10 mL) at 0 °C. and the reaction was heated at 75 ºC for 20 h. After cooling, 
the reaction was quenched with saturated K2CO3 and Et2O (inverse addition at 0 °C), and the 
aqueous layer was extracted with EtOAc (3×15 mL). The organic layers were combined, washed 
with brine (30 mL), dried over Na2SO4, and concentrated. The resulting residue was purified by 
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flash chromatography (SiO2, CH2Cl2:MeOH = 30:1 to 15:1) to give the desired compound (±)-
4.22 as a white solid (47.0 mg, 65%). 
 
Rf = 0.42 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.40 (d, J = 8.1 Hz, 1H), 7.35 (d, J = 8.2 Hz, 
1H), 7.27 (d, J = 2.1 Hz, 1H), 7.21 (t, J = 7.6 Hz, 1H), 7.12 (td, J = 7.5, 1.5 Hz, 
1H), 7.00 (dd, J = 8.2, 2.1 Hz, 1H), 6.81 (d, J = 7.5 Hz, 1H), 3.99 (dd, J = 9.4, 
5.5 Hz, 1H), 3.80 (t, J = 4.2 Hz, 1H), 2.55 (s, 3H), 2.13 – 1.98 (m, 3H), 1.90 – 
1.81 (m, 1H). 
13C NMR: (125 MHz, CDCl3) δ 147.2, 138.8, 138.3, 132.3, 130.8, 130.3, 130.1, 129.9, 129.3, 
128.3, 127.5, 126.7, 57.2, 45.3, 33.8, 28.4, 25.4. 
Both 1H NMR and 13C NMR are in accordance with literature precedent.[140] 
 
7.6 Experimental procedures for Chapter 5 
7.6.1 Dearomative syn-1,4-diamination of naphthalene with amine 
General procedure 5A for the dearomative syn-1,4-diamination of naphthalene with amines 
(Table 5-5, Table 5-6) 
 
MTAD (1.57a, 56.7 mg, 0.50 mmol, 1.0 eq.) was combined with naphthalene (1.2a, 128 mg, 1.0 
mmol) and a stir bar in a test tube with a septum as the cap under nitrogen atmosphere. Ethyl 
acetate (5.0 mL, 0.1 M) was added to the test tube at rt, the contents were stirred until completely 
dissolved and then cooled to –50 ºC. The resulting pink solution was stirred under irradiation with 
LED lights at –50 ºC until the solution became colorless (approximately 6 h). After turning off the 
lights, to this solution at –50 ºC were added an amine (2.0 mmol, 2.0 eq.) and a solution of a Pd 
236 
 
complex in THF (2.0 mL) [primary amines: Pd2(dba)3 (11.4 mg, 0.0125 mmol, 2.5 mol%) and 
dppf (16.6 mg, 0.03 mmol, 6.0 mol%); secondary amines: Pd(PPh3)4 (57.8 mg, 0.05 mmol, 5.0 
mol%)], and the resulting mixture was stirred at –20 ºC for 20 h. The reaction was then warmed 
up to rt, concentrated under reduced pressure, and purified by flash column chromatography (SiO2, 
CH2Cl2:MeOH mixture). 
 
Synthesis of (±)-5.1a (Table 5-5): Following the general procedure 5A, the 
title compound was isolated by flash chromatography (SiO2, CH2Cl2 to 
CH2Cl2:MeOH = 50:1) as a white solid (112.3 mg, 62%).  
Rf = 0.43 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.56 (dd, J = 7.4, 1.5 Hz, 1H), 7.41 (dd, J = 
7.1, 1.8 Hz, 1H), 7.36-7.27 (m, 7H), 6.62 (ddd, J = 10.0, 4.4, 0.8 Hz, 1H), 6.21 
(ddd, J = 10.0, 4.4, 0.8 Hz, 1H), 5.89 (t, J = 3.8 Hz 1H), 4.07 (t, J = 3.8 Hz 1H), 3.80 (d, J = 12.9, 
1H), 3.73 (d, J = 12.9 Hz, 1H), 3.09 (s, 3H), 2.20 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 153.9, 153.4, 137.7, 137.0, 133.2, 132.2, 130.2, 129.3, 128.7, 
128.48, 128.47, 128.3, 127.7, 127.5, 59.5, 59.2, 51.9, 38.6, 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C21H23N4O2 [M+H]+ calc.: 363.1816; found: 363.1834.  
IR: (ATR, neat, cm-1): 3466 (w), 3029 (w), 2842 (w), 1763 (m), 1691 (s), 1476 (m), 1453 (m), 
1019 (m), 753 (m), 700 (m). 
m.p.: 135–136 ºC. 
 
Synthesis of (±)-5.1b (Table 5-5): Following the general procedure 5A (except 
that dichloromethane was used in replace of ethyl acetate), the title compound 
was isolated by flash chromatography (SiO2, EtOAc then CH2Cl2:MeOH = 
19:1 to 4:1) as a yellow solid (102.5 mg, 72%). 
Rf = 0.11 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.46 (d, J = 7.4 Hz, 1H), 7.34 (td, J = 7.4, 1.4 
Hz, 1H), 7.30 (td, J = 7.4, 1.4 Hz, 1H), 7.25 (t, J = 9.6 Hz, 1H), 6.62 (dd, J = 9.5, 5.5 Hz, 1H), 6.37 
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(dd, J = 9.5, 6.0 Hz, 1H), 5.92 (d, J = 6.0 Hz, 1H), 3.71 (d, J = 5.5 Hz, 1H), 3.02 (s, 3H), 2.46 (s, 
6H). 
13C NMR: (125 MHz, CDCl3) δ 153.1, 152.6, 136.1, 135.2, 134.5, 130.5, 130.0, 129.8, 129.1, 
127.8, 62.1, 51.2, 43.0, 25.1. 
HRMS: (ESI-TOF, m/z) calcd. For C15H19N4O2 [M+H]+ calc.: 287.1503; found: 287.1512.  
IR: (ATR, neat, cm-1): 3397 (w), 3054 (w), 1686 (s), 1602 (s), 1464 (s), 1392 (m), 1278 (m), 1149 
(m), 1017 (s), 914 (s), 756 (s), 634 (m), 537 (m). 
m.p.: 49–51 ºC decomposed. 
 
Synthesis of (±)-5.1c (Table 5-5): Following the general procedure 5A (except 
that dichloromethane was used in place of ethyl acetate), the title compound 
was isolated by flash chromatography (SiO2, CH2Cl2:MeOH (sat. with NH3) = 
19:1 to 4:1) as a white solid (106.5 mg, 68%).  
Rf = 0.21 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: 7.46 (d, J = 7.2 Hz, 1H), 7.34 (td, J = 7.3, 1.7 Hz, 1H), 7.30 (td, J = 
7.5, 1.6 Hz, 1H), 7.27 (d, J = 7.3 Hz, 1H), 6.58 (dd, J = 9.6, 5.4 Hz, 1H), 6.39 (dd, J = 9.6, 5.8 Hz, 
1H), 5.91 (d, J = 5.8, 1H), 4.14 (d, J = 5.4, 1H), 3.02 (s, 3H), 2.93-2.82 (m, 4H), 1.15 (t, J = 7.2 
Hz, 6H). 
13C NMR: (125 MHz, CDCl3) δ 153.2 (overlap of 2 peaks found by HSQC), 135.9, 135.8, 133.6, 
130.6, 130.3, 129.8, 129.0, 127.7, 56.4, 51.1, 42.2, 25.1, 9.5. 
HRMS: (ESI-TOF, m/z) calcd. For C17H23N4O2 [M+H]+ calc.: 315.1816; found: 315.1820.  
IR: (ATR, neat, cm-1): 3412 (w), 2985 (w), 1694 (s), 1605 (s), 1463 (s), 1392 (m), 1280 (m), 758 
(s). 




Synthesis of (±)-5.1d (Table 5-5): Following the general procedure 5A, the 
title compound was isolated by flash chromatography (SiO2, EtOAc then 
CH2Cl2:MeOH = 19:1 to 4:1) as a yellow solid (118.9 mg, 76%).  
Rf = 0.23 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.42 (dd, J = 7.4, 1.7 Hz, 1H), 7.30 (td, J = 7.4, 
1.6 Hz, 1H), 7.26 (td, J = 7.4, 1.6 Hz, 1H), 7.20 (dd, J = 7.4, 1.7 Hz, 1H), 6.55 
(dd, J = 9.4, 5.7 Hz, 1H), 6.34 (dd, J = 9.4, 6.1 Hz, 1H), 5.88 (d, J = 6.0 Hz, 1H), 3.84 (dd, J = 5.9, 
1.7 Hz, 1H), 2.94 (s, 3H), 2.89-2.86 (m, 2H), 2.65-2.62 (m, 2H), 1.93-1.85 (m, 4H). 
13C NMR: (125 MHz, CDCl3) δ 152.8, 152.7, 136.2, 135.2, 134.1, 129.9, 129.6, 129.3, 129.0, 
127.9, 60.1, 51.9, 50.8, 24.9, 22.8. 
HRMS: (ESI-TOF, m/z) calcd. For C17H21N4O2 [M+H]+ calc.: 313.1659; found: 313.1656  
IR: (ATR, neat, cm-1): 3406 (w), 2886 (w), 1683 (s), 1614 (s), 1459 (s), 1391 (m), 1275 (m), 1146 
(m), 922 (m), 755 (s), 726 (s), 631 (m), 530 (m). 
m.p.: 84–86 ºC. 
 
Synthesis of (±)-5.1e (Table 5-5): Following the general procedure 5A, the title 
compound was isolated by flash chromatography (C18 reverse phase SiO2, 
H2O:MeOH = 9:1 to 1:1) as a yellow solid (146.1 mg, 90%).  
Rf = 0.26 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.48 (dd, J = 7.5, 1.0 Hz, 1H), 7.35 (td, J = 7.5, 
1.4 Hz, 1H), 7.29 (td, J = 7.5, 1.4 Hz, 1H), 7.19 (d, J = 7.4 Hz, 1H), 6.67 (dd, 
J = 9.5, 5.7 Hz, 1H), 6.40 (dd, J = 9.5, 6.2 Hz, 1H), 5.94 (d, J = 6.2 Hz, 1H), 3.73 (d, J = 5.7 Hz, 
1H), 3.03 (s, 3H), 2.84 (br, 2H), 2.66 (br, 2H), 1.75 (p, J = 5.7 Hz, 4H), 1.54 (br, 2H). 
13C NMR: (125 MHz, CDCl3) δ 152.7, 152.5, 135.8, 135.7, 135.0, 131.0, 130.2, 130.1, 129.1, 
127.5, 61.6, 52.5, 50.9, 25.0, 24.9, 23.9. 
HRMS: (ESI-TOF, m/z) calcd. For C18H23N4O2 [M+H]+ calc.: 327.1816; found: 327.1834.  
IR: (ATR, neat, cm-1): 3401 (w), 2942 (w), 1688 (m), 1598 (s), 1461 (m), 1390 (m), 760 (m). 
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m.p.: 85–87 ºC decomposed. 
 
Synthesis of (±)-5.1f (Table 5-5): Following the general procedure 5A, the 
title compound was isolated by flash chromatography (SiO2, CH2Cl2:MeOH 
= 19:1 to 9:1) as a white solid (80.3 mg, 49%).  
Rf = 0.35 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.48 (dd, J = 7.4, 1.2 Hz, 1H), 7.36 (td, J = 
7.4, 1.5 Hz, 1H), 7.32 (td, J = 7.4, 1.5 Hz, 1H), 7.23 (dd, J = 7.6, 1.3 Hz, 1H), 
6.66 (dd, J = 9.6, 5.5 Hz, 1H), 6.38 (dd, J = 9.6, 6.0 Hz, 1H), 5.94 (d, J = 6.0 Hz, 1H), 3.80-3.76 
(m, 5H) 3.05 (s, 3H), 2.84 (br, 2H), 2.67 (dt, J = 10.7, 4.7 Hz, 2H). 
13C NMR: (125 MHz, CDCl3) δ 152.8, 152.1, 135.4, 135.0, 134.7, 130.9, 130.0, 129.7, 129.2, 
127.8, 66.3, 61.4, 51.8, 51.3, 25.1. 
HRMS: (ESI-TOF, m/z) calcd. For C17H21N4O3 [M+H]+ calc.: 329.1608; found: 329.1620.  
IR: (ATR, neat, cm-1): 3471 (w), 2853 (w), 1768 (w), 1699 (s), 1474 (m), 1115 (m), 758 (m). 
m.p.: 122–124 ºC decomposed.  
 
Synthesis of (±)-5.1g (Table 5-5): Following the general procedure 5A, 
except that 1-methylpiperazine was dissolved in 1 mL of DCM prior to 
addition to the reaction, the title compound was isolated by flash 
chromatography (two columns: SiO2, MeOH:CH2Cl2 = 10:90 to 20:80; C18 
reverse phase SiO2, H2O:MeCN = 80:20 to 0:100) as a white solid (115.8 mg, 
68%). 
Rf = 0.36 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.46 (dd, J = 7.4, 1.5 Hz, 1H), 7.37 – 7.28 (m, 2H), 7.23 (dd, J = 
7.4, 1.5 Hz, 1H), 6.66 (dd, J = 9.6, 5.4 Hz, 1H), 6.35 (dd, J = 9.6, 5.9 Hz, 1H), 5.92 (d, J = 5.9 Hz, 
1H), 3.74 (d, J = 5.4 Hz, 1H), 3.03 (s, 3H), 2.89 – 2.30 (m, 8H), 2.30 (s, 3H). 
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13C NMR: (125 MHz, CDCl3) δ 152.6, 152.3, 135.6, 134.9, 134.2, 130.4, 129.49, 129.46, 128.8, 
127.6, 60.7, 53.9, 50.9, 50.7, 45.5, 24.9. 
HRMS: (ESI-TOF, m/z) calcd. For C18H24N5O2 [M+H]+ calc.: 342.1925; found: 342.1926.  
IR: (ATR, neat, cm-1): 2941 (w), 2802 (w), 1763 (w), 1698 (s), 1598 (s), 1466 (s), 1393 (m), 1282 
(m), 1145 (m), 1011 (m), 983 (m), 755 (s), 733 (s). 
m.p.: 149–151 ºC decomposed. 
 
Synthesis of (±)-5.1h (Table 5-5): Following the general procedure 5A, the 
title compound was isolated by flash chromatography (SiO2, 
CH2Cl2:EtOAc:MeOH (sat. with NH3) = 5:4:1 to 9:0:1) as a white solid (142.0 
mg, 71%).  
Rf = 0.31 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.44 (dd, J = 7.4, 0.9 Hz, 1H), 7.33 (td, J = 
7.4, 1.5 Hz, 1H), 7.29 (td, J = 7.4, 1.5 Hz, 1H), 7.22 (dd, J = 7.4, 0.9 Hz, 1H), 
6.62 (dd, J = 9.6, 5.4 Hz, 1H), 6.33 (dd, J = 9.6, 5.9 Hz, 1H), 5.89 (d, J = 5.9 Hz, 1H), 4.13 (q, J = 
7.1 Hz, 2H), 3.75 (d, J = 5.4 Hz, 1H), 3.02 – 3.00 (m, 4H), 2.86 (br, 1H), 2.65 (br, 1H), 2.47-2.44 
(m, 4H), 2.01-1.89 (m, 2H), 1.24 (t, J = 7.1 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 174.1, 152.9, 152.4, 135.9, 135.0, 134.6, 130.8, 129.7, 129.4, 
128.9, 127.7, 61.0, 60.6, 51.2, 50.4, 49.8, 39.5 (br), 27.1, 25.0, 14.3. 
HRMS: (ESI-TOF, m/z) calcd. For C21H27N4O4 [M+H]+ calc.: 399.2027; found: 399.2035.  
IR: (ATR, neat, cm-1): 3451 (w), 2947 (w), 1702 (s), 1627 (m), 1472 (m), 1192 (m), 1045 (w), 
1021 (w), 757 (m). 




Synthesis of (±)-5.1i (Table 5-6): Following the general procedure 5A, the 
title compound was isolated by flash chromatography (SiO2, EtOAc then 
CH2Cl2:MeOH = 19:1 to 4:1) as a white solid (123.1 mg, 82%).  
Gram-scale synthesis of (±)-5.1i (Table 5-6): MTAD (1.57a, 1.0 g, 8.8 mmol, 
1.0 eq.) and naphthalene (1.2a, 2.3 g, 17.7 mmol, 2.0 eq.) were placed in a 500 
mL clear borosilicate glass bottle (see Picture S2) with a septum as the cap 
under nitrogen atmosphere. Ethyl acetate (100 mL, 0.088 M) was added to the bottle at rt, and the 
mixture was stirred until both MTAD and the naphthalene were completely dissolved. Then the 
resulting pink solution was stirred under irradiation with LED lights at –50 ºC until the solution 
became a white suspension (about 48 hours). Following this discoloration, a solution of Pd2(dba)3 
(202 mg, 0.221 mmol, 2.5 mol%) and dppf (294 mg, 0.531 mmol, 6.0 mol%) in THF (50 mL) was 
added and the resulting mixture was stirred at –20 ºC for 20 h. The reaction was then warmed up 
to rt, concentrated under reduced pressure, and isolated by flash column chromatography (SiO2, 
CH2Cl2:MeOH = 19:1 to 4:1) as a white solid (1.97 g, 74%). 
 
Rf = 0.11 (CH2Cl2:MeOH = 9:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.43 (d, J = 7.6 Hz, 1H), 7.33 (dt, J = 7.7, 4.5 Hz, 1H), 7.244-
7.235 (m, 2H), 6.39-6.32 (m, 2H), 5.95 – 5.87 (m, 1H), 4.43 – 4.36 (m, 1H), 3.08 (s, 3H), 2.69-
2.58 (m, 2H), 1.54-1.40 (m, 2H), 0.77 (t, J = 7.4 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.9, 152.9, 136.9, 134.1, 132.5, 129.77, 129.74, 129.5, 128.4, 
127.8, 52.6, 49.6, 47.1, 25.4, 19.8, 11.6. 
HRMS: (ESI-TOF, m/z) calcd. For C16H21N4O2 [M+H]+ calc.: 301.1659; found: 301.1666.  
IR: (ATR, neat, cm-1): 3411 (w), 2967 (w), 1685 (s), 1614 (s), 1461 (s), 1390 (m), 1146 (m), 923 
(m), 777 (m), 753 (s), 729 (s), 634 (m). 




Synthesis of (±)-5.1j (Table 5-6): Following the general procedure 5A, the title 
compound was isolated by flash chromatography (SiO2, EtOAc then 
CH2Cl2:MeOH = 19:1 to 16:4) as a white solid (145.8 mg, 89%).  
Rf = 0.37 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.41 (d, J = 7.5 Hz, 1H), 7.33 – 7.30 (m, 1H), 
7.24 - 7.21 (m, 2H), 6.34 (br, 2H), 5.91 – 5.87 (m, 1H), 4.42 – 4.38 (m, 1H), 
3.07 (s, 3H), 2.71 - 2.54 (m, 2H), 1.57-1.46 (m, 2H), 1.20-1.12 (m, 4H), 0.82 (t, J = 7.1 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.9, 152.9, 136.9, 134.2, 132.3, 129.8, 129.7, 129.4, 128.2, 
127.7, 52.1, 49.6, 45.1, 29.1, 25.6, 25.3, 22.2, 14.0. 
HRMS: (ESI-TOF, m/z) calcd. For C18H25N4O2 [M+H]+ calc.: 329.1972; found: 329.1973.  
IR: (ATR, neat, cm-1): 3430 (w), 2957 (w), 1690 (s), 1623 (m), 1465 (m), 1390 (w), 1285 (w), 
1146 (w) 755 (m). 
m.p.: 144–145 ºC. 
 
Synthesis of (±)-5.1k (Table 5-6): Following the general procedure 5A, the title 
compound was isolated by flash chromatography (SiO2, EtOAc then 
CH2Cl2:MeOH = 19:1 to 9:1) as a white solid (130.0 mg, 87%). 
Rf = 0.23 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) 7.45 (d, J = 7.5 Hz, 1H), 7.37 - 7.28 (m, 2H), 7.25 
- 7.22 (m, 1H), 6.52 - 6.46 (m, 2H), 5.97 (d, J = 5.5 Hz, 1H), 4.59 (d, J = 5.0 Hz, 
1H), 3.12 – 2.99 (m, 4H), 1.14 – 1.13 (m, 3H), 0.81 (br, 3H). 
13C NMR: (125 MHz, CDCl3) 155.7, 152.9, 137.4, 134.3, 132.3, 129.9, 129.8 (overlap of 2 peaks 
found by HSQC), 128.6, 128.0, 50.0, 49.6, 46.8, 25.4, 19.4, 18.2.  
HRMS: (ESI-TOF, m/z) calcd. For C16H21N4O2 [M+H]+ calc.: 301.1659; found: 301.1663.  
IR: (ATR, neat, cm-1): 3407 (w), 2977 (w), 2423 (s), 1688 (m), 1612 (s), 1455 (s), 1388 (m), 1143 
(m), 945 (w), 751 (s), 520 (m). 
m.p.: 120–125 ºC. 
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Synthesis of (±)-5.1l (Table 5-6): Following the general procedure 5A, the title 
compound was isolated by flash chromatography (SiO2, CH2Cl2:MeOH (sat. 
with NH3) = 19:1 to 17:3) as a pale yellow solid (114.4 mg, 67%).  
Rf = 0.39 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.45 (d, J = 7.5 Hz, 1H), 7.35 – 7.25 (m, 3H), 
6.40 (br, 2H), 5.95 – 5.94 (m, 1H), 4.63 – 4.62 (m, 1H), 3.07 (s, 3H), 2.76 – 2.72 
(m, 1H), 1.90 – 1.54 (m, 5H), 1.22 – 0.81 (m, 5H). 
13C NMR: (125 MHz, CDCl3) δ 155.7, 152.9, 137.4, 134.3, 132.4, 129.8 (overlap of 2 peaks found 
by HSQC and HMBC), 129.5, 128.4, 127.9, 54.2, 49.6, 49.2, 29.3, 28.7, 25.4, 25.3, 24.9. 
HRMS: (ESI-TOF, m/z) calcd. For C19H25N4O2 [M+H]+ calc.: 341.1972; found: 341.1984.  
IR: (ATR, neat, cm-1): 3268 (w), 2926 (m), 2853 (m), 1682 (m), 1585 (s), 1450 (m), 1389 (m), 
1286 (m), 1150 (w), 912 (m), 754 (m), 728 (s), 640 (m). 
m.p.: 141–142 ºC. 
 
Synthesis of (±)-5.1m (Table 5-6): Following the general procedure 5A, the 
title compound was isolated by flash chromatography (SiO2, CH2Cl2:MeOH 
(sat. with NH3) = 19:1 to 17:3) as a white solid (114.4 mg, 73%).  
Rf = 0.27 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.44 – 7.42 (m, 1H), 7.35 – 7.28 (m, 3H), 7.06 
(br, 2H), 6.54 (dd, J = 9.6, 5.6 Hz, 1H), 6.29 (dd, J = 9.6, 6.1 Hz, 1H), 5.91 (d, 
J = 6.1 Hz, 1H), 4.54 (d, J = 5.6 Hz, 1H), 3.03 (s, 3H), 1.22 (s, 9H). 
13C NMR: (125 MHz, CDCl3) δ 153.1, 152.9, 138.1, 135.7, 134.7, 129.6, 129.4, 128.9, 128.70, 
128.65, 54.4, 50.5, 50.1, 29.3, 25.1. 
HRMS: (ESI-TOF, m/z) calcd. For C17H23N4O2 [M+H]+ calc.: 315.1816; found: 315.1820.  
IR: (ATR, neat, cm-1): 3412 (w), 2974 (w), 1684 (m), 1617 (s), 1465 (m), 792 (w), 754 (m). 




Synthesis of (±)-5.1n (Table 5-6): Following the general procedure 5A, the 
title compound was isolated by flash chromatography (SiO2, CH2Cl2:MeOH 
(sat. with NH3) = 98:2 to 90:10) as a white solid (102.4 mg, 59%).  
Rf = 0.37 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.39 – 7.36 (m, 3H), 7.31 – 7.28 (m, 3H), 7.26 
– 7.17 (m, 3H), 6.39 (dd, J = 9.5, 5.4 Hz, 1H), 6.33 (dd, J = 9.5, 5.7 Hz, 1H), 
5.88 (d, J = 5.7 Hz, 1H), 4.38 (d, J = 5.4 Hz, 1H), 3.65 (d, J = 13.5 Hz, 1H), 3.61 (d, J = 13.5 Hz, 
1H), 3.08 (s, 3 H). 
13C NMR: (125 MHz, CDCl3) δ 154.3, 152.7, 135.8, 134.2, 134.0, 132.4, 130.1, 129.6, 129.5, 
129.19, 129.18, 129.1, 128.6, 128.1, 52.3, 50.1, 49.8, 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C20H21N4O2 [M+H]+ calc.: 349.1659; found: 349.1664.  
IR: (ATR, neat, cm-1): 3417 (w), 3035 (w), 1690 (s), 1618 (s), 1467 (s), 1392 (w), 920 (w), 732 
(m), 753 (m). 
m.p.: 94–95 ºC. 
 
Synthesis of (±)-5.1o (Table 5-6): General procedure 5A with the following 
modifications was used to synthesize the title compound: during the setup 3-
butenylamine hydrochloride was dissolved in 2.5 mL of degassed CH2Cl2 
and added as the amine source and then 2.0 eq. (1.0 mmol) of triethylamine 
was added. This was followed by the addition of the palladium catalyst. (±)-
5.1o was isolated by flash chromatography (SiO2, CH2Cl2:EtOAc:MeOH = 
5:4:1 to 9:0:1) as a pale yellow solid (101.2 mg, 65%). 
Rf = 0.26 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.44 (d, J = 7.4 Hz, 1H), 7.34 (td, J = 7.4, 1.6 Hz, 1H), 7.28 (td, J 
= 7.3, 1.2 Hz, 1H), 7.25 (d, J = 7.3 Hz, 1H) 6.46 (dd, J = 9.5, 5.5 Hz, 1H), 6.36 (dd, J = 9.5, 5.9 
Hz, 1H), 5.94 (d, J = 5.8 Hz, 1H), 5.64 (ddt, J = 17.1, 10.6, 6.8 Hz, 1H), 5.07 – 5.03 (m, 2H), 4.38 
(d, J = 5.5 Hz, 1H), 3.07 (s, 3H), 2.84 – 2.73 (m, 2H), 2.34 – 2.21 (m, 2H). 
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13C NMR: (125 MHz, CDCl3) δ 154.4, 152.8, 135.9, 134.1, 133.7, 132.4, 130.4, 129.8, 129.7, 
129.2, 128.2, 118.2, 53.0, 50.2, 45.1, 31.5, 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C17H21N4O2 [M+H]+ calc.: 313.1659; found: 313.1667.  
IR: (ATR, neat, cm-1): 3397 (w), 2969 (w), 1681 (m), 1592 (s), 1464 (s), 1391 (m), 1286 (w), 1146 
(w), 923 (w), 774 (m), 755 (s), 641 (w). 
m.p.: 70–72 ºC decomposed. 
 
Synthesis of (±)-5.1p (Table 5-6): Following the general procedure 5A, the 
title compound was isolated by flash chromatography (SiO2, EtOAc until 
most impurities had been removed and then switched to a gradient of 
CH2Cl2:MeOH = 19:1 to 9:1) as a white solid (143.0 mg, 66%). 
Rf = 0.33 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.45 (d, J = 7.6 Hz, 1H), 7.33 (td, J = 7.6, 
2.1 Hz, 1H), 7.28 – 7.24 (m, 2H), 6.43 (dd, J = 9.5, 5.5 Hz, 1H), 6.36 (dd, J = 9.5, 5.9 Hz, 1H), 
5.92 (d, J = 5.9 Hz, 1H), 4.40 (d, J = 5.5 Hz, 1H), 3.50 – 3.43 (m, 2H), 3.06 (s, 3H), 2.84 (td, J = 
10.7, 9.6, 5.9 Hz, 1H), 2.77 (td, J = 11.8, 10.7, 5.9 Hz, 1H), 1.62 – 1.57 (m, 2H), 0.83 (s, 9H), -
0.01 (s, 3H), -0.03 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.3, 152.8, 136.7, 133.4, 133.3, 129.7, 129.64, 129.60, 129.4, 
127.9, 60.6, 52.8, 49.8, 43.4, 29.4, 26.0, 25.3, 18.3, -5.3, -5.4. 
HRMS: (ESI-TOF, m/z) calcd. For C22H35N4O3Si [M+H]+ calc.: 431.2473; found: 431.2475.  
IR: (ATR, neat, cm-1): 3456 (w), 2960 (w), 2861 (w), 1743 (m), 1694 (m), 1625 (s), 1460 (m), 
1376 (m), 1217 (w), 835 (m), 780 (m), 755 (m). 




Synthesis of (±)-5.1q (Table 5-6): Following the general procedure 5A, 
the title compound was isolated by flash chromatography (SiO2, 
CH2Cl2:EtOAc:MeOH = 5:4:1) as a white solid (151.3 mg, 84%).  
Rf = 0.22 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.29 (br, 2H), 7.44 – 7.42 (m, 1H), 7.32 
(td, J = 7.5, 1.5 Hz, 1H), 7.28 (td, J = 7.5, 1.5 Hz, 1H), 7.23 (dd, J = 7.5, 
1.2 Hz, 1H), 6.51 (dd, J = 9.6, 5.5 Hz, 1H), 6.31 (dd, J = 9.6, 5.8 Hz, 1H), 5.90 (d, J = 5.8 Hz, 1H), 
4.35 (d, J = 5.5 Hz, 1H), 4.10 (q, J = 7.1 Hz, 2H), 3.04 – 2.92 (m, 2H), 3.02 (s, 3H), 2.66 – 2.53 
(m, 2H), 1.22 (t, J = 7.2 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 171.4, 153.9, 152.7, 135.4, 134.7, 131.5, 131.4, 129.7, 129.4, 
129.2, 128.2, 61.1, 53.3, 50.4, 41.4, 32.1, 25.2, 14.2. 
HRMS: (ESI-TOF, m/z) calcd. For C18H23N4O4 [M+H]+ calc.: 359.1714; found: 359.1716.  
IR: (ATR, neat, cm-1): 3432 (w), 2972 (w), 1760 (m), 1696 (m), 1622 (s), 1469 (m), 1265 (m), 
1111 (s), 1030 (m), 784 (m), 757 (m). 
m.p.: 101–103 ºC decomposed. 
 
7.6.2 Dearomative syn-1,4-diamination of polynuclear arenes with n-propylamine  
General procedure 5B for the dearomative syn-1,4-diamination of naphthalene derivatives 
with n-propylamine (Table 5-7, 5-8) 
 
For solid arene: MTAD (1.57a, 113 mg, 1.0 mmol, 1.0 eq.) and arene (1.2, 2.0 mmol, 1.0 eq.) were 
placed in a test tube with a septum as the cap under nitrogen atmosphere. Ethyl acetate (10.0 mL, 
0.1 M) was added to the test tube at rt, and the mixture was stirred until both MTAD and the 
naphthalene were completely dissolved.  
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For liquid arene: MTAD (1.57a, 113 mg, 1.0 mmol, 1.0 eq.) was dissolved in ethyl acetate (8.0 
mL) at rt under nitrogen atmosphere. Then a solution of arene (1.2, 2.0 mmol, 1.0 eq.) in ethyl 
acetate (2.0 mL) was added. 
The resulting pink solution was stirred under irradiation with LED lights at –50 ºC until the 
solution became white suspension or colorless solution. To this solution were added  propylamine 
(2.0 mmol, 2.0 eq.) and a solution of Pd2(dba)3 (28.8 mg, 0.025 mmol, 2.5 mol%) and dppf (33.2 
mg, 0.060 mmol, 6.0 mol%) in THF (2.0 mL, pre-stirred at rt in THF for 30 min) and the resulting 
mixture was slowly warmed up from –50 to 0 ºC over 5 h. The reaction was then filtered through 
a pad of celite, and concentrated under reduced pressure. The product was purified by flash column 
chromatography (SiO2, CH2Cl2:MeOH mixture). 
 
Synthesis of ()-5.3 (Table 5-7): The reaction was conducted following the 
general procedure 5B, except the substitution step was done by stirring the 
mixture at –20 ºC for 20 h. The title compound was isolated by flash 
chromatography (SiO2, CH2Cl2:MeOH = 30:1 to 15:1) as a light-red solid 
(257.7 mg, 53%).  
Rf = 0.34 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.28 (s, 1H), 7.26 (s, 1H), 7.11 (br, 1H), 6.41 (dd, J = 9.4, 5.6 Hz, 
1H), 6.34 (dd, J = 94, 5.7 Hz, 1H), 5.91 (d, J = 5.7 Hz, 1H), 4.35 (d, J = 5.6 Hz, 1H), 3.05 (s, 3H), 
2.71 – 2.61 (m, 2H), 1.52 – 1.45 (m, 2H), 1.32 (s, 18H), 0.82 (t, J = 7.4 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 175.7, 175.4, 155.7, 152.8, 143.3, 142.0, 135.1, 133.3, 130.5, 
128.6, 124.9, 124.7, 52.0, 49.1, 47.2, 39.3, 39.2, 27.31, 27.25, 25.3, 19.8, 11.4. 
HRMS: (ESI-TOF, m/z) calcd. For C26H37N4O6 [M+H]+ calc.: 501.2729; found: 501.2713.  
IR: (ATR, neat, cm-1): 2973 (w), 1703 (m), 1622 (s), 1479 (w), 1458 (m), 1387 (w), 1262 (w), 
1114 (s), 1093 (s), 1029 (w), 782 (m), 757 (w), 631 (w). 




Synthesis of ()-5.5 (Table 5-7): The reaction was conducted following the 
general procedure 5B, except the reaction was run in dichloromethane (10 mL, 
0.1 M) with 10 mol% of Pd2dba3 and 12 mol% dppf. The title compound was 
isolated as a mixture of 5.5 and 5.5' by flash chromatography (SiO2, 
CH2Cl2:MeOH = 15:1 to 9:1) as a light-yellow solid (174.3 mg, 44%). The 
isomers were further separated by careful flash chromatography (SiO2, 
CH2Cl2:MeOH = 15:1 to 9:1). 
Rf = 0.34 (CH2Cl2:MeOH = 5:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.28 (dd, J = 8.0, 7.7 Hz, 1H), 7.19 (d, J = 7.7 Hz, 1H), 7.00 (d, J 
= 8.0 Hz, 1H), 6.40 – 6.34 (m, 2H), 5.98 (d, J = 5.4 Hz, 1H), 4.42 (d, J = 5.0 Hz, 1H), 3.05 (s, 3H), 
2.68 – 2.65 (m, 2H), 1.56 – 1.47 (m, 2H), 1.43 (s, 9H), 0.81 (t, J = 7.4 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 177.5, 155.1, 152.3, 149.4, 136.0, 133.3, 128.8, 128.5, 128.3, 
127.0, 123.4, 52.5, 47.6, 44.4, 39.6, 27.3, 25.2, 20.4, 11.6. 
HRMS: (ESI-TOF, m/z) calcd. For C21H29N4O4 [M+H]+ calc.: 401.2189; found: 401.2180.  
IR: (ATR, neat, cm-1): 2965 (w), 2341 (w), 1752 (w), 1703 (m), 1623 (s), 1456 (m), 1390 (w), 
1236 (w), 1100 (s), 980 (w), 871 (w), 785 (w), 758 (w), 746 (m), 635 (w). 
m.p.: 181–182 ºC. 










Rf = 0.53 (CH2Cl2:MeOH = 5:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.41 – 7.36 (m, 2H), 7.02 (dd, J = 7.6, 1.7 Hz, 
1H), 6.53 (dd, J = 9.4, 5.7 Hz, 1H), 6.34 (dd, J = 9.4, 6.0 Hz, 1H), 5.99 (d, J = 
6.0 Hz, 1H), 4.40 (d, J = 5.7 Hz, 1H), 3.03 (s, 3H), 2.81 – 2.76 (m, 1H), 2.65 – 
2.59 (m, 1H), 1.60 – 1.49 (m, 2H), 1.41 (s, 9H), 0.89 (t, J = 7.3 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 177.1, 153.6, 152.6, 148.6, 137.6, 131.6, 131.1, 130.2, 128.0, 
127.5, 122.2, 50.2, 48.7, 47.5, 39.5, 27.3, 25.2, 21.5, 11.8. 
HRMS: (ESI-TOF, m/z) calcd. For C21H29N4O4 [M+H]+ calc.: 401.2189; found: 401.2182.  
IR: (ATR, neat, cm-1): 2963 (w), 2320 (w), 1700 (m), 1617 (m), 1468 (m), 1446 (m), 1386 (w), 
1279 (w), 1233 (w), 1104 (s), 1027 (w), 950 (w), 784 (s), 754 (s), 635 (w).  
m.p.: 145–146 ºC. 
 
Synthesis of ()-5.6 (Table 5-7): The reaction was conducted following the 
general procedure 5B, except the reaction in dichloromethane (10 mL, 0.1 M). 
The title compound was isolated as a mixture of 5.6 and 5.6' by flash 
chromatography (SiO2, CH2Cl2:MeOH = 15:1 to 9:1) as a light-yellow solid 
(179.8 mg, 48%). The isomers were further separated by careful flash 
chromatography (SiO2, CH2Cl2:MeOH = 9:1 to 5:1). 
Rf = 0.45 (CH2Cl2:MeOH = 5:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.68 (d, J = 7.5 Hz, 1H), 7.32 (dd, J = 7.6, 7.5 Hz, 1H), 7.27 – 
7.25 (m, 1H), 6.35 – 6.32 (m, 2H), 6.29 – 6.27 (m, 1H), 5.76 (s, 1H), 4.44 – 4.42 (m, 1H), 3.42 (s, 
3H), 3.39 (s, 3H), 3.10 (s, 3H), 2.68 – 2.56 (m, 2H), 1.49 – 1.44 (m, 2H), 0.77 (t, J = 7.5 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.4, 152.2, 138.1, 134.2, 133.8, 133.7, 130.2, 128.3, 127.9, 
127.7, 100.9, 55.7, 53.8, 53.3, 47.5, 45.4, 25.4, 20.2, 11.6. 
HRMS: (ESI-TOF, m/z) calcd. For C19H27N4O4 [M+H]+ calc.: 375.2032; found: 375.2024.  
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IR: (ATR, neat, cm-1): 3491 (w), 2958 (w), 1681 (m), 1615 (s), 1571 (m), 1462 (w), 1444 (w), 
1103 (w), 1026 (s), 991 (w), 867 (w), 784 (m), 756 (m), 749 (m), 670 (w), 563 (w), 525 (w). 
m.p.: 192–193 ºC. 







Rf = 0.55 (CH2Cl2:MeOH = 5:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.51 – 7.48 (m, 1H), 7.37 – 7.32 (m, 2H), 6.55 
(dd, J = 9.5, 5.8 Hz, 1H), 6.44 (dd, J = 9.5, 6.1 Hz, 1H), 5.99 (d, J = 6.1 Hz, 
1H), 5.28 (s, 1H), 4.96 (d, J = 5.8 Hz, 1H), 3.55 (s, 3H), 3.31 (s, 3H), 2.99 (s, 
3H), 2.98 – 2.94 (m, 1H), 2.76 (ddd, J = 11.6, 8.3, 6.6 Hz, 1H), 1.875 – 1.66 
(m, 2H), 1.01 (t, J = 7.4 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 153.3, 152.8, 137.3, 135.5, 135.4, 132.2, 131.2, 130.7, 128.8, 
128.4, 106.7, 56.5, 54.1, 50.8, 49.1, 48.7, 25.0, 22.0, 11.8. 
HRMS: (ESI-TOF, m/z) calcd. For C19H27N4O4 [M+H]+ calc.: 375.2032; found: 375.2024.  
IR: (ATR, neat, cm-1): 3442 (w), 2938 (w), 2226 (w), 1684 (m), 1618 (s), 1459 (m), 1389 (w), 
1353 (w), 1192 (w), 1112 (w), 1044 (m), 1031 (w), 998 (w), 912 (w), 895 (w), 780 (m), 773 (m), 
759 (w), 723 (s), 637 (w).  




Synthesis of ()-5.11 (Table 5-7): Following the general procedure 5B, the title 
compound was isolated as a mixture of 5.11 and 5.11' by flash chromatography 
(SiO2, CH2Cl2:MeOH = 15:1 to 9:1) as a light-yellow solid (199.3 mg, 57%). 
The isomers were further separated by careful flash chromatography (SiO2, 
CH2Cl2:MeOH = 15:1 to 9:1). 
Rf = 0.54 (CH2Cl2:MeOH = 5:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.99 (d, J = 8.5 Hz, 1H), 7.88 (d, J = 8.1 Hz, 1H), 7.84 (d, J = 8.5 
Hz, 1H), 7.64 – 7.61 (m, 1H), 7.57 – 7.54 (m, 2H), 6.77 (dd, J = 9.5, 5.7 Hz, 1H), 6.47 (dd, J = 
9.5, 5.8 Hz, 1H), 6.08 (d, J = 5.8 Hz, 1H), 5.18 (d, J = 5.7 Hz, 1H), 3.03 (s, 3H), 2.95 – 2.88 (m, 
1H), 2.84 – 2.77 (m, 1H), 1.69 – 1.55 (m, 2H), 0.80 (t, J = 6.7 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 153.9, 152.8, 134.2, 133.3, 131.8, 131.3, 130.9, 130.6, 130.0, 
129.3, 127.5, 127.0, 126.6, 121.9, 51.1, 48.8, 48.1, 25.3, 21.4, 11.7. 
HRMS: (ESI-TOF, m/z) calcd. For C20H23N4O2 [M+H]+ calc.: 351.1821; found: 351.1833.  
IR: (ATR, neat, cm-1): 3052 (w), 2965 (w), 1692 (m), 1616 (s), 1461 (m), 1387 (w), 1283 (w), 
1197 (w), 1092 (w), 802 (w), 782 (s), 757 (m), 737 (w), 710 (w), 655 (w), 629 (m), 607 (w), 491 
(w). 
m.p.: 128–129 ºC. 






Rf = 0.45 (CH2Cl2:MeOH = 5:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.51 (d, J = 8.4 Hz, 1H), 7.83 (d, J = 8.2 Hz, 
1H), 7.76 (d, J = 8.4 Hz, 1H), 7.63 (ddd, J = 8.4, 6.8, 1.3 Hz, 1H), 7.51 (dd, J 
= 8.2, 6.8 Hz, 1H), 7.33 (d, J = 8.4 Hz, 1H), 6.51 (d, J = 5.8 Hz, 1H), 6.27 (br, 
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1H), 6.08 (br, 1H), 4.49 (d, J = 5.4 Hz, 1H), 3.10 (s, 3H), 2.58 (br, 1H), 2.47 (br, 1H), 1.41 – 1.17 
(m, 2H), 0.45 (br, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.9, 152.1, 134.6, 133.6, 133.1, 131.0, 130.7, 128.6, 128.5, 
127.8, 127.3, 127.0, 126.5, 124.3, 53.2, 47.2, 45.6, 25.4, 19.6, 11.1. 
HRMS: (ESI-TOF, m/z) calcd. For C20H23N4O2 [M+H]+ calc.: 351.1821; found: 351.1833.  
IR: (ATR, neat, cm-1): 3412 (w), 2968 (w), 1686 (w), 1622 (s), 1573 (w), 1470 (w), 1373 (w), 
1141 (w), 1025 (w), 819 (m), 783 (m), 754 (m), 655 (w), 634 (w), 618 (w), 574 (w). 
m.p.: 168–169 ºC. 
 
Synthesis of ()-5.12 (Table 5-8): Following the general procedure 5B, the 
title compound was isolated as a mixture of 5.12 and 5.12' by flash 
chromatography (SiO2, CH2Cl2:MeOH = 15:1 to 9:1) as a light-yellow solid 
(240.1 mg, 76%). The isomers were further separated by careful flash 
chromatography (SiO2, CH2Cl2:MeOH = 9:1 to 5:1). 
Rf = 0.46 (CH2Cl2:MeOH = 5:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.67 (d, J = 7.9 Hz, 1H), 7.15 (d, J = 7.9 Hz, 1H), 6.51 (dd, J = 
9.6, 5.4 Hz, 1H), 6.28 (dd, J = 9.6, 5.7 Hz, 1H), 5.95 (d, J = 5.7 Hz, 1H), 4.42 (d, J = 5.4 Hz, 1H), 
3.04 (s, 4H), 2.81 (t, J = 7.8 Hz, 2H), 2.55 (s, 4H), 1.73 – 1.66 (m, 1H), 1.57 – 1.50 (m, 1H), 0.91 
(t, J = 7.4 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 158.3, 154.8, 153.1, 152.9, 137.6, 130.9, 130.6, 128.5, 124.0, 
54.9, 49.9, 48.1, 25.3, 24.4, 21.0, 11.7. 
HRMS: (ESI-TOF, m/z) calcd. For C16H22N5O2 [M+H]+ calc.: 316.1774; found: 316.1779.  
IR: (ATR, neat, cm-1): 2890 (w), 1694 (m), 1615 (m), 1589 (s), 1574 (m), 1453 (s), 1408 (w), 
1381 (m), 1372 (m), 1300 (w), 1283 (w), 1142 (w), 802 (m), 777 (s), 756 (s), 643 (m), 602 (w), 
561 (w). 











Rf = 0.32 (CH2Cl2:MeOH = 5:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.59 (d, J = 7.9 Hz, 1H), 7.09 (d, J = 7.9 Hz, 
1H), 6.42 – 6.36 (m, 2H), 5.90 – 5.89 (m, 1H), 4.38 (d, J = 4.3 Hz, 1H), 3.08 
(s, 3H), 2.63 – 2.59 (m, 2H), 2.55 (s, 3H), 1.47 – 1.39 (m, 2H), 0.80 (t, J = 7.4 
Hz, 3H). 
13C NMR: (125 MHz, CDCl3) 159.6, 155.0, 153.7, 153.4, 137.3, 132.5, 129.3, 126.7, 122.6, 53.0, 
52.7, 47.7, 25.4, 24.5, 20.9, 11.6. 
HRMS: (ESI-TOF, m/z) calcd. For C16H22N5O2 [M+H]+ calc.: 316.1774; found: 316.1764.  
IR: (ATR, neat, cm-1): 3390 (w), 2967 (w), 1694 (m), 1620 (s), 1600 (w), 1473 (m), 1448 (m), 
1372 (w), 1146 (w), 1022 (w), 831 (w), 778 (m), 757 (s), 637 (m), 566 (w). 
m.p.: 131–132 ºC. 
 
Synthesis of ()-5.13 (Table 5-8): The reaction was conducted following the 
general procedure 5B, except the reaction was run with MTAD (1.57a, 0.5 
mmol, 1.0 eq.) in EtOAc (10 mL, 0.05 M). Single constitutional- and 
diastereoisomer was observed in crude 1H NMR. The title compound was 
isolated by flash chromatography (SiO2, CH2Cl2:MeOH = 9:1 to 5:1) as a 
light-yellow solid (115.3 mg, 61%).  
Rf = 0.44 (CH2Cl2:MeOH = 5:1, UV, KMnO4).  
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1H NMR: (500 MHz, CDCl3) δ 8.23 (d, J = 5.2 Hz, 1H), 7.58 (d, J = 5.2 Hz, 1H), 6.39 (dd, J = 
9.5, 5.5 Hz, 1H), 6.31 (dd, J = 9.5, 5.9 Hz, 1H), 6.16 (d, J = 5.9 Hz, 1H), 4.50 (d, J = 5.5 Hz, 1H), 
3.12 (s, 3H), 2.88 – 2.77 (m, 2H), 1.7 – 1.63 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.3, 154.9, 152.2, 149.1, 135.1, 132.6, 131.4, 128.8, 128.4, 
54.9, 49.7, 47.7, 25.4, 20.6, 11.6. 
HRMS: (ESI-TOF, m/z) calcd. For C15H19BrN5O2 [M+H]+ calc.: 380.0710; found: 380.0722.  
IR: (ATR, neat, cm-1): 3030 (w), 1705 (m), 1613 (s), 1455 (s), 1386 (m), 1279 (w), 1239 (w), 1019 
(w), 827 (m), 791 (s), 760 (s), 710 (w), 654 (w), 635 (m), 608 (m), 493 (m). 
m.p.: 136–137 ºC. 





Synthesis of ()-5.14 (Table 5-8): The reaction was conducted following the 
general procedure 5B, except the reaction was run with MTAD (1.57a, 0.5 
mmol, 1.0 eq.) in dichloromethane (5 mL, 0.1 M). The title compound was 
isolated by flash chromatography (SiO2, CH2Cl2:MeOH = 10:1 to 5:1) as a 
off-white solid (94.9 mg, 50%).  
Rf = 0.21 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 9.33 (s, 1H), 8.65 (d, J = 4.9 Hz, 1H), 8.61 (s, 2H), 7.24 (d, J = 
4.9 Hz, 1H), 6.48 (dd, J = 9.5, 5.6 Hz, 1H), 6.20 (dd, J = 9.5, 5.9 Hz, 1H), 5.77 (d, J = 5.9 Hz, 1H), 
4.61 (d, J = 5.6 Hz, 1H), 3.02 (s, 3H), 2.93 – 2.82 (m, 2H), 1.74 – 1.70 (m, 1H), 1.68 – 1.63 (m, 
1H), 0.94 (t, J = 7.4 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 159.2, 157.0, 155.9, 155.8, 154.5, 152.0, 149.3, 144.2, 131.0, 
130.9, 130.3, 129.2, 125.2, 55.5, 48.4, 47.6, 25.3, 21.3, 11.7. 
HRMS: (ESI-TOF, m/z) calcd. For C19H22N7O2 [M+H]+ calc.: 380.1835; found: 380.1846.  
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IR: (ATR, neat, cm-1): 1703 (m), 1612 (s), 1587 (w), 1453 (w), 1417 (m), 1381 (w), 1285 (w), 
1036 (w), 853 (w), 791 (w), 774 (w), 762 (w), 729 (m), 634 (s), 531 (w). 
m.p.: 138–139 ºC. 






Synthesis of ()-5.16 (Table 5-8): The reaction was conducted following 
the general procedure 5B, except the reaction was run with MTAD (1.57a, 
0.5 mmol, 1.0 eq.) in dichloromethane (5 mL, 0.1 M). The title compound 
was isolated by flash chromatography (SiO2, CH2Cl2:MeOH = 15:1 to 9:1) 
as a light-red solid (108.8 mg, 53%).  
Rf = 0.53 (CH2Cl2:MeOH = 5:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.06 (d, J = 8.4 Hz, 1H), 7.83 – 7.78 (m, 2H), 7.64 (ddd, J = 8.4, 
7.0, 1.2 Hz, 1H), 6.53 (dd, J = 9.5, 5.7 Hz, 1H), 6.34 (d, J = 6.1 Hz, 1H), 6.27 (dd, J = 9.5, 6.1 Hz, 
1H), 4.69 (d, J = 5.7 Hz, 1H), 4.16 (s, 3H), 3.06 (s, 3H), 2.86 (ddd, J = 11.9, 9.9, 5.7 Hz, 1H), 2.76 
(ddd, J = 11.9, 9.8, 5.7 Hz, 1H), 1.69 – 1.65 (m, 1H), 1.55 – 1.51 (m, 1H), 0.84 (t, J = 7.4 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 166.4, 154.9, 153.2, 152.2, 146.8, 140.1, 132.0, 131.1, 129.7, 
129.1, 128.7, 125.2, 125.0, 123.9, 55.5, 53.9, 47.7, 46.7, 25.3, 20.6, 11.5. 
HRMS: (ESI-TOF, m/z) calcd. For C21H24N5O4 [M+H]+ calc.: 410.1828; found: 410.1812.  
IR: (ATR, neat, cm-1): 2980 (w), 1743 (m), 1702 (m), 1688 (m), 1625 (s), 1471 (m), 1456 (m), 
1228 (m), 1213 (m), 785 (s), 770 (s), 747 (s), 728 (m), 624 (m). 
m.p.: 100–101 ºC. 
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7.6.3 Dearomative syn-1,4-diamination of benzene with amine 
General procedure 5C for the dearomative syn-1,4-diamination of benzene with amines 
(Table 5-9) 
 
MTAD (1.57a, 113 mg, 1.0 mmol, 1.0 eq.) was placed in a test tube with a septum as the cap under 
nitrogen atmosphere. Dichloromethane (5.0 mL, 0.2 M) was added to the test tube at rt, and cooled 
to –78 ºC. Benzene (1.1a, 0.89 mL, 10 mmol, 10 eq.) was added dropwise at –78 ºC, and the 
resulting pink solution was stirred under irradiation with LED lights at –78 ºC until the solution 
became colorless (approximately 12 h). To this solution were added an amine (2.0 mmol, 2.0 eq.) 
and a solution of Pd complex in THF (2.0 mL) [primary amine: Pd2(dba)3 (22.9 mg, 0.025 mmol, 
2.5 mol%) and dppf (33.3 mg, 0.06 mmol, 6.0 mol%), pre-stirred at rt in THF for 30 min; 
secondary amine: Pd(PPh3)4 (57.8 mg, 0.05 mmol, 5.0 mol%)], and the resulting mixture was 
stirred at –20 ºC for 20 h. The reaction was then warmed up to rt, filtered through a pad of celite, 
and concentrated under reduced pressure. The product was purified by flash column 




Synthesis of 5.2a (Table 5-9): Following the general procedure 5C, the title 
compound was isolated by flash chromatography (SiO2, CH2Cl2:MeOH (sat. with 
NH3) = 5:1 to 3:1) as a white solid (149.4 mg, 48%).  
Rf = 0.27 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.33 – 27 (m, 4H), 7.26 – 7.24 (m, 1H), 6.18 
(ddd, J = 10.4, 3.2, 1.9 Hz, 2H), 5.77 (ddd, J = 10.4, 3.2, 1.9 Hz, 2H), 5.16 – 5.12 
(m, 1H), 3.76 – 3.73 (m, 1H), 3.58 (s, 2H), 3.02 (s, 3H), 2.25 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.5, 154.5, 139.6, 132.0, 128.8, 128.4, 127.3, 125.1, 57.7, 56.0 
50.9, 38.8, 25.2. 
HRMS: (ESI-TOF, m/z) calcd. For C17H20N4NaO2 [M+Na]+ calc.: 335.1478; found: 335.1486.  
IR: (ATR, neat, cm-1): 3100 (w), 2831 (w), 1694 (s), 1593 (s), 1488 (s), 1453 (s), 1371 (m), 1138 
(m), 750 (s), 739 (s), 695 (s), 666 (m), 633 (m), 539 (m), 468 (m). 
m.p.: 120–121 ºC. 
 
Synthesis of 5.2b (Table 5-9): Following the general procedure 5C, the title 
compound was isolated by flash chromatography (SiO2, CH2Cl2:MeOH = 10:1 to 
5:1) as a white solid (144.2 mg, 55%).  
Rf = 0.18 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.14 (br, 1H), 6.14 (ddd, J = 10.3, 3.2, 1.7 Hz, 
2H), 5.84 (ddd, J = 10.3, 3.3, 1.7 Hz, 2H), 5.19 – 5.15 (m, 1H), 3.86 – 3.83 (m, 
1H), 3.08 (s, 3H), 2.63 (q, J = 7.2 Hz, 4H), 1.09 (t, J = 7.2 Hz, 6H). 
13C NMR: (125 MHz, CDCl3) δ 155.1, 154.6, 132.4, 125.6, 53.1, 50.4, 44.5, 25.4, 13.6. 
HRMS: (ESI-TOF, m/z) calcd. For C13H21N4O2 [M+H]+ calc.: 265.1665; found: 265.1676.  
IR: (ATR, neat, cm-1): 1693 (m), 1584 (s), 1464 (s), 1455 (s), 1389 (w), 1370 (w), 1286 (w), 795 
(w), 768 (m), 755 (m), 665 (w), 536 (w). 




Synthesis of 5.2c (Table 5-9): Following the general procedure 5C, the title 
compound was isolated by flash chromatography (SiO2, CH2Cl2:MeOH = 10:1 to 
5:1) as a white solid (156.7 mg, 57%).  
Rf = 0.40 (CH2Cl2:MeOH = 5:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 6.22 (ddd, J = 10.4, 3.6, 1.6 Hz, 2H), 5.91 (ddd, J 
= 10.4, 2.7, 1.6 Hz, 2H), 5.22 – 5.19 (m, 1H), 3.58 – 3.56 (m, 1H), 3.08 (s, 3H), 
2.64 – 2.62 (m, 4H), 1.67 – 1.62 (m, 4H), 1.49 – 1.45 (m, 2H). 
13C NMR: (125 MHz, CDCl3) δ 155.5, 155.1, 130.8, 124.6, 57.9 50.50, 50.46, 25.4, 23.6, 22.7. 
HRMS: (ESI-TOF, m/z) calcd. For C14H21N4O2 [M+H]+ calc.: 277.1665; found: 277.1667.  
IR: (ATR, neat, cm-1): 1695 (s), 1586 (m), 1466 (m), 1454 (m), 1413 (w), 1389 (w), 1370 (w), 
1032 (w), 800 (w), 748 (s), 692 (w), 664 (w), 624 (w), 593 (w). 
m.p.: 100–101ºC. 
 
Synthesis of 5.2d (Table 5-9): Following the general procedure 5C, the title 
compound was isolated by flash chromatography (SiO2, CH2Cl2:MeOH = 15:1 to 
9:1) as a white solid (172.6 mg, 62%).  
Rf = 0.27 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 6.15 (ddd, J = 10.3, 3.2, 1.7 Hz, 2H), 5.87 (ddd, J 
= 10.3, 3.4, 1.7 Hz, 2H), 5.19 – 5.15 (m, 1H), 3.72 – 3.70 (m, 4H), 3.64 – 3.62 (m, 
1H), 3.08 (s, 3H), 2.63 – 2.61 (m, 4H). 
13C NMR: (125 MHz, CDCl3) δ 155.2, 154.7, 131.7, 126.0, 67.4, 57.1, 50.6, 49.7, 25.4. 
HRMS: (ESI-TOF, m/z) calcd. For C13H18KN4O3 [M+K]+ calc.: 317.1010; found: 317.1009.  
IR: (ATR, neat, cm-1): 2950 (w), 2810 (w), 1690 (s), 1484 (m), 1403 (w), 1224 (w), 1112 (s), 1036 
(m), 1016 (m), 941 (w), 886 (w), 771 (s), 731 (m), 637 (m), 551 (m), 461 (m). 




Synthesis of 5.2e (Table 5-9): Following the general procedure 5C, the title 
compound was isolated by flash chromatography (SiO2, CH2Cl2:MeOH (sat. with 
NH3) = 5:1 to 3:1) as a white solid (155.0 mg, 62%).  
Rf = 0.27 (CH2Cl2:MeOH = 5:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.05 (br, 1H), 6.13 (ddd, J = 10.5, 3.7, 1.7 Hz, 
2H), 6.03 (dd, J = 10.2, 2.7 Hz, 2H), 5.36 – 5.33 (m, 1H), 3.94 – 3.89 (m, 1H), 
3.06 (s, 3H), 2.93 (t, J = 7.5 Hz, 2H), 1.76 (tq, J = 7.5, 7.4 Hz, 2H), 1.00 (t, J = 7.4 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 156.4, 152.8, 131.8, 124.3, 49.7, 47.4, 46.4, 25.4, 20.7, 11.5. 
HRMS: (ESI-TOF, m/z) calcd. For C12H19N4O2 [M+H]+ calc.: 251.1503; found: 251.1497. 
IR: (ATR, neat, cm-1): 2968 (w), 1698 (s), 1597 (s), 1462 (m), 1406 (w), 1375 (m), 1283 (w), 1155 
(w), 1022 (w), 850 (w), 781 (s), 758 (s), 693 (w), 640 (m), 562 (w), 479 (m). 
m.p.: 100–101 ºC. 
 
Synthesis of 5.2f (Table 5-9): Following the general procedure 5C, the title 
compound was isolated by flash chromatography (SiO2, CH2Cl2:MeOH = 9:1 to 
5:1) as a white solid (180.0 mg, 72%).  
Rf = 0.27 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 9.75 (br, 2H), 6.23 (dd, J = 9.8, 4.6 Hz, 2H), 6.18 
(dd, J = 9.8, 4.8 Hz, 2H), 5.36 (td, J = 4.8, 2.8 Hz, 1H), 4.06 (td, J = 4.6, 2.8 Hz, 
1H), 3.26 (hept, J = 6.5 Hz, 1H), 3.04 (s, 3H), 1.22 (d, J = 6.5 Hz, 6H). 
13C NMR: (125 MHz, CDCl3) δ 156.2, 153.1, 133.2, 126.4, 46.9, 45.9, 45.6, 25.4, 19.8. 
HRMS: (ESI-TOF, m/z) calcd. For C12H19N4O2 [M+H]+ calc.: 251.1503; found: 251.1513.  
IR: (ATR, neat, cm-1): 3242 (w), 2850 (w), 1677 (m), 1599 (s), 1473 (w), 1396 (w), 1376 (w), 





Synthesis of 5.2g (Table 5-9): Following the general procedure 5C, the title 
compound was isolated by flash chromatography (SiO2, CH2Cl2:MeOH = 9:1 to 
5:1) as a white solid (131.0 mg, 50%).  
Rf = 0.27 (CH2Cl2:MeOH = 5:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.12 (br, 2H), 6.15 (ddd, J = 10.3, 3.6, 1.6 Hz, 
2H), 5.88 (ddd, J = 10.3, 3.6, 1.4 Hz, 2H), 5.23 (dtt, J = 5.4, 3.6, 1.6 Hz, 1H), 
3.97 – 3.91 (m, 1H), 3.06 (s, 3H), 1.30 (s, 9H). 
13C NMR: (125 MHz, CDCl3) δ 155.4, 153.8, 130.8, 127.4, 54.1, 47.6, 45.5, 28.8, 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C13H20N4NaO2 [M+Na]+ calc.: 287.1478; found: 287.1466.  
IR: (ATR, neat, cm-1): 3320 (w), 2974 (w, br), 1692 (s), 1464 (m), 1393 (w), 1234 (w), 1005 (w), 
828 (m), 764 (m), 739 (m), 623 (w), 491 (m). 
m.p.: 153–155 ºC. 
 
Synthesis of 5.2h (Table 5-9): Following the general procedure 5C, the title 
compound was isolated by flash chromatography (SiO2, CH2Cl2:MeOH (sat. 
with NH3) = 20:1 to 10:1) as a white solid (202.9 mg, 53%).  
Rf = 0.54 (CH2Cl2:MeOH = 5:1, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.54 (br, 2H), 6.20 (dd, J = 9.8, 4.4 Hz, 2H), 
6.03 (dd, J = 9.8, 4.4 Hz, 2H), 5.29 (dt, J = 4.5, 4.4 Hz, 1H), 3.86 (dt, J = 
4.5, 4.4 Hz, 1H), 3.66 (t, J = 6.0 Hz, 2H), 3.05 (s, 3H), 2.92 (t, J = 6.8 Hz, 2H), 1.78 (tt, J = 6.0, 
6.8 Hz, 2H), 0.87 (s, 9H), 0.03 (s, 6H). 
13C NMR: (125 MHz, CDCl3) δ 155.8, 153.6, 130.4, 128.4, 60.7, 49.1, 47.3, 43.5, 30.8, 26.0, 25.3, 
18.3, –5.3. 
HRMS: (ESI-TOF, m/z) calcd. For C18H33N4O3Si [M+H]+ calc.: 381.2316; found: 381.2333.  
IR: (ATR, neat, cm-1): 2928 (w), 2856 (w), 1683 (w), 1591 (s), 1575 (s), 1500 (m), 1458 (m), 1373 
(m), 1252 (w), 1095 (s), 833 (s), 773 (s), 751 (s), 689 (m), 665 (s), 634 (m), 508 (w). 
m.p.: 143–146 ºC. 
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7.6.4 Asymmetric dearomative syn-1,4-diamination of naphthalene  
General procedure 5D for the asymmetric dearomative syn-1,4-diamination of naphthalene 
(Table 5-10) 
 
MTAD (1.57a, 56.7 mg, 0.50 mmol, 1.0 eq.) was combined with naphthalene (1.2a, 128 mg, 1.0 
mmol, 2.0 eq.) and a stir bar in a test tube with a septum as the cap under nitrogen atmosphere. 
Ethyl acetate (5.0 mL, 0.1 M) was added to the test tube at rt, the contents were stirred until 
completely dissolved and then cooled to –50 ºC. The resulting pink solution was stirred under 
irradiation with LED lights at –50 ºC until the solution became colorless (approximately 6 h). After 
turning off the lights, to this solution at –50 ºC were added an amine (2.0 mmol, 2.0 eq.) and a 
solution of Pd2(dba)3 (11.4 mg, 0.0125 mmol, 2.5 mol%) and (S,Sp)-tBu-Phosferrox (14.9 mg, 
0.03 mmol, 6.0 mol%) in THF (2.0 mL), and the resulting mixture was stirred at –20 ºC for 20 h. 
The reaction was then warmed up to rt, concentrated under reduced pressure, and purified by flash 
column chromatography (SiO2, CH2Cl2:MeOH mixture). 
 
Synthesis of 5.1e (Table 5-10): Following the general procedure 5D, the title 
compound was isolated by flash chromatography (SiO2, CH2Cl2:MeOH 
(saturated with NH3) = 95:5 to 85:15) as a white solid (107.5 mg, 66%). 
Enantiomeric excess was determined with HPLC analysis using Diacel 
Chiracel® OD-3 column, 25% iPrOH in n-hexane, 0.8 mL/min. 97:3 er, 






Synthesis of 5.1f (Table 5-10): Following the general procedure 5D, the title 
compound was isolated by flash chromatography (SiO2, CH2Cl2:MeOH (saturated 
with NH3) = 95:5 to 85:15) as a white solid (86.5 mg, 53%). Enantiomeric excess 
was determined with HPLC analysis using Diacel Chiracel® IA-3 column, 50% 
iPrOH in n-hexane, 0.8 mL/min. 99:1 er, tR(major) = 6.1 min, tR(minor) = 4.3 min. 
[α]D20 = +952.0 (c = 0.10 in CHCl3) 
 
Synthesis of 5.1i (Table 5-10): Following the general procedure 5D, the title 
compound was isolated by flash chromatography (SiO2, CH2Cl2:MeOH (saturated 
with NH3) = 98:2 to 85:15) as a white solid (140.2 mg, 93%). Both the free N–H 
bonds in 5.1i were acetylated prior to HPLC analysis and taking optical rotation. 
Enantiomeric excess was determined with HPLC analysis using Diacel Chiracel® 
IA-3 column, 10% iPrOH in n-hexane, 0.8 mL/min. 97:3 er, tR(major) = 10.4 min, 
tR(minor) = 8.5 min. [α]D20 = –363.9 (c = 0.50 in CHCl3) 
 
Synthesis of 5.1k (Table 5-10): Following the general procedure 5D, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 to 
1:1) as a white solid (131.8 mg, 88%). The double bond was hydrogenated and 
both the free N–H bonds in 5.1l were acetylated prior to HPLC analysis and taking 
optical rotations. Enantiomeric excess was determined with HPLC analysis using 
Diacel Chiracel® OD-3 column, 20% iPrOH in n-hexane, 0.8 mL/min. >99:1 er, 
tR(major) = 10.0 min, tR(minor) = 11.6 min. [α]D20 = +64.3 (c = 1.00 in CHCl3) 
 
Synthesis of 5.1l (Table 5-10): Following the general procedure 5D, the title 
compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc = 2:1 to 
1:1) as a white solid (142.6 mg, 84%). Both the free N–H bonds in 5.1l were 
acetylated prior to HPLC analysis and taking optical rotation. Enantiomeric excess 
was determined with HPLC analysis using Diacel Chiracel® IA-3 column, 25% 
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iPrOH in n-hexane, 0.8 mL/min. 97:3 er, tR(major) = 6.4 min, tR(minor) = 4.8 min. [α]D20 = –397.6 
(c = 0.50 in CHCl3) 
 
7.6.5. Derivatizations of (±)-5.1i 
Synthesis of (±)-5.27 (Scheme 5–4): 
 
Hydrogenation: To a round bottom flask charged with a stir bar was added (±)-5.1i (1.96 g, 6.5 
mmol, 1.0 eq.) and 5% Rh on Alumina (336 mg, 0.16 mmol, 0.025 eq.) and MeOH (65 mL, 0.10 
M). The flask was purged by bubbling nitrogen gas through the resulting suspension at room 
temperature. Then a hydrogen-containing balloon was used to bubble hydrogen gas through the 
suspension at room temperature for approximately five minutes before cooling to –20 °C and 
stirring under a hydrogen atmosphere until complete conversion was observed (as monitored by 
NMR; usually about 16 hours). After complete conversion, the reaction was warmed up to room 
temperature, purged with nitrogen atmosphere, and filtered over a pad of celite using MeOH. The 
resulting filtrate was concentrated under reduced pressure and purified by flash chromatography 
(SiO2, EtOAc then CH2Cl2/MeOH = 9:1 to 4:1) to afford (±)-5.26 as a white solid (1.64 g, 83%). 
Birch reduction: (±)-5.26 (75 mg, 1.0 eq., 0.25 mmol) was added to a 100 mL three-necked flask 
charged with a stir bar. Next, the flask and attached bubbler were purged thoroughly with nitrogen 
gas, and THF (10 mL, 0.025 M) was added to dissolve the substrate. The flask was cooled in an 
acetone/dry ice bath. Next, ammonia was introduced as a gas into the flask, and approximately 10 
mL of liquid ammonia was allowed to condense in the flask. After turning off the ammonia and 
putting the flask back under nitrogen pressure, small chunks of lithium metal (approximately 17.4 
mg, 10 eq., 2.5 mmol) were added to the reaction and allowed to stir until the whole solution 
became dark blue. At this point ammonium chloride was added to quench the remaining lithium 
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and then the reaction was poured over a saturated ammonium chloride solution (100 mL), extracted 
with CH2Cl2 (3  100 mL), dried over magnesium sulfate, and concentrated under reduced pressure. 
The resulting residue was purified by flash chromatography (SiO2 CH2Cl2:MeOH = 99:1 to 9:1) 
to afford (±)-5.27 as a yellow solid (39.7 mg, 71%). 
 
Rf = 0.19 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 10.42 (br, 2H), 7.49 (d, J = 7.6 Hz, 1H), 7.34 
(td, J = 7.6, 1.2 Hz, 1H), 7.21 (td, J = 7.5, 1.1 Hz, 1H), 7.07 (d, J = 7.5 Hz, 1H), 
5.63 (dd, J = 10.2, 3.5 Hz, 1H), 4.02-4.01 (m, 1H), 3.03 (s, 3H), 2.68 (td, J = 
11.7, 5.4 Hz, 1H), 2.61 (td, J = 11.7, 5.4 Hz, 1H), 2.28 – 2.22 (m, 1H), 2.16 – 
2.15 (m, 1H), 1.97 – 1.67 (m, 4H), 0.87 (t, J = 7.4 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.8, 152.2, 137.0, 132.7, 131.3, 130.6, 129.6, 127.8, 54.8, 48.4, 
46.8, 25.6, 25.3, 21.3, 19.8, 11.6. 
HRMS: (ESI-TOF, m/z) calcd. For C16H23N4O2 [M+H]+ calc.: 303.1816; found: 303.1813. 
IR: (ATR, neat, cm-1): 3383 (w), 2966 (w), 1682 (m), 1595 (s), 1467 (m), 1389 (w), 1288 (w), 
1159 (w), 758 (w), 732 (w), 650 (w). 
m.p.: 116–118 ºC. 
 
Rf = 0.29 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.34 (m, 1H), 7.17 – 7.12 (m, 2H), 7.09 – 7.07 
(m, 1H), 3.77 (t, J = 4.9 Hz, 1H), 2.81 (dt, J = 11.2, 5.6 Hz, 1H), 2.75 – 2.61 (m, 
3H), 2.00 – 1.91 (m, 1H), 1.89 – 1.85 (m, 2H), 1.77 – 1.70 (m, 1H), 1.54 (sextet, 
J = 7.3 Hz, 2H), 0.95 (t, J = 7.4 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 139.4, 137.4, 129.2, 128.8, 126.7, 125.8, 55.5, 49.4, 29.5, 28.5, 
23.7, 19.1, 12.1. 
HRMS: (ESI-TOF, m/z) calcd. For C13H20N [M+H]+ calc.: 190.1590; found: 190.1600.    
IR: (ATR, neat, cm-1): 3018 (w), 2928 (s), 2862 (m), 1489 (w), 1451 (m), 1107 (w), 739 (s). 
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m.p.: 160–162 ºC. 
 
Synthesis of (±)-5.28 (Scheme 5–4): 
 
(±)-5.26 (20 mg, 0.066 mmol) was dissolved in concentrated aqueous HCl (0.66 mL, 0.1 M) in a 
4 mL vial. The vial was sealed without any exclusion of air and heated to 80 °C for 16 hours. Upon 
cooling, the contents of the vial were concentrated under reduced pressure. The resulting residue 
was purified by flash chromatography (SiO2 CH2Cl2:MeOH = 99:1 to 9:1) as a yellow solid (7.1 
mg, 48%). 
 
Rf = 0.29 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.62 (d, J = 7.4 Hz, 1H), 7.37 (td, J = 7.5, 1.1 
Hz, 1H), 7.30 (td, J = 7.5, 1.1 Hz, 1H), 7.16 (d, J = 7.4 Hz, 1H), 6.61 (dd, J = 
9.7, 2.9 Hz, 1H), 6.03 (ddd, J = 8.9, 5.7, 2.4 Hz, 1H), 4.52 (d, J = 6.2 Hz, 1H), 
3.15 (ddd, J = 19.2, 5.7, 1.4 Hz, 1H), 2.78 – 2.73 (m, 2H), 2.62 – 2.56 (m, 1H), 1.85 – 1.76 (m, 
2H), 0.86 (t, J = 7.4 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 134.4, 130.5, 130.4, 128.2, 128.1, 127.3, 126.2, 125.0, 53.1, 45.3, 
26.8, 20.0, 11.5. 
HRMS: (ESI-TOF, m/z) calcd. For C13H18N [M+H]+ calc.: 188.1434; found: 188.1437. 
IR: (ATR, neat, cm-1): 3397 (w), 2965 (w), 1687 (s), 1590 (m), 1472 (m), 1266 (w), 980 (w), 761 
(s), 731 (s), 698 (m), 517 (m). 




Synthesis of (±)-5.29 (Scheme 5–4):  
 
(±)-5.1i (75 mg, 0.25 mmol, 1.0 eq.) was added to a 100 mL three-necked flask charged with a stir 
bar. To the flask was then attached a bubbler and purged thoroughly with nitrogen gas, and the 
flask was cooled in an acetone/dry ice bath. Next, ammonia was introduced as a gas into the flask, 
and approximately 10 mL of liquid ammonia was allowed to condense in the flask. After turning 
off the ammonia and putting the flask back under nitrogen pressure, small chunks of lithium metal 
(approximately 17.4 mg, 10 eq., 2.5 mmol) were added to the reaction and allowed to stir until the 
whole solution became dark blue. At this point ammonium chloride was added to quench the 
remaining lithium and then the reaction was poured over a saturated ammonium chloride solution 
(100 mL), extracted with dichloromethane (3  100 mL), dried over magnesium sulfate, and 
concentrated under reduced pressure. The resulting residue was purified by flash chromatography 
(SiO2, CH2Cl2:MeOH = 99:1 to 9:1) as a yellow solid (33.6 mg, 60%). 
 
Rf = 0.23 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.41 (d, J = 7.5 Hz, 1H), 7.24 (t, J = 7.4 Hz, 1H), 
7.20 (t, J = 6.8 Hz, 1H), 7.15 (d, J = 7.3 Hz, 1H), 6.10 (dt, J = 10.1, 3.4 Hz, 1H), 
6.03 (ddd, J = 10.1, 3.7, 1.7 Hz, 1H), 4.38 (q, J = 3.8 Hz, 1H), 3.46 – 3.41 (m, 1H), 
3.36 – 3.31 (m, 1H), 2.53 (dt, J = 11.1, 7.1 Hz, 1H), 2.39 (dt, J = 11.1, 7.3 Hz, 1H), 1.46 (sextet, J 
= 7.0 Hz, 2H), 0.88 (t, J = 7.4 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 136.9, 135.2, 128.4, 128.3, 128.2, 127.1, 126.6, 126.3, 53.9, 46.9, 
30.0, 23.8, 12.0. 
HRMS: (ESI-TOF, m/z) calcd. For C13H18N [M+H]+ calc.: 188.1434; found: 188.1436.  
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IR: (ATR, neat, cm-1): 3392 (w), 3024 (m), 2949 (s), 1742 (s), 1604 (m), 1460 (m), 1374 (m), 
1217 (w), 750 (s). 
m.p.: 205–207 ºC. 
 
Synthesis of (±)-5.30 (Scheme 5–5): 
 
The title compound was synthesized by dissolving (±)-5.26 (36 mg, 0.12 mmol, 1.0 eq.) in 1 M 
aqueous HCl (1.2 mL, 0.1 M). Following dissolution, tBuOCl (16 uL, 0.14 mmol) in MeCN (1.2 
mL, 0.1 M) was added dropwise to the aqueous solution containing the substrate. Upon waiting 
five minutes, the contents of the vial were concentrated under reduced pressure and isolated by 
flash chromatography (SiO2, n-hexanes:EtOAc = 9:1 to EtOAc) as a white solid (14.4 mg, 50%). 
 
Rf = 0.37 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 9.97 (br, 2H), 8.07 (d, J = 7.7 Hz, 1H), 7.79 (d, J 
= 7.7 Hz, 1H), 7.61 (t, J = 7.3 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 4.58 (b, 1H), 3.17 
(dt, J = 17.5, 6.7 Hz, 1H), 2.85 (t, J = 7.7 Hz, 2H), 2.67 (dt, J = 17.5, 5.7 Hz, 1H), 
2.57 – 2.54 (m, 2H), 1.90 – 1.89 (m, 2H), 0.93 (t, J = 7.3 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 195.3, 135.5, 134.2, 133.0, 130.0, 129.3, 128.1, 54.9, 46.2, 34.6, 
24.9, 19.8, 11.5. 
HRMS: (ESI-TOF, m/z) calcd. For C13H18NO [M+H]+ calc.: 204.1383; found: 204.1386.  
IR: (ATR, neat, cm-1): 3387 (w), 2967 (w), 2791 (w), 1685 (s), 1604 (m), 1451 (m), 1287 (w), 767 
(m), 733 (m). 
m.p.: 105–107 ºC decomposed. 
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Synthesis of (±)-5.33 (Scheme 5–6): 
 
Mono-Boc protection: The title compound was synthesized by dissolving (±)-5.26 (100 mg, 0.33 
mmol, 1.0 eq.) in CH2Cl2 (3.3 mL, 0.10 M) and then triethyl amine (276 μL, 1.98 mmol, 6.0 eq.) 
and di-tert-butyl dicarbonate (334 μL, 1.65 mmol, 5.0 eq.) was added at 0 oC. The reaction was 
allowed to stir for 24 hours at room temperature (or until complete conversion by TLC). Then, 
NaOMe (25% weight solution in MeOH, 2 mL) was added dropwise to the mixture and the reaction 
was allowed to stir for five more minutes at room temperature. The contents were then diluted with 
50 mL of CH2Cl2 and 1 M HCl was added until the pH = 1. The aqueous layer was then extracted 
with CH2Cl2 (3  50 mL), and the combined organic layers were dried over MgSO4, filtered, and 
concentrated under reduced pressure. The desired compound was isolated by flash 
chromatography (SiO2, EtOAc) to afford (±)-5.31 as a white solid (105 mg, 79%). 
 
Alkylation: The title compound was synthesized by combining (±)-5.31 (500 mg, 1.2 mmol, 1.0 
eq.) with K2CO3 (858 mg, 6.2 mmol, 5.0 eq.) in 12 mL of CH2Cl2 and then 2-bromoacetophenone 
(371 mg, 1.9 mmol, 1.5 eq.) was added as a solid.  The reaction was allowed to stir at room 
temperature for 24 hours and then 50 mL of water was added, and the aqueous layer was extracted 
with CH2Cl2 (3  100 mL). The organic layers were combined, dried over MgSO4, and 
concentrated under reduced pressure. The desired compound was isolated by flash 
chromatography (SiO2, n-hexane:EtOAc = 4:1 to 1:1) to afford (±)-5.32 as a white solid (523 mg, 
81%). 
 
Hydrolysis: A degassed mixture of compound ()-5.32 (100 mg, 0.192 mmol, 1.0 eq.) and 40% 
aq. potassium hydroxide (0.40 mL, 2.88 mmol, 15 eq.) in methanol (1.0 mL, 0.2 M) in a pressure 
tube was heated at 80 ºC for 30 h and then at 160 ºC for 20 h under nitrogen atmosphere. After 
269 
 
cooling the reaction to rt, volatiles were removed under reduced pressure. The crude residue was 
purified by flash column chromatography (SiO2, CH2Cl2:MeOH = 5:1, then CH2Cl2:MeOH (sat. 
with NH3) = 4:1) to afford the compound ()-5.33 as a colorless oil (25.0 mg, 64%). 
 
Rf = 0.20 (EtOAc, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) 7.30 - 7.15 (m, 4H), 5.35 – 5.34 (m, 1H), 4.28 (br, 
1H), 3.43 – 3.33 (m, 2H), 3.08 (s, 3H), 2.44 - 2.42 (m, 1H), 2.28 – 2.25 (m, 1H), 
2.07 – 1.95 (m, 2H), 1.74 – 1.67 (m, 2H), 1.39 (s, 9H), 0.97 (t, J = 6.5 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 154.7 (overlap of 2 peaks detected by HSQC 
and HMBC), 152.2, 139.1, 131.5, 130.6, 129.4, 127.4, 126.0, 81.0, 57.9, 52.8 
(overlap of 2 peaks detected by HSQC), 28.6, 28.3, 25.1, 23.25, 23.17, 11.5. 
HRMS: (ESI-TOF, m/z) calcd. For C21H30N4NaO4 [M+Na]+ calc.: 425.2159; found: 425.2156.  
IR: (ATR, neat, cm-1): 3137 (w), 2968 (w), 1767 (w), 1687 (s), 1474 (m), 1410 (m), 1366 (m), 
1148 (m), 742 (m). 
m.p.: 73-74 ºC. 
 
Rf = 0.36 (n-hexane:EtOAc = 2:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.55 – 7.41 (m, 3H), 7.23 – 7.15 (m, 4H) 6.90 
(t, J = 7.7 Hz, 1H), 6.60 (t, J = 7.3 Hz, 1H), 5.46 – 5.40 (m, 1H), 5.03 (d, J = 
18.9 Hz, 1H), 4.68 (d, J = 18.9 Hz, 1H), 4.24 (br, 1H), 3.36 – 3.29 (m, 2H), 
3.24 (s, 3H), 2.60 (d, J = 14.7 Hz, 1H), 2.27 – 2.04 (m, 2H), 2.01 – 1.90 (m, 
1H), 1.78 – 1.61 (m, 2H), 1.50 (s, 9H), 0.97 (t, J = 7.5 Hz, 3H). 
13C NMR: (125 MHz, CDCl3) δ 193.1, 158.0, 156.0, 154.6, 138.3, 134.3, 133.6, 132.9, 129.4, 
128.3 (overlap of 2 peaks detected by HSQC), 127.9, 127.3, 125.6, 79.6, 58.7, 53.6, 52.7, 51.9, 
28.6, 26.7, 26.0, 24.5, 23.2, 11.6. 
HRMS: (ESI-TOF, m/z) calcd. For C29H37N4O5 [M+H]+ calc.: 521.2764; found: 521.2755.  
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IR: (ATR, neat, cm-1): 2967 (w), 1711 (m), 1684 (s), 1364 (w), 1246 (w), 1151 (s), 769 (w), 741 
(m), 687 (w), 594 (w), 552 (w). 
m.p.: 80–81 ºC. 
 
Rf = 0.40 (CH2Cl2:MeOH(sat. with NH3) = 4:1, KMnO4).  
1H NMR: (500 MHz, CD3OD) δ 7.49 – 7.42 (m, 3H), 7.32 – 7.27 (m, 1H), 4.48 
(dd, J = 5.7, 3.9 Hz, 1H), 4.24 (dd, J = 4.9, 3.2 Hz, 1H), 2.81 (ddd, J = 11.8, 8.9, 
6.0 Hz, 1H), 2.58 (ddd, J = 11.8, 8.9, 6.4 Hz, 1H), 2.38 – 2.26 (m, 1H), 2.26 – 1.97 
(m, 3H), 1.71 – 1.51 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H). 
13C NMR: (125 MHz, CD3OD) δ 141.2, 139.0, 129.8, 129.3, 128.9, 128.4, 74.5, 56.7, 50.4, 28.4, 
26.0, 23.6, 12.1. 
HRMS: (ESI-TOF, m/z) calcd. For C13H21N2 [M+H]+ calc.: 205.1705; found: 205.1707.  
IR: (ATR, neat, cm-1): 2930 (w), 1594 (m), 1493 (w), 1450 (w), 1366 (m), 1281 (w), 1056 (w), 
1027 (w), 953 (w), 757 (m), 734 (w), 698 (s), 530 (w). 
 
7.6.6. Synthesis and derivatizations of (±)-5.1r 
Synthesis of (±)-5.1r (Scheme 5-10): 
 
(±)-5.1r was synthesized following the general procedure 5A, with the following modifications: 
the reaction was run on a 1.50 mmol (MTAD, 1.57a) scale and the other reagents were scaled 
accordingly; memantine was prepared from dissolving 5 mmol of Memantine•HCl salt in 100 mL 
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of H2O and 100 mL of CH2Cl2 and increasing the pH of the aqueous layer to at least 12 with KOH, 
stirred rapidly until everything was dissolved, and then extracted with 3:1 CHCl3:iPrOH (3  100 
mL). The title compound was isolated by flash column chromatography (two columns: (SiO2, 
CH2Cl2:MeOH = 19:1 to 9:1) and (C18 reverse phase SiO2, H2O:MeOH = 19:1 to 9:1) as a white 
solid (416.3 mg, 66%).  
 
Rf = 0.39 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.42 – 7.41 (m, 1H), 7.31 – 7.27 (m, 2H), 7.21 
– 7.20 (m, 1H), 6.51 (dd, J = 9.7, 5.4 Hz, 1H), 6.17 (dd, J = 9.6, 5.9 Hz, 1H), 
5.86 (d, J = 5.8 Hz, 1H), 4.55 (d, J = 5.3, 1H), 2.99 (s, 3H), 2.15 (m, 1H), 1.63 
(q, J = 11.5 Hz, 2H), 1.50 (d, J = 11.6 Hz, 1H), 1.43 – 1.27 (m, 7H), 1.16 – 
1.10 (m, 2H), 0.85 (s, 6H). 
13C NMR: (125 MHz, CDCl3) δ 152.6, 152.2, 139.4, 136.0, 134.7, 129.5, 128.8, 128.5, 128.1, 
127.3, 55.5, 50.7, 50.6, 49.1, 48.1, 42.55, 42.52, 41.7, 32.75, 32.74, 30.27, 30.23, 30.21, 25.0. 
HRMS: (ESI-TOF, m/z) calcd. For C25H33N4O2 [M+H]+ calc.: 421.2598; found: 421.2588.  
IR: (ATR, neat, cm-1): 3402 (w), 2945 (w), 2904 (m), 1691 (s), 1611 (s), 1461 (m), 754 (m). 
m.p.: 120–121 ºC. 
 
Synthesis of (±)-5.44 (Scheme 5-10): 
(±)-5.1r (100 mg, 1.0 eq., 0.237 mmol) was added to a 100 mL three-necked flask charged with a 
stir bar. Next, the flask and attached bubbler were purged thoroughly with nitrogen gas, and then 
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the flask was cooled in an acetone/dry ice bath. Next, ammonia was released as a gas into the flask, 
and approximately 10 mL of liquid ammonia was allowed to condense in the flask. After turning 
off the ammonia and putting the flask back under nitrogen pressure, very small chunks of lithium 
metal were added to the reaction and allowed to stir until the whole solution became dark blue. At 
this point ammonium chloride was added to quench the remaining lithium, and then the reaction 
was poured over a saturated ammonium chloride solution (100 mL), extracted with CH2Cl2 (3  
100 mL), dried over magnesium sulfate, and concentrated under reduced pressure. The resulting 
residue was purified by flash chromatography (SiO2, n-hexane:EtOAc = 100:0 to 1:1) to afford 
(±)-5.44 as a white solid (52.4 mg, 64%). 
 
Rf = 0.30 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.48 (d, J = 7.7 Hz, 1H), 7.22 (td, J = 7.4, 1.3 
Hz, 1H), 7.14 (td, J = 7.4, 1.3 Hz, 1H), 7.09 (d, J = 7.7 Hz, 1H), 5.98 – 5.91 
(m, 2H), 4.37 (q, J = 4.4, 3.7 Hz, 1H), 3.45 - 3.39 (m, 1H), 3.31 – 3.24 (m, 1H), 
2.18 (dt, J = 6.1, 3.1 Hz, 1H), 1.65 – 1.15 (m, 12H), 0.88 (s, 6H). 
13C NMR: (125 MHz, CDCl3) δ 139.6, 134.5, 131.6, 129.2, 128.1, 126.5, 126.2, 124.6, 53.4, 51.1, 
50.62, 50.60, 46.7, 43.1, 42.9, 32.7, 30.60, 30.57, 29.7. 
HRMS: (ESI-TOF, m/z) calcd. For C22H30N [M+H]+ calc.: 308.2373; found: 308.2379.  
IR: (ATR, neat, cm-1): 2907 (s), 2841 (m), 1740 (m), 1454 (m), 1355 (w), 1196 (w), 746 (m). 
m.p.: 68–69 ºC. 




Hydrogenation: To a 250 mL round bottom flask charged with a stir bar was added (±)-5.1r (40 
mg, 0.095 mmol, 1.0 eq.) and 5% Rh on Alumina (5 mg 0.0024 mmol, 0.025 eq.), and 1 mL (0.1 
M) of MeOH. The flask was thoroughly purged by bubbling nitrogen gas through the resulting 
suspension at room temperature. Then a hydrogen-containing balloon was used to bubble hydrogen 
gas through the suspension at room temperature for approximately five minutes before cooling to 
-20 °C and stirring under a hydrogen atmosphere until complete conversion was observed (as 
monitored by NMR; usually about 16 hours). After complete conversion, the reaction was warmed 
up to room temperature, purged with nitrogen atmosphere, and filtered over a pad of celite using 
MeOH. The resulting filtrate was concentrated under reduced pressure and purified by flash 
chromatography (SiO2, CH2Cl2:MeOH = 99:1 to 9:1) to afford (±)-5.45 as a white solid (23.0 mg, 
57%). 
Oxidation: The title compound was synthesized by dissolving (±)-5.45 (38 mg, 0.090 mmol, 1.0 
eq.) in 1M aqueous HCl (0.90 mL, 0.1 M). Following dissolution, tBuOCl (24 uL, 0.22 mmol, 2.4 
eq.) in MeCN (1.2 mL, 0.1 M) was added dropwise to the aqueous solution containing the substrate. 
Upon waiting five minutes, the contents of the vial were concentrated under reduced pressure and 
isolated by flash chromatography (SiO2, n-hexane:EtOAc = 9:1 to EtOAc) to afford (±)-5.46 as a 
white solid (25.8 mg, 80%). 
 
Rf = 0.41 (CH2Cl2:MeOH = 9:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.22 – 7.17 (m, 4H), 6.27 (br, 2H), 5.41 (t, 
J = 7.9 Hz, 1H), 4.24 (br, 1H), 3.02 (s, 3H), 2.42 – 2.39 (m, 1H), 2.22 – 
2.19 (m, 2H), 2.06 (br, 1H), 1.91 (t, J = 13.2 Hz, 1H), 1.74 (d, J = 10.9 Hz, 
1H), 1.67 (d, J = 10.9 Hz, 1H), 1.59 – 1.44 (m, 4H), 1.32 (s, 4H), 1.15 (q, 
J = 12.6 Hz, 2H), 0.87 (s, 6H). 
13C NMR: (125 MHz, CDCl3) δ 154.9, 153.4, 137.2, 136.4, 129.4, 129.2, 
128.8, 127.8, 57.6, 51.5, 50.5, 48.8, 47.5, 47.4, 42.5, 40.2, 32.76, 32.75, 30.3, 30.2, 28.7, 25.3, 
22.5. 
HRMS: (ESI-TOF, m/z) calcd. For C25H35N4O2 [M+H]+ calc.: 423.2755; found: 423.2764.  
IR: (ATR, neat, cm-1): 2912 (m), 2846 (w), 1694 (s), 1610 (m), 1468 (m), 1020 (w), 731 (w). 
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m.p.: 121–124 ºC decomposed. 
 
Rf = 0.24 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.98 (d, J = 7.8 Hz, 1H), 7.61 (d, J = 7.7 
Hz, 1H), 7.53 (t, J = 7.2 Hz, 1H), 7.33 (t, J = 7.5 Hz, 1H), 4.14 (dd, J = 6.8, 
3.4 Hz, 1H), 3.07 (ddd, J = 17.1, 8.4, 4.2 Hz, 1H), 2.57 (ddd, J = 17.2, 8.5, 
4.4 Hz, 1H), 2.24 (ddt, J = 12.6, 8.2, 3.9 Hz, 1H), 2.18 (dt, J = 5.5, 2.7 Hz, 
1H), 2.03 – 1.96 (m, 1H), 1.64 – 1.05 (m, 12H), 0.88 (s, 6H). 
13C NMR: (125 MHz, CDCl3) δ 198.7, 148.7, 133.9, 132.1, 128.5, 127.3, 127.1, 53.4, 51.1, 50.5, 
48.5, 43.1, 42.8, 36.0, 33.2, 32.7, 30.5, 29.9. 
HRMS: (ESI-TOF, m/z) calcd. For C22H30NO [M+H]+ calc.: 324.2322; found: 324.2321.  
IR: (ATR, neat, cm-1): 3384 (w), 3035 (m), 2921 (m), 2313 (w), 1685 (s), 1500 (m), 1401 (m), 
1117 (m), 1069 (m), 760 (m). 
m.p.: 114–116 ºC decomposed. 
 
Synthesis of (±)-5.49 (Scheme 5-10): 
 
 
Alkylation: A mixture of compound ()-5.1r (50.0 mg, 0.12 mmol, 1.0 eq.), 2’-
bromoacetophenone (71.0 mg, 0.36 mmol, 3.0 eq.), and K2CO3 (82.2 mg, 0.60 mmol, 5.0 eq.) in 
dichloromethane (1.2 mL, 0.1 M) was stirred at 50 ºC for 2 h. After cooling to rt, water (2.0 mL) 
was added, and the organic phase was separated. The aqueous layer was extracted with 
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dichloromethane (3 × 2.0 mL), the combined organic extracts were washed with saturated aqueous 
sodium chloride solution (20 mL), dried over anhydrous magnesium sulfate, and concentrated 
under reduced pressure. The crude residue was purified by flash column chromatography (SiO2, 
n-hexane:EtOAc = 4:1) to afford the compound ()-5.47 as a colorless oil (45.2 mg, 71%). 
 
Dihydroxylation: Compound ()-5.47 (90.0 mg, 0.167 mmol, 1.0 eq.) and 4-methylmorpholine N-
oxide (25.4 mg, 0.217 mmol, 1.3 eq.) were dissolved in acetone (1.7 mL, 0.1 M) and water (60.0 
μL, 3.34 mmol, 20 eq.). To this solution was dropwise added osmium tetroxide (42 μL, 0.2 M 
solution in acetonitrile, 0.0084 mmol, 5.0 mol%) and the resulting solution was stirred at rt for 3 
h. Then the reaction was quenched with saturated aqueous sodium thiosulfate solution (0.3 mL), 
and diluted with EtOAc (3.0 mL) and water (3.0 mL). The organic phase was separated, then the 
aqueous layer was extracted with EtOAc (3 × 3.0 mL), the combined organic extracts were washed 
with saturated aqueous sodium chloride solution (3.0 mL), dried over anhydrous magnesium 
sulfate, and concentrated under reduced pressure. The crude residue was purified by flash column 
chromatography (SiO2, n-hexane:EtOAc = 1:4) to afford the compound ()-5.48 as a colorless oil 
(76.5 mg, 80%). 
 
Hydrolysis: A degassed mixture of compound ()-5.48 (100 mg, 0.175 mmol, 1.0 eq.) and 40% 
aq. potassium hydroxide (0.24 mL, 1.75 mmol, 10 eq.) in methanol (1.7 mL, 0.1 M) in a pressure 
tube was heated at 80 ºC for 24 h and then at 160 ºC for 12 h under nitrogen atmosphere. After 
cooling the reaction to rt, volatiles were removed under reduced pressure. The crude residue was 
purified by flash column chromatography (SiO2, CH2Cl2:MeOH = 10:1) to afford the compound 




Rf = 0.63 (n-hexane:EtOAc = 1:4, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.60 – 7.58 (m, 2H), 7.54 (td, J = 7.5, 1.3 
Hz, 1H), 7.41 (d, J = 7.8 Hz, 1H), 7.36 – 7.33 (m, 2H), 7.13 – 7.08 (m, 2H), 
6.91 (t, J = 7.5 Hz, 1H), 6.14 (ddd, J = 10.2, 3.9, 2.0 Hz, 1H), 5.86 – 5.84 
(m, 1H), 5.72 (dd, J = 10.2, 3.6 Hz, 1H), 4.96 (d, J = 18.4 Hz, 1H), 4.45 (d, 
J = 18.4 Hz, 1H), 4.40 – 4.32 (m, 1H), 3.25 (s, 3H), 2.25 – 2.22 (m, 1H), 
1.71 – 1.66 (m, 1H), 1.63 – 1.60 (m, 1H), 1.54 – 1.31 (m, 8H), 1.23 – 1.16 
(m, 2H), 0.92 (s, 6H). 
13C NMR: (125 MHz, CDCl3) δ 192.1, 156.9, 155.7, 139.3, 135.6, 134.3, 133.9, 131.4, 129.3, 
128.6, 128.5, 128.1, 127.9, 127.4, 122.4, 53.8, 52.8, 52.5, 51.0, 50.5, 45.8, 43.0, 42.8, 32.8, 32.7, 
30.5, 26.0. 
HRMS: (ESI-TOF, m/z) calcd. For C33H39N4O3 [M+H]+ calc.: 539.3022; found: 539.3029.  
IR: (ATR, neat, cm-1): 2899 (w), 1770 (w), 1708 (s), 1693 (s), 1598 (w), 1469 (m), 1449 (m), 1397 
(w), 1355 (w), 1225 (m), 1192 (w), 1002 (w), 963 (w), 790 (s), 728 (m), 686 (m), 649 (w), 592 
(m). 
 
Rf = 0.44 (CH2Cl2:MeOH = 5:1, UV, KMnO4).  
1H NMR: (500 MHz, CD3OD) δ 7.60 – 7.56 (m, 3H), 7.40 – 7.37 (m, 2H), 
7.22 (d, J = 7.8 Hz, 1H), 7.09 (d, J = 7.8 Hz, 1H), 7.01 (t, J = 7.6 Hz, 1H), 
6.67 (t, J = 7.6 Hz, 1H), 5.44 (d, J = 10.1 Hz, 1H), 4.98 (d, J = 18.6 Hz, 1H), 
4.63 (dd, J = 10.1, 2.1 Hz, 1H), 4.35 (d, J = 18.6 Hz, 1H), 4.10 – 4.05 (d, J 
= 2.5 Hz, 1H), 4.08 – 4.04 (m, 1H), 3.21 (s, 3H), 2.23 – 2.21 (m, 1H), 1.77 
(d, J = 11.4 Hz, 1H), 1.62 (d, J = 11.7 Hz, 1H), 1.56 – 1.34 (m, 8H), 1.20 – 
1.17 (m, 2H), 0.92 (s, 6H). 
13C NMR: (125 MHz, CD3OD) δ 194.1, 159.1, 158.9, 139.3, 135.5, 135.2, 135.1, 131.9, 129.7, 
129.4, 128.9, 128.5, 127.3, 76.8, 67.7, 60.4, 56.4, 55.0, 54.3, 52.0, 51.0, 50.9, 43.99, 43.97, 43.2, 
33.6, 33.5, 31.9, 30.9, 26.1. 
HRMS: (ESI-TOF, m/z) calcd. For C33H41N4O5 [M+H]+ calc.: 573.3077; found: 573.3068.  
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IR: (ATR, neat, cm-1): 2903 (w), 1770 (w), 1692 (s), 1477 (m), 1450 (w), 1226 (m), 753 (w), 686 
(w). 
 










Rf = 0.44 (CH2Cl2:MeOH = 5:1, UV, KMnO4).  
1H NMR: (500 MHz, CD3OD) δ 7.46 – 7.31 (m, 4H), 4.32 – 4.21 (m, 2H), 
4.14 – 4.06 (m, 1H), 4.01 – 3.98 (m, 1H), 2.20 (s, 1H), 1.72 (d, J = 12.7 Hz, 
1H), 1.57 (d, J = 11.9 Hz, 1H), 1.53 – 1.43 (m, 8H), 1.21 – 1.15 (m, 2H), 
0.90 (s, 6H). 
13C NMR: (125 MHz, CD3OD) δ 139.3, 134.5, 132.1, 129.9, 128.7, 126.8, 
76.2, 70.2, 56.2, 54.8, 53.4, 51.9, 51.0, 50.9, 44.0, 43.2, 33.52, 33.51, 31.9, 30.9. 
HRMS: (ESI-TOF, m/z) calcd. For C22H33N2O2 [M+H]+ calc.: 357.2542; found: 357.2540.  
IR: (ATR, neat, cm-1): 2898 (br), 2839 (m), 2454 (w), 1559 (w), 1453 (s), 1336 (w), 1066 (m), 






7.6.7. Dearomative syn-1,2-diamination of benzene with isocyanate 
General procedure 5E for the dearomative syn-1,2-diamination of benzene with isocyanate 
(Table 5-12) 
 
MTAD (1.57a, 45.2 mg, 0.4 mmol, 1.0 eq.) was placed in a test tube with a septum as the cap 
under nitrogen atmosphere. Dichloromethane (4.0 mL, 0.1 M) was added to the test tube at rt, and 
cooled to –78 ºC. Benzene (1.1a, 0.36 mL, 4.0 mmol, 10 eq.) was added dropwise at –78 ºC, and 
the resulting pink solution was stirred under irradiation with LED lights at –78 ºC until the solution 
became colorless (approximately 12 h). To this solution were added isocyanate (0.8 mmol, 2.0 eq.), 
1,3-cyclohexadiene (38 µL, 0.4 mmol, 1.0 eq.), and a solution of Pd(PPh3)4 (23.1 mg, 0.02 mmol, 
5.0 mol%) in dichloromethane (1.0 mL), and the resulting mixture stirred at –20 ºC for 12 h. The 
reaction was then quenched with water, and the organic phase was separated. The aqueous phase 
was extracted with dichloromethane (3 × 5 mL), and combined organic layer was washed with 
saturated aqueous sodium chloride solution (2 mL), dried over anhydrous magnesium sulfate, and 
then concentrated in vacuo. The resulting residue was purified by flash chromatography (SiO2, n-
hexane:EtOAc). 
 
Synthesis of (±)-5.50 (Table 5–12): Following the general procedure 5E, the 
title compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc 
= 1:2 to 1:4) to afford compound (±)-5.50 as a white solid (66.4 mg, 53%). 
Rf = 0.40 (EtOAc, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.44 – 7.38 (m, 2H), 7.38 – 7.31 (m, 1H), 7.21 
(d, J = 7.4 Hz, 2H), 6.24 (dddd, J = 9.8, 5.3, 2.2, 1.0 Hz, 1H), 6.08 (dd, J = 9.7, 5.3 Hz, 1H), 5.87 
– 5.80 (m, 1H), 5.46 (dd, J = 9.8, 4.9 Hz, 1H), 5.10 (dd, J = 6.5, 3.0 Hz, 1H), 4.64 (dd, J = 6.5, 4.8 
Hz, 1H), 3.17 (s, 3H). 
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13C NMR: (125 MHz, CDCl3) δ 151.0, 146.8, 145.5, 137.6, 129.5, 128.4, 128.3, 127.8, 126.9, 
124.1, 123.3, 53.5, 51.5, 25.7. 
HRMS: (ESI-TOF, m/z) calcd. For C16H15N4O3 [M+H]+ calc.: 311.1144; found: 311.1144. 
IR: (ATR, neat, cm-1): 1796 (w), 1731 (s), 1465 (w), 1413 (m), 1390 (m), 1372 (w), 1309 (w), 
1247 (w), 1220 (m), 1177 (w), 762 (w), 754 (m), 739 (w), 717 (m), 696 (m), 601 (w), 554 (w). 






Rf = 0.33 (EtOAc, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.56 – 7.49 (m, 2H), 7.46 (td, J = 7.4, 1.4 Hz, 
1H), 7.30 (d, J = 7.4 Hz, 2H), 6.61 (ddd, J = 7.5, 5.4, 1.8 Hz, 1H), 6.59 – 6.53 
(m, 1H), 5.47 (ddd, J = 5.3, 2.8, 1.8 Hz, 1H), 5.10 (dd, J = 9.0, 2.8 Hz, 1H), 
4.83 – 4.76 (m, 1H), 4.69 (dd, J = 9.0, 3.2 Hz, 1H), 3.17 (s, 3H), 2.98 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 157.4, 157.0, 150.4, 146.9, 146.0, 137.2, 130.5, 130.4 ,129.4, 
129.1, 127.8, 57.5, 52.8, 51.8, 50.2, 25.9, 25.8. 
HRMS: (ESI-TOF, m/z) calcd. For C19H18N7O5 [M+H]+ calc.: 424.1369; found: 424.1370.  
IR: (ATR, neat, cm-1): 1803 (w), 1781 (w), 1735 (s), 1713 (s), 1455 (w), 1422 (m), 1391 (m), 1280 
(w), 1182 (w), 1014 (w), 758 (m), 737 (w), 712 (m), 705 (m), 695 (w), 630 (w). 






7.7 Experimental procedures for Chapter 6 
7.7.1 Dearomative syn-1,4-oxyamination of naphthalene with oxygen-based nucleophiles 
General procedure 6A for the dearomative syn-1,4-oxyamination of naphthalene with oxime 
(Table 6-5) 
 
MTAD (1.57a, 56.5 mg, 0.5 mmol, 1.0 eq.) and naphthalene (1.2a, 128 mg, 1.0 mmol, 2.0 eq.) 
were placed in a test tube with a septum as the cap under nitrogen atmosphere. Propionitrile (5.0 
mL) was added to the test tube at rt, and the mixture was stirred until both MTAD and the 
naphthalene were completely dissolved. Then the resulting pink solution was stirred under 
irradiation with LED lights at –50 ºC until the solution became white suspension (about 6 hours). 
In a separate flask, n-BuLi (0.59 mL, 0.95 mmol, 1.9 eq., 1.6 M solution in hexane) was added 
dropwise to a solution of oxime (1.0 mmol, 2.0 eq.) in PhMe (2.5 mL) under nitrogen atmosphere 
at –78 ºC. The mixture was stirred for 15 min. at –78 ºC, and then cannulated into the solution of 
cycloadduct (at this point the LED lights were turned off). Subsequently, a solution of Pd(PPh3)4 
(28.9 mg, 0.025 mmol, 5 mol%) in PhMe (1.0 mL, pre-stirred at rt until Pd(PPh3)4 completely 
dissolved) was added, and the resulting mixture was warmed from –50 ºC to 0 ºC over 4 h. The 
reaction was then quenched with saturated aqueous NH4Cl (3.0 mL), and EtOAc (10 mL) and 
water (10 mL) were added. Aqueous HCl solution (1 M) was added to acidify the solution to pH~5 
and the organic phase was separated. The aqueous phase was extracted with EtOAc (3 × 10 mL), 
then the combined organic extracts were washed with saturated aqueous sodium chloride solution 
(10 mL), dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The 




Synthesis of (±)-6.1a (Table 6-5): Following the general procedure 6A, the 
title compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc 
= 2:1 to 1:1) as a white solid (132.6 mg, 70%).  
Gram-scale synthesis of (±)-6.1a (Table 6-5): MTAD (1.57a, 1.0 g, 8.8 mmol, 
1.0 eq.) and naphthalene (1.2a, 2.25 g, 17.6 mmol, 2.0 eq.) were placed in a 
500 mL clear borosilicate glass bottle with a septum as the cap under nitrogen 
atmosphere. Propionitrile (88 mL, 0.1 M) was added to the bottle at rt, and the mixture was stirred 
until both MTAD and the naphthalene were completely dissolved. Then the resulting pink solution 
was stirred under irradiation with LED lights at –50 ºC until the pink solution became white 
suspension (about 24 hours). In a separate flask, nBuLi (10.38 mL, 16.72 mmol, 1.9 eq., 1.6 M 
solution in hexane) was added dropwise to a solution of acetophenone oxime (2.37 g, 17.6 mmol, 
2.0 eq.) in PhMe (50 mL) under nitrogen atmosphere at –78 ºC. The mixture was stirred for 15 
min. at –78 ºC, and then cannulated into the solution of cycloadduct (at this point the LED lights 
were turned off). Subsequently, a solution of Pd(PPh3)4 (508.6 mg, 0.44 mmol, 5 mol%) in PhMe 
(15 mL, pre-stirred at rt until Pd(PPh3)4 completely dissolved) was added, and the resulting mixture 
was warmed from –50 ºC to 0 ºC over 4 h. The reaction was then quenched with saturated aqueous 
NH4Cl (50 mL), and EtOAc (50 mL) and water (50 mL) were added. Aqueous HCl solution (1 M) 
was added to acidify the solution to pH~5 and the organic phase was separated. The aqueous phase 
was extracted with EtOAc (3 × 50 mL), then the combined organic extracts were washed with 
saturated aqueous sodium chloride solution (100 mL), dried over anhydrous magnesium sulfate, 
and concentrated under reduced pressure. The product was purified by flash column 
chromatography (SiO2, n-hexane:EtOAc mixture = 2:1 to 1:1) as a white solid (2.17 g, 66%). 
 
Rf = 0.41 (n-hexane:EtOAc = 1:1, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.73 – 7.60 (m, 1H), 7.59 – 7.55 (m, 1H), 7.52 – 7.48 (m, 2H), 
7.39 – 7.33 (m, 6H), 6.51 (ddd, J = 10.1, 4.0, 1.4 Hz, 1H), 6.10 (ddd, J = 10.1, 4.1, 1.2 Hz, 1H), 
5.87 (ddd, J = 4.0, 1.3, 1.2 Hz, 1H), 5.72 – 5.64 (ddd, J = 4.1, 1.4, 1.3 Hz, 1H), 3.03 (s, 3H), 2.27 
(s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 157.3, 153.8, 152.7, 136.3, 135.1, 132.0, 132.0, 129.5, 129.4, 
128.9, 128.84, 128.80, 127.9, 126.9, 126.4, 73.7, 51.2, 25.3, 14.1. 
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HRMS: (ESI-TOF, m/z) calcd. For C21H21N4O3 [M+H]+ calc.: 377.1614; found: 377.1599.  
IR: (ATR, neat, cm-1): 3145 (w), 1760 (m), 1690 (s), 1484 (s), 1340 (m), 1237 (m), 1190 (w), 
1021 (m), 941 (m), 755 (s), 609 (s). 
m.p.: 174–175 ºC. 
 
Synthesis of (±)-6.1b (Table 6-5): Following the general procedure 
6A, the title compound was isolated by flash chromatography (SiO2, 
n-hexane:EtOAc = 2:1 to 1:1) as a brown solid (96.4 mg, 46%).  
Rf = 0.33 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.67 (br, 1H), 7.58 (dd, J = 6.6, 2.7 
Hz, 1H), 7.47 – 7.40 (m, 2H), 7.39-7.30 (m, 3H), 6.67 (d, J = 8.9 Hz, 
2H), 6.53 (ddd, J = 10.1, 4.0, 1.5 Hz, 1H), 6.08 (ddd, J = 10.1, 3.9, 1.3 Hz, 1H), 5.86 (dd, J = 4.0, 
1.3 Hz, 1H), 5.63 (dd, J = 3.9, 1.5 Hz, 1H), 3.06 (s, 3H), 2.96 (s, 6H), 2.23 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 157.1, 154.0, 152.8, 151.3, 135.5, 132.5, 132.1, 129.5, 128.8, 
128.7, 127.9, 127.4, 126.6, 123.9, 112.1, 73.5, 51.4, 40.4, 29.8, 25.3, 13.7. 
HRMS: (ESI-TOF, m/z) calcd. For C23H25N5O3Na [M+Na]+ calc.: 442.1855; found: 442.1844.  
IR: (ATR, neat, cm-1): 3199 (w), 2907 (w), 1696 (m), 1603 (s), 1525 (m), 1411 (m), 1362 (m), 
1316 (m), 1232 (m), 1199 (m), 999 (m), 911 (s), 817 (s), 555 (m).  
m.p.: 191–192 ºC.  
 
Synthesis of (±)-6.1c (Table 6-5): Following the general procedure 6A, 
the title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (142.0 mg, 70%).  
Rf = 0.35 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.57 (d, J = 7.3 Hz, 1H), 7.49 – 7.44 
(m, 3H), 7.39 – 7.32 (m, 3H), 6.92 – 6.85 (m, 2H), 6.52 (ddd, J = 10.0, 
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4.0, 1.4 Hz, 1H), 6.11 (ddd, J = 10.0, 4.0, 1.2 Hz, 1H), 5.88 (dd, J = 4.0, 1.4 Hz, 1H), 5.68 – 5.61 
(m, 1H), 3.81 (s, 3H), 3.06 (s, 3H), 2.25 (s, 3H).  
13C NMR: (125 MHz, CDCl3) δ 160.7, 156.8, 153.9, 152.6, 135.3, 132.3, 132.1, 129.6, 128.9, 
128.89, 128.84, 128.0, 127.8, 126.8, 114.2, 73.6, 55.5, 51.3, 25.3, 14.0. 
HRMS: (ESI-TOF, m/z) calcd. For C22H23N4O4 [M+H]+ calc.: 407.1719; found: 407.1710.  
IR: (ATR, neat, cm-1): 3094 (w), 1759 (m), 1693 (s), 1605 (m), 1513 (m), 1477 (m), 1397 (m), 
1245 (s), 1039 (m), 927 (s), 705 (s), 545 (m).  
m.p.: 187–188 ºC. 
 
Synthesis of (±)-6.1d (Table 6-5): Following the general procedure 6A, 
the title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (124.8 mg, 56%).  
Rf = 0.43 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.69 – 7.60 (m, 4H), 7.58 – 7.55 (m, 
1H), 7.40 – 7.34 (m, 3H), 7.24 (br, 1H), 6.52 (ddd, J = 10.1, 3.9, 1.5 
Hz, 1H), 6.10 (ddd, J = 10.1, 4.0, 1.2 Hz, 1H), 5.89 – 5.83 (m, 1H), 5.74 – 5.68 (m, 2H), 3.07 (s, 
3H), 2.27 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 155.6, 154.2, 153.3, 139.70, 139.69, 134.9, 131.9, 131.2 (q, J = 
32.5 Hz), 129.5, 129.0, 128.9, 127.9, 126.9, 126.6, 125.7 (q, J = 3.8 Hz), 124.1 (q, J = 272.2 Hz), 
74.2, 51.6, 25.4, 13.7. 
19F NMR: (471 MHz, CDCl3) δ –62.7. 
HRMS: (ESI-TOF, m/z) calcd. For C22H20F3N4O3 [M+H]+ calc.: 445.1488; found: 445.1491.  
IR: (ATR, neat, cm-1):3208 (w), 1771 (w), 1678 (s), 1478 (m), 1336 (m), 1230 (m), 1160 (m), 
1102 (s), 980 (s), 832 (m), 765 (s), 596 (m). 




Synthesis of (±)-6.1e (Table 6-5): Following the general procedure 6A, 
the title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (137.9 mg, 70%).  
Rf = 0.45 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.67 (br, 1H), 7.57 – 7.53 (m, 1H), 7.53 
– 7.47 (m, 2H), 7.39 – 7.30 (m, 3H), 7.07 – 7.00 (m, 2H), 6.49 (ddd, J = 
10.1, 3.9, 1.5 Hz, 1H), 6.07 (ddd, J = 10.1, 4.0, 1.2 Hz, 1H), 5.87 – 5.81 (m, 1H), 5.65 (ddd, J = 
4.5, 2.7, 1.0 Hz, 1H), 3.01 (s, 3H), 2.23 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 163.5 (d, J = 247.5 Hz), 155.9, 154.0, 153.1, 135.0, 132.4(d, J = 
3.8 Hz), 131.92, 131.88, 129.3, 128.8 (d, J = 7.3 Hz), 128.23, 128.16, 127.8, 126.7, 115.7 (d, J = 
21.3 Hz), 73.8, 51.4, 25.3, 13.9. 
19F NMR: (471 MHz, CDCl3) δ –111.55. 
HRMS: (ESI-TOF, m/z) calcd. For C21H20FN4O3 [M+H]+ calc.: 395.1519; found: 395.1529.  
IR: (ATR, neat, cm-1): 3084 (w), 1762 (m), 1696 (s), 1475 (m), 1396 (m), 1224 (m), 1001 (m), 
929 (m), 825 (m), 703 (s), 691 (m), 557 (m). 
m.p.: 172–173 ºC.  
 
Synthesis of (±)-6.1f (Table 6-5): Following the general procedure 6A, 
the title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (108.7 mg, 53%). 
Rf = 0.43 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.58 – 7.54 (m, 1H), 7.50 – 7.44 (m, 
2H), 7.39 – 7.32 (m, 5H), 7.23 (br, 1H), 6.51 (ddd, J = 10.1, 4.0, 1.4 Hz, 
1H), 6.11 (ddd, J = 10.1, 4.1, 1.2 Hz, 1H), 5.92 – 5.86 (m, 1H), 5.70 – 5.63 (m, 1H), 3.08 (s, 3H), 
2.26 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 156.0, 154.1, 153.0, 135.6, 135.1, 134.8, 132.1, 132.0, 129.5, 




HRMS: (ESI-TOF, m/z) calcd. For C21H20ClN4O3 [M+H]+ calc.: 411.1224; found: 411.1213.  
IR: (ATR, neat, cm-1): 3089 (w), 1762 (m), 1695 (s), 1476 (m), 1394 (m), 1239 (w), 1094 (m), 
929 (s), 760 (s), 694 (w).  
m.p.: 210–211 ºC.  
 
Synthesis of (±)-6.1g (Table 6-5): Following the general procedure 6A, 
the title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a pale yellow solid (113.3 mg, 50%). 
Rf = 0.40 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.55 (dd, J = 6.3, 3.0 Hz, 1H), 7.52 – 
7.48 (m, 2H), 7.43 – 7.40 (m, 2H), 7.41 – 7.31 (m, 3H), 7.25 – 7.19 (br, 
1H), 6.51 (ddd, J = 10.0, 3.8, 1.5 Hz, 1H), 6.14 – 6.07 (m, 1H), 5.89 – 5.85 (m, 1H), 5.70 – 5.65 
(m, 1H), 3.07 (s, 3H), 2.24 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 156.0, 154.1, 153.1, 135.3, 135.0, 132.0, 131.98, 131.96, 129.5, 
129.0, 128.9, 128.0, 127.9, 126.9, 123.9, 74.1, 51.5, 25.4, 13.7. 
HRMS: (ESI-TOF, m/z) calcd. For C21H20BrN4O3 [M+H]+ calc.: 455.0719; found: 455.0732.  
IR: (ATR, neat, cm-1): 3124 (w), 2921 (w), 1761 (w), 1696 (s), 1476 (s), 1393 (m), 1239 (m), 1068 
(w), 1002 (m), 929 (s), 761 (s), 601 (w). 
m.p.: 214-215 ºC.  
 
Synthesis of (±)-6.1h (Table 6-5): Following the general procedure 6A, the 
title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (118.9 mg, 61%).  
Rf = 0.39 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.93 (br, 1H), 7.48 – 7.42 (m, 1H), 7.32 – 
7.28 (m, 1H), 7.26 – 7.21 (m, 2H), 7.19-7.14 (m, 1H), 7.12-7.05 (m, 2H), 
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6.97 (d, J = 7.5 Hz, 1H), 6.38 (dd, J = 10.1, 4.2 Hz, 1H), 6.02 (ddd, J = 10.1, 4.3, 1.1 Hz, 1H), 5.82 
– 5.76 (m, 1H), 5.57 – 5.51 (m, 1H), 2.90 (s, 3H), 2.12 (s, 3H), 1.97 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 159.6, 153.2, 151.4, 136.6, 135.5, 135.2, 132.8, 131.9, 131.0, 
129.4, 129.0, 128.9, 128.9, 128.3, 128.1, 127.6, 126.1, 73.2, 50.6, 25.2, 19.7, 17.5. 
HRMS: (ESI-TOF, m/z) calcd. For C22H23N4O3 [M+H]+ calc.: 391.1770; found: 391.1780.  
IR: (ATR, neat, cm-1): 3205 (w), 1761 (m), 1690 (s), 1481 (s), 1455 (m), 1221 (m), 1023 (m), 929 
(m), 749 (s), 689 (m), 545 (m). 
m.p.: 153–154 ºC. 
 
Synthesis of (±)-6.1i (Table 6-5): Following the general procedure 6A, the 
title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (140.1 mg, 69%).  
Rf = 0.32 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.13 (br, 1H), 7.59 – 7.52 (m, 1H), 7.41 – 
7.31 (m, 4H), 7.04 (dd, J = 7.5, 1.8 Hz, 1H), 6.93 – 6.86 (m, 2H), 6.48 (ddd, 
J = 10.1, 4.1, 1.3 Hz, 1H), 6.11 (ddd, J = 10.1, 4.2, 1.2 Hz, 1H), 5.91 – 5.85 (m, 1H), 5.66 – 5.60 
(m, 1H), 3.74 (s, 3H), 3.00 (s, 3H), 2.22 (s, 3H).  
13C NMR: (125 MHz, CDCl3) δ 158.6, 157.3, 153.3, 151.6, 135.3, 132.6, 132.0, 130.6, 129.5 
(overlap of two peaks observed from HSQC), 128.83, 128.80, 128.1, 127.4, 126.1, 121.0, 111.6, 
73.2, 55.5, 50.7, 25.2, 16.9.  
HRMS: (ESI-TOF, m/z) calcd. For C22H23N4O4 [M+H]+ calc.: 407.1719; found: 407.1718.  
IR: (ATR, neat, cm-1): 3215 (w), 2852 (w), 1759 (m), 1688 (s), 1480 (s), 1440 (m), 1245 (m), 927 
(m), 898 (m), 761 (s), 601 (m). 




Synthesis of (±)-6.1j (Table 6-5): Following the general procedure 6A, the 
title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (122.1 mg, 62%).  
Rf = 0.40 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.71 (br, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.34 
– 7.23 (m, 4H), 7.18 – 7.14 (m, 1H), 7.08 – 7.02 (m, 1H), 7.01-6.96 (m, 
1H), 6.40 (ddd, J = 10.1, 4.0, 1.5 Hz, 1H), 6.03 (ddd, J = 10.1, 4.1, 1.3 Hz, 1H), 5.82 – 5.77 (m, 
1H), 5.61 – 5.55 (m,1H), 2.93 (s, 3H), 2.20 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 160.4 (d, J = 248.8 Hz), 155.5, 153.5, 152.1, 134.9, 132.3, 131.7, 
131.1 (d, J = 7.5 Hz), 129.6 (d, J = 3.8 Hz), 129.4, 128.9 (d, J = 6.3 Hz), 128.0, 127.4, 124.8, 
124.70, 124.67, 116.4 (d, J = 22.5 Hz), 73.7, 50.9, 25.2, 16.4 (d, J = 3.8 Hz). 
19F NMR: (471 MHz, CDCl3) δ –114.66. 
HRMS: (ESI-TOF, m/z) calcd. For C21H20FN4O3 [M+H]+ calc.: 395.1519; found: 395.1514.  
IR: (ATR, neat, cm-1): 3040 (w), 2923 (w), 1763 (m), 1685 (s), 1477 (m), 1371 (w), 1257 (m), 
1195 (m), 1076 (w), 974 (m), 862 (w), 759 (s), 603(m).  
m.p.: 155–156 ºC. 
 
Synthesis of (±)-6.1k (Table 6-5): Following the general procedure 6A, 
the title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (93.7 mg, 44%).  
Rf = 0.40 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3)  δ 7.94 (s, 1H), 7.86 – 7.78 (m, 4H), 7.62 
(d, J = 7.5 Hz, 1H), 7.52 – 7.46 (m, 2H), 7.42-7.28 (m, 4H), 6.58 (dd, J 
= 10.2, 4.0 Hz, 1H), 6.12 (dd, J = 10.2, 4.0 Hz, 1H), 5.91 – 5.86 (m, 1H), 5.78 – 5.72 (m, 1H), 3.07 
(s, 3H), 2.38 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 156.6, 154.2, 153.2, 135.2, 133.9, 133.8, 133.2, 132.2, 132.0, 




HRMS: (ESI-TOF, m/z) calcd. For C25H23N4O3 [M+H]+ calc.: 427.1770; found: 427.1789.  
IR: (ATR, neat, cm-1): 3168 (w), 1761 (m), 1691 (s), 1481 (m), 1307 (m), 1236 (m), 1024 (m), 
899 (m), 745 (s), 608 (m). 
m.p.: 213–214 ºC. 
 
Synthesis of (±)-6.1l (Table 6-5): Following the general procedure 6A, the 
title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (157.8 mg, 72%).  
Rf = 0.48 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.54 (d, J = 7.6 Hz, 1H), 7.48 – 7.37 (m, 
5H), 7.36 – 7.30 (m, 9H), 6.50 (ddd, J = 10.1, 4.1, 1.5 Hz, 1H), 6.14 (ddd, 
J = 10.1, 4.2, 1.3 Hz, 1H), 5.92 – 5.85 (m, 2H), 5.65 – 5.60 (m, 1H), 3.05 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 159.2, 153.9, 152.4, 136.2, 135.1, 133.5, 132.3, 131.8, 129.9, 
129.5, 129.3, 129.0, 128.9, 128.7, 128.4, 128.3, 128.1, 127.4, 74.0, 51.2, z25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C26H23N4O3 [M+H]+ calc.: 439.1770; found: 439.1771.  
IR: (ATR, neat, cm-1): 3152 (w), 2921 (w), 1758 (m), 1681 (s), 1475 (m), 1295 (w), 1158 (w), 950 
(m), 755 (s), 696 (s), 603 (m). 
m.p.: 179–180 ºC. 
 
Synthesis of (±)-6.1m (Table 6-5): Following the general procedure 6A, the 
title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (144.1 mg, 74%).  
Rf = 0.42 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.63 (br, 1H), 7.56 (dd, J = 7.4, 1.4 Hz, 1H), 
7.48 (ddd, J = 6.5, 2.7, 1.5 Hz, 2H), 7.40 – 7.33 (m, 6H), 6.50 (ddd, J = 10.2, 
4.0, 1.5 Hz, 1H), 6.08 (ddd, J = 10.2, 4.0, 1.3 Hz, 1H), 5.89 – 5.83 (m, 1H5.69 – 5.63 (m, 1H), 
3.03 (s, 3H), 2.77 (q, J = 7.6 Hz, 2H), 1.13 (t, J = 7.6 Hz, 3H). 
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13C NMR: (125 MHz, CDCl3) δ 162.2, 153.9, 152.7, 135.4, 135.1, 132.0, 131.9, 129.5, 129.3, 
128.8, 128.8, 128.8, 127.9, 126.8, 126.6 (overlap of two peaks observed by HSQC), 73.7, 51.3, 
25.2, 21.4, 11.1. 
HRMS: (ESI-TOF, m/z) calcd. For C22H23N4O3 [M+H]+ calc.: 391.1770; found: 391.1752.  
IR: (ATR, neat, cm-1): 3243 (w), 1762 (m), 1691 (s), 1476 (m), 1405 (m), 1309 (w), 1226 (m), 
1023 (s), 957 (m), 765 (s), 681 (s), 592 (m). 
m.p.: 145–146 ºC.  
 
Synthesis of (±)-6.1n (Table 6-5): Following the general procedure 6A, the 
title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a colorless oil (76.9 mg, 49%).  
Rf = 0.37 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 10.00 (br, 1H), 7.45 – 7.40 (m, 1H), 7.38 – 
7.29 (m, 3H), 6.36 (ddd, J = 10.1, 4.4, 1.3 Hz, 1H), 6.18 (ddd, J = 10.1, 4.4, 1.3 Hz, 1H), 5.95 – 
5.87 (m, 1H), 5.46 (dd, J = 4.5, 2.6 Hz, 1H), 3.05 (s, 3H), 1.94 (s, 3H), 1.91 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 158.5, 152.0, 151.3, 135.1, 133.2, 132.0, 129.5, 129.04, 129.02, 
128.4, 128.1, 72.4, 49.7, 25.1, 21.7, 16.7.  
HRMS: (ESI-TOF, m/z) calcd. For C16H18N4O3Na [M+ Na]+ calc.: 337.1277; found:337.1278.  
IR: (ATR, neat, cm-1): 3066 (w), 2919 (w), 1761 (m), 1689 (s), 1472 (s), 1368 (m), 1200 (m), 937 
(m), 758 (s), 525 (m). 
 
Synthesis of (±)-6.1o (Table 6-5): Following the general procedure 6A, 
the title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (120.7 mg, 60%).  
Rf = 0.49 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 9.92 (br, 1H), 7.65 – 7.58 (m, 2H), 7.49 
– 7.44 (m, 1H), 7.42 – 7.31 (m, 5H), 7.27-7.22 (m, 1H), 7.12 (d, J = 16.2 
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Hz, 1H), 6.88 (d, J = 16.2 Hz, 1H), 6.42 (ddd, J = 10.0, 4.4, 1.0 Hz, 1H), 6.23 (ddd, J = 10.0, 4.6, 
1.1 Hz, 1H), 5.99 – 5.92 (m, 1H), 5.70 – 5.59 (m, 1H), 3.12 (s, 3H), 2.17 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 159.0, 152.0, 151.5, 136.04, 135.99, 134.7, 133.1, 131.8, 129.5, 
129.3, 129.2, 128.85, 128.79, 128.5, 128.4, 127.6, 124.0, 73.1, 49.6, 25.3, 11.1. 
HRMS: (ESI-TOF, m/z) calcd. For C23H23N4O3 [M+H]+ calc.: 403.1770; found: 403.1772.  
IR: (ATR, neat, cm-1): 3165 (w), 2920 (w), 1762 (m), 1690 (s), 1479 (m), 1452 (m), 1306 (w), 
1158 (w), 1023 (m), 956 (s), 947 (s), 768 (s), 608 (m). 
m.p.: 131–132ºC. 
 
General procedure 6B for the dearomative syn-1,4-oxyamination of naphthalene with 
benzylalcohols (Table 6-6) 
 
MTAD (1.57a, 56.5 mg, 0.5 mmol, 1.0 eq.) and naphthalene (1.2a, 128 mg, 1.0 mmol, 2.0 eq.) 
were placed in a test tube with a septum as the cap under nitrogen atmosphere. Propionitrile (5.0 
mL) was added to the test tube at rt, and the mixture was stirred until both MTAD and the 
naphthalene were completely dissolved. Then the resulting pink solution was stirred under 
irradiation with LED lights at –50 ºC until the solution became white suspension (about 6 hours). 
In a separate flask, n-BuLi (0.59 mL, 0.95 mmol, 1.9 eq., 1.6 M solution in hexane) was added 
dropwise to a solution of alcohol nucleophile (1.0 mmol, 2.0 eq.) in PhMe (2.5 mL) under nitrogen 
atmosphere at 0 ºC. Then the mixture was stirred for 15 min, and cannulated into the solution of 
cycloadduct (at this point the LED lights were turned off). Subsequently, a solution of Pd(PPh3)4 
(28.9 mg, 0.025 mmol, 5 mol%) in PhMe (1.0 mL, pre-stirred at rt until Pd(PPh3)4 completely 
dissolved) was added, and the resulting mixture was warmed from –50 ºC to 0 ºC over 4 h. The 
reaction was then quenched with saturated aqueous NH4Cl (3.0 mL), and EtOAc (10 mL) and 
water (10 mL) were added. Aqueous HCl solution (1 M, 3.0 mL) was added to acidify the solution 
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to pH~5 and the organic phase was separated. The aqueous phase was extracted with EtOAc (3 × 
10 mL), then the combined organic extracts were washed with saturated aqueous sodium chloride 
solution (10 mL), dried over anhydrous magnesium sulfate, and concentrated under reduced 
pressure. The product was purified by flash column chromatography (SiO2, mixture of n-hexane 
and EtOAc). 
 
Synthesis of (±)-6.2a (Table 6-6): Following the general procedure 6B, the 
title compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc 
= 2:1 to 1:1) as a colorless oil (108.2 mg, 62%).  
Rf = 0.39 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.88 (br, 1H), 7.52 (d, J = 7.5 Hz, 1H), 7.40 
– 7.30 (m, 8H), 6.46 (ddd, J = 10.2, 4.0, 1.5 Hz, 1H), 6.06 (dd, J = 10.2, 3.9 Hz, 1H), 5.84 – 5.76 
(m, 1H), 5.10 – 5.03 (m, 1H), 4.54 (d, J = 11.3 Hz, 1H), 4.44 (d, J = 11.3 Hz, 1H), 3.02 (s, 3H).  
13C NMR: (125 MHz, CDCl3) δ 154.3, 153.9, 137.9, 135.3, 132.2, 132.1, 129.1, 128.9, 128.8, 
128.7, 128.2, 128.1, 128.0, 127.3, 70.0, 69.0, 51.8, 25.3. 
HRMS: (ESI-TOF, m/z) calcd. For C20H19N3O3Na [M+Na]+ calc.: 372.1324; found: 372.1321.  
IR: (ATR, neat, cm-1): 3095 (w), 1767 (m), 1695 (s), 1479 (m), 1396 (w), 1063 (m), 1025 (m), 
756 (m), 699 (m). 
 
Synthesis of (±)-6.2b (Table 6-6): Following the general procedure 6B, 
the title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (100.4 mg, 53%). 
Rf = 0.28 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.79 (br, 1H), 7.43 – 7.40 (m, 1H), 7.34-
7.26 (m, 3H), 7.20 – 7.18 (m, 2H), 6.84 – 6.80 (m, 2H), 6.39 (dd, J = 10.2, 4.0 Hz, 1H), 6.00 (dd, 
J = 10.2, 4.0 Hz, 1H), 5.78 – 5.69 (m, 1H), 4.97 – 4.90 (m, 1H), 4.43 (d, J = 10.9 Hz, 1H), 4.34 (d, 
J = 10.9 Hz, 1H), 3.73 (s, 3H), 2.98 (s, 3H). 
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13C NMR: (125 MHz, CDCl3) δ 159.6, 154.2, 153.7, 135.4, 132.3, 132.2, 129.9, 129.2, 128.9, 
128.8, 128.1, 127.3, 114.1, 69.8, 69.1, 55.4, 51.8, 25.4.  
HRMS: (ESI-TOF, m/z) calcd. For C21H21N3O4Na [M+Na]+ calc.: 402.1430; found: 402.1414.  
IR: (ATR, neat, cm-1): 3089 (w), 1771 (m), 1684 (s), 1479 (s), 1393 (m), 1255 (m), 956 (m), 774 
(m), 759 (s), 646 (m), 518 (w). 
m.p.: 144–145 ºC. 
 
Synthesis of (±)-6.2c (Table 6-6): Following the general procedure 6B, the 
title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (101.6 mg, 56%). 
Rf = 0.35 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.05 (br, 1H), 7.50 (d, J = 7.4 Hz, 1H), 
7.40-7.32 (m, 3H), 7.24 – 7.21 (m, 2H), 7.16 (d, J = 8.1 Hz, 2H), 6.44 (ddd, J = 10.0, 3.9, 1.6 Hz, 
1H), 6.08 – 6.01 (m, 1H), 5.83 – 5.75 (m, 1H), 5.06 – 5.00 (m, 1H), 4.51 (d, J = 11.3 Hz, 1H), 4.41 
(d, J = 11.3 Hz, 1H), 3.01 (s, 3H), 2.35 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 154.2, 153.8, 137.9, 135.3, 134.8, 132.2, 132.1, 129.3, 129.1, 
128.8, 128.7, 128.3, 128.0, 127.2, 69.8, 69.0, 51.8, 25.3, 21.3.  
HRMS: (ESI-TOF, m/z) calcd. For C21H21N3O3Na [M+Na]+ calc.: 386.1481; found: 386.1498.  
IR: (ATR, neat, cm-1): 3205 (w), 2917 (w), 1773 (m), 1688 (s), 1473 (m), 1308 (w), 1053 (m), 
997 (m), 803 (m), 759 (s), 700 (m), 609 (m).  
m.p.: 168–169 ºC. 
 
Synthesis of (±)-6.2d (Table 6-6): Following the general procedure 6B, the 
title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a white solid (103.3 mg, 51%). 
Rf = 0.40 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
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1H NMR: (500 MHz, CDCl3) δ 7.54 – 7.50 (m, 1H), 7.42-7.36 (m, 5H), 7.30 – 7.26 (m, 3H), 6.47 
(ddd, J = 10.1, 3.9, 1.5 Hz, 1H), 6.10 – 6.01 (ddd, J = 10.1, 3.8, 1.5 Hz, 1H), 5.85 – 5.78 (m, 1H), 
5.08 – 5.01 (m, 1H), 4.53 (d, J = 11.1 Hz, 1H), 4.43 (d, J = 11.1 Hz, 1H), 3.04 (s, 3H), 1.32 (s, 
9H). 
13C NMR: (125 MHz, CDCl3) δ 154.2, 153.7, 151.2, 135.5, 134.7, 132.6, 132.3, 129.3, 129.0, 
128.8, 128.2, 127.4, 127.0, 125.7, 69.9, 69.1, 51.9, 34.7, 31.5, 25.4. 
HRMS: (ESI-TOF, m/z) calcd. For C24H27N3O3Na [M+Na]+ calc.: 428.1950; found: 428.1943.  
IR: (ATR, neat, cm-1): 3098 (w), 2955 (w), 1749 (m), 1682 (s), 1482 (s), 1330 (w), 1243 (m), 1020 
(s), 959 (m), 748 (s), 729 (s), 623 (m). 
m.p.: 108–109 ºC. 
 
Synthesis of (±)-6.2e (Table 6-6): Following the general procedure 6B, the 
title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a colorless oil (128.5 mg, 70%). 
Rf = 0.36 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.55 (br, 1H), 7.51 – 7.49 (m, 1H), 7.42 - 
7.36 (m, 3H), 7.33 – 7.29 (m, 2H), 7.08 – 7.00 (m, 2H), 6.51 – 6.43 (ddd, J = 10.1, 3.9, 1.2 Hz, 
1H), 6.11 (ddd, J = 10.1, 4.0, 1.2 Hz, 1H), 5.86 – 5.79 (m, 1H), 5.09 – 5.02 (m, 1H), 4.52 (d, J = 
11.1 Hz, 1H), 4.41 (d, J = 11.1 Hz, 1H), 3.07 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 162.6 (d, J = 245.0 Hz), 154.3, 153.9, 135.2, 133.7 (d, J = 2.5 
Hz), 132.19, 132.16, 130.0 (d, J = 7.5 Hz), 129.2, 129.0, 128.9, 128.1, 127.5, 115.6 (d, J = 21.3 
Hz), 70.1, 68.4, 51.9, 25.4.  
19F NMR: (471 MHz, CDCl3) δ –114.6. 
HRMS: (ESI-TOF, m/z) calcd. For C20H18FN3O3Na [M+ Na]+ calc.: 390.1230; found: 390.1237.  
IR: (ATR, neat, cm-1): 2923 (m), 2854 (m), 1766 (m), 1696 (s), 1509 (m), 1478 (m), 1223 (m), 




Synthesis of (±)-6.2f (Table 6-6): Following the general procedure 6B, the 
title compound was isolated by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1 to 1:1) as a colorless oil (124.1 mg, 58%). 
Rf = 0.40 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.73 (br, 1H), 7.50 (d, J = 7.1 Hz, 1H), 7.47 
(d, J = 8.1 Hz, 2H), 7.40 – 7.34 (m, 3H), 7.19 (d, J = 8.2 Hz, 2H), 6.43 (ddd, J = 10.2, 3.8, 1.6 Hz, 
1H), 6.07 (ddd, J = 10.2, 3.9, 1.3 Hz, 1H), 5.83 – 5.77 (m, 1H), 5.10 – 5.04 (m, 1H), 4.47 (d, J = 
11.5 Hz, 1H), 4.35 (d, J = 11.5 Hz, 1H), 3.03 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 154.4, 154.1, 137.0, 135.0, 132.02, 131.97, 131.8, 129.7, 129.1, 
129.0, 128.9, 128.0, 127.5, 121.9, 70.2, 68.0, 51.9, 25.4.  
HRMS: (ESI-TOF, m/z) calcd. For C20H18BrN3O3Na [M+ Na]+ calc.: 450.0429; found: 450.0444.  
IR: (ATR, neat, cm-1): 3080 (w), 2924 (w), 1766 (m), 1692 (s), 1480 (s), 1398 (m), 1274 (m), 
1069 (m), 1011 (m), 802 (w), 757 (m), 611 (w). 
 
Synthesis of (±)-6.2g (Table 6-6): Following the general procedure 6B, the 
title compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc 
= 2:1 to 1:1) as a colorless oil (97.7 mg, 51%). 
Rf = 0.40 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.82 (br, 1H), 7.60 – 7.54 (m, 1H), 7.49 (dd, 
J = 7.3, 1.9 Hz, 1H), 7.41 – 7.33 (m, 4H), 7.28 – 7.23 (m, 2H), 6.48 (ddd, J = 
10.2, 3.8, 1.6 Hz, 1H), 6.08 (ddd, J = 10.2, 4.0, 1.3 Hz, 1H), 5.84 – 5.77 (m, 1H), 5.18 – 5.11 (m, 
1H), 4.64 (d, J = 12.1 Hz, 1H), 4.50 (d, J = 12.1 Hz, 1H), 2.97 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 154.4, 154.2, 135.8, 135.0, 133.3, 131.9, 131.8, 129.7, 129.5, 
129.2, 129.1, 128.94, 128.87, 127.9, 127.4, 127.1, 70.5, 65.9, 51.9, 25.3.  
HRMS: (ESI-TOF, m/z) calcd. For C20H18ClN3O3Na [M+ Na]+ calc.: 406.0934; found: 406.0943.  
IR: (ATR, neat, cm-1): 3067 (w), 2924 (w), 1765 (m), 1687 (s), 1475 (s), 1273 (m), 1200 (m), 
1068 (m), 1022 (m), 752 (s), 502 (m) 
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Synthesis of (±)-6.2h (Table 6-6): Following the general procedure 6B, the 
title compound was isolated by flash chromatography (SiO2, n-hexane:EtOAc 
= 2:1 to 1:1) as a colorless oil (139.1 mg, 65%). 
Rf = 0.40 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.57 (d, J = 7.5 Hz, 1H), 7.54 (dd, J = 8.0, 1.3 
Hz, 1H), 7.50 (dd, J = 7.7, 1.7 Hz, 1H), 7.46 – 7.30 (m, 5H), 7.17 (td, J = 7.7, 
1.7 Hz, 1H), 6.52 (ddd, J = 10.1, 3.9, 1.5 Hz, 1H), 6.12 (ddd, J = 10.1, 4.0, 1.2 Hz, 1H), 5.86 – 
5.80 (m, 1H), 5.17 – 5.12 (m, 1H), 4.65 (d, J = 12.1 Hz, 1H), 4.51 (d, J = 12.1 Hz, 1H) 3.04 (s, 
3H). 
13C NMR: (125 MHz, CDCl3) δ 154.5, 154.0, 137.4, 135.1, 132.8, 132.03, 131.97, 129.7, 129.4, 
129.3, 129.1, 129.0, 128.1, 127.7, 127.6, 123.2, 70.6, 68.5, 51.9, 25.4.  
HRMS: (ESI-TOF, m/z) calcd. For C20H18BrN3O3Na [M+ Na]+ calc.: 450.0429; found: 450.0444.  
IR: (ATR, neat, cm-1): 3078 (w), 1765 (m), 1687 (s), 1473 (s), 1268 (m), 1241 (m), 1023 (m), 752 
(s), 732 (s), 540 (m). 
 
7.7.2. Asymmetric Dearomative syn-1,4-oxyamination of arenes with oxygen-based 
nucleophiles  
Preparation of naphthalene cycloadduct 1.48 
 
MTAD (1.57a, 2.06 g, 18.2 mmol, 1.0 eq.) and naphthalene (1.2a, 4.67 g, 36.4 mmol, 2.0 eq.) 
were placed in a 500 mL clear borosilicate glass bottle. Acetone (182.0 mL) was added to the 
bottle at rt, and the mixture was stirred until both MTAD and the naphthalene were completely 
dissolved. Then the resulting pink solution was stirred under irradiation with LED lights at –50 ºC 
until the solution became white suspension (about 2 days).  The white suspension was poured into 
a 500 mL round bottom flask and concentrated under reduced pressure with ice bath. When most 
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of the solvents were removed, the residue was poured onto a funnel with frit and wash with pentane 
(3 × 10 mL). Finally, the resulting white solid was dried in vacuo to afford 1.48 (3.63 g, 83%).  
 
General procedure 6C for the dearomative syn-1,4-oxyamination of naphthalene with 
oxygen-based nucleophiles (Table 6-9, conditions A) 
 
MTAD (1.57a, 33.9 mg, 0.3 mmol, 1.0 eq.) and naphthalene (1.2a, 76.8 mg, 0.6 mmol, 2.0 eq.) 
were placed in a test tube with a septum as the cap under nitrogen atmosphere. DCM (3.0 mL) was 
added to the test tube at rt, and the mixture was stirred until both MTAD and the naphthalene were 
completely dissolved. Then the resulting pink solution was stirred under irradiation with LED 
lights at –50 ºC until the solution became white suspension (about 6 hours). . In a separate flask, 
n-BuLi (0.36 mL, 0.57 mmol, 1.9 eq., 1.6 M solution in hexane) was added dropwise to a solution 
of oxime or alcohol nucleophile (0.6 mmol, 2.0 eq.) in PhMe (1.5 mL) under nitrogen atmosphere 
at 0 ºC. The resulting mixture was stirred at 0 ºC for 15 min., then cannulated into the solution of 
cycloadduct (at this point the LED lights were turned off). Subsequently, a solution of Pd2dba3 
(6.8 mg, 0.0075 mmol, 2.5 mol%) and (S,S)-DACH-phenyl Trost ligand (12.4 mg, 0.018 mmol, 6 
mol%) in PhMe (1.0 mL, pre-stirred at rt until completely dissolved) was added, and the resulting 
mixture was warmed from –50 ºC to 0 ºC over 4 h. The reaction was then quenched with saturated 
aqueous NH4Cl (3.0 mL), and EtOAc (10 mL) and water (10 mL) were added. Aqueous HCl 
solution (1 M) was added to acidify the solution to pH~5 and the organic phase was separated. The 
aqueous phase was extracted with EtOAc (3 × 10 mL), then the combined organic extracts were 
washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous 
magnesium sulfate, and concentrated under reduced pressure. The product was purified by flash 
column chromatography (SiO2, mixture of n-hexane and EtOAc). 
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General procedure 6D for the asymmetric dearomative syn-1,4-oxyamiantions of 
naphthalene-cycloadduct with oxygen-based nucleophiles (Table 6-9, conditions B) 
 
Naphthalene-cycloadduct 1.48 (0.3 mmol, 1.0 eq.) was placed in a test tube with a septum as the 
cap under nitrogen atmosphere. DCM (3.0 mL, 0.1 M) was added to the test tube at –50 oC, the 
resulting colorless solution was stirred under irradiation with LED lights at –50 ºC. In a separate 
flask, n-BuLi (0.36 mL, 0.57 mmol, 1.9 eq., 1.6 M solution in hexane) was added dropwise to a 
solution of oxime or alcohol nucleophile (0.6 mmol, 2.0 eq.) in PhMe (1.5 mL) under nitrogen 
atmosphere at 0 ºC. The resulting mixture was stirred at 0 ºC for 15 min., then cannulated into the 
solution of cycloadduct (at this point the LED lights were turned off). Subsequently, a solution of 
Pd2dba3 (6.8 mg, 0.0075 mmol, 2.5 mol%) and (S,S)-DACH-phenyl Trost ligand (12.4 mg, 0.018 
mmol, 6 mol%) in PhMe (1.0 mL, pre-stirred at rt until completely dissolved) was added, and the 
resulting mixture was warmed from –50 ºC to 0 ºC over 4 h. The reaction was then quenched with 
saturated aqueous NH4Cl (3.0 mL), and EtOAc (10 mL) and water (10 mL) were added. Aqueous 
HCl solution (1 M) was added to acidify the solution to pH~5 and the organic phase was separated. 
The aqueous phase was extracted with EtOAc (3 × 10 mL), then the combined organic extracts 
were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous 
magnesium sulfate, and concentrated under reduced pressure. The product was purified by flash 




Synthesis of 6.2a (Table 6-9): Following the general procedure 6C, the title 
compound was isolated as colorless oil (42.9 mg, 41%). Following the general 
procedure 6D, the title compound was isolated by flash chromatography (SiO2, 
n-hexane:EtOAc = 2:1 to 1:1) as colorless oil (52.4 mg, 50%). Enantiomeric 
excess was determined with HPLC analysis using Diacel Chiracel® IC-3 
column, 10% iPrOH in n-hexane, 0.8 mL/min. 98:2 er, tR(minor) = 23.1 min, 
tR(major) = 25.3 min. [α]D25 = +5.8 (c = 0.18 in CHCl3). 
 
Synthesis of 6.2e (Table 6-9): Following the general procedure 6C, the title 
compound was isolated as colorless oil (48.4 mg, 44%). Following the 
general procedure 6D, the title compound was isolated by flash 
chromatography (SiO2, n-hexane:EtOAc = 2:1 to 1:1) as colorless oil (60.5 
mg, 55%). Enantiomeric excess was determined with HPLC analysis using 
Diacel Chiracel® IC-3 column, 10% iPrOH in n-hexane, 0.8 mL/min. 99.5:0.5 er, tR(minor) = 18.0 
min, tR(major) = 20.3 min. [α]D25 = –0.8 (c = 0.76 in CHCl3). 
 
Synthesis of 6.1h (Table 6-9): Following the general procedure 6C, the title 
compound was isolated as white solid (56.2 mg, 48%). Following the general 
procedure 6D, the title compound was isolated by flash chromatography 
(SiO2, n-hexane:EtOAc = 2:1 to 1:1) as white solid (84.2 mg, 72%). 
Enantiomeric excess was determined with HPLC analysis using Diacel 
Chiracel® IC-3 column, 10% iPrOH in n-hexane, 0.4 mL/min. 99:1 er, 
tR(minor) = 49.9 min, tR(major) = 42.4 min. [α]D25 = –78.0 (c = 1.00 in CHCl3). 
 
Synthesis of 6.1e (Table 6-9): Following the general procedure 6C, the title 
compound was isolated as white solid (63.8 mg, 54%). Following the 
general procedure 6D, the title compound was isolated by flash 
chromatography (SiO2, n-hexane:EtOAc = 2:1 to 1:1) as white solid (109.6 
mg, 93%). Enantiomeric excess was determined with HPLC analysis using 
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Diacel Chiracel® IC-3 column, 5% iPrOH in n-hexane, 0.8 mL/min. 98.5:1.5 er, tR(minor) = 58.9 
min, tR(major) = 61.4 min. [α]D25 = –62.2 (c = 1.00 in CHCl3). 
 
Synthesis of 6.2n (Table 6-9): Following the general procedure 6C, the title 
compound was isolated as white solid (61.2 mg, 65%). Following the general 
procedure 6D, the title compound was isolated by flash chromatography (SiO2, 
n-hexane:EtOAc = 2:1 to 1:1) as white solid (83.8 mg, 89%). Enantiomeric 
excess was determined with HPLC analysis using Diacel Chiracel® OJ-3 
column, 5% iPrOH in n-hexane, 0.8 mL/min. 99:1 er, tR(minor) = 23.0 min, 
tR(major) = 28.6 min. [α]D25 = –111.4 (c = 1.00 in CHCl3). 
 
7.7.3. Derivatization of (±)-6.2b 
Synthesis of compound (±)-6.10 (Scheme 6-3): 
 
Compound (±)-6.2b (175.0 mg, 0.46 mmol, 1.0 eq.) and Rh/Al2O3 (47.3 mg, 5 wt%, 0.023 mmol, 
5.0 mol%) in EtOAc (4.6 mL) were stirred at rt under hydrogen atmosphere for 12 h. The mixture 
was passed through a plug of celite, and then concentrated under reduced pressure. The resulting 
residue was purified by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) to afford compound 




Rf = 0.15 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.25 – 7.19 (m, 6H), 7.04 (br, 1H), 6.85 – 
6.80 (m, 2H), 5.32 (dd, J = 9.2, 6.6 Hz, 1H), 4.52 (d, J = 11.4 Hz, 1H), 
4.43 (d, J = 11.4 Hz, 1H), 4.39 – 4.33 (m, 1H), 3.74 (s, 3H), 3.02 (s, 3H), 
2.31 – 2.18 (m, 2H), 1.96 – 1.85 (m, 1H), 1.82 – 1.74 (m, 1H).  
13C NMR: (125 MHz, CDCl3) δ 159.5, 154.5, 154.3, 138.0, 133.4, 130.7, 130.3, 129.6, 129.1, 
128.4, 127.4, 114.1, 72.9, 70.5, 55.4, 54.5, 26.0, 25.4, 21.2. 
HRMS: (ESI-TOF, m/z) calcd. For C21H24N3O4 [M+H]+ calc.: 382.1767; found: 382.1765.  
IR: (ATR, neat, cm-1): 3459 (w), 3024 (w), 2947 (w), 1738 (s), 1690 (s), 1474 (s), 1361 (m), 1229 
(m), 1216 (m), 983 (m), 802 (m), 607 (w).  
m.p.: 98–99 ºC.  
 
Synthesis of (±)-6.11 (Scheme 6-3):  
 
Alkylation of urazole: NaH (5.3 mg, 0.22 mmol, 1.1 eq., 95% purity) was suspended in THF (1.0 
mL) under nitrogen atmosphere at 0 ºC and a solution of compound (±)-6.10 (76.2 mg, 0.2 mmol, 
1.0 eq.) in THF (0.5 mL) was added dropwise. After stirring at 0 ºC for 1 h, a solution of 2-
bromoacetophenone (59.7 mg, 0.3 mmol, 1.5 eq.) in THF (0.5 mL) was added, and the reaction 
was further stirred at rt for 12 h. The mixture was then quenched with saturated aqueous NH4Cl 
(2.0 mL) and water (5 mL). The resulting solution was extracted with Et2O (3 × 5 mL), the 
combined organic extracts were washed with saturated aqueous sodium chloride solution (5 mL), 
dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The crude 
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residue was purified by flash column chromatography (SiO2, n-hexane:EtOAc = 3:1) to afford the 
compound (±)-S6.1 as a white solid (84.8 mg, 85%). 
Hydrolysis of urazole: A degassed mixture of compound (±)-S6.1 (230.0 mg, 0.46 mmol, 1.0 eq.) 
and potassium hydroxide (286.2 mg, 4.6 mmol, 10 eq., 90% purity) in methanol (4.6 mL, 0.1 M) 
in a pressure tube was heated at 80 ºC for 24 h and then at 160 ºC for 12 h under nitrogen 
atmosphere. After cooling the reaction to rt, water (2.0 mL) was added. The resulting solution was 
extracted with CH2Cl2 (3 × 2 mL), the combined organic extracts were washed with saturated 
aqueous sodium chloride solution (3 mL), dried over anhydrous magnesium sulfate, and 
concentrated under reduced pressure. The crude residue was purified by flash column 
chromatography (SiO2, CH2Cl2:MeOH = 30:1 to 10:1) to afford the compound (±)-6.11 as a brown 
solid (123.7 mg, 95%). 
 
Rf = 0.36 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.45 (t, J = 7.3 Hz, 1H), 7.35 (d, J = 8.5 
Hz, 2H), 7.30 – 7.27 (m, 2H), 7.25 – 7.18 (m, 2H), 7.16 (d, J = 7.7 Hz, 
1H), 7.09 – 7.05 (m, 1H), 6.95 – 6.91 (m, 2H), 6.85 – 6.79 (m, 1H), 6.77 
(td, J = 7.5, 1.5 Hz, 1H), 5.56 (dd, J = 10.7, 7.4 Hz, 1H), 4.69 – 4.54 (m, 
4H), 4.44 – 4.41 (m, 1H), 3.82 (s, 3H), 3.25 (s, 3H), 2.55 (tdd, J = 13.9, 
10.8, 3.4 Hz, 1H), 2.36 (dq, J = 14.1, 3.6 Hz, 1H), 1.96 (ddd, J = 14.0, 7.3, 3.7 Hz, 1H), 1.85 (tt, J 
= 14.1, 3.0 Hz, 1H).  
13C NMR: (125 MHz, CDCl3) δ 191.9, 159.4, 156.5, 155.1, 136.6, 134.2, 134.0, 133.7, 130.6, 
130.1, 129.1, 129.0, 128.6, 128.4, 127.8, 127.5, 114.1, 73.4, 70.3, 55.5, 53.9, 51.8, 26.4, 26.0, 20.1. 
HRMS: (ESI-TOF, m/z) calcd. For C29H30N3O5 [M+H]+ calc.: 500.2185; found: 500.2190.  
IR: (ATR, neat, cm-1): 3457 (w), 3008 (w), 2970 (w), 1767 (s), 1722 (s), 1688 (s), 1475 (s), 1366 
(m), 1228 (s), 1217 (s), 988 (w), 901 (w), 799 (w), 760 (m), 687 (w).  




Rf = 0.30 (DCM:MeOH = 10:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.66 – 7.51 (m, 1H), 7.33 – 7.26 (m, 5H), 
6.93 – 6.85 (m, 2H), 5.57 (br, 2H), 4.53 (d, J = 11.5 Hz, 1H), 4.50 – 4.45 
(m, 2H), 4.34 – 4.23 (m, 1H), 3.79 (s, 3H), 2.33 – 2.16 (m, 2H), 2.12 – 
2.02 (m, 1H), 1.97 – 1.86 (m, 1H). 
13C NMR: (125 MHz, CDCl3) δ 159.4, 137.1, 136.2, 130.2, 129.7, 129.2, 129.0, 128.9, 128.4, 
114.1, 74.1, 70.0, 55.4, 49.6, 25.9, 25.0. 
HRMS: (ESI-TOF, m/z) calcd. For C18H22NO2 [M+H]+ calc.: 284.1651; found: 284.1657.  
IR: (ATR, neat, cm-1): 3350 (w), 2939 (w), 1733 (s), 1611 (m), 1513 (m), 1453 (w), 1368 (s), 1248 
(s), 1217 (s), 1031 (m), 763 (w), 528 (w). 
m.p.: 233–234 ºC. 
 
Synthesis of compound (±)-6.13 (Scheme 6-3): 
 
Dihydroxylation: Compound (±)-6.2b (151.6 mg, 0.40 mmol, 1.0 eq.) and 4-methylmorpholine N-
oxide (92.0 mg, 0.80 mmol, 2.0 eq.) were dissolved in acetone (4.0 mL) and water (144 μL, 8.0 
mmol, 20 eq.). To this solution was dropwisely added osmium tetroxide (100 μL, 0.2 M solution 
in acetonitrile, 0.02 mmol, 5.0 mol%) and the resulting solution was stirred at rt for 12 h. Then the 
reaction was quenched with saturated aqueous sodium thiosulfate solution (2 mL) and diluted with 
EtOAc (5 mL) and water (5 mL). Aqueous HCl solution (1 M) was added to acidify the solution 
to pH~5 and the organic phase was separated. The aqueous layer was extracted with EtOAc (3 × 
5 mL), the combined organic extracts were washed with saturated aqueous sodium chloride 
solution (10 mL), dried over anhydrous magnesium sulfate, and concentrated under reduced 
pressure. The crude residue was purified by flash column chromatography (SiO2, 
CH2Cl2:MeOH=15:1 to 10:1) to afford the compound (±)-6.12 as a brown solid (119.0 mg, 72%). 
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Oxidation: Compound (±)-6.12 (82.6 mg, 0.2 mmol, 1.0 eq.) was dissolved in MeCN (4.0 mL, 
0.05 M) at rt and bleach (2.0 mL) was added dropwise. After stirring the yellow solution for 5 min, 
the reaction was quenched with saturated aqueous sodium thiosulfate solution (1.0 mL), and then 
diluted with EtOAc (2.0 mL) and water (2.0 mL). The organic phase was separated. The aqueous 
layer was extracted with EtOAc (3 × 2.0 mL), the combined organic extracts were washed with 
saturated aqueous sodium chloride solution (3.0 mL), dried over anhydrous magnesium sulfate, 
and concentrated under reduced pressure. The crude residue was purified by flash column 
chromatography (SiO2, DCM:MeOH = 20:1) to afford the compound (±)-6.13 as a colorless oil 
(31.4 mg, 50%). 
 
Rf = 0.22 (DCM:MeOH = 10:1, UV, KMnO4).  
1H NMR: (500 MHz, CD3OD) δ 7.36 – 7.27 (m, 6H), 6.94 – 6.89 (m, 
2H), 5.46 (d, J = 10.0 Hz, 1H), 4.70 (d, J = 11.3 Hz, 1H), 4.65 (d, J = 
11.3 Hz, 1H), 4.51 (d, J = 3.4 Hz, 1H), 4.42 (dd, J = 10.0, 2.1 Hz, 1H), 
4.35 (dd, J = 3.4, 2.1 Hz, 1H), 3.79 (s, 3H), 3.10 (s, 3H). 
13C NMR: (125 MHz, CD3OD) δ 161.0, 157.4, 156.1, 136.0, 134.7, 132.6, 131.5, 130.9, 129.8, 
129.1, 127.6, 114.9, 80.1, 72.9, 72.3, 68.1, 59.2, 55.7, 25.4. 
HRMS: (ESI-TOF, m/z) calcd. For C21H24N3O6 [M+H]+ calc.: 414.1665; found: 414.1671.  
IR: (ATR, neat, cm-1): 3055 (w), 1694 (m), 1611 (w), 1483 (m), 1264 (s), 1174 (w), 1055 (w), 731 
(s), 703 (s), 522 (w).  
m.p.: 119–120 ºC. 
 
Rf = 0.39 (DCM:MeOH = 10:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.05 (d, J = 7.7 Hz, 1H), 7.62 (td, J = 7.6, 
1.4 Hz, 1H), 7.48 (td, J = 7.6, 1.2 Hz, 1H), 7.33 – 7.26 (m, 3H), 6.94 – 6.88 
(m, 2H), 4.94 (d, J = 3.0 Hz, 1H), 4.75 (d, J = 3.0 Hz, 1H), 4.70 (d, J = 3.0 
Hz, 1H), 4.69 (d, J = 11.6 Hz, 1H), 4.65 (d, J = 11.6 Hz, 1H), 3.86 (br, 1H), 
3.82 (s, 3H), 2.66 (br, 1H). 
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13C NMR: (125 MHz, CDCl3) δ 198.0, 159.7, 139.2, 134.8, 131.3, 130.1, 129.8, 129.6, 129.3, 
127.3, 114.2, 76.3, 73.4, 72.4, 71.9, 55.5. 
HRMS: (ESI-TOF, m/z) calcd. For C18H18O5Na [M+Na]+ calc.: 337.1052; found: 337.1053.  
IR: (ATR, neat, cm-1): 3456 (w), 3011 (w), 2970 (w), 2123 (w), 1740 (s), 1514 (w), 1368 (s), 1229 
(s), 1217 (s), 999 (w), 901 (w), 819 (w), 539 (w).  
 
Synthesis of compound (±)-6.14 (Scheme 6-4): 
 
Compound (±)-6.1a (564.0 mg, 1.5 mmol, 1.0 eq.) and Rh/Al2O3 (233.0 mg, 5 wt%, 0.075 mmol, 
5.0 mol%) in EtOAc (15 mL) were stirred at rt under hydrogen atmosphere for 12 h. The mixture 
was passed through a plug of celite, and then concentrated under reduced pressure. The resulting 
residue was purified by flash chromatography (SiO2, n-hexane:EtOAc = 1:1) to afford compound 
(±)-6.14 as a white solid (481.8 mg, 85%). 
 
Rf = 0.33 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.67 – 7.63 (m, 2H), 7.53 – 7.49 (m, 1H), 7.39 
– 7.36 (m, 3H), 7.35 – 7.28 (m, 3H), 5.38 (dd, J = 10.3, 5.7 Hz, 1H), 5.28 (dd, 
J = 3.4, 3.2 Hz, 1H), 3.06 (s, 3H), 2.55 – 2.40 (m, 1H), 2.31 – 2.21 (m, 1H), 
2.18 (s, 3H), 2.04 – 1.91 (m, 2H).  
13C NMR: (125 MHz, CDCl3) δ 155.3, 154.8, 154.7, 136.6, 136.5, 133.9, 
131.7, 129.3, 129.2, 128.5, 128.4, 126.7, 126.1, 77.3, 55.3, 26.5, 25.4, 21.0, 13.1. 
HRMS: (ESI-TOF, m/z) calcd. For C21H22N4O3Na [M+ Na]+ calc.: 401.1590; found: 401.1583.  
IR: (ATR, neat, cm-1): 3457 (w), 3027 (w), 2948 (w), 1739 (s), 1685 (s), 1476 (s), 1367 (s), 1305 
(w), 1217 (s), 971 (m), 926 (m), 760 (m), 693 (m).  
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m.p.: 178–179 ºC. 
 
Synthesis of compound (±)-6.15 (Scheme 6-4): 
To a suspension of compound (±)-6.14 (37.8 mg, 0.1 mmol, 1.0 eq.) in MeCN (2.0 mL, 0.05 M) 
was added t-butyl hypochlorite (29 μL, 2.5 eq.) and the resulting orange solution was stirred for 5 
min at rt. A solution of saturated aqueous sodium bicarbonate (1 mL) was added and the mixture 
was further stirred for 5 min. The reaction was quenched with saturated aqueous sodium thiosulfate 
solution (0.5 mL) and then diluted with EtOAc (2.0 mL) and water (2.0 mL). The organic phase 
was separated. The aqueous layer was extracted with EtOAc (3 × 2.0 mL), the combined organic 
extracts were washed with saturated aqueous sodium chloride solution (3.0 mL), dried over 
anhydrous magnesium sulfate, and concentrated under reduced pressure. The crude residue was 
purified by flash column chromatography (SiO2, n-hexane:EtOAc = 10:1) to afford the compound 
(±)-6.15 as a colorless oil (20.1 mg, 64%, dr = 4:1). 
 
Synthesis of compound (±)-6.16 (Scheme 6-4): 
 
Compound (±)-6.14 (37.8 mg, 0.1 mmol, 1.0 eq.) was dissolved in a mixture of MeCN (1.0 mL), 
water (1.0 mL), and acetic acid (0.33 mL) at rt, and t-butyl hypochlorite (23 μL, 0.2 mmol, 2.0 eq.) 
was added dropwise. The resulting yellow solution was stirred for 5 min, then quenched with 
saturated aqueous sodium thiosulfate solution (0.5 mL), and then diluted with EtOAc (2.0 mL) and 
water (2.0 mL). The organic phase was separated and the aqueous layer was extracted with EtOAc 
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(3 × 2.0 mL), the combined organic extracts were washed with saturated aqueous sodium chloride 
solution (5.0 mL), dried over anhydrous magnesium sulfate, and concentrated under reduced 
pressure. The crude residue was purified by flash column chromatography (SiO2, n-hexane:EtOAc 
= 10:1) to afford the compound (±)-6.16 as a colorless oil (14.5 mg, 52%). 
 
Rf = 0.46 (n-hexane:EtOAc = 5:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.09 – 8.05 (m, 1H), 7.70 – 7.66 (m, 2H), 7.64 
– 7.58 (m, 2H), 7.46 (ddd, J = 8.3, 7.0, 1.7 Hz, 1H), 7.41 – 7.37 (m, 3H), 5.50 
(dd, J = 6.2, 3.7 Hz, 1H), 2.96 (ddd, J = 17.2, 9.4, 4.9 Hz, 1H), 2.66 (ddd, J = 
17.2, 7.0, 4.8 Hz, 1H), 2.59 – 2.45 (m, 2H), 2.25 (s, 3H).  
13C NMR: (125 MHz, CDCl3) δ 197.9, 155.5, 142.2, 136.6, 133.8, 132.2, 129.4, 129.0, 128.8, 
128.6, 127.1, 126.2, 78.2, 34.7, 28.7, 13.1. 
HRMS: (ESI-TOF, m/z) calcd. For C18H18NO2 [M+H]+ calc.: 280.1338; found: 280.1342.  
IR: (ATR, neat, cm-1): 3458 (w), 3025 (w), 2970 (w), 1739 (s), 1688 (s), 1455 (w), 1368 (s), 1284 
(m), 1229 (s), 1217 (s), 1025 (w), 933 (m), 762 (m), 693 (m), 527 (w).  
 
Synthesis of compound (±)-2.19 (Scheme 6-4): 
Reductive N–O cleavage: To a solution of oxime (±)-6.14 (375.0 mg, 1.0 mmol, 1.0 eq.) in 20 mL 
AcOH-THF-water (3:1:1), zinc powder (650 mg, 10 mmol, 10.0 eq.) was added in one portion at 
room temperature. Then the mixture was stirred at 60 oC. The reaction was monitored by TLC. 
After 2.5 h, the mixture was quenched by 20 mL water and extracted by ethyl acetate (10 mL×3), 
the combined organic layer was dried over Na2SO4, the solvent was removed under reduced 
pressure. The crude residue was purified by flash column chromatography (SiO2, n-hexane:EtOAc 
= 1:1) to afford the compound (±)-S6.2 as a white solid (209.1 mg, 80%). 
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Oxidation: Compound (±)-S6.2 (117.5 mg, 0.45 mmol, 1.0 eq.) was dissolved in a mixture of 
MeCN (4.5 mL), water (4.5 mL), and acetic acid (1.5 mL) at rt, and t-butyl hypochlorite (102 μL, 
0.90 mmol, 2.0 eq.) was added dropwise. The resulting yellow solution was stirred for 5 min, then 
quenched with saturated aqueous sodium thiosulfate solution (1.5 mL), and then diluted with 
EtOAc (6.0 mL) and water (6.0 mL). The organic phase was separated and the aqueous layer was 
extracted with EtOAc (3 × 6.0 mL), the combined organic extracts were washed with saturated 
aqueous sodium chloride solution (10.0 mL), dried over anhydrous magnesium sulfate, and 
concentrated under reduced pressure. The crude residue was purified by flash column 
chromatography (SiO2, n-hexane:EtOAc = 3:1) to afford the compound (±)-2.19 as a brown oil 
(43.8 mg, 60%). 
 
Rf = 0.10 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.37 – 7.33 (m, 1H), 7.32 – 7.28 (m, 2H), 7.23 – 
7.19 (m, 1H), 5.39 (d, J = 3.5 Hz, 1H), 5.10 – 4.40 (m, 3H), 3.06 (s, 3H), 2.29 – 
2.18 (m, 1H), 2.12 – 2.03 (m, 1H), 2.02-1.92 (m, 2H). 
13C NMR: (125 MHz, CDCl3) δ 154.0, 153.3, 139.2, 132.6, 130.2, 129.2, 128.9, 
127.7, 67.1, 54.0, 29.4, 25.4, 21.6. 
HRMS: (ESI-TOF, m/z) calcd. For C13H15N3O3Na [M+ Na]+ calc.: 284.1011; found: 284.1015.  
IR: (ATR, neat, cm-1): 3416 (w), 3072 (w), 2944 (w), 1760 (m), 1682 (s), 1480 (s), 1399 (m), 1211 
(w), 1022 (m), 907 (w), 763 (m), 708 (m), 645 (m).  
m.p.: 95–96 ºC. 
 
Rf = 0.10 (n-hexane:EtOAc = 3:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 8.04 – 7.95 (m, 1H), 7.64 – 7.53 (m, 2H), 7.40 
(ddd, J = 8.2, 5.4, 3.2 Hz, 1H), 4.97 (dd, J = 8.1, 4.1 Hz, 1H), 2.92 (ddd, J = 17.4, 
7.6, 4.5 Hz, 1H), 2.59 (ddd, J = 17.4, 9.7, 4.5 Hz, 1H), 2.39 (dddd, J = 13.0, 7.6, 
4.5, 4.1 Hz, 1H), 2.17 (dddd, J = 13.0, 9.7, 8.1, 4.5 Hz, 1H). 
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13C NMR: (125 MHz, CDCl3) δ 197.7, 145.5, 134.2, 131.2, 128.4, 127.23, 127.16, 67.9, 35.3, 
32.2. 
The analytical data was in accordance with previously reported values.[139] 
 
Synthesis of compound (±)-6.17 (Scheme 6-5): 
 
Hydrogenation: Compound (±)-6.1n (314.1 mg, 1.0 mmol, 1.0 eq.) and Rh/Al2O3 (155.0 mg, 5 
wt%, 0.05 mmol, 5.0 mol%) in EtOAc (10 mL) were stirred at rt under hydrogen atmosphere for 
12 h. The mixture was passed through a plug of celite, and then concentrated under reduced 
pressure. The resulting residue was purified by flash chromatography (SiO2, n-hexane:EtOAc = 
1:1) to afford compound (±)-S6.3 as a white solid (259.4 mg, 82%). 
Methylation: Compound (±)-S6.3 (189.6 mg, 0.6 mmol, 1.0 eq.) in DCM (6 mL, 0.1 M) was added 
MeI (0.187 mL, 3.0 mmol, 5.0 eq.), K2CO3 (0.83 g, 6.0 mmol, 10.0 eq.) and stirred under 35 oC 
for overnight. The reaction mixture was passed through a plug of celite, and then concentrated 
under reduced pressure. The resulting residue was purified by flash chromatography (SiO2, n-
hexane:EtOAc = 2:1) to afford compound (±)-6.17 as a white solid (158.4 mg, 80%). 
 
Rf = 0.21 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.93 (br, 1H), 7.44 (dd, J = 7.2, 2.0 Hz, 1H), 
7.36 – 7.26 (m, 2H), 7.25 (dd, J = 6.5, 1.7 Hz, 1H), 5.37 (dd, J = 7.9, 5.0 Hz, 
1H), 5.20 – 5.12 (m, 1H), 3.08 (s, 3H), 2.37 (dddd, J = 14.4, 9.0, 5.4, 3.3 Hz, 
1H), 2.21 (dddd, J = 13.2, 9.0, 7.9, 3.3 Hz, 1H), 2.04 (dtd, J = 14.4, 5.8, 5.4, 
Hz, 1H), 1.95 (dddd, J = 13.2, 5.8, 5.0, 2.6 Hz, 1H), 1.90 (s, 3H), 1.85 (s, 3H). 
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13C NMR: (125 MHz, CDCl3) δ 156.4, 153.9, 153.9, 137.3, 133.8, 131.0, 128.9, 128.8, 127.7, 
76.2, 54.6, 25.29, 25.27, 23.6, 22.0, 16.2. 
HRMS: (ESI-TOF, m/z) calcd. For C16H21N4O3 [M+H]+ calc.: 317.1614; found: 317.1614.  
IR: (ATR, neat, cm-1): 3457 (w), 3027 (w), 2970 (w), 1738 (s), 1685 (s), 1476 (m), 1367 (s), 1217 
(s), 1022 (w), 921 (m), 712 (m), 514 (m).  
m.p.: 134–135 ºC. 
 
Rf = 0.43 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.47 – 7.38 (m, 2H), 7.35 – 7.27 (m, 2H), 5.51 
(dd, J = 11.1, 6.5 Hz, 1H), 5.11 – 5.04 (m, 1H), 3.14 (s, 3H), 2.74 (s, 3H), 2.42 
(dq, J = 13.0, 3.1 Hz, 1H), 2.34 – 2.23 (m, 1H), 1.92 – 1.83 (m, 5H), 1.79 (s, 
3H). 
13C NMR: (125 MHz, CDCl3) δ 155.4, 155.1, 155.0, 135.8, 135.5, 131.5, 128.8, 128.0, 127.6, 
76.6, 55.5, 34.3, 26.6, 25.8, 22.1, 20.4, 15.8. 
HRMS: (ESI-TOF, m/z) calcd. For C17H23N4O3 [M+H]+ calc.: 331.1770; found: 331.1764.  
IR: (ATR, neat, cm-1): 3459 (w), 3016 (w), 2970 (w), 1738 (s), 1708 (s), 1482 (m), 1457 (m), 1367 
(m), 1229 (m), 1217 (m), 922 (w), 771 (w), 516 (w).  
m.p.: 94–95 ºC. 
 




Compound (±)-6.17 (33.0 mg, 0.1 mmol, 1.0 eq.) and PIDA (48.0 mg, 0.15 mmol, 1.5 eq.) were 
charged in a scintillation vial, followed by Pd(OAc)2 (0.22 mg, 0.001 mmol, 1 mol%) and a solvent 
mixture of AcOH (0.5 mL) and Ac2O (0.1 mL). The vial was tightly capped and stirred at 100 oC 
for overnight. The reaction mixture was purified by flash chromatography (SiO2, n-hexane:EtOAc 
= 2:1) to afford compound (±)-6.18 as a colorless oil (28.7 mg, 74%). 
 
Rf = 0.20 (n-hexane:EtOAc = 1:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.40 – 7.32 (m, 2H), 7.09 – 7.01 (m, 1H), 5.49 
(dd, J = 11.7, 6.3 Hz, 1H), 5.33 – 5.26 (m, 1H), 3.13 (s, 3H), 2.75 (s, 3H), 2.41 
(dq, J = 13.9, 3.4 Hz, 1H), 2.33 – 2.20 (m, 4H), 1.87 (s, 3H), 1.84 – 1.75 (m, 
2H), 1.73 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 169.3, 155.3, 155.2, 154.8, 150.1, 137.5, 129.3, 128.3, 125.0, 
122.4, 70.9, 55.3, 34.4, 26.3, 25.8, 21.9, 21.0, 19.9, 15.6. 
HRMS: (ESI-TOF, m/z) calcd. For C19H24N4O5Na [M+ Na]+ calc.: 411.1644; found: 411.1631.  
IR: (ATR, neat, cm-1): 3460 (w), 3016 (w), 2970 (w), 1764 (s), 1739 (s), 1705 (s), 1481 (m), 1460 
(m), 1368 (s), 1198 (s), 1013 (w), 943 (m), 732 (m), 527 (w).  
 
Synthesis of compound (±)-6.19 (Scheme 6-5): 
 
Compound (±)-6.17 (33.0 mg, 0.1 mmol, 1.0 eq.), Pd(OAc)2 (2.2 mg, 0.01 mmol, 10 mol%), TBHP 
(36.0 μL, 5.5 M in decane, 0.2 mmol, 2.0 eq.), benzaldehyde (20.3 μL, 0.2 mmol, 2.0 eq.) and 
DCE (1 mL) were charged in a scintillation vial with cap, purged with N2 for 5 minutes, then 
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stirred under N2 at 80 oC for 8 h. The reaction mixture was purified by flash chromatography (SiO2, 
n-hexane:EtOAc = 2:1) to afford compound (±)-6.19 as a colorless oil (37.7 mg, 87%). 
 
Rf = 0.10 (n-hexane:EtOAc = 2:1, UV, KMnO4).  
1H NMR: (500 MHz, CDCl3) δ 7.75 (dd, J = 7.7, 1.5 Hz, 2H), 7.61 (d, J 
= 7.9 Hz, 1H), 7.58 – 7.52 (m, 1H), 7.40 (dt, J = 13.1, 7.6 Hz, 3H), 7.24 
(dd, J = 7.4, 1.3 Hz, 1H), 5.54 (dd, J = 10.9, 6.4 Hz, 1H), 5.41 (t, J = 3.4 
Hz, 1H), 3.16 (s, 3H), 2.82 (s, 3H), 2.39 (dt, J = 14.1, 3.8 Hz, 1H), 2.33 – 
2.25 (m, 1H), 1.97 – 1.89 (m, 1H), 1.88 – 1.83 (m, 1H), 1.56 (s, 3H), 1.36 
(s, 3H). 
13C NMR: (125 MHz, CDCl3) 13C NMR (126 MHz, CDCl3) δ 197.5, 155.4, 155.1, 154.7, 141.0, 
137.5, 136.6, 134.3, 133.3, 130.4, 129.2, 128.3, 127.7, 127.4, 71.8, 55.9, 34.5, 26.3, 25.9, 21.7, 
20.6, 15.1. 
HRMS: (ESI-TOF, m/z) calcd. For C24H27N4O4 [M+ H]+ calc.: 435.2032; found: 435.2019.  
IR: (ATR, neat, cm-1): 3055 (w), 2987 (w), 1732 (s), 1670 (m), 1463 (m), 1374 (w), 1197 (w), 
1045 (m), 847 (w), 615 (w).  
 
7.7.4 Dearomative syn-1,4-oxyamination of benzene with oxygen-based nucleophiles 
Synthesis of compound (±)-6.20 (Scheme 6-6): 
 
MTAD (1.57a, 45.2 mg, 0.4 mmol, 1.0 eq.) was placed in a test tube with a septum as the cap 
under nitrogen atmosphere. Dichloromethane (4.0 mL, 0.1 M) was added to the test tube at rt, and 
cooled to –78 ºC. Benzene (0.36 mL, 4.0 mmol, 10 eq.) was added dropwise at –78 ºC, and the 
resulting pink solution was stirred under irradiation with LED lights at –78 ºC until the solution 
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became colorless (approximately 12 h). In a separate flask, n-BuLi (0.47 mL, 0.76 mmol, 1.9 eq., 
1.6 M solution in hexane) was added dropwise to a solution of acetophenone oxime (0.8 mmol, 
2.0 eq.) in PhMe (2.5 mL) under nitrogen atmosphere at –78 ºC. The mixture was stirred for 15 
min. at –78 ºC, and then cannulated into the solution of cycloadduct (at this point the LED lights 
were turned off). Subsequently, a solution of Pd(PPh3)4 (23.1 mg, 0.02 mmol, 5.0 mol%) in PhMe 
(1.0 mL, pre-stirred at rt until Pd(PPh3)4 completely dissolved) was added, and the resulting 
mixture was warmed from –50 ºC to 0 ºC over 4 h. The reaction was then quenched with saturated 
aqueous NH4Cl (3.0 mL), and EtOAc (10 mL) and water (10 mL) were added. Aqueous HCl 
solution (1 M) was added to acidify the solution to pH~5 and the organic phase was separated. The 
aqueous phase was extracted with EtOAc (3 × 10 mL), then the combined organic extracts were 
washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous 
magnesium sulfate, and concentrated under reduced pressure. The product was purified by flash 
column chromatography (SiO2, mixture of n-hexane and EtOAc). 
 
Rf = 0.38 (n-hexane:EtOAc = 1:2, UV, KMnO4). 
1H NMR: (500 MHz, CDCl3) δ 7.61 – 7.57 (m, 2H), 7.45 – 7.37 (m, 3H), 7.11 
(br, 1H), 6.30 (ddd, J = 10.2, 3.5, 1.6 Hz, 2H), 5.89 (ddd, J = 10.2, 3.5, 1.4 Hz, 
2H), 5.22 (dtt, J = 6.8, 3.5, 1.6 Hz, 1H), 5.10 (dtt, J = 6.8, 3.5, 1.4 Hz, 1H), 
3.08 (s, 3H), 2.27 (s, 3H). 
13C NMR: (125 MHz, CDCl3) δ 156.8, 154.1, 153.4, 136.6, 1131.7, 129.5, 128.9, 126.4, 125.9, 
71.5, 49.5, 25.4, 13.8. 
HRMS: (ESI-TOF, m/z) calcd. For C17H19N4O3 [M+H]+ calc.: 327.1457; found: 327.1458.  
IR: (ATR, neat, cm-1): 1759 (w), 1678 (s), 1476 (m), 1397 (w), 1295 (w), 1041 (m), 1032 (w), 993 
(w), 947 (w), 906 (w), 785 (m), 762 (s), 732 (w), 694 (m), 604 (m), 589 (w). 





7.8 Crystallographic data 
Crystallographic data for compound (±)-3.1a 
Single crystals of compound (±)-3.1a were obtained by slow 
recrystallization from CH2Cl2/pentane mixtures. A suitable 
crystal was selected and diffraction data were collected on a 
Bruker D8 Venture/Photon 100 diffractometer. The crystal was 
kept at 100.02 K during data collection.  
 
Identification code    CCDC 1582110 
Empirical formula    C22H21N3O4  
Formula weight    391.42  
Temperature/K    100.02  
Crystal system    monoclinic  
Space group    P21/c  
a/Å    12.8590(4)  
b/Å    10.0892(3)  
c/Å    15.2092(4)  
α/°    90  
β/°    102.1558(9)  
γ/°    90  
Volume/Å3    1928.95(10)  
Z    4  
ρcalcg/cm3    1.348  
μ/mm-1    0.773  
F(000)    824.0  
Crystal size/mm3    0.225 × 0.221 × 0.166  
Radiation    CuKα (λ = 1.54178)  
2Θ range for data collection/°   7.032 to 136.612  
Index ranges    -15 ≤ h ≤ 15, -12 ≤ k ≤ 12, -18 ≤ l ≤ 18  
Reflections collected    45426  
Independent reflections    3536 [Rint = 0.0364, Rsigma = 0.0135]  
Data/restraints/parameters    3536/0/268  
Goodness-of-fit on F2    1.073  
Final R indexes [I>=2σ (I)]    R1 = 0.0375, wR2 = 0.0911  
Final R indexes [all data]    R1 = 0.0391, wR2 = 0.0925  




Crystallographic data for compound (±)-3.1h 
Single crystals of compound (±)-3.1h were obtained by slow 
recrystallization from CH2Cl2/pentane mixtures. A suitable 
crystal was selected and diffraction data were collected on a 
Bruker D8 Venture/Photon 100 diffractometer. The crystal 
was kept at 99.99 K during data collection. 
 
Identification code  CCDC 1582111 
Empirical formula  C45H44Cl2N6O6  
Formula weight  835.76  
Temperature/K  99.99  
Crystal system  triclinic  
Space group  P-1  
a/Å  10.6521(4)  
b/Å  12.9904(5)  
c/Å  15.8802(7)  
α/°  109.1710(10)  
β/°  91.7910(10)  
γ/°  101.3100(10)  
Volume/Å3  2024.37(14)  
Z  2  
ρcalcg/cm3  1.371  
μ/mm-1  0.219  
F(000)  876.0  
Crystal size/mm3  0.626 × 0.227 × 0.206  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.54 to 52.9  
Index ranges  -13 ≤ h ≤ 13, -16 ≤ k ≤ 16, -19 ≤ l ≤ 19  
Reflections collected  56734  
Independent reflections  8332 [Rint = 0.0403, Rsigma = 0.0224]  
Data/restraints/parameters  8332/321/617  
Goodness-of-fit on F2  1.039  
Final R indexes [I>=2σ (I)]  R1 = 0.0398, wR2 = 0.0885  
Final R indexes [all data]  R1 = 0.0479, wR2 = 0.0932  




Crystallographic data for compound 3.1p 
Single crystals of compound 3.1p were obtained by slow 
recrystallization from hexanes/diethyl ether mixtures. A 
suitable crystal was selected, and diffraction data were collected 
on a Bruker D8 Venture/Photon 100 diffractometer. The crystal 
was kept at 100.0 K during data collection. The absolute 
stereochemistry at C1 (R) and C8 (S) were determined by calculating Hooft parameter. 
 
Identification code  CCDC 1582112 
Empirical formula  C21H25N3O3  
Formula weight  367.44  
Temperature/K  100.0  
Crystal system  monoclinic  
Space group  P21  
a/Å  11.9039(3)  
b/Å  6.01000(10)  
c/Å  14.3731(3)  
α/°  90  
β/°  112.4284(8)  
γ/°  90  
Volume/Å3  950.50(4)  
Z  2  
ρcalcg/cm3  1.284  
μ/mm-1  0.702  
F(000)  392.0  
Crystal size/mm3  0.388 × 0.144 × 0.128  
Radiation  CuKα (λ = 1.54178)  
2Θ range for data collection/°  6.652 to 149.068  
Index ranges  -14 ≤ h ≤ 14, -7 ≤ k ≤ 7, -17 ≤ l ≤ 17  
Reflections collected  21301  
Independent reflections  3871 [Rint = 0.0404, Rsigma = 0.0242]  
Data/restraints/parameters  3871/1/249  
Goodness-of-fit on F2  1.095  
Final R indexes [I>=2σ (I)]  R1 = 0.0308, wR2 = 0.0697  
Final R indexes [all data]  R1 = 0.0335, wR2 = 0.0715  
Largest diff. peak/hole / e Å-3  0.16/-0.12  




Crystallographic data for compound (±)-3.1s major isomer 
Single crystals of compound (±)-3.1s major isomer were 
obtained by slow recrystallization from hexanes/diethyl ether 
mixtures. A suitable crystal was selected and diffraction data 
were collected on a Bruker D8 Venture/Photon 100 
diffractometer. The crystal was kept at 99.99 K during data 
collection.  
 
Identification code  CCDC 1582113 
Empirical formula  C20H23N3O3  
Formula weight  353.41  
Temperature/K  99.99  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  14.6098(4)  
b/Å  9.8496(3)  
c/Å  12.5608(4)  
α/°  90  
β/°  100.9060(10)  
γ/°  90  
Volume/Å3  1774.86(9)  
Z  4  
ρcalcg/cm3  1.323  
μ/mm-1  0.090  
F(000)  752.0  
Crystal size/mm3  0.224 × 0.2 × 0.118  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.016 to 56.678  
Index ranges  -19 ≤ h ≤ 19, -13 ≤ k ≤ 12, -16 ≤ l ≤ 16  
Reflections collected  33228  
Independent reflections  4425 [Rint = 0.0366, Rsigma = 0.0193]  
Data/restraints/parameters  4425/0/265  
Goodness-of-fit on F2  1.024  
Final R indexes [I>=2σ (I)]  R1 = 0.0411, wR2 = 0.1018  
Final R indexes [all data]  R1 = 0.0470, wR2 = 0.1061  




Crystallographic data for compound (±)-3.1t major isomer 
Single crystals of compound (±)-3.1t major isomer were obtained 
by slow recrystallization from hexanes/diethyl ether mixtures. A 
suitable crystal was selected and diffraction data were collected on 
a Bruker D8 Venture/Photon 100 diffractometer. The crystal was 
kept at 100.0 K during data collection. 
 
Identification code  CCDC 1582114 
Empirical formula  C43H52N6O6Cl2  
Formula weight  819.80  
Temperature/K  100.0  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  23.3397(5)  
b/Å  10.4840(2)  
c/Å  17.3377(4)  
α/°  90  
β/°  110.1730(10)  
γ/°  90  
Volume/Å3  3982.17(15)  
Z  4  
ρcalcg/cm3  1.367  
μ/mm-1  0.221  
F(000)  1736.0  
Crystal size/mm3  0.316 × 0.213 × 0.082  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.622 to 50.784  
Index ranges  -28 ≤ h ≤ 28, -12 ≤ k ≤ 12, -20 ≤ l ≤ 20  
Reflections collected  53785  
Independent reflections  7329 [Rint = 0.0684, Rsigma = 0.0360]  
Data/restraints/parameters  7329/0/522  
Goodness-of-fit on F2  1.013  
Final R indexes [I>=2σ (I)]  R1 = 0.0453, wR2 = 0.1063  
Final R indexes [all data]  R1 = 0.0671, wR2 = 0.1186  




Crystallographic data for compound (±)-3.1u major isomer 
Single crystals of compound (±)-3.1u major isomer were 
obtained by slow recrystallization from hexanes/ethyl acetate 
mixtures. A suitable crystal was selected and diffraction data 
were collected on a Bruker APEX-II CCD diffractometer. The 
crystal was kept at 100.15 K during data collection.  
 
Identification code  CCDC 1582115 
Empirical formula  C23H23N3O4  
Formula weight  405.44  
Temperature/K  100.15  
Crystal system  monoclinic  
Space group  C2/c  
a/Å  27.2520(6)  
b/Å  9.6333(2)  
c/Å  16.9545(4)  
α/°  90  
β/°  116.8920(10)  
γ/°  90  
Volume/Å3  3969.68(16)  
Z  8  
ρcalcg/cm3  1.357  
μ/mm-1  0.094  
F(000)  1712.0  
Crystal size/mm3  0.302 × 0.222 × 0.182  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.892 to 56.676  
Index ranges  -36 ≤ h ≤ 36, -12 ≤ k ≤ 12, -22 ≤ l ≤ 22  
Reflections collected  57205  
Independent reflections  4947 [Rint = 0.0445, Rsigma = 0.0200]  
Data/restraints/parameters  4947/0/292  
Goodness-of-fit on F2  1.046  
Final R indexes [I>=2σ (I)]  R1 = 0.0378, wR2 = 0.0950  
Final R indexes [all data]  R1 = 0.0445, wR2 = 0.1005  




Crystallographic data for compound (±)-3.1v major isomer 
Single crystals of compound (±)-3.1v major isomer were 
obtained by slow recrystallization from hexanes/ethyl acetate 
mixtures. A suitable crystal was selected and diffraction data were 
collected on a Bruker D8 Venture/Photon 100 diffractometer. The 
crystal was kept at 99.99 K during data collection. 
Identification code  CCDC 1582116 
Empirical formula  C32H32N4O4  
Formula weight  536.61  
Temperature/K  99.99  
Crystal system  triclinic  
Space group  P-1  
a/Å  9.7641(3)  
b/Å  12.0253(4)  
c/Å  13.4320(4)  
α/°  108.7790(10)  
β/°  108.3500(10)  
γ/°  98.9080(10)  
Volume/Å3  1358.43(7)  
Z  2  
ρcalcg/cm3  1.312  
μ/mm-1  0.088  
F(000)  568.0  
Crystal size/mm3  0.256 × 0.199 × 0.176  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.02 to 50.816  
Index ranges  -11 ≤ h ≤ 11, -14 ≤ k ≤ 14, -16 ≤ l ≤ 16  
Reflections collected  65143  
Independent reflections  4981 [Rint = 0.0461, Rsigma = 0.0168]  
Data/restraints/parameters  4981/0/370  
Goodness-of-fit on F2  1.037  
Final R indexes [I>=2σ (I)]  R1 = 0.0326, wR2 = 0.0738  
Final R indexes [all data]  R1 = 0.0392, wR2 = 0.0777  





Crystallographic data for compound (±)-3.13a 
Single crystals of compound (±)-3.13a were obtained 
by slow recrystallization from hexanes/diethyl ether 
mixtures. A suitable crystal was selected and 
diffraction data were collected on a Bruker D8 
Venture/Photon 100 diffractometer. The crystal was 
kept at 100.01 K during data collection. 
 
Identification code  CCDC 1582117  
Empirical formula  C18H19N3O4  
Formula weight  341.36  
Temperature/K  100.01  
Crystal system  monoclinic  
Space group  C2/c  
a/Å  22.0040(9)  
b/Å  9.7666(4)  
c/Å  17.3783(7)  
α/°  90  
β/°  116.7290(10)  
γ/°  90  
Volume/Å3  3335.6(2)  
Z  8  
ρcalcg/cm3  1.360  
μ/mm-1  0.098  
F(000)  1440.0  
Crystal size/mm3  0.209 × 0.2 × 0.101  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.658 to 54.284  
Index ranges  -28 ≤ h ≤ 28, -12 ≤ k ≤ 12, -22 ≤ l ≤ 22  
Reflections collected  33389  
Independent reflections  3709 [Rint = 0.0502, Rsigma = 0.0248]  
Data/restraints/parameters  3709/0/234  
Goodness-of-fit on F2  1.044  
Final R indexes [I>=2σ (I)]  R1 = 0.0376, wR2 = 0.0844  
Final R indexes [all data]  R1 = 0.0490, wR2 = 0.0898  




Crystallographic Data for compound (±)-4.2a 
Single crystals of compound (±)-4.2a were obtained by slow 
recrystallization from dichloromethane/ethyl acetate mixtures. A 
suitable crystal was selected and diffraction data were collected on a 
Bruker D8 Venture/Photon 100 diffractometer. The crystal was kept 
at 100.04 K during data collection.  
Identification code  dd51msa  
Empirical formula  C21H20N4O3  
Formula weight  376.41  
Temperature/K  100.04  
Crystal system  triclinic  
Space group  P-1  
a/Å  5.9571(2)  
b/Å  10.5985(3)  
c/Å  14.9981(4)  
α/°  97.6188(8)  
β/°  96.7033(8)  
γ/°  94.5052(8)  
Volume/Å3  927.89(5)  
Z  2  
ρcalcg/cm3  1.347  
μ/mm-1  0.755  
F(000)  396.0  
Crystal size/mm3  0.69 × 0.133 × 0.115  
Radiation  CuKα (λ = 1.54178)  
2Θ range for data collection/°  5.994 to 136.818  
Index ranges  -7 ≤ h ≤ 7, -12 ≤ k ≤ 12, -18 ≤ l ≤ 18  
Reflections collected  28328  
Independent reflections  3389 [Rint = 0.0504, Rsigma = 0.0247]  
Data/restraints/parameters  3389/0/259  
Goodness-of-fit on F2  1.050  
Final R indexes [I>=2σ (I)]  R1 = 0.0341, wR2 = 0.0790  
Final R indexes [all data]  R1 = 0.0371, wR2 = 0.0811  




Crystallographic Data for compound (±)-4.3a 
Single crystals of compound (±)-4.3a were obtained by slow 
recrystallization from dichloromethane/ethyl acetate mixtures. A 
suitable crystal was selected and diffraction data were collected on 
a Bruker D8 Venture/Photon 100 diffractometer. The crystal was 
kept at 100.0 K during data collection. 
 
Identification code  dd22ps  
Empirical formula  C19H17N3O2  
Formula weight  319.35  
Temperature/K  100.0  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  8.8937(4)  
b/Å  18.0440(7)  
c/Å  10.0130(4)  
α/°  90  
β/°  101.1175(14)  
γ/°  90  
Volume/Å3  1576.71(11)  
Z  4  
ρcalcg/cm3  1.345  
μ/mm-1  0.090  
F(000)  672.0  
Crystal size/mm3  0.204 × 0.203 × 0.066  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.668 to 54.228  
Index ranges  -11 ≤ h ≤ 11, -23 ≤ k ≤ 23, -12 ≤ l ≤ 12  
Reflections collected  52687  
Independent reflections  3489 [Rint = 0.0580, Rsigma = 0.0200]  
Data/restraints/parameters  3489/0/222  
Goodness-of-fit on F2  1.073  
Final R indexes [I>=2σ (I)]  R1 = 0.0401, wR2 = 0.0919  
Final R indexes [all data]  R1 = 0.0508, wR2 = 0.0975  




Crystallographic Data for compound (±)-5.1a 
Single crystals of compound (±)-5.1a were obtained by slow 
recrystallization from n-hexanes/ethyl acetate mixtures. A 
suitable crystal was selected and diffraction data were collected 
on a Bruker D8 Venture/Photon 100 diffractometer. The crystal 
was kept at 100.03 K during data collection. 
 
Identification code  CCDC 1877219  
Empirical formula  C21H22N4O2  
Formula weight  362.42  
Temperature/K  100.03  
Crystal system  triclinic  
Space group  P-1  
a/Å  9.5948(2)  
b/Å  12.3669(3)  
c/Å  16.3965(4)  
α/°  99.9720(10)  
β/°  104.3150(10)  
γ/°  91.5190(10)  
Volume/Å3  1851.78(8)  
Z  4  
ρcalcg/cm3  1.300  
μ/mm-1  0.692  
F(000)  768.0  
Crystal size/mm3  0.143 × 0.129 × 0.048  
Radiation  CuKα (λ = 1.54178)  
2Θ range for data collection/°  5.66 to 136.796  
Index ranges  -11 ≤ h ≤ 11, -14 ≤ k ≤ 14, -19 ≤ l ≤ 19  
Reflections collected  27751  
Independent reflections  6678 [Rint = 0.0355, Rsigma = 0.0293]  
Data/restraints/parameters  6678/0/498  
Goodness-of-fit on F2  1.068  
Final R indexes [I>=2σ (I)]  R1 = 0.0365, wR2 = 0.0805  
Final R indexes [all data]  R1 = 0.0449, wR2 = 0.0851  





Crystallographic Data for compound (±)-5.1i 
Twin crystals of compound (±)-5.1i were obtained by slow 
recrystallization from CH2Cl2/diethyl ether mixtures. A 
suitable crystal was selected and diffraction data were 
collected on a Bruker D8 Venture/Photon 100 diffractometer. 
The crystal was kept at 100.01 K during data collection. 
 
Identification code  CCDC 1877220 
Empirical formula  C16H21.31N4O2.66  
Formula weight  312.20  
Temperature/K  100.01  
Crystal system  triclinic  
Space group  P-1  
a/Å  9.8206(4)  
b/Å  11.1581(5)  
c/Å  15.3236(7)  
α/°  101.9240(10)  
β/°  100.7390(10)  
γ/°  100.1540(10)  
Volume/Å3  1573.33(12)  
Z  4  
ρcalcg/cm3  1.318  
μ/mm-1  0.092  
F(000)  666.0  
Crystal size/mm3  0.561 × 0.39 × 0.238  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.33 to 56.72  
Index ranges  -13 ≤ h ≤ 13, -14 ≤ k ≤ 14, -20 ≤ l ≤ 20  
Reflections collected  117799  
Independent reflections  117799 [Rint = 0.0542, Rsigma = 0.0645]  
Data/restraints/parameters  117799/1/463  
Goodness-of-fit on F2  1.028  
Final R indexes [I>=2σ (I)]  R1 = 0.0550, wR2 = 0.1245  
Final R indexes [all data]  R1 = 0.0798, wR2 = 0.1374  





Crystallographic Data for compound 5.2d 
Single crystals of compound 5.2d were obtained by slow 
recrystallization from dichloromethane/diethyl ether mixtures. A 
suitable crystal was selected and diffraction data were collected 
on a Bruker D8 Venture/Photon 100 diffractometer. The crystal 
was kept at 99.95 K during data collection.  
 
Identification code  CCDC 1877221 
Empirical formula  C13H18N4O3  
Formula weight  278.31  
Temperature/K  99.95  
Crystal system  monoclinic  
Space group  C2/c  
a/Å  22.4136(10)  
b/Å  6.0223(3)  
c/Å  19.9058(8)  
α/°  90  
β/°  94.244(2)  
γ/°  90  
Volume/Å3  2679.5(2)  
Z  8  
ρcalcg/cm3  1.380  
μ/mm-1  0.101  
F(000)  1184.0  
Crystal size/mm3  0.404 × 0.222 × 0.128  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.284 to 54.372  
Index ranges  -28 ≤ h ≤ 28, -7 ≤ k ≤ 7, -25 ≤ l ≤ 25  
Reflections collected  28276  
Independent reflections  2980 [Rint = 0.0367, Rsigma = 0.0170]  
Data/restraints/parameters  2980/0/196  
Goodness-of-fit on F2  1.050  
Final R indexes [I>=2σ (I)]  R1 = 0.0376, wR2 = 0.0947  
Final R indexes [all data]  R1 = 0.0402, wR2 = 0.0969  





Crystallographic Data for compound 5.2f  
Single crystals of compound 5.2f were obtained by slow 
recrystallization from dichloromethane/diethyl ether mixtures. 
A suitable crystal was selected and diffraction data were 
collected on a Bruker D8 Venture/Photon 100 diffractometer. 
The crystal was kept at 99.99 K during data collection.  
 
Identification code  CCDC 1877222 
Empirical formula  C12H20N4O3  
Formula weight  268.32  
Temperature/K  99.99  
Crystal system  triclinic  
Space group  P-1  
a/Å  8.0480(3)  
b/Å  8.8580(4)  
c/Å  10.9924(5)  
α/°  69.1109(16)  
β/°  76.8504(17)  
γ/°  68.7540(16)  
Volume/Å3  678.01(5)  
Z  2  
ρcalcg/cm3  1.314  
μ/mm-1  0.096  
F(000)  288.0  
Crystal size/mm3  0.317 × 0.154 × 0.08  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.176 to 52.886  
Index ranges  -10 ≤ h ≤ 10, -11 ≤ k ≤ 11, -13 ≤ l ≤ 13  
Reflections collected  5557  
Independent reflections  2779 [Rint = 0.0192, Rsigma = 0.0255]  
Data/restraints/parameters  2779/0/188  
Goodness-of-fit on F2  1.107  
Final R indexes [I>=2σ (I)]  R1 = 0.0472, wR2 = 0.0940  
Final R indexes [all data]  R1 = 0.0584, wR2 = 0.0980  





Crystallographic Data for compound (±)-6.1a 
Single crystals of compound (±)-6.1a were obtained by slow 
recrystallization from n-hexanes/ethyl acetate mixtures. A suitable 
crystal was selected and diffraction data were collected on a Bruker 
D8 Venture/Photon 100 diffractometer. The crystal was kept at 
100.04 K during data collection. 
 
Identification code  dd51msa  
Empirical formula  C21H20N4O3  
Formula weight  376.41  
Temperature/K  100.04  
Crystal system  triclinic  
Space group  P-1  
a/Å  5.9571(2)  
b/Å  10.5985(3)  
c/Å  14.9981(4)  
α/°  97.6188(8)  
β/°  96.7033(8)  
γ/°  94.5052(8)  
Volume/Å3  927.89(5)  
Z  2  
ρcalcg/cm3  1.347  
μ/mm-1  0.755  
F(000)  396.0  
Crystal size/mm3  0.69 × 0.133 × 0.115  
Radiation  CuKα (λ = 1.54178)  
2Θ range for data collection/°  5.994 to 136.818  
Index ranges  -7 ≤ h ≤ 7, -12 ≤ k ≤ 12, -18 ≤ l ≤ 18  
Reflections collected  28328  
Independent reflections  3389 [Rint = 0.0504, Rsigma = 0.0247]  
Data/restraints/parameters  3389/0/259  
Goodness-of-fit on F2  1.050  
Final R indexes [I>=2σ (I)]  R1 = 0.0341, wR2 = 0.0790  
Final R indexes [all data]  R1 = 0.0371, wR2 = 0.0811  
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